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OUTLINE OF THE THESIS 
 
Tumor necrosis factor (TNF) is an inflammatory cytokine with a potent antitumor 
activity. Both in experimental animal models and in human patients it can rapidly 
induce a haemorrhagic necrosis of tumors. The clinical use of TNF is, however, 
severely hampered by the potentially life-threatening side-effects which emerge when 
the high doses of TNF required to produce an antitumor effect are administered 
systemically. The research described in this dissertation is part of a larger research 
project that aims to unravel the molecular basis of the antitumor and shock-inducing 
effects of TNF, so that a safe, systemic TNF-based treatment could be developed. 
More in particular, the aim of the thesis was to study factors that influence the 
sensitivity to the antitumor activity of TNF, in order to interfere with them 
therapeutically, so that lower doses of TNF would be sufficient to obtain a similar 
antitumor effect.  
In the first part of the thesis we introduce the subject by summarizing the current 
knowledge of the different molecular players and systems. The signaling cascade 
initiated by TNF and the inflammatory and antitumor properties of this cytokine are 
summarized in chapter 1. Already during the first experiments performed by 
Brouckaert and colleagues it became clear that co-treatment with another 
inflammatory cytokine, interferon- (IFN-), could significantly enhance the 
antitumor effect of TNF. These and similar findings by other groups has even led to 
the addition of IFN- to TNF-based isolated limb perfusion (ILP) settings. The 
mechanism behind this remarkable effect is however still largely unknown and is one 
of the subjects of this thesis. Therefore, IFN- is reviewed in the introductory chapter 
2, with the emphasis on its role in immunity and its synergy with TNF. Another 
approach that is followed to develop a safer TNF-based anticancer therapy is to 
combine low doses of TNF with agents that sensitize for the antitumor effect of TNF. 
In a preliminary study we identified a phosphatidylinositol 3-kinase (PI3K) inhibitor 
as such an agent. A second aim of this research was to further elaborate this finding 
and identify new potential targets within the PI3K/Akt survival pathway. Therefore, 
the PI3K/Akt pathway and its most important components, PI3K, Akt and mammalian 
target of rapamycin (mTOR) are discussed in chapter 3 of the introduction. It has 
become clear that TNF-based anticancer therapies act principally by modifying and 
disrupting the tumor neovasculature. To better understand the complex nature of this 
tumor vasculature, the process of (tumor) angiogenesis will be discussed in chapter 4. 
A general overview of current vascular-targeted therapies is given in chapter 5. A 
third and final subject of this thesis is the role of the immune system in the antitumor 
effects of TNF and IFN-. Some reports suggest that certain immune cells may 
actively contribute to the antitumor response initiated by TNF. However, the nature of 
these immune cells remains unclear. As our research, described in this thesis, points to 
a potential role for natural killer T (NKT) cells, a relatively recently discovered type 
 
8   
of immune cell with some remarkable properties, these cells will be discussed in 
chapter 6 of the introduction. 
In the second part of the thesis we report the results of our experimental work. In 
chapter 8 we report our observations regarding the effects interfering with the 
PI3K/Akt pathway has on the antitumor effect of TNF. In chapter 9 we report our 
observations on the role of NKT cells in this antitumor effect while in chapter 10 the 
mechanisms underlying the synergistic effect of IFN- are reported. 
Finally, chapter 11 of the thesis contains a general summary and discussion of our 
results. 
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11 Introduction: Tumor Necrosis Factor 
1. TUMOR NECROSIS FACTOR 
 
Chapter foreword 
 
Tumor necrosis factor (TNF) is a fascinating protein. Its name as well as its history 
are closely linked to cancer. However, despite the fact that everyone nowadays agrees 
that this is a protein with great anticancer potential, still no TNF-based therapy has 
been proven to prolong survival of human cancer patients. TNF is primarily a pro-
inflammatory cytokine, and it has become clear that it plays a central role in 
inflammatory disorders such as sepsis, rheumatoid arthritis, inflammatory bowel 
disease and others. Hence, anti-TNF therapy has found its way to clinical practice, 
and often with success. Decades of research have now made clear that TNF has a 
remarkably broad range of often contradictory activities: it is involved in 
inflammation as well as anti-inflammation, angiogenesis as well as disruption of 
blood vessels, carcinogenesis as well as tumor necrosis, and cell survival as well as 
cell death. Therefore, TNF is often called a „Janus face‟, referring to the Roman god 
of gates, doors, beginnings and endings, who was usually depicted with two faces 
looking in opposite directions. Yet, despite its long history and decades of research, 
many aspects of its biology are still covered with mystery. Fortunately, there is great 
scientific interest in TNF: searching PubMed for “tumor necrosis factor” delivers 
more than 88000 articles, of which an overwhelming 6300 were published during the 
last year alone. In this chapter some general aspects of TNF biology will be discussed, 
with the emphasis on signaling to cell death and inflammation, and on its remarkable 
antitumor effect.  
 
 
1.1. A brief history 
 
The story of the discovery of TNF began with William B. Coley, a surgeon at 
Memorial Hospital in New York from 1892 to 1931. During the 19
th
 century several 
physicians reported that cancer patients who suffered from severe bacterial infections 
sometimes had spontaneous regression of their tumors. Coley was the first to translate 
this observation into clinical practice. In the beginning he treated cancer patients with 
live bacteria, with some success, but due to difficulties to control the infection, Coley 
was forced to change his strategy. Instead of using live bacteria he now treated cancer 
patients with extracts of killed bacteria, which came to be known as Coley‟s toxins. 
These reproduced many of the symptoms of bacterial infection, such as fever and 
chills, but they could be administered without the risk of producing a real infection. 
Although Coley‟s approach was quite successful in the beginning of the 20th century, 
it was soon abandoned when chemotherapeutics and radiation therapy entered the 
field of cancer therapy 
1
.  
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The interest in Coley‟s toxins however lived on in the laboratory. Investigators 
confirmed that some infectious agents and their products had anticancer effects in 
animals. In particular, they demonstrated that the injection of gram-negative bacteria 
could cause haemorrhagic necrosis of mouse tumors. In 1943 Murray J. Shear and his 
colleagues identified and purified the active component of gram-negative bacteria: a 
complex fat-and-sugar compound of the bacterial cell wall, now called 
lipopolysaccharide (LPS) 
2
. Although LPS could induce haemorrhagic necrosis of 
tumors in mice, in test-tube studies it could not inhibit or kill tumor cells directly, 
suggesting that its in vivo action was indirect and mediated by something in the host. 
More than 30 years later Lloyd J. Old and his colleagues identified in the serum of 
mice infected with Bacillus Calmette-Guérin (BCG) and 1 to 3 weeks later treated 
with LPS a factor that was capable of inducing haemorrhagic necrosis and regression 
of a methylcholanthrene A (methA) induced sarcoma in mice. Since the same factor 
had cytotoxic activity against certain tumor cell lines in vitro, among others the mouse 
fibrosarcoma cell line L929, they decided to name this factor “Tumor Necrosis 
Factor” 3. 
At the same time, another research group identified a serum factor that was a central 
mediator of cachexia, an infection- and cancer-associated chronic weight loss, and 
hence it was called “cachectine”. After purification and partial sequencing cachectine 
appeared to be identical to TNF 
4
. 
In 1984 and 1985 the genes for human and mouse TNF were cloned 
5-7
. 
 
 
1.2. TNF and its receptors 
 
TNF belongs to a superfamily of TNF protein homologues (with 15-20% identity to 
each other) consisting of 19 members that signal through 29 different receptors 
(Fig.1.1.). Unlike TNF, most members have specific activities and are specialized in 
one type of signal. For example, TNF-related apoptosis-inducing ligand (TRAIL) and 
FasL appear to be specialized in apoptosis. 
The human TNF gene is located on chromosome 6p21.3 and is mainly expressed by 
activated macrophages, natural killer (NK) cells and T lymphocytes, although many 
other cell types (e.g. fibroblasts, Kuppfer cells, smooth muscle cells, keratinocytes, 
astrocytes, and tumor cells) have been shown to contain TNF messenger RNA 
(mRNA) 
8
. TNF expression results in a 26kDa membrane-bound pro-peptide (pro-
TNF) which associates into homotrimers. TNF is released from the cell surface after 
cleavage by the TNF--converting enzyme (TACE), a member of the a-disintigrin-
and-metalloproteinase (ADAM) family 
9, 10
. The soluble active form of TNF is a 
52kDa homotrimer 
11
.  
 
TNF transduces its signals via two cell surface receptors: TNF-receptor 1 (TNF-R1) 
(or p55TNFR or CD120a), constitutively expressed on all cell types, and TNF-R2 (or 
 
13 Introduction: Tumor Necrosis Factor 
p75TNFR or CD120b), of which the expression is inducible and appears to be 
restricted to immune and endothelial cells 
12
. TNF-R1 can be fully activated by both 
the membrane-bound and soluble forms of TNF, while TNF-R2 only responds fully to 
the membrane-bound form of the TNF homotrimer 
13
. Like TNF, these receptors can 
self-assemble into homomultimers. This ligand-independent assembly is mediated by 
an extracellular domain called preligand binding assembly domain (PLAD) 
14
.  
Both TNF-receptors can undergo ectodomain shedding to produce soluble TNF-
receptors (sTNF-Rs). These sTNF-Rs can act as circulating decoy receptors and this is 
an important mechanism of negative regulation of the biological activity of TNF 
15
. 
Like TNF, TNF-R2 is cleaved by TACE 
16
. It is still unclear which proteolytic 
enzymes are responsible for the cleavage of TNF-R1, but recently it was shown that 
the shedding of TNF-R1 was greatly reduced in TACE-deficient neutrophils and 
macrophages 
17
. The cleavage of TNF-R1 is obviously an important step in the 
regulation of cellular TNF responsiveness as cleavage-resistant TNF-R1 mutations are 
linked with a dominantly inherited auto-inflammatory syndrome, called TNF-R1-
associated periodic syndrome 
18
. Elevated levels of sTNF-Rs are also found in certain 
diseases, e.g. in rheumatoid arthritis high serum levels of sTNF-Rs are associated with 
a greater risk of mortality due to cardiovascular disease 
19
. 
While the extracellular region of both TNF receptors is very similar, their intracellular 
regions display no homology 
20
. The intracellular region of the TNF-R1 contains a 
death domain (DD), which is required for most TNF-R1-mediated signaling events, 
including gene induction, death-inducing signaling complex (DISC) formation and the 
activation of the acidic sphingomyelinase (aSMase) 
21-23
. The TNF-R1 also contains a 
second, more membrane-proximal, domain, called neutral sphingomyelinase domain 
(NSD), which is important for the recruitment and activation of the neutral 
sphingomyelinase (nSMase) 
24, 25
. The intracellular region of the TNF-R2 is much 
shorter and transduces signals through its TNF receptor associated factor (TRAF)-
interacting motif (TIM) 
26
. This domain is required for the recruitment of TRAF 
family members, which in turn can associate with members of the mitogen-activated 
protein kinase (MAPK) and nuclear factor-B (NF-B) pathways, and anti-apoptotic 
factors such as the inhibitor of apoptosis protein (IAP) family members c-IAP1 and 2 
22, 27
. 
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Fig. 1.1. The TNF superfamily. TNF superfamily numbers are indicated in green boxes, TNF receptor 
superfamily numbers in blue boxes. Most ligands are type-II transmembrane proteins (with 
carboxyterminal extracellular domain responsible for binding the receptor, aminoterminal intracellular 
domain, and a single transmembrane domain). LT and TL1A are secreted proteins. BAFF, EDA1, 
EDA2, APRIL and TWEAK are released from the cell surface by members of the Furin protease 
family; TNF, LT, RANKL and FasL are cleaved off by other proteases. Most receptors are type-I 
transmembrane proteins (extracellular N-terminus and intracellular C-terminus). BCMA, TACI, BAFF-
R and XEDAR lack a signal peptide sequence and are considered type-III transmembrane proteins. 
OPG and DcR3 are secreted proteins. Encircled receptors can be found in soluble form and act as 
circulating decoy receptors. DD-containing receptors are represented in red, decoy receptors in green. 
The mouse homologues for the human TRAIL-R1 and TRAIL-R2, for the human TRAIL-R3, and for 
the human TRAIL-R4 are respectively TRAIL-R2, DcTRAIL-R1, and DcTRAIL-R2L and DcTRAIL-
R2S. ** Do not belong to the TNF Superfamily. Adapted from Mocellin et al., 2005 
22
. 
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1.3. Regulation of TNF production 
 
The production of TNF is regulated on the transcriptional, translational and post-
translational level.  
The TNF gene promoter contains potential binding sites for several transcription 
factors, including AP-1, AP-2, NF-B, Ets, NFAT, cyclic AMP response element 
(CRE) and C/EBP, which allow the regulation of gene expression by many different 
stimuli 
28-34
. For example, in macrophages the induction of TNF by LPS requires the 
transcription factor NF-B 35. Besides LPS, also other microbial compounds and 
cytokines such as interleukin (IL)-1, IL-2, GM-CSF, and TNF itself can induce TNF 
production. Several anti-inflammatory agents, such as glucocorticoids and the 
cytokines IL-10 and transforming growth factor- (TGF-), function as inhibitors of 
TNF production 
8
. 
The 3‟untranslated region (3‟UTR) of the TNF mRNA contains an AU-rich element 
(ARE) that is important for the translational regulation of TNF 
36
. This ARE interacts 
with a variety of ARE-binding proteins that regulate the transport of mRNA, its decay 
in the cytoplasm and its translational efficiency 
37
. In nonstimulated macrophages, 
spliced TNF mRNA is retained in the nucleus by an ARE-dependent mechanism. 
Stimulation with LPS induces export of the mRNA into the cytoplasm in a Tpl2- and 
extracellular signal-related kinase (ERK)-dependent pathway 
38
. Once in the 
cytoplasm, the rate of mRNA decay is stringently controlled. Decay is mediated 
through binding of the zinc finger protein tristetraprolin (TTP) to the ARE and 
requires proteasomal activity 
39, 40
. Phosphorylation of TTP by MAPK-activated 
protein kinase-2 (MK2), a downstream target of p38 MAPK, leads to reduced affinity 
for the mRNA and increased mRNA stability 
41
. Recently it was shown that TNF 
mRNA stabilization also requires activation of the ERK pathway 
40
. Two other RNA 
binding proteins with high affinity for the TNF ARE have been identified: T cell 
restricted intracellular antigen-1 (TIA-1) and TIA-1-related protein (TIAR). TIA-1, 
and probably also TIAR, is involved in silencing at the level of translation 
37, 42
. 
Downstream of the ARE another mRNA-destabilizing element has been identified 
which is the target of a second mRNA degradation pathway that is independent of 
ARE-mediated decay 
43
. 
Finally, also post-translational regulation of TNF production may occur 
44
. 
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1.4. TNF-R1 signaling 
 
1.4.1. General aspects of TNF-R1 signaling 
 
The initial step in TNF-R1 signaling is binding of the TNF homotrimer to the 
extracellular domain of pre-assembled receptor complexes. This induces a 
conformational change that results in the release of the inhibitory protein silencer of 
death domains (SODD) from the TNF-R1 intracellular DD. The function of SODD is 
to repress spontaneous TNF-R1 signaling by blocking the binding of adaptor proteins 
to the DD of TNF-R1 
45
. After SODD release, TNF-receptor associated DD protein 
(TRADD) binds to the DD of TNF-R1 and functions as a platform to recruit the 
additional adaptor proteins receptor-interacting protein (RIP)-1, via its DD, and 
TRAF, via an aminoterminal domain of TRADD 
46, 47
. Within minutes after TNF 
binding a membrane-bound complex is formed composed of TNF-R1, TRADD, RIP, 
TRAF-2 and c-IAP1 (Fig.1.2.). This complex is called complex I and induces 
activation of NF-B (see chapter 1.4.2.), but no apoptosis 48. Complex I is formed in 
cholesterol- and sphingolipid-enriched membrane microdomains, termed lipid rafts. It 
was shown that disruption of lipid rafts by cholesterol depletion results in a switch of 
TNF-induced NF-B activation to apoptosis 49. However, the role of lipid rafts in 
TNF-R1 signaling may be cell-type dependent. In primary mouse macrophages it was 
shown that lipid rafts are required for TNF-R1 signaling to ERK, but not to NF-B 50. 
In a human endothelial cell line disruption of lipid rafts resulted in inhibition of 
activation of phosphatidylinositol (PI) 3-kinase (PI3K), but not of NF-B signaling 51. 
 
After a lag of several hours and internalization of complex I, a secondary complex is 
formed in the cytoplasm, which lacks TNF-R1 but includes Fas-associated DD protein 
(FADD) and the procaspases-8 and/or -10 (Fig.1.2.) 
48
. FADD is recruited to the 
complex by homophilic interaction of the carboxyterminal DD of FADD with the DD 
of TRADD, whereas the procaspases bind to FADD by homophilic interaction 
between the aminoterminal death effector domain (DED) of FADD and a DED in the 
prodomain of the procaspases 
52
. This secondary complex is called complex II or 
DISC and can initiate apoptosis (see chapter 1.4.4.). It was recently shown that DISC 
formation is critically dependent on endocytosis of the TNF-R1, and a domain, named 
TNF-R1 internalization domain (TRID), has been identified that is required for 
internalization of the receptor. The vesicles containing the internalized TNF-R1 are 
called TNF receptosomes 
53
.  
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Fig. 1.2. TNF-R1 signaling via two sequential complexes. After binding of TNF to TNF-R1, rapid 
recruitment of TRADD, RIP and TRAF2 occurs (Complex I). Subsequently TNF-R1, TRADD and RIP 
become modified () and the complex dissociates from TNF-R1. The liberated DD of TRADD and/or 
RIP now bind FADD, resulting in recruitment of procaspase-8/10 (Complex II). If NF-B activation 
triggered by complex I is successful, c-FLIP levels are sufficiently elevated to block the activation of 
caspase-8/10 by complex II. From Micheau et al., 2003 
48
. 
 
1.4.2. The NF-B pathway 
 
NF-B is a dimeric transcription factor that regulates the expression of many genes 
involved in inflammation and immunity. NF-B also upregulates the expression of 
several genes that participate in controlling cell survival, such as, Bcl-xL, cellular Fas-
associated DD-like IL-1-converting enzyme (FLICE)-inhibitory protein (c-FLIP), 
proteins of the IAP family, and the Bcl-2 homologue A1, which are important to 
counteract the TNF-R1-induced apoptotic machinery 
54-60
. 
The term NF-B refers to a collection of homo- or heterodimers formed by members 
of the NF-B/Rel family, which consists of five members: NF-B1 (or p50) and its 
precursor p105, NF-B2 (or p52) and its precursor p100, RelA (or p65), RelB, and c-
Rel. NF-B/Rel family members are involved in cellular responses to stimuli such as 
cytokines, for example TNF and IL-1, bacterial components, for example LPS, and 
some forms of physical stress, for example reactive oxygen species (ROS) or 
ultraviolet radiation 
61
. The NF-B/Rel proteins have a conserved Rel homology 
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domain that mediates dimerization, nuclear translocation, DNA binding and 
interaction with members of the inhibitor of NF-B (IB) family 62. In unstimulated 
cells NF-B activity is inhibited by association with IB proteins, which mask its 
nuclear localization sequence and inhibit its DNA-binding activity 
63
. NF-B can be 
activated through two distinct pathways. Pro-inflammatory stimuli, such as LPS, TNF 
or IL-1, activate NF-B by the so-called canonical (or type 1) NF-B pathway, 
whereas non-inflammatory stimuli, associated with the development of lymphoid 
organs, have been shown to activate NF-B by an alternative (or type 2) pathway 64. 
The primary NF-B isoform induced by the canonical pathway is the NF-B1:RelA 
dimer, also called classical NF-B 65. 
 
The activation of NF-B by TNF is mediated by the canonical IB kinase (IKK) 
complex (Fig.1.3.). This complex consists of a heteromer of two related IB kinases 
IKK1 and IKK2 (or IKK and IKK), the regulatory protein NF-B essential 
modulator (NEMO) (or IKK), a homodimer of the heat shock protein-90 (Hsp90), 
and two or three molecules of the Hsp90-associated protein cdc37 
66-69
. TRAF-2 plays 
an essential role in the recruitment of the IKK complex to the TNF-R1 signaling 
complex I, whereas RIP is essential for the activation of the IKK complex 
70
. RIP 
recruits the MAPK kinase kinase (MAP3K) TGF--activated kinase 1 (TAK1) to the 
complex and TAK1 cooperates with a second MAP3K, MAPK/ERK kinase kinase 3 
(MEKK3), to activate the IKK complex 
71-73
. It has been shown that ubiquitination of 
RIP, probably by TRAF-2, is required for NF-B activation. The polyubiquitin chains 
(lysine 63-linked) on RIP may provide a docking site for the association with the 
TAK1-associated protein TAB2 
74-76
. Upon activation, the IKK complex 
phosphorylates the canonical IB proteins IB, IB and IB on two N-terminal 
serines, which then act as a docking platform for the ubiquitin ligase -transducin 
repeat-containing protein (-TRCP) 77, 78. Subsequent ubiquitination (lysine 48-linked 
chains) induces proteasome-mediated degradation of the IB proteins without 
affecting the bound NF-B dimer. The liberated dimer can then bind DNA at B sites 
and activate or repress gene transcription 
65
. 
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Fig. 1.3. Current model of NF-B activation by TNF. P: phosphorylation, Ub: ubiquitin(ation).  
 
Next to signal-induced degradation of the inhibitory IB proteins, NF-B 
transcriptional activity is also regulated through crosstalk with other signaling 
pathways. For example, activation of the serine/threonine kinase Akt in response to 
IL-1 has been shown to increase the DNA-binding activity of NF-B by 
phosphorylation of the NF-B1 subunit 79. The PI3K/Akt pathway has also been 
implicated as a critical mediator for TNF-dependent activation of NF-B in certain 
cell types 
80, 81
. Furthermore, casein kinase II (CKII), IKK2, protein kinase A (PKA) 
and mitogen- and stress-activated kinase-1 (MSK-1) have been shown to directly 
phosphorylate RelA, thereby increasing its transcriptional activity 
82-85
. Also protein 
kinase C (PKC), glycogen synthase kinase 3 (GSK), IKK1, and the MAPKs 
p38 and ERK have been shown to regulate the transcriptional activity of NF-B, 
presumably by direct or indirect phosphorylation 
81, 86-89
. Finally, several studies have 
shown that acetylation of NF-B occurs and that NF-B can associate with histone 
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acetyltransferases (HATs), e.g. cAMP response element-binding (CREB)-binding 
protein (CBP), and histone deacetylases (HDACs) 
90-92
.  
 
Upon cell stimulation increases in nuclear NF-B activity can be detected within 10 
minutes, and some NF-B-responsive promoters are induced almost immediately. 
One such early responding promoter is that of IB, which mediates a powerful 
negative feedback loop that is responsible for repression of NF-B activity upon 
removal of the stimulus 
93
. During chronic stimulation this may result in oscillatory 
NF-B activity 94. However, a second negative feedback loop mediated by IB, 
which is delayed and functions in anti-phase to IB, may counteract this oscillatory 
activity 
95
. 
 
1.4.3. The MAPK pathway 
 
MAPKs are serine/threonine kinases that respond to extracellular stimuli, mitogens, 
and regulate various cellular activities, including gene expression, cell division, 
differentiation, migration and survival/apoptosis. Extracellular stimuli lead to 
activation of a MAPK via a signaling cascade composed of MAPK, MAPK kinase 
(MAP2K or MKK) and MAPK3K (Fig.1.4.). A MAP3K that is activated by an 
extracellular stimulus phosphorylates a MAP2K on specific serine and threonine 
residues, and subsequently this MAP2K activates a MAPK through phosphorylation 
of specific serine and tyrosine residues. The activated MAPK can then activate its 
substrates through phosphorylation of specific serine and threonine residues. The 
MAPK family can be divided into three groups: p38 MAPK, which contains a Thr-
Ala-Tyr motif, c-Jun NH2-terminal kinas/stress activated protein kinase (JNK/SAPK), 
which contains a Thr-Pro-Tyr motif, and ERK, which contains a Thr-Glu-Tyr motif 
96, 
97
. TNF can activate all three MAPKs. 
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Fig. 1.4. Major MAPK cascades in mammalian cells. Adapted from Zhang et al., 2002 
97
. 
 
 JNK 
 
TNF-R1-induced activation of JNK occurs through a TRAF-2-dependent pathway 
(Fig.1.5.) 
98-100
. JNK can be activated by two MKKs, MKK4 and MKK7. TNF 
activates only MMK7, not MKK4 
101
. However, MMK4 appears to be required for 
optimal TNF-induced JNK activation 
102
. MKK4 and MKK7 are target of a variety of 
MAP3Ks, among these are apoptosis signal-regulating kinase-1 (ASK-1), TAK1 and 
MEKK1. All of these kinases have been shown to interact with TRAF-2 
103-105
. The 
role of MEKK1 in TNF-mediated JNK activation is unclear. One group reported that 
embryonic stem cells with a functional deletion of MEKK1 showed a total block of 
TNF-induced JNK activation, while another group reported that MEKK1 knockout 
macrophages showed normal JNK activation in response to TNF 
106, 107
. However, 
since germinal center kinase (GCK), a known activator of MEKK1, also interacts with 
TRAF-2, it is likely that, at least in certain cell types or conditions, MEKK1 is 
involved in JNK activation downstream of TNF-R1 
108
. The role of ASK-1 in TNF-R1 
signaling is much better described. Overexpression of a dominant negative form of 
ASK-1 or genetic deletion of ASK-1 results not only in defective JNK activation but 
also in inhibition of apoptosis in response to TNF treatment 
104, 109, 110
.  The current 
model for ASK-1 activation by TNF involves several critical steps, including the 
release of the inhibitory proteins thioredoxin and 14-3-3, TRAF-dependent 
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dimerization/polymerization, and ASK-1 autophosphorylation 
111, 112
. Thioredoxin is a 
protein with a redox-active center composed of two cysteine residues. Only the 
reduced form of thioredoxin is able to interact with and inhibit ASK-1 
113
. Stimulation 
of TNF-R1 can result in a TRAF-2-dependent increase of ROS of mitochondrial 
origin 
114
. This increase of ROS leads to oxidation of thioredoxin, which is then no 
longer able to interact with ASK-1. The released ASK-1 can then associate with 
TRAF-2 to activate JNK 
115
. Besides thioredoxin, also 14-3-3, a family of dimeric 
phosphoserine-binding proteins, has been identified as an inhibitor of ASK-1 
116
. The 
release of 14-3-3 involves the ASK-interacting protein 1 (AIP1), a member of the Ras 
GTPase-activating protein family. In endothelial cells, AIP1 is localized to the plasma 
membrane, where it associates with TNF-R1. In response to TNF, AIP1 becomes 
phosphorylated at the 14-3-3 binding site by RIP, dissociates from the TNF-R1 and 
forms in the cytoplasm a complex composed of TRADD, TRAF-2, RIP and AIP1, 
called AIP1 complex. AIP1 then associates with ASK-1 close to its 14-3-3 binding 
site, leading to dissociation of 14-3-3 from ASK-1 and subsequent activation of JNK 
117, 118
. The JNK pathway plays an important role in TNF-induced apoptosis (see next 
chapter). 
 
 
 
Fig. 1.5. Current model of JNK activation by TNF. P: phosphorylation.  
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 p38 
 
The activation of the p38 MAPK pathway by TNF occurs through a similar 
mechanism as the activation of JNK and also involves TRAF-2, AIP1, ASK-1 and 
MEKK1 
108, 110, 118, 119
. Nevertheless, there is clear evidence that upstream and 
downstream of the MAP3K level differences exist between JNK and p38 activation. 
For example, GCKs are unable to stimulate the p38 MAPK cascade 
120, 121
. Moreover, 
it has been shown that a deletion mutant of RIP, lacking its intermediate domain, 
abolished the TRAF-2-induced p38 activation, but failed to inhibit the activation of 
JNK 
108
. Also the MKKs involved appear to be different. While MKK4/MKK7 double 
knockout mouse embryonic fibroblasts (MEFs) were defective in the TNF-induced 
activation of JNK, the activation of p38 in these MEFs was largely unaffected 
102
. On 
the other hand, MEFs of MKK3-deficient mice showed a strong reduction in TNF-
induced activation of p38, but not of JNK 
122
. 
The p38 pathway is an important mediator of the TNF-induced inflammation. The 
production of the inflammatory cytokines IL-1 and IL-6 upon TNF stimulation was 
almost completely blocked in MKK3 knockout MEFs 
122
. The p38 MAPK pathway 
acts by activation of a variety of transcription factors, among others activating 
transcription factor-2 (ATF-2), Elk-1, CREBs, growth arrest and DNA damage 153 
(GADD153), MEF2A and MEF2C, and Sap-1a 
123-126
. The p38 pathway can also 
increase the stability of ARE-containing mRNAs through activation of its downstream 
target MK2 
127
. TTP, an ARE-destabilizing protein is phosphorylated by MK2, which 
results in decreased affinity of TTP for the ARE-containing mRNA and increased 
mRNA stability 
41
. Many inflammatory cytokines, including IL-1 and IL-6, have an 
ARE-sequence in the 3‟ UTR of their mRNA 128. Another important downstream 
target of the p38 pathway is cytosolic phospholipase A2 (cPLA2) (see chapter 1.4.5) 
129
. The p38 MAPK has also been implicated as a mediator of NF-B transactivation 
88
. 
 
 ERK 
 
TNF can also activate the ERK pathway, but it is still unclear by which mechanism 
this occurs 
130
. More than ten years ago a protein termed MAPK-activating DD 
protein (MADD) was identified as a link between the TNF-R1 and ERK activation, 
but very few publications on this protein have appeared ever since 
131
. Recently, it 
was shown that FADD, caspase-8 and c-FLIP are required for ERK activation in 
response to TNF, suggesting that ERK activation occurs at the level of complex II 
132
.  
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1.4.4. TNF-induced cell death 
 
TNF can induce two main forms of programmed cell death: (1) classical apoptosis and 
apoptosis-like cell death, characterized by chromatin condensation and fragmentation, 
membrane blebbing, and generation of apoptotic bodies, and (2) necrosis-like cell 
death, characterized mainly by a disruption of membrane integrity and a lack of the 
nuclear features of apoptosis (Fig.1.6.) 
133
. 
 
 
 
Fig. 1.6. Characteristics of apoptosis and necrosis. 
 
 Classical apoptosis 
 
Caspases are cysteine proteases that cleave their target proteins at specific aspartic 
acid residues. They play a central role in apoptosis through a so-called caspase 
cascade. There are two types of apoptotic caspases, called initiator caspases, e.g. the 
human caspase-2, -8, -9, -10 and -12, and effector caspases, e.g. the human caspase-3, 
-6, -7 and -14. The mouse genome lacks a counterpart of human caspase-10 
134
. In 
most cells, caspases are constitutively present as inactive procaspases. A procaspase 
consist of an aminoterminal prodomain, followed by a large p20 subunit and a 
carboxyterminal small p10 subunit. Activation of the caspase requires a first cleavage 
between the p10 and p20 subunits and a second cleavage to remove the prodomain. 
Two p10 and two p20 subunits associate then to form the active caspase. Since both 
cleavages required for activation occur at conserved aspartic acid residues, 
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procaspases are a substrate of other caspases or can self-activate. Upon activation, 
initiator caspases can activate effector caspases, which can then cleave other protein 
substrates within the cell at specific aspartic acid residues, resulting in the apoptotic 
process. The best characterized mechanism of TNF-induced apoptosis is mediated by 
the cytoplasmic complex II (Fig.1.7.). Procaspase-8 is recruited to this complex by 
interaction of one of the two DEDs in the prodomain of procaspase-8 with the DED of 
FADD 
52
. This complex is also called DISC, in analogy with the FADD- and caspase-
8-containing complex that is formed upon stimulation of Fas and TRAIL receptors. 
The second DED in the prodomain of caspase-8 allows clustering of procaspase-8, 
followed by self-activation of the caspase. Caspase-8 can then activate the effector 
caspases-3 and -7, which in turn cleave specific substrates. Besides FADD, a second 
DD-containing adaptor protein has been identified that can recruit caspases 
downstream of TNF-R1. This adaptor protein, called RIP-associated ICH-1/CED-3 
homologues protein with DD (RAIDD), can associate via its carboxyterminal DD 
with RIP, and via its aminoterminal caspase activation and recruitment domain 
(CARD) with the CARD in the prodomain of caspase-2, allowing autocatalytic 
activation of caspase-2 
135
.  
A characteristic substrate of effector caspases, in particular caspase-3, is inhibitor of 
caspase-activated DNase (ICAD). Cleavage of ICAD leads to activation of the 
caspase-activated DNase (CAD), which then degrades the chromosomal DNA into 
nucleosomal units (multimers of approx. 180 base pairs), a hallmark of apoptotic cell 
death 
136, 137
. Other important substrates of caspases are poly(ADP-ribose) polymerase 
(PARP), p21-activated kinase 2 (PAK2), Rho kinase-I (ROCK-I), actin, gelsolin, and 
nuclear lamins 
138-145
. PARP is a nuclear enzyme that mediates repair of DNA single 
strand breaks via the activation and recruitment of DNA repair enzymes. Lamins are 
structural components of the nuclear envelope, and cleavage of nuclear lamins during 
apoptosis causes nuclear fragmentation and chromatin condensation. Caspase-
mediated cleavage of PAK2 produces an activated fragment, which may be involved 
in inducing certain morphological changes that are characteristic for apoptosis 
144
. 
Cleavage of ROCK-I by caspase-3 also generates a truncated active form. The activity 
of ROCK proteins is necessary and sufficient for the formation of membrane blebs 
during apoptosis and for re-localization of fragmented DNA into blebs and apoptotic 
bodies 
146
.  
 
In certain cell types, called type I cells, the death receptor induced activation of 
caspase-8 alone is sufficient to robustly activate caspase-3 and the execution phase of 
apoptosis. However, in most cell types, called type II cells, e.g. hepatocytes, caspase-
8-mediated activation of caspase-3 is inefficient and the apoptotic process therefore 
depends on a mitochondria-dependent amplification loop (Fig.1.7.) 
147, 148
. In type II 
cells, active caspase-8 can cleave the Bcl-2 family member Bid 
149, 150
. The site of 
action of Bcl-2 family members is the outer mitochondrial membrane, where they 
play an important role in controlling the release of pro-apoptotic proteins, in particular 
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cytochrome c, from the mitochondria. Bcl-2 family members can be either pro- or 
anti- apoptotic. Anti-apoptotic Bcl-2 family members, such as Bcl-2 and Bcl-xL, can 
neutralize pro-apoptotic family members, such as Bax, Bak, Bad and Bid, by forming 
heterodimers. Therefore, the balance between the pro- and anti-apoptotic members 
will determine the sensitivity of a cell to apoptosis 
151
. Cleavage of Bid by caspase-8 
produces a potent pro-apoptotic carboxyterminal fragment of Bid, called truncated 
Bid (tBid). tBid translocates to the outer mitochondrial membrane, where it triggers 
the homo-oligomerization of Bax and Bak, resulting in the release of cytochrome c 
and second mitochondria-derived activator of caspases (Smac)/direct IAP-binding 
protein with low pI (DIABLO) 
152-155
. tBid has also been shown to interact with 
components of the mitochondrial permeability transition pore, resulting in 
mitochondrial membrane depolarization 
156, 157
.  It has been reported that this 
mitochondrial membrane transition is essential for TNF-induced apoptosis in primary 
rat hepatocytes 
158
. The release of cytochrome c from mitochondria into the cytosol 
allows the formation of a caspase-3-activating complex, called apoptosome. This 
apoptosome is a wheel-like protein structure, consisting of an oligomer of apoptotic 
protease activating factor-1 (Apaf-1), cytochrome c, caspase-9, and ATP or 2‟-deoxy 
ATP (dATP) 
159
. Apaf-1 contains a CARD that interacts with a CARD in the 
prodomain of caspase-9. The apoptosome can then cleave and activate caspase-3 
160, 
161
. Complementary to the actions of the apoptosome, Smac/DIABLO binds and 
antagonizes IAPs 
155, 162
. Activated caspase-3 is able to activate caspase-8, thereby 
creating a positive feedback loop 
163
. 
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Fig. 1.7. Cell death pathways induced by TNF. Note that not all pathways may be induced 
simultaneously. Black arrows: apoptotic pathway including mitochondrial amplification loop. Green 
arrows: lysosomal death pathway. Blue arrows: necrotic death pathway. 
 
 Lysosomal death pathway 
 
Another apoptosis pathway activated by TNF is the lysosomal death pathway, which 
is mainly mediated by cathepsins (Fig.1.7.). Cathepsins are proteases of which the 
activity is usually confined to the lysosomes. Like caspases, they become activated 
after proteolytic cleavage. The hallmark of the lysosomal death pathway is the 
lysosomal membrane permeabilization that results in the release of active cathepsins 
into the cytosol. It has been shown that TNF can induce the release of the lysosomal 
cysteine protease cathepsin B in certain cell types (e.g. hepatocytes, MEFs, and a 
number of cancer cell lines) and that cathepsin B is an important mediator of TNF-
induced apoptosis in these cells 
148, 164, 165
. Moreover, mice deficient for cathepsin B 
are resistant to TNF-induced hepatocyte apoptosis and liver injury 
166
. Active 
cathepsin B can cleave several substrates involved in apoptosis, such as caspases and 
Bid 
167-169
. However, it is currently unclear whether Bid and caspases act really 
downstream of the released cathepsin B. Werneburg and colleagues reported that, in 
cultured hepatocytes, TNF-induced lysosomal membrane permeabilization required 
caspase-8, Bid, and cathepsin B itself 
170, 171
. They suggested that a truncated form of 
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Bid (different from tBid) is able to associate with the lysosomal membrane and 
mediate the release of cathepsin B in analogy with the release of cytochrome c from 
the mitochondria. More recently, Gyrd-Hansen and co-workers reported that TNF-
induced lysosomal membrane permeabilization and apoptosis in MEFs critically 
depended on caspase-9 
172
. Other factors implicated in the TNF-induced lysosomal 
death pathway are the sphingomyelinases (SMases). TNF can activate both nSMase 
and aSMase (see next chapter). SMases are enzymes that catalyze the hydrolysis of 
sphingomyelin, an important component of cell membranes, to phosphocholine and 
ceramide. It was shown that lysosomal membrane permeabilization observed in 
cultured hepatocytes after stimulation with TNF is dependent on factor associated 
with nSMase activation (FAN), an adaptor protein that interacts with the TNF-R1 and 
is required for nSMase activation 
171, 173
. Interestingly, it was recently shown that an 
internalization-defective TNF-R1 which is unable to assemble a DISC still allowed 
for residual activation of caspase-3 and cell death. This activation was independent of 
caspase-9, but was critically dependent on interaction of the TNF-R1 with FAN 
174
. 
 
Also the aspartyl protease cathepsin D has been implicated as a mediator of TNF-
induced cell death 
175
. The activation of aSMase upon TNF-R1 stimulation results in 
the production of ceramide in the endolysosomal compartment. Heinrich and 
colleagues showed that ceramide can interact with cathepsin D, followed by 
proteolytic activation of the cathepsin 
176
. They further reported that TNF and 
ceramide induce the translocation of active cathepsin D from the endosomal 
compartment to the cytosol in HeLa cells, and that cathepsin D can cleave Bid, 
leading to activation of the mitochondrial apoptosis pathway. Moreover, they showed 
that the TNF-induced cleavage of Bid was absent in cathepsin D- or aSMase-deficient 
cells. Interestingly, translocation of cathepsin B was not observed after TNF or 
ceramide treatment of HeLa cells 
177
. 
 
 Necrotic cell death 
 
TNF can also induce a necrosis-lie cell death that depends on the production of ROS 
(Fig.1.7.). Evidence for a caspase-independent TNF-induced cell death comes from 
experiments with cells or mice treated with the pan-caspase inhibitor zVAD-fmk 
(which also inhibits cathepsin B 
178
): L929 mouse fibrosarcoma cells or human 
neutrophils treated with TNF plus zVAD-fmk display augmented, instead of inhibited, 
TNF-induced cell death; and treatment of mice with TNF plus zVAD-fmk 
exacerbated the TNF-induced toxicity by enhancing oxidative stress and 
mitochondrial damage 
133, 179, 180
. In L929 cells, the augmented cell death after TNF 
and zVAD-fmk treatment could be reversed with a mitochondrial permeability 
transition inhibitor or a PARP inhibitor 
180
. Furthermore, depletion of reduced 
glutathione can sensitize cultured mouse hepatocytes to TNF-induced cell death, 
suggesting that ROS play an important role in TNF-induced liver injury 
181
. ROS, 
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including superoxide anion, hydrogen peroxide and hydroxyl radicals, are normally 
rapidly eliminated by antioxidant enzymes, such as superoxide dismutases (SODs), 
catalase, glutathione peroxidases and peroxiredoxins 
182
. However, in certain 
circumstances, such as in cells treated with TNF and zVAD-fmk, excessive ROS 
production by the mitochondria may occur 
183
. This leads to DNA damage, followed 
by the activation of the DNA repair enzyme PARP-1. Excessive action of PARP-1 
consumes high amounts of energy, leading to ATP depletion, thereby creating 
conditions that favor necrosis instead of apoptosis 
184, 185
. It is currently unclear how 
TNF triggers the mitochondria-dependent production of ROS, but the Bcl-2 family 
may play an important role herein 
186, 187
. It was reported that Bid is required for the 
majority of TNF-induced mitochondrial ROS production in cultured mouse 
hepatocytes 
188
. 
TNF can also induce ROS production by NADPH oxidases. NADPH oxidases are 
membrane-bound enzyme complexes specialized in generating superoxide from 
NADPH and O2. Recently, the NAPDH oxidase components Nox1 and the small 
GTPase Rac1 were shown to play an important role in TNF-induced necrotic cell 
death of mouse fibroblasts 
189, 190
. Interestingly, in endothelial cells an NADPH 
oxidase consisting of Nox1, Nox2, Nox4, Nox5, p22
phox
, p47
phox
 and Rac1, localizes 
(together with eNOS and nSMase; see further) to caveolae, a type of membrane rafts. 
Perturbation of these caveolae by cholesterol-sequestering was shown to inhibit TNF-
induced ROS production 
191
. 
 
 Regulation of TNF-induced cell death 
 
In contrast to other death receptors, like Fas or TRAIL receptors, TNF-R1 only 
signals to cell death in certain circumstances. Most often, TNF-R1 signaling results in 
the transcription of inflammatory genes, suggesting that the TNF-R1 also provides a 
mechanism to counteract the various TNF-induced cell death pathways. Consistent 
with this, mice deficient in RelA or other components involved in NF-B activation 
are embryonically lethal or die early after birth due to massive TNF-dependent liver 
failure 
192-195
. Thus, the NF-B pathway plays an essential role in blocking the cell 
death machinery induced by TNF. NF-B activation induces the expression of many 
anti-apoptotic factors, including IAP family members, Bcl-xL, c-FLIP and A1 
54-60
. c-
FLIP is recruited to complex II, where it inhibits caspase-8 activation. So, when 
complex I or other exogenous factors trigger sufficient NF-B activation, gene 
expression of c-FLIP is sufficiently induced to block the activation of caspase-8 by 
complex II 
48
. On the other hand, once the apoptotic program is triggered, caspases 
interfere with the activation of NF-B by cleavage of several components utilized by 
this pathway, including RIP, IKK2, NF-B1, RelA and Akt 196-200. RIP is already 
cleaved by caspase-8 during the initiation phase of apoptosis, thereby blocking the 
anti-apoptotic NF-B response 201. 
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It was reported that TNF induced the accumulation of ROS in RelA-deficient MEFs, 
but not in wild-type cells. This suggests that another survival mechanism induced by 
NF-B is inhibition ROS accumulation 202. Notably, manganous SOD (MnSOD), 
which acts as a scavenger of superoxide radicals, is an NF-B-dependent target gene 
of TNF 
203, 204
. 
 
JNK is an important modulator of TNF-induced apoptosis. JNK activation can have 
both pro- and anti-apoptotic effects. TRAF-2-deficient MEFs, which have largely 
intact NF-B signaling but reduced JNK activation, and JNK1 or JNK2 knockout 
MEFs display increased sensitivity to TNF-induced apoptosis 
100, 205
. On the other 
hand, ASK1 knockout MEFs, which have normal rapid TNF-induced JNK activation, 
but reduced prolonged activation, are significantly protected against apoptosis 
109
. 
This suggests that transient JNK signaling mediates anti-apoptotic effects, while 
sustained JNK signaling is associated with apoptosis. Consistent with this, it was 
found that the transient activation of JNK is inhibited in MKK7-deficient MEFs, 
while the prolonged activation of JNK, which correlates with apoptosis induction, is 
blocked by caspase inhibitors 
102, 206
. The length of JNK activation is also controlled 
by NF-B; JNK activation by TNF is transient in wild-type fibroblasts, but prolonged 
in cells deficient for either IKK2 or RelA 
207
. The NF-B target genes A20, 
GADD45 and X-chromosome-linked IAP (XIAP) have been shown to attenuate 
TNF-induced JNK activation upon ectopic expression 
207-209
. GADD45 can directly 
bind with MKK7, thereby blocking its catalytic activity 
210, 211
. The role of A20 is less 
clear. A20-deficient MEFs displayed unaltered TNF-induced JNK activation, 
suggesting that this protein is not involved in the attenuation of JNK activation, or a 
yet to be identified compensation mechanism exists 
212
. TNF-induced ROS production 
may induce the sustained activation of JNK through oxidation of the ASK-1 inhibitor 
thioredoxin. Since NF-B can inhibit the TNF-induced accumulation of ROS, 
presumably by upregulation of MnSOD, this forms another mechanism by which NF-
B could inhibit prolonged JNK activation 202, 213. 
The anti-apoptotic effect of JNK signaling is mainly mediated by activation and 
increased expression of the transcription factor JunD, a component of the dimeric 
transcription factor AP-1. JunD can collaborate with NF-B to increase the expression 
of anti-apoptotic genes such as cIAP2. Interestingly, it was observed that the TNF-
induced activation of Akt was reduced in JNK1/2 double knockout MEFs 
214
. 
JNK can also induce the expression of pro-apoptotic genes by activation of the 
transcription factor c-Jun, another component of AP-1. c-Jun/AP-1 mediates the 
transcription of Bim, a pro-apoptotic member of the Bcl-2 family 
215
. JNK has been 
shown to phosphorylate Bcl-2 family members. This phosphorylation inhibits the 
anti-apoptotic family member Bcl-2, but activates the pro-apoptotic family members 
Bim and Bmf 
216-218
. Moreover, it has been reported that the TNF-induced activation 
of MKK7/JNK can lead to the caspase-8-independent cleavage of Bid. The cleavage 
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product, termed jBid, can translocate to the mitochondria and trigger the release of 
Smac/DIABLO, but not of cytochrome c. It is proposed that the released 
Smac/DIABO then interferes with the cIAP1/TRAF-2 complex to allow activation of 
caspase-8 
219
. However, evidence for an inhibitory association of cIAPs and caspase-8 
is still lacking 
220
. More recently, it was shown that in hepatocytes TNF induces JNK-
mediated phosphorylation and activation of the E3 ubiquitin ligase Itch, which then 
specifically ubiquitinates the caspase-8 inhibitor c-FLIP, thereby inducing its 
degradation 
221, 222
. 
 
1.4.5. Other TNF-induced pathways 
 
 Phospholipase A2 
 
Phospholipase A2 (PLA2) was one of the first identified downstream targets of TNF 
223
. cPLA2 is an important regulator of the inflammatory process. It is a Ca
2+
 
dependent lipase that specifically recognizes the sn-2 acyl bond of phospholipids and 
hydrolyzes this bond, thereby releasing arachidonic acid and lysophospholipids. 
cPLA2 does not require Ca
2+
 for its catalytic activity, but elevated intracellular Ca
2+
 
concentrations are required to induce its translocation to cellular membranes 
(including plasma membrane, nuclear envelope, and endoplasmatic reticulum), where 
its substrate is 
224
. The activity of cPLA2 is also regulated by phosphorylation of the 
serine residues Ser505 and Ser727. The TNF-R1-induced activation of cPLA2 
critically depends on the p38 MAPK pathway, which mediates phosphorylation of 
cPLA2 on both Ser505 and Ser727 
129, 225
. The ERK pathway may also contribute to 
cPLA2 activation 
226
. As translocation of cPLA2 to cellular membranes is stimulated 
by an increase of intracellular Ca
2+
 concentration and TNF-R1 stimulation does not 
induce such an increase, it is to be expected that TNF alone will only induce a 
moderate activation of cPLA2 
226, 227
. However, very early during the inflammatory 
process, G-protein-coupled receptors (GPCRs), such as the histamine H1 receptor, 
become activated on endothelial cells, leading to activation of phospholipase C 
(PLC) followed by an increase of cytosolic free Ca2+ levels by releasing the Ca2+ 
from endoplasmatic reticulum stores and entry of extracellular Ca
2+
. This rise in 
cytosolic Ca
2+
 concentration supports then the TNF-induced activation of cPLA2 later 
on during the inflammatory process 
228
. In addition, it has been reported that TNF can 
induce gene expression of cPLA2 
229
. 
Free arachidonic acid produced by cPLA2 is rapidly processed by cyclooxygenases 
(COXs) and lipoxygenases (LOXs) to eicosanoids (Fig.1.8.). Eicosanoids are 
paracrine and autocrine signaling molecules that play an important role in 
inflammation, hemostasis and the regulation of vascular tone. COXs convert 
arachidonic acid to prostaglandin (PG) D2, E2 and F2, prostacyclin (PGI2) and 
thromoboxane (TX), while 5-LOX converts arachidonic acid to leukotriens (LT) 
230
. 
PGs are produced by all cells at a basal level, but their production is strongly induced 
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during inflammation by upregulation of COX-2 expression by TNF 
231, 232
. PGD2 and 
PGE2 both act as vasodilators. TXs are produced by activated platelets. TXs stimulate 
platelet aggregation and induce vasoconstriction. The effects of TXs are balanced by 
PGI2 produced in endothelial cells, which inhibits platelet aggregation and induces 
vasodilation. LTs are produced in leukocytes, such as granulocytes, mast cells and 
monocytes, and are important mediators of inflammation. LTB4, for example, has a 
chemotactic and anti-apoptotic effect on neutrophils 
230, 233
. An increased production 
of eicosanoids, especially of PGE2 and LTB4, has been observed in many types of 
cancer. Moreover, inhibitors of COX, LOX, and eicosanoid signaling have been 
reported to induce apoptosis of certain cancer cell lines, suggesting that eicosanoids 
can confer survival signals to these cells 
234-239
. Importantly, it has also been shown 
that inhibitors of arachidonic acid metabolism can sensitize cancer cells to TNF-
induced apoptosis 
240, 241
. 
 
 
 
Fig. 1.8. Biosynthesis and important properties of eicosanoids. Major sites of eicosanoid synthesis 
are indicated in italic. The immune cells wherein leukotriens are synthesized include mast cells, 
neutrophils, eosinophils, basophils, monocytes and alveolar macrophages.  
 
cPLA2 may also play an important role in the TNF-induced ROS production. Cauwels 
and colleagues demonstrated that the zVAD-fmk-induced sensitization of mice to 
TNF-induced lethality, which is associated with excessive ROS production and 
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mitochondrial damage, could be completely reverted by either antioxidant treatment 
or inhibition of PLA2 
179
. How PLA2 activity leads to ROS production is not fully 
understood at this moment, but several reports have implied that the oxidative 
metabolism of AA into eicosanoids would generate ROS 
242-244
. Furthermore, it was 
shown that PLA2 may also trigger mitochondrial ROS production 
243, 245
. 
 
 NO synthases 
 
When TNF is administered to animals in a sufficiently high dose, it induces a lethal 
shock syndrome. This shock syndrome is characterized by a severe hypotension that is 
induced by the vasodilator nitric oxide (NO) 
246, 247
. NO is produced by NO synthases 
(NOSs) from the terminal nitrogen atom of L-arginine in the presence of NADPH and 
O2. Three isoforms of NOS have been identified: neuronal NOS (nNOS) (or NOS-1), 
inducible NOS (iNOS) (or NOS-2), and endothelial NOS (eNOS) (or NOS-3). eNOS 
is constitutively expressed in endothelial cells (and other cells) and is activated by an 
increase in intracellular Ca
2+
 concentration and by phosphorylation. iNOS on the 
other hand does not require an activation step, but its activity is controlled at the 
transcriptional level. iNOS is predominantly induced in immune cells and cells of the 
cardiovascular system 
248-250
. NO is a short-lived signaling molecule that is freely 
diffusible across membranes. As it is a free radical, it rapidly reacts with proteins and 
other molecules. One of the main targets of NO is soluble guanylate cyclase (sGC). 
Nitrosylation of the haem-iron in sGC results in a strong activation of the enzyme. 
Activated sGC produces the second messenger cGMP, which mediates many of the 
cardiovascular effects induced by NO, including vasorelaxation, increase of vascular 
permeability, as well as inhibition of platelet aggregation and anti-oxidant effects 
249
. 
NO can also react with superoxide to produce peroxynitrite, a powerful oxidant which 
mediates the cytotoxic effects of NO, such as DNA damage, tyrosine nitration, LDL 
oxidation, and inhibition of mitochondrial respiration. The latter reaction is one of the 
effector mechanisms used by macrophages and neutrophils to kill pathogens 
251
. 
TNF induces the production of NO by activating eNOS and by inducing the 
expression of iNOS. The induction of iNOS gene expression by TNF, or other 
inflammatory stimuli, is critically dependent on NF-B 252-254. However, the JNK, 
ERK, and p38 MAPK pathways may also be involved, depending on the cell type and 
stimuli investigated 
255-257
. The activation of eNOS by TNF requires sequential action 
of nSMase, sphingosine kinase-1 (SK-1), PI3K and Akt 
258, 259
. Akt activates eNOS by 
phosphorylation of a specific serine residue 
260, 261
. Since it has been shown that TNF-
R1, nSMase as well as eNOS are present in caveolae, and that disruption of caveolae 
can interfere with the TNF-induced activation of PI3K, it is most likely that the 
activation of eNOS by TNF also occurs in these membrane raftse 
51, 262, 263
. TNF also 
negatively regulates eNOS by decreasing its promoter activity and by destabilizing its 
mRNA 
264-266
.  
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The NO production induced by TNF may have, as many aspects in TNF biology, both 
beneficial and detrimental effects. Cauwels and colleagues demonstrated that 
inhibition of sGC completely protected mice against the TNF-induced shock and 
lethality. However, when mice were treated with a non-selective NOS inhibitor, no 
protection against TNF-induced toxicity and death could be observed. This suggests 
that NO also mediates an sGC-independent protective effect in this lethal shock model 
267
. More recently, Cauwels and colleagues reported that this beneficial effect of NO 
consists of tempering the TNF-induced oxidative stress, in particular the lipid 
peroxidation in liver and kidney, which was shown to be largely dependent on PLA2 
268
. One of the mechanisms by which NO can protect against oxidative stress is by 
neutralizing superoxide. An excess of superoxide or equimolar concentrations of NO 
and superoxide promote the formation of toxic peroxynitrite and lipid peroxidation, 
whereas an excess of NO neutralizes superoxide and inhibits lipid peroxidation 
269
. 
NO can also protect against apoptosis, e.g. in endothelial cells and hepatocytes 
270
. It 
has been shown that NO can inhibit caspases, including caspase-3, -8, and -9, by S-
nitrosylation of specific cysteine residues 
271-274
. Furthermore, low, physiological 
concentrations of NO have been shown to inhibit mitochondrial permeability 
transition and cytochrome c release, whereas higher concentrations had adverse 
effects 
275
. The pro-apoptotic effects of NO mainly comprise the induction of DNA 
and mitochondrial damage 
270
. In addition, NO may inhibit NF-B by S-nitrosylation 
of the NF-B1 subunit 276. 
 
 SMases 
 
As discussed above, engagement of TNF with TNF-R1 has been reported to activate 
both nSMase and aSMase, resulting in sphingomyelin degradation and formation of 
ceramide. aSMase has a low pH optimum and is mainly present in the endosomal-
lysosomes compartment. However, it has been shown that stimulation of cells can 
result in the translocation of aSMase to the outer leaflet of the cell membrane 
277, 278
. 
The TNF-triggered activation of aSMase is dependent on both TRADD and FADD, 
placing the activation of aSMase somewhere at the level of complex II 
23, 279
. In 
addition, it was shown that activation of aSMase is dependent on TRID, and it was 
suggested that aSMase activation occurs after fusion of TNF receptosomes with 
aSMase-containing trans-Golgi vesicles 
53
. The TNF-induced activation of aSMase 
results in the production of ceramide in the endolysosomal compartment, which can 
lead to activation of cathepsin D and subsequent activation of the mitochondrial 
apoptosis pathway 
176, 177
. The importance of this pathway in vivo is demonstrated by 
the fact that aSMase knockout mice are resistant to TNF-induced hepatocyte apoptosis 
and liver injury 
280
. nSMase has a neutral pH optimum and is mainly associated with 
the plasma membrane. The activation of nSMase by TNF requires the adapter protein 
FAN, which directly binds to a short motif in the intracellular part of the TNF-R1 
termed NSD 
173
. A few years ago, the scaffolding protein receptor for activated C-
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kinase 1 (RACK1) was identified as an interaction partner of FAN, but it is still 
unclear how this protein is involved in the regulation of nSMase 
281, 282
. Expression of 
a dominant negative form of FAN in human fibroblasts abrogated the TNF-induced 
ceramide generation and reduced caspase processing and apoptosis, suggesting that 
nSMase rather than aSMase is responsible for ceramide production and regulation of 
cell death in these cells 
283
. Moreover, expression of a dominant negative FAN in 
hepatocytes blocked the TNF-induced activation of caspase-8, lysosomal 
permeabilization, and subsequent release of cathepsin B 
171
. Another mechanisms by 
which ceramide may contribute to apoptosis is by inducing clustering of receptors. It 
has been shown that activation of Fas induced the translocation of aSMase to the cell 
membrane, followed by ceramide production in lipid rafts and clustering of Fas within 
these rafts. These events were shown to be essential for Fas-induced apoptosis of 
lymphocytes and hepatocytes 
277, 278, 284-286
.  
Increased amounts of ceramide or its derivate ganglioside GD3 are also found in the 
mitochondria of TNF-treated cells, where it may induce mitochondrial permeability 
transition, cytochrome c release and ROS production 
287-289
. 
 
 The PI3K/Akt pathway 
 
Several reports have shown that TNF is capable of activating the PI3K/Akt pathway 
and that this pathway may play an important role in the activation of NF-B 80, 290-292. 
In agreement with this it was shown that re-expression of phosphatase and tensin 
homolog (PTEN), a phosphatase that counteracts PI3K by dephosphorylating the 3‟-
position of the inositol ring of inositol phospholipids, inhibits the transcription of NF-
B-driven genes in certain cancer cells 293, 294. It is still unclear how TNF can trigger 
the activation of PI3K, but it most likely involves the sequential activation of nSMase 
and SK-1 
259, 295
. The PI3K/Akt pathway is essentially a survival pathway and will be 
discussed elsewhere in this thesis (see chapter 3). 
 
 
1.5. TNF-R2 signaling 
 
As mentioned above, TNF-R2 only fully responds to the membrane-bound form of 
TNF, and thus requires direct cell-to-cell contact to become activated. Upon 
activation, TRAF-2 is recruited to the intracellular TIM of TNF-R2. TRAF-2 then 
recruits TRAF-1 and cIAP1 and -2 to the receptor complex and mediates further 
signaling that may lead to the activation of NF-B and JNK 26, 27, 296. However, it is 
still unclear which signaling events occur downstream of TNF-R2. 
 
Although TNF-R2 has no DD and cannot directly induce the activation of caspases or 
other cell death effectors, it may regulate the apoptotic process through crosstalk with 
TNF-R1. cIAP1, that is recruited to the TNF-R2 signaling complex, has ubiquitin 
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protein ligase (E3) activity 
297
. It was shown that TNF-induced activation of TNF-R2 
leads to cIAP1-dependent ubiquitination and proteasomal degradation of TRAF-2 and 
ASK-1 
298
. Degradation of ASK-1 may be an important mechanism to prevent 
prolonged TNF-induced MAPK signaling 
299
. Depletion of TRAF-2 on the other hand 
may significantly sensitize for TNF-R1-mediated apoptosis 
300
. Furthermore, TNF-R2 
has been shown to induce cell death through expression of membrane-bound TNF and 
subsequent activation of TNF-R1 
301
. This mechanism may play an important role in 
the apoptosis of activated T cells 
302, 303
. 
 
 
1.6. TNF in inflammation and immunity 
 
Inflammation is the body‟s response to infection or other forms of tissue injury. It 
serves to keep the infection localized, to trigger and amplify the innate, and later 
adaptive, immune responses, and to promote the repair of the injured tissue. The five 
basic symptoms of acute inflammation are swelling, pain, heat, redness of the skin, 
and, possibly, loss of function of the organ or tissue involved. These symptoms are 
mostly due to vasodilation and increased permeability of the local blood vessels and 
infiltration of plasma proteins and leukocytes to the site of infection. Inflammation at 
a site of infection is in most cases initiated when tissue macrophages respond to 
pathogens. Small molecular motifs, termed pathogens-associated molecular patterns 
(PAMPs), found consistently on the surface of pathogens are recognized by pattern 
recognition receptors (PRRs) on tissue macrophages and other cells. For example, 
LPS, a major component of the outer membrane of Gram-negative bacteria, is 
specifically recognized by the PRR Toll-like receptor 4 (TLR4) 
304
. Tissue 
macrophages that are activated in this way very rapidly produce PGs, LTs, and 
platelet-activating factor (PAF), which together are called lipid mediators of 
inflammation because they are produced through enzymatic pathways that degrade 
membrane phospholipids. Subsequently, activated macrophages synthesize and 
secrete chemokines and cytokines, in particular TNF 
305-307
. Another way in which 
recognition of pathogens triggers an inflammatory response is through activation of 
the complement system. Several complement components can bind directly to PAMPs 
on the surface of pathogens, thereby inducing a complement cascade that eventually 
results in the production of the cleavage product C5a, which is a powerful small 
peptide mediator of inflammation. The actions of C5a include increasing the vascular 
permeability, inducing the expression of adhesion molecules on endothelial cells and 
neutrophils, attracting circulating granulocytes and monocytes, and activating 
neutrophils and local mast cells 
308, 309
. Activated mast cells will in turn release 
granules containing the inflammatory molecule histamine and TNF 
310, 311
. 
 
Endothelial cells play a central role in the inflammatory process. Histamine and the 
lipid mediators that are released very early in the inflammatory process signal via 
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GPCRs that are present on endothelial cells. These mediators are responsible for the 
so-called type I activation of endothelial cells. Triggering of the involved GPCRs 
results in activation of phospholipase C (PLC), which catalyzes the release of 
inositol-1,4,5-triphosphate (InsP3) from the membrane lipid PI-4,5-biphosphate. InsP3 
induces the release of Ca
2+
 from endoplasmatic reticulum stores. The cytosolic free 
Ca
2+
 concentrations may be further increased by entry of extracellular Ca
2+
. The 
elevated cytosolic Ca
2+
 levels allow then the activation of cPLA2 and, through 
binding with calmodulin, of eNOS. The arachidonic acid produced by cPLA2 is 
rapidly converted to PGI2, which synergizes with NO to induce vasodilation. 
Triggering of the GPCRs also induces activation of myosin light chain (MLC) kinase 
(MLCK), which phosphorylates MLC. Phosphorylated MLC initiates contraction of 
actin filaments that are attached to tight junctions and adherens junctions, resulting in 
the formation of gaps between adjacent endothelial cells, which enhances leakage of 
plasma proteins and facilitates the transmigration of neutrophils. Type I activated 
endothelial cells also display P-selectin and a membrane-bound form of PAF on the 
luminal plasma membrane, which together initiate neutrophils extravasation 
(Fig.1.9.). The endothelial cell membranes at the cell-cell junctions are enriched in 
platelet-endothelial cell adhesion molecule (PECAM) and CD99 (or CD-Like 2 in 
mice 
312
), two proteins that are essential for the transmigration of neutrophils and 
monocytes through homophilic interactions (see Pober et al., 2007 and references 
therein 
228
). 
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Fig. 1.9. Leukocyte extravasation and cell adhesion molecules involved in the adhesion of 
leukocytes to endothelial cells. Adapted from Ulbrich et al., 2003 
313
.  
 
Signals by GPCRs last for only 10-20 minutes, after which the receptors become 
desensitized. A more persistent form of endothelial cell activation, called type II 
activation, is induced by cytokines. TNF is the prototypic mediator of type II 
activation (Fig.1.10). Since the pro-inflammatory effects of TNF involve new gene 
transcription mediated by NF-B and AP-1, type II activation of endothelial cells 
requires a longer time to be initiated 
228
. Type I agonist, such as histamine, have also 
been shown to induce TACE-dependent shedding of TNF-R1 from the surface of 
endothelial cells, thereby desensitizing these cells to TNF. TNF-R1 molecules stored 
in the Golgi apparatus are then brought to the cell surface to restore the sensitivity 
314
. 
This may be another reason for the temporal lag between type I and type II activation. 
Similar to type I activation, type II activation leads to increased blood flow, vascular 
leakage and leukocyte recruitment. TNF increases the blood flow by activating 
cPLA2 and eNOS through phosphorylation, and upregulation of COX-2 expression, 
resulting in a strong production of the vasodilators PGI2 an NO 
223, 231, 259
. TNF has 
also been shown to induce the formation of gaps between adjacent endothelial cells, 
thereby increasing the endothelial permeability and leakage of plasma proteins to the 
site of inflammation. How TNF increases endothelial permeability is not yet 
completely understood but Petrache and colleagues reported that TNF induces 
opening of vascular endothelial (VE)-cadherin junctions by a mechanism that is 
independent of MLC phosphorylation but involves a p38-dependent rearrangement of 
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the actin and tubulin cytoskeleton 
315
. More recently, Angelini and colleagues have 
shown that TNF induces tyrosine phosphorylation of VE-cadherin through activation 
of the protein tyrosine kinase (PTK) Fyn, a member of the Src family. Tyrosine 
phosphorylation of VE-cadherin decreases the cadherin ectodomain homophilic 
adhesion, thereby facilitating the formation of intercellular gaps 
316
. TNF furthermore 
induces the expression of chemokines and adhesion molecules which results in a more 
sustained recruitment of leukocytes in comparison to type I activation. TNF-activated 
endothelial cells have been shown to express E-selectin, vascular cell adhesion 
molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 
317
. In mice, but 
not in humans, TNF also increases the expression of P-selectin (Fig.1.9.) 
318
. E-
selectin has a similar function as P-selectin and mainly mediates the recruitment of 
neutrophils 
319, 320
. ICAM-1 is the ligand for the integrins LFA-1 and Mac-1, VCAM-
1 is the ligand for the integrin VLA-4. The expression of VCAM-1 and ICAM-1, 
together with the TNF-induced expression of chemokines like CC-chemokine ligand 2 
(CCL2), formerly called monocyte chemoattractant protein-1 (MCP-1), favors the 
recruitment of monocytes, resulting in a switch of neutrophil-rich infiltrates to 
mononuclear cell-rich infiltrates 
228, 321
.  
 
 
 
Fig. 1.10. TNF in type II activation of endothelial cells. See text for details. Adapted from Pober et 
al., 2007 
228
.  
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Another protective mechanism triggered by TNF is the coagulation cascade. TNF 
inhibits the synthesis of the anti-coagulant protein thrombomodulin, while it induces 
the expression of tissue factor, the principal initiator of coagulation 
322-325
. 
Intravascular thrombus formation leads to occlusion of local blood vessels and serves 
to prevent the spread of pathogens through the bloodstream. Thrombosis may, 
however, also induce vascular damage and haemorrhage 
228
. Furthermore, TNF, alone 
or in combination with other mediators that are released during inflammation, such as 
interferon- (IFN-), may induce endothelial cell death 326-329. These vascular-
damaging properties of TNF will be further discussed elsewhere in this thesis (see 
chapter 5). 
 
TNF is also an important regulator of the innate and adaptive immune responses that 
accompany the inflammatory process (Table 1.1.). In short, TNF attracts neutrophils 
and macrophages to the site of inflammation and stimulates their effector functions. 
At the same time, TNF stimulates the migration of dendritic cells and other antigen-
presenting cells to the draining lymph nodes, thereby supporting the initiation of an 
adaptive immune response. Furthermore, TNF has been shown to play an important 
role in the regulation of proliferation, apoptosis and some effector functions of 
lymphocytes. The important role of TNF in immunity is delineated by the fact that 
TNF knockout mice or TNF-R1 knockout mice are highly susceptible to infection by 
many pathogens, including Candida albicans, Mycobacterium tuberculosis, Listeria 
monocytogenes, Salmonella typhimurium, Trypanosoma cruzi, and Leishmania major 
330-335
. Surprisingly however, TNF knockout mice appear to have relatively normal 
macrophage phagocytic activity, T cell proliferation, cytokine release and 
cytotoxicity, and B cell response to thymus-independent antigens. Moreover, TNF 
knockout mice developed a delayed, but vigorous inflammatory response to heat-
killed Corynebacterium parvum, leading to death, suggesting that TNF may also have 
an important anti-inflammatory function. 
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Table 1.1. Effects of TNF on leukocytes. 
Leukocytes Effects References 
Neutrophils Activation, stimulation of phagocytosis, oxidative burst, release 
of elastase and production of LTB4 
Increased expression of Mac-1, increased adhesion to 
endothelial cells and extracellular matrix proteins 
Apoptosis 
[133, 336-341] 
Mast cells Activation, release of histamine and TNF [342, 343] 
Monocytes/ 
macrophages 
Activation, oxidative burst, phagocytosis, production of TNF 
Chemotaxis 
Increased IFN--induced NO production and tumoricidal activity 
Inhibition of proliferation and differentiation 
Apoptosis 
[8, 311, 344-350] 
T lymphocytes Stimulation of colony formation, proliferation 
Stimulation of cytotoxic T cell invasiveness 
Apoptosis of mature T cells 
[302, 351-353] 
B lymphocytes Superoxide production in EBV-transformed B cell line [354] 
NK cells Increased IFN- production and cytotoxic activity [355, 356] 
Dendritic cells Development, differentiation 
Migration to lymph nodes 
[357-359] 
 
If the acute inflammatory reactions fail to resolve the infection, or when a cellular 
immune response is triggered (e.g. in the case of viral infections, certain 
malignancies, or autoimmune responses), the inflammatory process will evolve to a 
more chronic form. Chronic inflammation may last anywhere from a week to an 
indefinite time frame. It is characterized by infiltration of T lymphocytes, 
monocytes/macrophages and plasma cells, the so-called mononuclear infiltrate. A 
typical pathogen that will induce chronic inflammation is Mycobacterium 
tuberculosis. Tuberculosis is associated with the formation of lesions in the lungs, 
called granulomas, consisting of a central area of infected macrophages, surrounded 
by a mantle of activated lymphocytes. The formation of granulomas serves to prevent 
the spread of the pathogen, but it often fails to completely eradicate the pathogen. 
Surviving mycobacteria may become dormant, causing no disease. However, when 
the immune system is weakened, for example in HIV-infected patients, reactivation of 
these dormant mycobacteria may occur, causing disease and even death 
360
. It was 
shown that TNF is expressed in granulomas and is important for the organization of 
granulomas and the control of infection. Neutralization of TNF in mice with latent 
Mycobacterium tuberculosis infection resulted in outbreak of the disease and 100% 
mortality 
361
. Reactivation of latent tuberculosis infections was also observed in 
human patients that were treated with TNF-blocking agents 
362
. Thus, screening for 
latent tuberculosis is now indicated before the start of anti-TNF therapy. TNF-
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blocking agents that are currently used in the clinic include infliximab, etanercept, 
lenercept, adalimumab and certolizumab. They are used to treat patients with chronic 
inflammatory disorders, such as rheumatoid arthritis, inflammatory bowel disease, 
and psoriasis 
363-366
. The good clinical responses obtained with these agents 
demonstrates the important role of TNF in the maintenance of chronic inflammation 
367
. 
 
If an infection spreads to the bloodstream, the same mechanisms by which TNF so 
effectively contains local infection may become catastrophic. The presence of 
infection in the bloodstream may induce the systemic release of pro-inflammatory 
cytokines, particularly TNF, which may cause a pathological condition called sepsis 
or, generally, systemic inflammatory response syndrome (SIRS). It is one of the major 
causes of death in intensive care units. The systemic release of TNF induces 
vasodilation and loss of plasma volume due to increased vascular permeability, which 
may result in a life-threatening hypovolemic shock, or septic shock. TNF may 
furthermore trigger disseminated intravascular coagulation, leading to occlusion of 
small vessels and massive consumption of clotting proteins. This condition may lead 
to failure of vital organs such as the kidneys, liver, heart and lungs, and eventually 
death 
311
.  
TNF was identified as one of the main mediators of septic shock. The injection of 
high doses of TNF or LPS causes a septic shock-like syndrome in mice, while TNF-
R1-deficient mice were shown to be resistant to lethal doses of LPS 
332, 368
. Infusion of 
anti-TNF antibodies in baboons or mice could protect against septic shock induced by 
LPS or Escherichia coli 
369-371
. However, in these animal studies the TNF-neutralizing 
antibodies were only effective when administered before or just after the challenge. 
Clinical trials with anti-TNF therapy in sepsis patients did not show improved 
survival, and in one case even an increase of mortality was reported 
372-375
. This 
suggests that, although TNF is clearly involved in the development of septic shock, it 
has no essential role during the later stages of the disease. Therefore, the focus of anti-
cytokine therapy in sepsis has now shifted to cytokines downstream of TNF 
376
.  
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1.7. TNF in cancer therapy 
 
Carswell and colleagues demonstrated already in 1975 that serum containing TNF 
could induce haemorrhagic necrosis of methA sarcomas and other transplanted tumors 
in mice 
3
. In vitro these methA tumor cells were rather insensitive to TNF, which 
suggested that the in vivo antitumor effect of TNF was not due to direct cytotoxic 
effects on tumor cells. The same was observed by Brouckaert and colleagues in 1986, 
who used the first completely syngeneic tumor model, namely C57BL/6 mice injected 
subcutaneously with B16Bl6 melanoma cells. These B16Bl6 cells were resistant to 
the cytotoxic effects of TNF in vitro, unless TNF was given together with IFN-. In 
vivo on the other hand, TNF induced complete eradication of B16Bl6 tumors. In the 
same report they demonstrated the species-specificity of TNF. While a complete 
regression of the tumor could be induced with murine TNF (mTNF), human TNF 
(hTNF) could only do so in combination with IFN-. Moreover, it was observed that 
mTNF caused considerably higher systemic toxicity in mice than hTNF 
377, 378
. It was 
found that hTNF can only trigger the murine TNF-R1, not the TNF-R2 
379
. However, 
Ameloot and colleagues demonstrated that not the difference in receptor binding, but 
different pharmacokinetics are responsible for the different toxicity of hTNF and 
mTNF. They showed that hTNF is cleared much faster than mTNF, and that repetitive 
administration of low doses of hTNF induced toxicity similar to mTNF, suggesting 
that prolonged exposure rather than peak levels determine the toxic effects of TNF in 
mice 
380
. 
It has now become clear that the antitumor effect of TNF is completely host-mediated. 
Stoelcker and co-workers showed that TNF administration could still result in tumor 
necrosis in TNF-R2 deficient mice, but not in TNF-R1 deficient mice. After 
implantation of TNF-R1 knockout tumors to wild-type mice, it was shown that TNF-
induced tumor necrosis was completely independent of TNF-R1 expression on tumor 
cells. Moreover, bone marrow transplantation of wild-type hematopoietic cells to 
TNF-R1 knockout mice could not restore the antitumor effect of TNF in these mice, 
suggesting that leukocytes are no direct targets cells for the antitumor effect of TNF 
381
. Several reports have suggested that the endothelial cells of the tumor vasculature 
are the direct target cells of TNF, mostly based on the observation that TNF appears 
to induce a selective destruction of the tumor vasculature 
382-384
. However, there was 
no solid proof for this assumption until recently Goethals and colleagues 
demonstrated that mice expressing the TNF-R1 exclusively on endothelial cells 
(controlled by a Flk-1-promoter) were still sensitive to the antitumor effect of TNF, 
while the toxic side-effects of TNF were markedly reduced 
385
. These date together 
with observations made by other groups clearly demonstrate that the endothelial cells 
of the tumor vasculature are the main target cells for the antitumor effect of TNF. 
 
Despite the success of TNF as an antitumor agent in experimental animal models, the 
first clinical trials performed with TNF were disappointing. Doses of 10 to 50 times 
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lower than the estimated effective dose already caused severe toxic side-effects, such 
as hypotension, thrombocytopenia and liver toxicity, characteristics of septic shock-
like syndrome 
386-391
. Unfortunately, doses close to the maximum tolerated dose 
(about 150-400µg/m
2
) produced only rare and minimal tumor responses 
392-395
. These 
disappointing results prompted Lienard, Lejeune and colleagues in 1988 to administer 
TNF via the technique of isolated limb perfusion (ILP) 
396, 397
. In ILP, isolation of the 
blood circulation of the affected limb is achieved by clamping the major vein and 
artery, ligation of the collateral vessels, and application of a tourniquet around the 
basis of the limb to compress the remaining small vessels. The main artery and vein is 
cannulated and connected to an oxygenated extracorporeal circuit wherein the drugs 
are injected (Fig.1.11.). In this way, high local concentrations of a drug can be 
achieved with minimal risk of systemic leakage and side-effects. After the procedure 
(60-90 minutes of perfusion) a washout is performed to ensure minimal systemic 
exposure to the drug 
398
. ILP can be performed with mild hyperthermia (38,5-40°C) to 
improve local drug uptake 
399
.  
 
 
 
Fig. 1.11. Setup of ILP for a large soft tissue sarcoma in the upper leg. Adapted from Lejeune et 
al., 2006 
400
. 
 
The standard drug used in ILP is the alkylating agent melphalan. ILP with melphalan 
alone was found to produce a complete response  rate of around 50% in in-transit 
melanoma metastasis, but had only minimal effect on unresectable soft tissue 
sarcomas of the limbs. Some pilot studies of ILP with TNF alone were performed, but 
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only minimal responses were observed 
401
. However, when Lienard and colleagues 
added TNF and IFN- to ILP with melphalan, tumor response was significantly 
increased 
396
. Nowadays, the complete response rate for ILP with TNF plus melphalan 
(with or without IFN-) is around 80% for melanoma and around 20% for sarcoma, 
and an objective response rate of respectively >90% and around 80%. For soft tissue 
sarcoma this results in limb salvage in around 80% of the cases, where amputation 
used to be the only adequate treatment 
400
. 
There is evidence for two important effects of TNF in ILP: (1) early after infusion 
(within 30 minutes) it increases the permeability of the tumor vasculature, resulting in 
a higher drug uptake in the tumor, and (2) later (24 hours to a few days) it induces a 
selective destruction of the tumor vasculature 
400
. Increase of vascular permeability is 
a well-known effect of TNF, and it appears that tumor-associated blood vessels are 
more sensitive for this effect than normal vessels. In rat limb sarcoma models ILP 
with TNF was shown to increase the penetration of melphalan or doxorubicin in the 
tumor, while there was no change in uptake in normal skin and muscle 
402, 403
. It was 
furthermore demonstrated that systemic administration of TNF selectively increased 
the uptake of monoclonal antibodies or stealth liposomal doxorubicin (Doxil) in a 
human colorectal carcinoma xenograft in nude mice or in a B16Bl6 melanoma in 
C57BL/6 mice, respectively 
404, 405
. An increased drug uptake resulting from an 
increase in vascular permeability may however only be a short-lived effect as an 
increase in vascular permeability may also cause an elevation of interstitial fluid 
pressure (IFP) which is known to counteract drug uptake, in particular of 
macromolecules 
406
. Angiograms taken from patients treated with TNF-based ILP 
confirmed that TNF induces a selective destruction of the tumor vasculature, while 
leaving the normal vasculature unharmed (Fig.1.12.) 
398, 400
. TNF also triggers an 
inflammatory response during ILP, resulting in the rapid recruitment of 
polymorphonuclear cells to the tumor site, followed by the infiltration of macrophages 
and lymphocytes after several days 
407
. It is still unclear whether these immune cells 
play a role in the vascular- or tumor-destructing effects of the treatment. However, at 
least one study showed that total body irradiation of tumor-bearing rats, thereby 
inducing general leukopenia, markedly decreased the tumor response and skin 
necrosis at the tumor site following ILP with TNF and melphalan 
408
. 
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Fig. 1.12. Selective destruction of the tumor-associated vasculature in TNF-based ILP. 
Angiograms of unresectable sarcoma of the leg were taken before (left) or 7 days after ILP with TNF, 
IFN- and melphalan (right). From Lejeune et al., 2006 400. 
 
The success of ILP for the treatment of unresectable tumors of the limbs has led to the 
adjustment of this technique for the treatment of other organs, particularly the liver, 
which is then called isolated hepatic perfusion (IHP). Clinical trials of IHP with 
melphalan were successful, however, only minimal improvement of tumor response 
was noticed when TNF was added 
409-411
. 
 
Despite the antitumor activities just mentioned, no TNF-based treatment thus far has 
proved to affect patient survival. The reason for this discrepancy lies in the fact that 
patient survival is mainly determined by the presence of distant metastasis, which are 
not affected by ILP. Thus, in order to really know the anticancer potential of TNF, 
systemic administration is required. Several strategies may be followed to allow 
systemic treatment with TNF: (1) combining low-dose TNF with other drugs to 
increase drug uptake, (2) the development of TNF muteins with lower toxicity, (3) 
combining low-dose TNF with sensitizers for the antitumor effect of TNF, (4) specific 
delivery systems to target TNF to the tumor, and (5) using high-dose TNF in 
combination with inhibitors of the toxic side-effects of TNF. The latter may be the 
easiest solution. Cauwels and colleagues demonstrated that inhibition of sGC protects 
mice against the lethality induced by treatment with mTNF plus IFN-, without 
interfering with the antitumor activities of this treatment 
267
. However, using 
potentially lethal doses of TNF together with an inhibitor of the toxic side-effects is 
not an attractive solution for human cancer therapy as failure of the inhibitor could 
lead to death of the patient. It was shown by Ameloot and colleagues that prolonged 
exposure to TNF rather than high peak concentrations causes toxicity, suggesting that 
TNF muteins with faster clearance will most likely be less toxic 
380
. However, as 
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demonstrated by the lower antitumor efficacy of hTNF in murine tumor models, faster 
cleared TNF muteins will probably require combination with sensitizers for the 
antitumor activity of TNF, such as IFN- 377. Most chemical sensitizers that have been 
identified interfere with the anti-apoptotic machinery induced by TNF, in essence the 
NF-B and PI3K/Akt pathways. For instance, gambogic acid, a drug that has recently 
been shown to suppress NF-B activation through a mechanism that involves the 
transferrin receptor, can sensitize a human leukemia cell line to apoptosis induced by 
TNF 
412
. Another promising NF-B pathway inhibitor is the proteasome inhibitor 
bortezomib. This drug has already entered clinical trials in combination with 
conventional chemotherapeutics 
413
. The first combined treatments of TNF and 
bortezomib in tumor-bearing mice showed a significantly increased response 
compared to either drug alone 
414
. Matschurat and colleagues demonstrated that co-
injection of the PI3K inhibitor wortmannin and TNF markedly reduced the effective 
dose of TNF to induce haemorrhage and necrosis in a murine methA tumor model. 
Interestingly, in the same report it was shown that inhibition of PI3K increased the 
TNF-induced expression of tissue factor on HUVECs 
415
. Another interesting target is 
eNOS. The coadministration of TNF and the NOS inhibitor N-nitro-L-arginine-
methyl-ester (L-NAME) significantly increased the tumor response in ILP treatment 
of soft tissue sarcoma in rats, and in B16Bl6 melanoma-bearing mice 
416, 417
. It was 
also shown that eNOS deficient mice are more sensitive to the antitumor effect of 
TNF 
417
. Goethals and colleagues also found that inhibition of PLA2 with the 
inhibitors aristolochic acid or ATK significantly lowered the effective dose of TNF in 
the murine B16Bl6 melanoma model 
417
. However, the mechanism involved in this 
sensitization remains to be elucidated. 
New delivery systems are being developed to selectively target TNF to the tumor 
microenvironment, with minimal exposure to the rest of the body (summarized in 
Table 1.2.). Some of these TNF delivery systems, including NGR-TNF and 
TNFerade, are currently tested in clinical studies, with encouraging results. 
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Table 1.2. Specific TNF delivery systems. 
Name Description / Results References 
TNF-PEGL TNF encapsulated in pegylated (Stealth) liposomes, which increases its 
circulation time and accumulation in tumor tissue.  
TNF-PEGL has been shown to enhance the antitumor activity of Doxil in 
rats without causing the toxic side-effects of free TNF. 
[418, 419] 
NGR-TNF Fusion protein of TNF with the tumor-homing peptide Cys-Asn-Gly-Arg-
Cys (CNGRC), a ligand of aminopeptidase-N, which is expressed on tumor 
vasculature.  
The therapeutic index of NGR-TNF was shown to be 12-15 higher than 
free TNF. NGR-TNF has potent antitumor activity in combination with 
chemotherapeutics in murine tumor models. NGR-TNF is currently being 
tested in clinical studies. 
[420-423] 
TNF-L19 Fusion protein of TNF and an antibody fragment (L19) specific to the 
extradomain B  of fibronectin, a marker of angiogensis.  
L19 has been shown to specifically target tumors in animal models and in 
cancer patients. TNF-L19 was shown to have synergistic antitumor 
activity with melphalan or IL-12-L19 in murine tumor models. 
[424-426] 
TNFerade A replication-deficient adenovector carrying the TNF cDNA regulated by 
the radiation-sensitive promoter Egr-1.  
TNFerade allows irradiation-induced expression of TNF in tumor tissue, 
with minimal systemic exposure and toxic side-effects. Phase I and II 
clinical trials of TNFerade with radiation therapy and other 
chemotherapeutics showed impressive tumor responses in patients with 
prior treatment-refractory solid tumors. 
[427-430] 
PT-cAu-TNF TNF encapsulated in PEG-coated colloidal gold nanoparticles.  
PT-cAu-TNF has been shown to rapidly accumulate in solid tumors, with 
little to no accumulation in other organs following intravenous injection 
in mice. PT-cAu-TNF alone or in combination with thermal therapy has 
potent antitumor activity in murine tumor models. 
[431-433] 
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2. INTERFERON- 
 
2.1. IFN- and its receptor 
 
Interferons are a family of proteins that were originally discovered as agents that 
interfere with viral replication 
1
. They are classified into type I and type II according 
to receptor specificity and acid stability. Type I IFNs include IFN-, IFN-, IFN-, 
and IFN-, all of which are acid-stable and bind to a common receptor known as the 
IFN- receptor. IFN- is the only type II IFN. It is acid-labile and signals through the 
IFN- receptor (IFN-R). The major function of type I IFNs is indeed the defense 
against viral infection, but IFN-, also called immune IFN, has besides its anti-viral 
activity a more general function in the immune system 
2
. 
Initially it was believed that IFN- is produced exclusively by activated NK cells, 
CD4
+
 T helper type 1 (Th1) cells, and CD8
+
 cytotoxic T cells, but now it is clear that 
many other immune cells can produce IFN-, including NKT cells,  T cells, and 
professional antigen-presenting cells (APCs) (dendritic cells, macrophages and B 
cells) 
2-6
. IFN- production early during infection is mainly controlled by cytokines 
secreted by APCs. Especially IL-12 and IL-18 appear to play a major role in the 
stimulation of IFN- production. IL-12 and IL-18 have been shown to synergistically 
increases IFN- production in dendritic cells, macrophages, NK, Th1 and B cells 7-9. T 
lymphocytes are the major source of IFN- in the adaptive immune response and 
secrete IFN- upon triggering of their T cell receptor (TCR). Negative regulators of 
IFN- production include IL-4, IL-10, TGF-, and glucocorticoids 10. 
The promoter region of the IFN- gene contains binding sites for many transcription 
factors, such as NFAT, NF-B, STAT4 and T-bet, suggesting that the regulation of its 
expression is very complex 
2
. IFN- gene expression results in a polypeptide of 17kDa 
(in humans), followed by N-glycosylation, association of two polypeptides into a non-
covalent homodimer, which is the biological active form of IFN-, and secretion 11-13. 
N-glycosylation of the protein is not required for its biological activity but was shown 
to influence its clearance from circulation 
14-16
. 
 
The IFN-R is comprised of two subunits, called IFN-R1, which is responsible for 
ligand binding, and IFN-R2 17, 18. Both receptor chains contain sequences in their 
carboxyterminal intracellular regions for constitutive association with members of the 
Janus kinase (JAK) family of tyrosine kinases. IFN-R1 specifically associates with 
JAK-1, while IFN-R2 is constitutively associated with JAK-2 19-21. 
The IFN-R is constitutively expressed on most cells 22. IFN-R1 is usually in surplus, 
but the expression level of IFN-R2 appears to be tightly regulated according to the 
state of cellular differentiation and activation. For example, CD4
+
 Th1 cells express 
only low levels of IFN-R2n and are insensitive to the growth-inhibitory effects of 
 
72 Chapter 2 
IFN-, while CD4+ Th2 cells express high levels of IFN-R2 and stimulation of these 
cells with IFN- inhibits their proliferation and can induce apoptosis 10, 23-25. 
 
 
2.2. IFN-R signaling 
 
Signal transduction starts with the interaction of the IFN- homodimer with two IFN-
R1 chains, thereby inducing dimerization of the receptor. This brings inactive JAKs 
in close proximity with one another, resulting in activation of JAK-2 through 
autophosphorylation (Fig.2.1.). Activated JAK-2 phosphorylates and activates JAK-1, 
which then phosphorylates a specific tyrosine residue near the carboxyterminus of the 
IFN-R1 chain 26, 27. This phosphorylated tyrosine residue serves as a docking site for 
the Src homology 2 (SH2) domain of the transcription factor signal transducer and 
activator of transcription 1 (STAT1) 
28
. After association with the receptor, STAT1 is 
tyrosine phosphorylated by JAKs, which leads to rapid dissociation of the receptor 
and SH2 domain-dependent dimerization of STAT1 
29, 30
. At some point during its 
activation, STAT1 becomes phosphorylated on a specific serine residue, which is 
required for maximal transcriptional activity 
31
. Recently it was shown that IFN--
induced serine phosphorylation of STAT1 is regulated by PI3K, mammalian target of 
rapamycin (mTOR) and PKC activity, and occurs in a macromolecular complex that 
contains STAT1, mTOR and PKC 32-34. PKC has also been shown to mediate serine 
phosphorylation of STAT1 in response to type I IFNs 
35
. Upon activation, the STAT1 
homodimer is transported to the nucleus where it can bind to specific DNA sequences, 
known as gamma-activated sites (GASs), to initiate or suppress gene transcription 
36
. 
This results within 15-30 minutes after stimulation with IFN- in a first wave of 
transcription, called primary response. Many of the induced genes are in fact 
transcription factors, most importantly IFN regulatory factor-1 (IRF-1). These 
transcription factors further drive the regulation of the next wave of transcription, 
called secondary response 
10
. The total number of IFN--regulated genes is estimated 
to be around 500 
37
.  
 
Important genes that are upregulated during the primary response include genes 
related to antigen presentation (CIITA, TAP-1/2, LMP-2/7/10), cell adhesion (VLA-4, 
ICAM-1, VCAM-1), and negative regulation of IFN signaling (suppressor of cytokine 
signaling 1 (SOCS1) and IRF-8). IRF-1 binds to a DNA sequence called IFN-
stimulated response element (ISRE) and upregulates the expression of iNOS, IFN-, 
caspase-1, STAT1 and IRF-2 during the secondary response 
37
. IRF-2 and IRF-8 also 
bind to ISREs, but act as transcriptional repressors, thereby antagonizing IRF-1 
38-40
. 
IRF-1 plays an important role in immune development, which is highlighted by the 
phenotype of IRF-1 deficient mice. These mice have a reduced number of mature 
CD8
+
 T cells due to impaired peptide loading of MHC class I, which is required for 
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the maturation of these cells in the thymus 
41, 42
. IRF-1 knockout mice appear to have 
normal thymic maturation of CD4
+
 T cells but display increased numbers of memory 
or effector CD4
+
 T cells 
43
. Moreover, these mice fail to develop a Th1-type immune 
response and instead produce a Th2-type immune response 
44, 45
. Since IRF-1 controls 
the expression of IL-15, a cytokine that is crucial for the maturation of NK cells in the 
bone marrow, IRF-1 knockout mice also lack mature NK and NK1.1
+
 T cells 
46-48
.  
 
 
 
Fig. 2.1. IFN- signaling pathways. Negative regulation of IFN- signaling is indicated with red 
arrows. P: phosphorylation, encircled P: phosphotyrosine or phosphoserine, Y: tyrosine residue, S: 
serine residue. Adapted from Ramana et al., 2002 and Schroder et al., 2004 
10, 49
. 
 
SOCS proteins negatively regulate cytokine signaling by binding via an SH2 domain 
to phosphorylated tyrosine residues in cytokine receptors or associated kinases, such 
as JAKs. Besides an SH2 domain, SOCS proteins also contain a second domain, 
named SOCS-box, by which they can interact with the elongins B and C and cullin-2 
to form an E3 ubiquitin ligase complex. So, binding of SOCS proteins may lead to 
ubiquitination of associated signaling proteins, which marks these proteins for 
proteasomal degradation 
50-52
. IFN- has been shown to upregulate the expression of 
SOCS1 and SOCS3 
53
. SOCS1 inhibits IFN- signaling by binding to a 
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phosphorylated tyrosine residue in the catalytic site of JAK-2, which inhibits its 
kinase activity 
54
. Expression of SOCS3 has also been shown to block activation of 
STAT1 in response to IFN-, although it is less clear how SOCS3 mediates this 
inhibitory effect 
55
. It was suggested that SOCS3 inhibits activation of JAKs by direct 
interaction with cytokine receptors 
56-58
. Other negative regulators of IFN- signaling 
are SH2 domain-containing tyrosine phosphatase-2 (SHP-2) and protein inhibitor of 
activated STAT (PIAS). SHP-2 has been shown to interact with JAK-1 and JAK-2, 
which results in inactivation of these JAKs 
59, 60
. PIAS proteins on the other hand can 
associate with and inhibit activated STAT1 homodimers. PIAS1 mediates this 
inhibitory effect by blocking the DNA binding activity of STAT1, while PIASy 
functions as a transcriptional corepressor of STAT1 without blocking its DNA 
binding activity 
61, 62
. 
 
Besides STAT1 homodimers, IFN- signaling has also been shown to produce 
STAT1:STAT2 heterodimers and STAT1:STAT2:IRF-9 and STAT1:STAT1:IRF-9 
heterotrimers, which allows further modulation of gene expression downstream of the 
IFN-R 63, 64. It has now become clear that IFN- can, in addition to the well-known 
JAK-STAT pathway, also activate additional signaling pathways, which can lead to 
STAT1-independent gene transcription (Fig.2.1.) 
49
. It has been shown that JAK-2 
associates with and activates the MAPK proline-rich tyrosine kinase 2 (Pyk2) and that 
Pyk2 then mediates further signaling to ERK and serine phosphorylation of STAT1 
65
. 
JAK-2 and Pyk2 have also been shown to associate with the Src family member Fyn 
66
. IFN- can furthermore activate the adaptor proteins c-Cbl, CrkL, CrkII and Vav, 
and the G-protein-linked signaling molecules C3G and Ras GTPase-activating 
protein-1 (Rap-1) 
49, 67-69
. 
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2.3. IFN- in immunity 
 
The IFN system regulates the host defense against viral infection. While both types of 
IFNs trigger direct cellular defense mechanisms against viral infection, IFN- also 
coordinates the innate and adaptive immune responses that will establish a longer-
lasting protection against viral infection. The immunoregulatory functions of IFN- 
include the regulation of antigen presentation, Th1- versus Th2-type immune 
response, leukocyte trafficking, and phagocyte activity. 
 
The direct antiviral activities of IFN- are mainly mediated by transcriptional 
induction of three genes, namely double-stranded RNA (dsRNA) activated protein 
kinase (PKR), 2’-5’ oligoadenylate synthetase (2-5A synthetase), and dsRNA specific 
adenosine deaminase (dsRAD) 
37
. PKR is activated by binding to dsRNA structures. 
Both RNA and DNA viruses produce RNA intermediates that can activate PKR. Once 
activated, PKR phosphorylates the -subunit of eukaryotic initiation factor 2 (eIF2), 
which inhibits viral and cellular protein synthesis 
70, 71
. PKR has also been implicated 
in the activation of NF-B and the splicing of TNF mRNA 72, 73. 2-5A synthetase is 
also stimulated by dsRNA but converts ATP into 2’-5’-linked adenylates. These 
adenylates in turn activate RNaseL, which degrades single-stranded RNAs, thereby 
inhibiting protein synthesis and viral growth 
74-76
. Finally, dsRAD catalyzes the 
deamination of adenosine to inosine, which produces edited mRNAs whose 
translation does not lead to a functional protein 
37, 77-79
. 
 
IFN- increases antigen presentation by both MHC class I and class II. Upregulation 
of antigen presentation by MHC class I is important for host responses to intracellular 
pathogens as it increases the potential for cytotoxic CD8
+
 T cell recognition and thus 
promotes cell-mediated immunity. IFN- induces the expression of the proteasome 
subunits LMP-2, LMP-7 and MECL-1, which replace the constitutive subunits 1, 2, 
and 5 of the proteasome to form the immunoproteasome 80. Peptide fragments 
generated by this immunoproteasome are transported by the transporter associated 
with antigen processing (TAP) to the ER lumen, where they are loaded on the MHC 
class I complex which is then brought to the cell surface. IFN- upregulates the 
expression of both TAP-1 and TAP-2 subunits of the TAP transporter as well as the 
MHC class I heavy chain and 2-microglobulin subunits of the MHC class I complex. 
Other MHC class I pathway components upregulated by IFN- include tapasin and the 
proteasome activator PA28 (see Schroder et al., 2004 and references therein 
10
). 
Unlike type I IFNs, IFN- can efficiently upregulate the MHC class II antigen 
presentation pathway and thus promote the activation of specific CD4
+
 T cells. MHC 
class II molecules present peptides derived from extracellular pathogens or pathogens 
that are living in macrophage vesicles. Internalized proteins and pathogens are 
degraded to peptides by lysosomal cathepsins. IFN- has been shown to upregulate 
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the expression of the cathepsins B, D, H and L 
81-83
. Vesicles derived from the ER that 
contain MHC class II molecules stabilized with the invariant chain protein Ii fuse with 
endolysosomal vesicles that contain the degraded proteins, whereafter the Ii chain is 
degraded, peptides are loaded on the MHC class II complex aided by the protein DM, 
and the complex is brought to the cell surface. The expression of all subunits of the 
MHC class II complex, the Ii chain and DM are upregulated by the class II 
transactivator (CIITA), which is induced by IFN- 37, 84. CIITA has no DNA binding 
activity, but regulates the expression of class II genes by binding with the 
transcription factor RFX 
85
. CIITA was shown to be the limiting factor for the class II 
gene expression 
86
. 
 
As mentioned above, IFN- is mainly produced by NK, NKT, CD8+ T and Th1 cells. 
These are effector cells of the cell-mediated or Th1-type immunity, and the IFN- 
produced by these cells will further skew the immune response towards a Th1 
phenotype. The phenotype adopted by naïve CD4
+
 T cells during T cell activation is 
strongly influenced by the cytokines present at the time of TCR triggering. IFN- and 
IL-12 direct differentiation to Th1, while IL-4 directs differentiation to Th2. IL-12 is 
secreted by activated dendritic cells, neutrophils and macrophages, and stimulates 
IFN- production by NK cells and naïve CD4+ T cells 87-89. IFN- on the other hand 
stimulates IL-12 production by macrophages and neutrophils, thus creating a positive 
feedback loop 
90, 91
. Moreover, IFN- inhibits the proliferation of Th2 cells, and 
inhibits the secretion of IL-4 by these cells, which further polarizes the immune 
response towards a Th1 phenotype 
23, 92
.  
Consistent with its role in promoting cell-mediated immunity, IFN- stimulates 
immunoglobulin isotype switching in B cells to IgG2a and IgG3, which together with 
the upregulation of FcRI on macrophages and other cells increases the phagocytosis 
of antibody-coated pathogens and antibody-dependent cell-mediated cytotoxicity 
(ADCC) 
93-95
. IFN- also antagonizes the IL-4-induced isotype switching to IgG1 and 
IgE and upregulation of FcRII on B cells, basophils and mast cells 6, 37, 96, 97. 
The importance of IFN- in regulating the immune response is illustrated by the fact 
that some chronic allergic diseases such as asthma have been correlated with reduced 
IFN- production 98. Allergic diseases are closely related to Th2-type immune 
responses, which are characterized by high levels of IL-4, IL-5, IL-9 and IL-13, IgE 
isotype switching, and the recruitment and activation of effector cells such as 
eosinophils and mast cells. It has been suggested that the induction of Th1 responses, 
for example with IFN- or IL-12, could protect against Th2-related allergic diseases 
(Fig.2.2.) 
2
. 
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Fig. 2.2. IFN- in the control of Th immune and allergic responses. IFN- may counteract several 
steps of allergic responses, by enhancing IL-12 production by APCs, inducing Th1 differentiation, 
suppressing the proliferation and function of Th2 cells, blocking IgE isotype switching in B cells, and 
inducing eosinophils apoptosis. From Teixeira et al., 2005 
2
. 
 
IFN- orchestrates the recruitment of monocytes and lymphocytes to sites of 
inflammation by inducing the expression of specific chemokines and adhesion 
molecules. IFN- upregulates the expression of the adhesion molecules ICAM-1 and 
VCAM-1 on endothelial cells, and induces the expression of chemokines (e.g. 
CXCL9, CXCL10, CCL2, CCL3, CCL4 and CCL5) in macrophages, lymphocytes, 
endothelial cells and fibroblasts 
37, 99-104
. Many of these IFN--induced chemokines, 
which are secreted by various cell types at the site of inflammation, are captured and 
presented on the luminal surface of endothelial cells by association with 
glycosaminoglycans (GAGs), such as heparan sulphate proteoglycans, and Duffy 
antigen/receptor for chemokines (DARC) 
105, 106
. 
 
Another important function of IFN- is the stimulation of microbicidal activities of 
macrophages and neutrophils. Stimulation of these cells with IFN- increases their 
phagocytic activity 
10, 107
. Phagocytes primarily kill ingested pathogens by producing 
ROS and NO in a process known as oxidative (or respiratory) burst. IFN- upregulates 
the expression of several subunits of the NADPH oxidase, which is the enzyme 
responsible for the production of superoxide during oxidative burst 
108-110
. The NO 
production in phagocytes is mediated by iNOS. IFN- enhances NO production by 
upregulating the expression of argininosuccinate synthetase, which produces the L-
arginine substrate of iNOS, GTP-cyclohydrolase I, which supplies the 
tetrahydrobiopterin cofactor required for NO production, and the iNOS enzyme itself 
111-114
. IFN- furthermore upregulates the expression of FcRI and the complement 
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receptor CR3 on macrophages and neutrophils, thereby promoting the phagocytosis 
and killing of antibody- or complement-coated pathogens 
93, 115-117
. 
 
 
2.4. Synergy with TNF 
 
Since both TNF and IFN- are produced simultaneously at sites of inflammation, 
potentially by the same cells, it is not really surprising that these two cytokines can 
influence each other actions. In fact, same actions only become apparent when both 
cytokines are present. For example, Williamson and colleagues observed already in 
1983 that some tumor cell lines were insensitive to the cytotoxic effects of TNF in 
vitro, but when they treated these cells with a combination of TNF and IFN-, a 
pronounced cytotoxic effect was observed 
118
. During the next years, a synergistic 
cytotoxic or anti-proliferative effect of TNF and IFN- was found for many cell lines, 
including many tumor cell lines such as the murine melanoma line B16Bl6, and 
human breast, cervix, colon, and pancreas carcinoma cell lines, but also non-
transformed cells such as MEFs and HUVECs 
119-123
. As IFN- was found to 
upregulate the expression of TNF-R2 on several tumor cell lines, it was originally 
thought that this would at least in part explain the synergistic effect of IFN- and TNF 
124-126
. However, this hypothesis was soon abandoned since IFN- also upregulated 
TNF-R2 expression in other cell lines without sensitizing for TNF cytotoxicity, and 
the synergistic cytotoxic effect of TNF and IFN-was not abrogated by IFN-, even 
though the latter cytokine inhibited the IFN--induced upregulation of TNF-R2 127-129. 
Other candidate proteins upregulated by IFN- that could explain the synergistic 
cytotoxic effect of TNF and IFN- are the cathepsins B and D and several caspases 81, 
83, 130-132
. IFN- upregulates the expression of caspase-1 in a IRF-1-dependent manner 
and caspase-1 was shown to be required for IFN--induced apoptosis of HeLa and 
some other cell lines 
130, 133
. The cathepsins B and D have been implicated in TNF-
induced cell death of hepatocytes and some other cells 
134-136
. It was shown that 
cathepsin D is involved in IFN- or TNF-induced cell death in HeLa cells 83. 
Recently, Li and colleagues demonstrated that IFN- can trigger the release of 
cathepsin B from lysosomes in cultured endothelial cells and that cathepsin B 
contributes to TNF plus IFN--induced cell death in these cells 137. IFN- was also 
shown to increase the expression of procaspase-8 in cultured endothelial cells and 
sensitize these cells to Fas-mediated apoptosis 
131
. 
IFN- also upregulates the expression of the pro-apoptotic proteins Bak, XIAP 
associated factor-1 (XAF-1), death-associated proteins (DAPs), and DAP-kinase, 
while it downregulates the expression of the anti-apoptotic proteins Bcl-2 and Hsp27 
138-143
. XAF-1 can associate with XIAP to block its caspase-inhibiting and survivin-
stabilizing activity 
144
. The chaperone protein Hsp27 can protect cells from apoptosis 
by interacting with the cytochrome c released from the mitochondria, thereby 
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preventing the apoptosome-mediated activation of procaspase-9 
145, 146
. The pro-
apoptotic activities of DAPs and DAP-kinase are still largely unknown. Inhibition of 
DAP3 expression by antisense RNA was shown to protect cells from IFN- or TNF-
induced apoptosis 
139, 147
. DAP3 has also been linked to anoikis. Cells attached to the 
extracellular matrix receive survival signals via integrins, in essence by activation of 
the PI3K/Akt pathway. Akt can phosphorylate and inactivate DAP3. Detachment of 
cells would lead to activation of DAP3, followed by association of DAP3 with FADD 
and activation of caspase-8 
148, 149
. DAP-kinase is Ca
2+
/calmodulin-dependent, DD-
containing serine/threonine kinase that was demonstrated to participate in apoptosis 
induced by various stimuli 
150-153
. Recently it was shown that DAP-kinase, which is 
localized to the actin cytoskeleton, phosphorylates MLC, induces cytoskeletal 
reorganization, and inhibits integrin-mediated cell adhesion and signal transduction 
154-156
. 
 
Many genes that are inducible by IFN are also inducible by TNF, and often the 
induction is synergistic. Among many others this is the case for the 
monocyte/lymphocyte chemokines CCL2, CCL5 and CXCL10, the adhesion 
molecules ICAM-1 and VCAM-1,  and iNOS 
103, 157-161
. Most of these genes contain 
an ISRE or GAS sequence as well as a B-site in their promoter to allow the binding 
of both NF-B and an IFN--induced transcription factor 37. Moreover, it was shown 
that NF-B can physically interact with STAT1, IRF-1 and IRF-2 162-164. Suk and 
colleagues demonstrated that transfection of a phosphorylation-defective STAT1 
inhibited TNF plus IFN--induced apoptosis in a cervical cancer cell line, whereas 
transfection of IRF-1 sensitized these cells to TNF-induced apoptosis, suggesting that 
IRF-1 is required for synergistic cytotoxic effect of TNF and IFN- 165. 
IFN- can also enhance the TNF-induced activation of NF-B by stimulating 
degradation of IB, possibly in a PKR-dependent manner 72, 166, 167. TNF on the other 
hand may enhance the activation of STAT1 through phosphorylation of JAK-2 
168
. 
More recently, it was shown that inactive STAT1 can interact with the TNF-
R1/TRADD complex and inhibit the TNF-induced activation of NF-B. Stimulation 
of cells with IFN- would then lead to activation and nuclear translocation of STAT1 
and thus depletion of STAT1 from the cytoplasm, allowing for optimal NF-B 
activation by TNF 
169, 170
. Furthermore, TRADD and STAT1 were shown to form a 
nuclear complex that may regulate the transcriptional activity of STAT1 
171
. So, TNF 
and IFN- appear to reciprocally control each others’ signaling pathways at many 
levels. 
 
The in vitro synergistic effects of TNF and IFN- on tumor cell lines prompted 
researchers to use this combination in experimental tumor models. In 1986, Balkwill 
and colleagues were the first to report a synergistic antitumor effect of hTNF and 
IFN- on human tumor xenografts in nude mice 172. However, they treated these nude 
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mice with human IFN-, which has no effect on murine cells, suggesting that this 
synergistic antitumor effect was due to direct cytotoxic effects on the tumor cells. In 
the same year, Brouckaert and colleagues reported the synergistic antitumor activity 
of hTNF and murine IFN- in a syngeneic tumor model, namely murine B16Bl6 
tumors grown subcutaneously in C57BL/6 mice 
120
. While hTNF alone had a static 
effect on tumor growth in these mice, the combination of hTNF and IFN- induced 
complete necrosis and regression of these tumors. In the years after, many reports 
have been published demonstrating the synergistic antitumor activity of TNF and 
IFN- in various experimental tumor models 173-178. These observations in mice has 
led to the addition of IFN- to ILP with TNF and melphalan for the treatment of 
human patients with unresectable sarcomas or melanomas of the limbs. Although the 
differences in response rates are small and statistically non-significant, clinical studies 
using ILP with the triple combination of TNF, IFN- and melphalan appear to result 
in consistently higher response rates than those without IFN-, suggesting that the 
synergistic effect of TNF and IFN- is also present in this system (Fig.2.3.) 179. 
 
 
 
Fig. 2.3. Complete response rates obtained after ILP in melanoma. Complete response rates 
obtained of after ILP with TNF, IFN- and melphalan are indicated in red, with TNF and melphalan in 
orange, and with melphalan alone in blue. The data are from 11 clinical studies (phase II and III) and 
include more than 200 patients. From Lejeune et al., 2006 
179
. 
 
The mechanism underlying the in vivo synergistic antitumor effect of TNF and IFN- 
is still largely unknown. However, as was the case for TNF monotherapy, histological 
analysis of tumors treated with TNF plus IFN- revealed a selective destruction of the 
tumor vasculature, suggesting that endothelial cells are also the target cells of IFN- 
178, 180
. This was confirmed by the work of Hostens and colleagues, who created a 
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transgenic mouse strain that expresses a dominant negative IFN-R1 chain only in 
endothelial cells (controlled by a Flk-1-promoter), thereby rendering these cells 
insensitive to IFN-. The synergistic antitumor effect of TNF and IFN- was 
complexly abrogated in these mice, although all other cells, including leukocytes and 
tumor cells, still expressed a functional IFN-R, demonstrating that a functional IFN-
R on endothelial cells is essential for the synergistic antitumor activity of TNF and 
IFN- 181. They furthermore showed, using IRF-1 knockout mice, that the 
transcription factor IRF-1 is to some extent important for the antitumor effects of TNF 
and IFN-. In fact, the synergism of TNF and IFN- is still present in these mice, but 
neither treatment with mTNF alone or with hTNF plus IFN- resulted in complete 
regression of the B16Bl6 tumor. This defect could be partly restored by reconstitution 
with wild-type splenocytes, suggesting that certain immune cells could play a role in 
the antitumor effect of TNF and IFN- 182. Rüegg and co-workers implied the integrin 
V3 in the vascular-disrupting effect of TNF and IFN- 
183
. They found that 
treatment of HUVECs with TNF and IFN- suppressed the activation of this integrin, 
leading to decreased endothelial cell adhesion and survival. They furthermore 
observed detachment and apoptosis of v3-positive endothelial cells of the tumor 
vasculature in melanoma patients treated with TNF and IFN-. 
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3. THE PI3K/AKT PATHWAY 
 
3.1. PI3K 
 
3.1.1. The PI3K family 
 
PI3Ks are a family of related enzymes that are capable of phosphorylating the 3’-OH 
position of the inositol ring of inositol phospholipids, thereby producing three lipid 
products, namely PI 3-phosphate (PI(3)P), PI 3,4-biphosphate (PI(3,4)P2) and PI 
3,4,5-triphosphate (PI(3,4,5)P3) 
2
. These phosphorylated PIs function as docking sites 
for proteins containing a pleckstrin homology (PH) domain, which then mediate 
further signaling. The serine/threonine kinase Akt, also called protein kinase B (PKB), 
was one of the first proteins identified with such a PH domain 
3-5
. The PH domain of 
Akt appears to specifically bind to PI3K lipid products, and a firm link between PI3K 
and Akt signaling has now been established, hence the name ‘PI3K/Akt pathway’. 
 
To date, eight different mammalian PI3Ks have been identified, which have been 
divided into three classes, based on sequence homology, in vitro substrate preference, 
and method of activation and regulation (Fig.3.1. and 3.2.) 
6
. Only the class I PI3Ks 
are known to activate Akt and will be discussed in more detail below. The three class 
II PI3Ks, PI3K-C2, -C2 and –C2, are large proteins that are most likely 
constitutively associated with membrane structures, and in contrast to the class I and 
III PI3Ks do not appear to associate with regulatory adaptor proteins. They have 
several domains that are homologous to protein-protein interaction and lipid-binding 
domains found in other proteins. Particularly the characteristic carboxyterminal C2 
domain, homologous to the Ca
2+
/lipid binding C2 domains found in classical PKC 
isoforms, could mediate the membrane association of class II PI3Ks. Their main in 
vivo product is PI(3)P, although in vitro they can also phosphorylate PI(4)P to 
PI(4,5)P2 
1
. Class II PI3Ks can be activated by many extracellular signals, including 
growth factors such as insulin and epidermal growth factor (EGF), chemokines such 
as MCP-1, and integrin engagement 
7-10
. However, the mechanism involved in their 
activation as well as their cellular functions are still largely unknown. PI3K-C2 and 
–C2 are ubiquitously expressed, while the expression of PI3K-C2 appears to be 
limited to hepatocytes 
11, 12
. The sole class III PI3K is Vps34 (sometimes referred to as 
hVps34 when the mammalian homologue of Vps34 is intended). Vps34 was 
originally identified as the only PI3K present in Saccharomyces cerevisiae 
13, 14
. 
Vps34 is associated with a regulatory subunit, Vps15, with serine/threonine kinase 
activity that is required for Vps34 function. Vps34 is ubiquitously expressed, is 
mainly associated with intracellular membranes, and uses only PI as a substrate, 
thereby producing PI(3)P. In yeast, Vps34 has an essential role in protein trafficking 
to the vacuole. This pathway and function are conserved in mammalian cells, where 
Vps34 is involved in vesicular trafficking in the endosomal/lysosomal system 
1, 15, 16
. 
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Recently Vps34 has also been implicated in other important signaling processes, such 
as nutrient sensing in the mTOR/p70 S6 kinase (S6K) pathway 
17, 18
. 
 
A number of other enzymes have been identified with catalytic domains that closely 
resemble those of PI3Ks (Fig.3.1.). These include the PI 4-kinases (PI4Ks), which 
phosphorylate the inositol ring of PI at the 4’-position to produce PI(4)P. There are 
also some PI3K-related protein serine/threonine kinases which are sometimes called 
class IV PI3Ks. In mammals, four such protein kinases have been identified: mTOR, 
ataxia telangiectasia mutated (ATM), ATM-related (ATR), and DNA-dependent 
protein kinase (DNA-PK). ATM, ATR and DNA-PK are all involved in the activation 
of DNA repair machinery and the linking of this to cell cycle control. The functions of 
mTOR will be discussed in more detail below (see chapter 3.3) 
1, 6
. 
 
 
 
Fig. 3.1. The PI3K superfamily. Dendrogram showing the degree of sequence homology between the 
catalytic domains of PI3Ks and related kinases. From Stein et al., 2001 
6
. 
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3.1.2. Class I PI3Ks 
 
Class I PI3Ks are heterodimeric proteins consisting of a catalytic subunit of 
approximately 110 kDa that is constitutively associated with a regulatory/adaptor 
subunit. Class I PI3Ks are largely cytosolic in resting cells, but upon stimulation are 
recruited to membranes via interactions with receptors or adaptor proteins. They are 
thought to function primarily at the plasma membrane, but there are reports of class I 
PI3Ks associated with vesicular and nuclear membranes. They become activated by a 
plethora of extracellular stimuli and have been implicated in a wide range of cellular 
processes, including cell growth, cell cycle progression, proliferation, motility, 
adhesion and survival. The preferred in vitro substrate of class I PI3Ks is PI(4,5)P2, 
hence the principal lipid generated by their in vivo actions is believed to be 
PI(3,4,5)P3. PI(3,4,5)P3 mediates further downstream signaling of class I PI3Ks by 
recruiting PH domain-containing proteins, including (1) members of the Tec family of 
tyrosine kinases, which link PI3K signaling to PLC and Ca2+/PKC activity; (2) 
guanine nucleotide exchange factors (GEFs) for Rho and Rac GTPases, which are 
involved in reorganization of the actin cytoskeleton; and (3) the serine/threonine 
kinases Akt and PI(3,4,5)P3-dependent protein kinase-1 (PDK-1) (see below) 
19
. 
Besides their lipid kinase activity, class I PI3Ks also have a protein serine kinase 
activity, which has been implicated in the regulation of the lipid kinase activity 
through either autophosphorylation of the catalytic subunit or transphosphorylation of 
the regulatory subunit 
20-23
. There are four distinct p110 isoforms identified in 
vertebrates, which have been divided in a class Ia and class Ib on the basis of their 
mechanism of activation and the regulatory subunit they associate with 
1, 19
. 
 
The class Ia PI3K catalytic subunits are p110, p110 and p110. These p110 
subunits are constitutively associated with a p85 regulatory/adaptor subunit via 
binding of the aminoterminal p85 binding domain of p110 with the inter-SH2 domain 
of p85. At least eight distinct p85 isoforms have been identified (encoded by three 
different genes): p85, p55, p50, p85 p55, and some other splice variants. There 
does not appear to be preferential association of any of the p110 isoforms with 
particular p85 isoforms, but there is variation in tissue distribution of catalytic and 
adapter subunit isoforms. p110, p110, p85 and p85 are expressed in almost all 
tissues. p110 and p55 on the other hand display a more restricted tissue distribution: 
p110 is predominantly expressed in leukocytes, while p55 is highly expressed in 
brain and testis 
24-26
. All of the p85 family members contain two SH2 domains which 
allow binding of the PI3K to specific phosphorylated tyrosine residues in receptors 
and other proteins. Some of the p85and p85 splice forms also possess an SH3 
domain, which allows binging to proline-rich regions in proteins, and a Bcr/Rac GAP 
homology domain, which allows binding to some additional binding partners 
27-29
. 
The p110 subunit also contains a C2 domain for membrane association and a Ras-
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binding domain 
30
. Thus, the number of potential binding partners of the p85/p110 
dimer is tremendous (Fig.3.3.). 
 
 
 
Fig. 3.3. Domain structure, interaction partners and regulatory activities of the p85/p110 PI3K. 
Broken arrows represent the protein serine kinase activity of p110, which can lead to downregulation of 
the lipid kinase activity of the complex. This occurs by transphosphorylation of the inter-SH2 (iSH2) 
domain of p85 in the case of p110, or by autophosphorylation in the case of p110 and p110. 
Regulatory subunits stabilize the p110 proteins, but at the same time inhibit their catalytic activity. This 
inhibition can be alleviated by engagement of the SH2 domains of p85 with phosphotyrosine sequences 
(pY) in other proteins. The Bcl/Rac GAP homology (BH) domain of p85 and p85 is flanked by two 
proline-rich regions. In p55, p50 and p55 the aminoterminal (N) SH3 domain, proline-rich region 
and BH domain are absent. Adapted from Vanhaesebroeck et al., 2005 
30
. 
 
The model for PI3K activation was first worked out in the context of the platelet-
derived growth factor (PDGF) receptor in fibroblasts. Stimulation of this receptor 
leads to autophosphorylation of a specific tyrosine residue within the cytoplasmic tail 
of the receptor, which then recruits the p85/p110 PI3K by a high-affinity interaction 
of the SH2 domains in the p85 adaptor subunit with the tyrosine-phosphorylated 
sequence in the PDGF receptor 
31-33
. The p85-mediated translocation of the p110 
catalytic subunit from the cytosol to the plasma membrane is sufficient for the 
activation of the PI3K, as constitutive membrane targeting of the p110 catalytic 
subunit creates a constitutively active PI3K that generates PI(3,4,5)P3 when expressed 
in cells 
34
. However, the p85 subunit is more than just a vehicle to bring the catalytic 
subunit to the plasma membrane, it may also regulate the activity of the PI3K. The 
catalytic activity of free p110 was shown to be higher than that of unbound p85/p110 
heterodimers, suggesting that p85 has an inhibitory effect on the catalytic activity of 
the p110 subunit. Binding of p85 to specific phosphotyrosine sequences would 
alleviate this inhibition 
35, 36
. It is now clear that class Ia PI3Ks are activated by many 
receptors with intrinsic tyrosine kinase activity (RTKs) such as growth factor 
receptors, but also by non-receptor tyrosine kinases, such as JAKs and Src family 
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members, which have been implicated in PI3K activity downstream of many cytokine 
receptors, B and T cell antigen receptors, co-stimulatory molecules such as CD28, 
integrins and other cell adhesion molecules. In addition, class I PI3Ks can be activated 
by the small GTPase Ras 
2
. Moreover, a recent study indicated that p110 also signals 
downstream of GPCRs 
37
.  
 
The only class Ib catalytic subunit is p110. It associates with a p101 or p84 
regulatory/adaptor subunit which appears to lack all the protein binding domains of 
p85, but contains a domain that is capable of binding to G subunits of 
heterotrimeric G-proteins 
38, 39
. Hence, the p110 functions downstream of GPCRs, 
such as chemokine receptors and the receptors for PAF and histamine. p110 is 
predominantly expressed in leukocytes, although its presence has also been 
demonstrated in endothelial cells and cardiomyocytes 
40, 41
. Like the class Ia p110 
isoforms, p110 contains a C2 domain and a Ras-binding domain, which allow lipid 
membrane and Ras binding 
1
. 
 
Two unrelated, broad-spectrum PI3K inhibitors are often used to study the 
involvement of PI3K signaling in cellular processes: wortmannin and LY294002. 
Wortmannin is an irreversible PI3K inhibitor, probably by covalent modification of a 
lysine residue in the ATP binding site of PI3K 
42
. It is reasonably specific for PI3K, 
with an IC50 of 1-10nM for all class I PI3Ks, PI3K-C2, PI3K-C2, and class III 
PI3K, whereas PI3K-C2 and the class IV PI3K-related enzymes are markedly less 
sensitive to wortmannin. However, as wortmannin is an irreversible inhibitor, it may 
have cumulative effects. LY294002 on the other hand is a pure competitive inhibitor 
of ATP and far less potent than wortmannin. It inhibits all class I, II and III PI3Ks 
with an IC50 of 1-50M. At these concentrations it also potently inhibits class IV 
PI3K-related enzymes such as mTOR and DNA-PK, and unrelated kinases such as 
casein kinase 2 (CK2) 
6
. Thus, some caution is needed when interpreting results 
obtained with these broad-spectrum inhibitors. Many pharmaceutical companies are 
now developing p110 isoform-selective inhibitors, which are suitable for studying the 
role of specific PI3K isoforms in cellular processes. Particularly p110- and p110-
selective inhibitors are being developed, as these isoforms are promising targets for 
the treatment of allergic and chronic inflammatory diseases 
43
. 
Another approach to study the role of specific PI3K isoforms is the generation of 
p110 isoform-deficient mice. This has however proven to be difficult as both p110 
and p110 knockout mice are not viable, and genetic deletion of p110 isoforms, 
particularly p110, was shown to alter the expression levels of p85 adaptor subunits, 
which may influence the phenotype of the knockout mice. The latter problem has 
been overcome by the generation of p110 isoform kinase-death knockin mice, which 
display normal expression levels of p110 and p85 subunits 
30
. The phenotypes of p110 
isoform-deficient mice are summarized in Table 3.1. Notably, recent studies with 
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heterozygous p110 knockin/wild-type mice and endothelial-specific p110 or p110 
knockout mice pointed to a critical role of p110 in angiogenesis to control 
endothelial cell migration 
44
. 
 
The PI(3,4,5)P3 produced by class I PI3Ks is degraded by two distinct lipid 
phosphatases: SH2 domain-containing inositol 5-phosphatase (SHIP) and PTEN. 
SHIP dephosphorylates the 5'-position of the inositol ring of PI(3,4,5)P3, yielding 
PI(3,4)P2 
45
. Most PH domains of proteins that bind to PI(3,4,5)P3 can also bind to 
PI(3,4)P2, although often with lower affinity. SHIP mediates an important negative 
feedback to PI3K signaling in leukocytes 
46, 47
. PTEN dephosphorylates PI(3,4,5)P3 to 
PI(4,5)P2, thereby directly counteracting the activity of class I PI3Ks. Cells that lack 
PTEN display constitutive activation of Akt and other PI3K-induced signaling 
pathways 
48-50
. As PTEN is capable of deactivating Akt signaling, it is not surprising 
that PTEN was identified as an important tumor suppressor gene. Mutations of PTEN 
are associated with Cowden syndrome, an inherited disorder characterized by the 
formation of benign tumors, called hamartomas, and an increased risk of developing 
several types of cancer, including cancers of the breast, thyroid, and uterus 
51
. PTEN 
mutations are frequently found in many types of cancer, especially glioblastoma, 
advanced prostate cancer, endometrial cancer, melanoma, and to a lesser extent breast, 
head and neck, and thyroid cancer 
52-65
. Moreover, p53, another major tumor 
suppressor, was shown to activate the transcription of PTEN and repress the 
transcription of p110, suggesting that p53 may also suppress tumorigenesis by acting 
as a negative regulator of PI3K signaling 
66, 67
. Another class of Akt activating 
mutations that was recently identified in human cancers are p110 gain-of-function 
mutations, which are particularly frequent in breast, ovarium, colorectal and other 
epithelial cancers 
68-70
. Two hotspots for gain-of-function mutations are identified in 
p110: one in the helical domain and a second in the kinase domain (Fig.3.4.) 71. 
Helical and kinase domain mutations were shown to operate by two different 
mechanisms, and both mutations can act synergistically. While kinase domain 
mutations require interaction with p85, helical domain mutations require interaction 
with Ras-GTP and are independent of p85 
72
. 
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Fig. 3.4. Mutations of the p110 gene PIK3CA found in human cancers. Arrowheads indicate the 
location of missense mutations. The percentages of mutations detected within the p85 binding domain, 
helical domain, and kinase domain are indicated below. From Samuels et al., 2004 
71
. 
 
Inhibition of PI3K has been shown to sensitize many cancer cell lines and other cells 
to the cytotoxic effects of cytokines, chemotherapeutics or irradiation 
91-95
. 
Particularly interesting in light of this thesis is the finding that inhibition of PI3K can 
sensitize cultured endothelial cells to TNF-induced apoptosis 
96-98
. Madge and co-
workers showed that TNF triggers a PI3K-mediated anti-apoptotic response in 
HUVECs that is independent of Akt and NF-B, and that inhibition of PI3K results in 
cathepsin B-dependent, but caspase-independent cell death. This suggests that PI3K 
can prevent the TNF-induced lysosomal permeabilization or activation of cathepsin B, 
and that this is sufficient to protect endothelial cells from apoptosis induced by TNF 
98, 99
. Matschurat and colleagues on the other hand reported that inhibition of PI3K 
strongly enhanced the expression of tissue factor on HUVECs costimulated with 
vascular endothelial growth factor (VEGF) and TNF. They furthermore showed that 
co-injection of wortmannin promoted the TNF-induced necrosis of MethA tumors in 
mice, suggesting that inhibition of PI3K can also sensitize tumor endothelial cells to 
TNF in vivo 
100
. 
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3.2. Akt 
 
The serine/threonine kinase Akt is a key target of class I PI3Ks and regulates cell 
survival, cell cycle progression as well as protein synthesis. In mammals, three closely 
related isoforms of Akt have been identified, Akt-1, -2, and -3 . All Akt isoforms have 
a broad tissue distribution and consist of an aminoterminal PH domain, a central 
kinase domain with an activation loop, and a carboxyterminal regulatory tail that 
contains a hydrophobic motif 
101
. The PH domain of Akt preferentially binds to 
PI(3,4,5)P3 and with somewhat lower affinity to PI(3,4)P2 
102
. Akt is cytosolic in 
unstimulated cells but translocates to the plasma membrane upon activation of PI3K 
103
. Binding of Akt to PI(3,4,5)P3 does not activate its protein kinase activity, but it 
induces a conformational change which enables PDK-1 to phosphorylate a specific 
threonine residue (Thr308 in Akt-1) in the activation loop of Akt 
102, 104, 105
. PDK-1 is 
a serine/threonine kinase that contains a PH domain that binds with high affinity to 
PI(3,4,5)P3 and PI(3,4)P2 . Like Akt, it is mainly cytosolic in unstimulated cells, and 
is recruited to the plasma membrane upon activation of PI3K 
106, 107
. PDK-1 was first 
identified by its ability to phosphorylate Thr308 of Akt-1, but meanwhile it has 
become clear that PDK-1 is also important for the regulation of other kinases that act 
downstream of PI3K, such as PKC isoforms and S6K, by phosphorylating key 
residues in their respective activation loops 
108, 109
. Full activation of Akt also requires 
phosphorylation of a serine residue (Ser473 in Akt-1) in the carboxyterminal 
hydrophobic motif 
110
. During the last ten years, a number of enzymes have been 
shown to be capable of phosphorylating this specific serine residue, including PDK-1 
(in a complex with PKC-related kinase 2), integrin-linked kinase (ILK), PKC, 
PKCII, DNA-PK, ATM, and Akt itself through autophosphorylation 111-117. Most 
recently, mTOR, in a complex with Rictor, G protein -like (GL) and SAPK-
interacting protein 1 (SIN1) (see below) was shown to mediate the phosphorylation of 
Akt-1 on Ser473 in many cell types 
118-120
. Thus, the enzyme responsible for serine 
phosphorylation of Akt will most likely differ depending on the cell type and/or the 
PI3K-activating stimulus. Once fully activated, Akt translocates from the plasma 
membrane to the cytosol and the nucleus, where it phosphorylates specific substrates 
and ultimately undergoes dephosphorylation by phosphatases, such as protein 
phosphatase 2A (PP2A), to return to its inactive state 
121, 122
.  
 
Akt plays a key role in survival signaling (Fig.3.5.). Akt directly phosphorylates and 
inactivates proteins that promote apoptosis, including Bad, human caspase-9, and 
Forkhead box O (FOXO) transcription factors 
123-128
. The residue that Akt 
phosphorylates in human caspase-9 is not conserved in other species, and Akt is 
unable to phosphorylate other important caspases such as caspase-8 and -3, suggesting 
that caspase inhibition is not a major pathway by which Akt promotes cell survival 
128, 
129
. Akt-mediated phosphorylation of Bad causes Bad to dissociate from Bcl-xL at the 
mitochondrial membrane and to form a complex with 14-3-3 proteins in the 
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cytoplasm 
130
. Similarly, phosphorylation of FOXO transcription factors promotes 
their export from the nucleus to the cytosol, where they interact with 14-3-3 proteins 
124, 131
. In addition, phosphorylation of FOXO transcription factors, and other Akt 
substrates such as tuberin, has been shown to promote the proteasomal degradation of 
these proteins 
127, 132
. FOXO transcription factors promote apoptosis by regulating the 
transcription of pro-apoptotic proteins, including FasL, TRAIL, TRADD, the pro-
apoptotic Bcl-2 family member Bim, and Bcl-6, a strong transcriptional repressor of 
Bcl-xL 
124, 133-136
. FOXO transcription factors also inhibit cell cycle progression by 
upregulating the expression of the cyclin-dependent kinase inhibitor p27
Kip1
 and 
downregulating the expression of cyclin D 
137-139
. 
Akt also directly promotes cell cycle progression by phosphorylating p27
Kip1
 and 
p21
Cip1/WAF1
. Akt-mediated phosphorylation of p27
Kip1
 induces nuclear exclusion of 
this proteins, thereby inhibiting its nuclear function, while in the case of p21
Cip1/WAF1
 
this phosphorylation increases its stability and inhibits its interaction with 
proliferating cell nuclear antigen (PCNA), a protein involved in DNA replication 
140, 
141
. Akt has also been shown to phosphorylate murine double minute homolog 2 
(MDM2), which induces its translocation from the cytoplasm to the nucleus and 
enhances its E3 ubiquitin ligase activity for p53 
142, 143
. Ubiquitination of p53 targets 
this protein for proteasomal degradation and thus inhibits p53-mediated transcription, 
cell cycle arrest, and apoptosis. 
Another substrate of Akt is ASK-1, a MAP3K involved in the activation of JNK and 
p38 MAPKs. Phosphorylation of ASK-1 by Akt was shown to inhibit the activation of 
JNK and protect cells from ASK-1-induced apoptosis 
144
. Likewise, Akt has been 
shown to phosphorylate the MAP3Ks mixed lineage kinase-3 (MLK-3) and 
SAPK/ERK kinase-1 (SEK-1), thereby promoting cell survival 
145, 146
. 
Akt also stimulates the transcription of anti-apoptotic genes by activating the 
transcription factors NF-B and CREB. Akt can directly phosphorylate CREB, 
thereby increasing its transcriptional activity which may result in the expression of 
anti-apoptotic proteins such as Bcl-2 
147, 148
. Akt may affect NF-B through multiple 
mechanisms. IL-1 has been shown to stimulate the transactivation potential of NF-B 
by phosphorylation of RelA, and the DNA-binding activity of NF-B by 
phosphorylation of NF-B1, both in a PI3K/Akt-dependent manner 149-151. 
Furthermore, Akt can associate with and activate Cot/Tpl-2, a MAP3K that has been 
implicated in the activation of NF-B by activating the IKK complex 152. TNF has 
also been shown to induce Akt-dependent phosphorylation of IKK, and this 
phosphorylation event was shown to be essential to allow the activation of NF-B 153. 
Moreover, Akt was shown to transiently interact with the IKK complex and induce 
IKK activation in cells stimulated with PDGF 
154
. A recent report by Gustin and 
colleagues delineated that the involvement of Akt in NF-B activation may differ 
depending on the cell type investigated. They demonstrated that the ratio of IKK to 
IKK varies among cell types, and that cells that express high levels of IKK, such as 
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HUVECs, do not depend on the PI3K/Akt pathway for TNF-induced activation of 
NF-B, while cells that express high levels of IKK, the target of Akt 
phosphorylation, such as the 293 cell line, do require PI3K signaling to allow NF-B 
activation 
155
. 
Finally, besides direct and transcriptional control of cell survival, Akt can also 
mediate metabolic control over cell survival through phosphorylation of GSK3 
156
. 
GSK3 was initially identified as the enzyme that regulates glycogen synthesis in 
response to insulin. When high levels of insulin are present, GSK3 is inhibited 
through phosphorylation by Akt, with the result that the storage of glucose as 
glycogen is promoted. It is now clear, however, that GSK3 phosphorylates, besides 
glycogen synthase, a broad range of substrates which are involved in cell metabolism, 
cell cycle progression, transcription, translation initiation, and even mitochondrial 
permeability transition; and GSK3 has emerged as a key target of Akt survival 
signaling under certain conditions 
157-160
. 
 
 
 
Fig. 3.5. The PI3K/Akt survival pathway. Activated class I PI3Ks produce PI(3,4,5)P3, which results 
in the recruitment of PDK-1 and Akt to the plasma membrane, where Akt becomes activated by 
phosphorylation of a specific threonine (T) and serine (S) residue. Once activated, Akt translocates to 
the cytosol and nucleus where it promotes cell survival by direct inactivation of proteins involved in the 
apoptotic cascade, by regulating the activity of transcription factors that control the expression of pro- 
and anti-apoptotic genes, by promoting cell cycle progression, and by regulating cell metabolism, 
translation and cell growth. Encircled P: phosphoserine or -threonine. 
 
As activation of Akt can promote cell survival under many conditions, including 
triggering of cell death receptors, oxidative stress, loss of cell adhesion, growth factor 
withdrawal, or starvation, it is not surprisingly that overactivation of Akt is found in 
cancer. Besides inactivation of the tumor suppressors PTEN or p53, or p110 gain-of-
function mutations, this can also be achieved by overexpression of Akt itself, which is 
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in most cases a consequence of Akt gene amplification. Overexpression of Akt is 
frequently found in breast, ovarian, prostate and pancreatic cancers 
161-163
. Perifosine 
is an Akt inhibitor that is currently evaluated in clinical trials. Perifosine is an orally 
bioavailable alkylphospholipid that structurally resembles naturally occurring 
phospholipids, such as PIs. The putative mechanism of its inhibitory effect on Akt is 
that it would interfere with the PH domain-mediated membrane recruitment of Akt 
164
. 
 
A large number of proteins have been identified that can interact with Akt. Most of 
these proteins are substrates of Akt. However, several of these interacting proteins 
have been shown to regulate the activity of Akt (Fig.3.6.) 
165
. T cell leukemia 1 
(TCL1) family members, including TCL1, TCL1b and MTCP1, are proto-oncogenes 
that specifically interact with the PH domain of Akt 
166
. Binding of TCL1 induces 
oligomerization of Akt, and this facilitates the phosphorylation of Akt. Thus, TCL1 
functions as a coactivator of Akt 
167
. In addition, TCL1 may also promote the 
translocation of activated Akt to the nucleus 
168
. Other proteins that interact with the 
PH domain of Akt include JNK-interacting protein 1 (JIP1), growth factor receptor-
binding protein 10 (Grb10), and Ras GTPase-activating protein (RasGAP), all of 
which appear to increase the activity of Akt 
169-171
. Hsp90 is a molecular chaperone 
that facilitates protein folding and protects proteins from degradation during stress. 
Hsp90 forms together with the co-chaperone Cdc37 a complex that binds a variety of 
cellular proteins, including tyrosine and serine/threonine kinases. One of these kinases 
is Akt, which interacts with the Hsp90/Cdc37 complex via its kinase domain 
172
. Since 
the Hsp90/Cdc37 complex binds to many proteins, this may facilitate the interaction 
of Akt with some of its substrates, such as eNOS 
173
. Homolog 3 of Drosophila 
Tribbles (TRB3) is a protein that interacts with the activation loop in the kinase 
domain of Akt and thereby inhibits both the serine and threonine phosphorylations of 
Akt that are required for its activation 
174
. TRB3 has also been shown to interact with 
the RelA subunit of NF-B, and downregulation of TRB3 by RNAi was shown to 
inhibit TNF-induced apoptosis of 293 cells 
175
. Carboxyterminal modulator protein 
(CTMP) inhibits the phosphorylation of Akt by interacting with the carboxyterminal 
regulatory tail of Akt. Unphosphorylated CTMP is membrane-associated and 
inactivates bound Akt at the plasma membrane. Stimulation of cells promotes the 
phosphorylation of CTMP and the release and subsequent activation of Akt 
176
. 
Another negative regulator of Akt is Keratin-10, a major component of intermediate 
filaments of the cytoskeleton. Binding of Keratin-10 sequestrates Akt to the 
cytoskeleton and inhibits its intracellular translocation 
177
. 
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Fig. 3.6. Interacting proteins that regulate the activity of Akt. The interacting proteins are listed 
under the domain of Akt they interact with. * The domain of Akt that Keratin-10 interacts with is 
currently unknown. Adapted from Du and Tsichlis, 2005 
165
. 
 
To determine the role of the individual Akt isoforms, Akt isoform-specific knockout 
and double knockout mice have been generated. Akt-1 knockout mice display 
increased perinatal mortality and a 20-30% reduction in body weight. MEFs isolated 
from Akt-1-deficient mice are more susceptible to apoptosis induced by TNF or other 
stimuli 
178
. Akt-1 knockout mice also show impaired platelet aggregation and 
responses, increased pathological angiogenesis and impaired maturation of new blood 
vessels 
179, 180
. Consistent with this vascular phenotype, Akt-1 was shown to be the 
main isoform expressed in endothelial cells 
180
. Akt-2-deficient mice have normal 
growth, but develop a diabetes-like syndrome with insulin resistance, 
hyperinsulinemia, hyperglycemia and glucose intolerance, suggesting an important 
role of Akt-2 in glucose metabolism 
181, 182
. A point mutation of Akt-2 has also been 
found in one case of familial diabetes 
183
. Like Akt-1-deficient mice, Akt-2-deficient 
mice show defects in platelet aggregation and thrombus formation 
184
. Akt-3 knockout 
mice are viable but exhibit a reduction in brain size due to decreased neuronal cell 
size and numbers 
185, 186
. Mice lacking both Akt-1 and Akt-2 die shortly after birth, 
display severe growth deficiencies and fail to develop normal skin, skeletal muscle, 
bones, and fat tissue 
187
. Mice lacking both Akt-1 and Akt-3 die around embryonic 
day 12, with severe impairments in growth, cardiovascular development, and 
organization of the nervous system 
188
. In contrast, mice deficient for both Akt-2 and 
Akt-3 are viable, but display a substantial reduction in body weight and organ size, 
and severe defects in glucose metabolism. Even mice lacking both Akt-2 and Akt-3 
that have only one functional allele for Akt-1 were shown to be viable, demonstrating 
that minimal amounts of Akt-1 are sufficient for embryonic development and 
postnatal survival 
189
. 
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3.3. mTOR 
 
Besides cell survival, the PI3K/Akt pathway is also a major regulator of mRNA 
translation, through activation of mTOR. Akt activates mTOR by inactivation of the 
tuberous sclerosis complex (TSC), which negatively regulates mTOR kinase activity. 
The TSC is formed by two proteins, called TSC1 (or hamartin) and TSC2 (or tuberin). 
Akt directly phosphorylates TSC2, which disrupts the complex with TSC1 and leads 
to proteasome-mediated degradation of this protein 
127, 190, 191
. Interestingly, also MK2 
has been shown to phosphorylate TSC2, which creates a 14-3-3 binding site 
192
. The 
heterodimeric TSC complex negatively regulates mTOR by inhibiting Ras homolog 
enriched in brain (Rheb), a small GTPase required for the activation of mTOR 
193-195
. 
TSC2 has a GTPase-activating protein (GAP) activity for Rheb and stimulates the 
conversion of the active GTP-bound form of Rheb to the inactive GDP-bound form 
196
. Rheb interacts with mTOR and GL, and activates the kinase activity of mTOR 
via a still unknown mechanism (Fig.3.7.) 
197
. 
 
mTOR is a large serine/threonine kinase belonging to the PI3K-related kinase (PIKK) 
family, also called class IV PI3Ks. It contains from amino- to carboxyterminus: a 
protein-protein interaction domain containing 20 HEAT repeats, a focal adhesion 
targeting (FAT) domain, a FKB12-rapamycin-binding (FRB) domain, and a second 
carboxyterminal FAT domain. In the cell, mTOR is present in two distinct mTOR 
complexes (mTORCs), called mTORC1 and mTORC2. mTORC1 consists of three 
proteins: mTOR, GL (or mLST8), and regulatory associated protein of mTOR 
(Raptor). This complex largely controls translation and cell growth in response to 
nutrients. mTORC2 consists of mTOR, GL, rapamycin-insensitive companion of 
mTOR (Rictor), and SIN1. mTORC2 controls actin cytoskeleton dynamics, but has 
also been shown to be responsible for the activating serine phosphorylation of Akt 
(Fig.3.7.) 
118, 198
. Only mTORC1 is sensitive to direct inhibition by the drug 
rapamycin. Rapamycin binds within the cell with the protein FKBP12, and this 
complex binds to the FRB domain of mTORC1, but not of mTORC2. Consequently, 
acute rapamycin treatment does not lead to a decrease in Akt phosphorylation and 
activity 
118
. However, Sarbassov and co-workers demonstrated that prolonged 
exposure to rapamycin inhibits mTORC2 function by blocking the association of 
newly formed mTOR with Rictor and thus the formation of mTORC2 
199
. Therefore, 
prolonged treatment with rapamycin may inhibit Akt activity in certain cell types. 
This was recently shown to be the case in HUVECs stimulated with TNF, VEGF or 
insulin 
200
. 
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Fig. 3.7. The mTOR pathway. See text for details. It is currently unclear whether Rheb also regulates 
the mTOR-Rictor complex (mTORC2). Adapted from Corradetti and Guan, 2006 
198
. 
 
The best described function of mTORC1 is its regulation of translation by 
phosphorylating the key translation regulators S6K and eukaryotic initiation factor 4E 
(eIF4E) binding protein 1 (4EBP1) (Fig.3.7.). Under basal conditions, 4EBP1 and 
S6K are bound to, respectively, eIF4E on the mRNA 5’cap, and eIF3 in the translation 
pre-initiation complex; but upon stimulation, mTOR associates with eIF3 and 
phosphorylates S6K and 4EBP1, causing their dissociation from eIF3 and eIF4E 
201
. 
S6K then associates with PDK-1, which phosphorylates the activation loop of S6K, 
resulting in full activation 
109
. S6K subsequently phosphorylates the 40S ribosomal 
protein S6, the RNA-binding protein eIF4B and other targets. eIF4B can then 
associate with eIF3 and eIF4A, allowing the binding of eIF4G and the assembly of a 
functional translation initiation complex 
201
. eIF4G is a large scaffolding protein that 
interacts with many proteins. eIF4G is phosphorylated in a mTOR-dependent manner, 
although the function of this phosphorylation is still unclear 
202
. eIF4A is an ATP-
dependent RNA helicase required to unwind regions of secondary structure in the 
mRNA 
203
. The translation initiation complex thus formed is particularly efficient in 
the translation of (1) mRNAs encoding proteins involved in ribosome biogenesis due 
to S6 phosphorylation, (2) mRNAs with 7-methyl guanine caps due to mTOR-
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dependent phosphorylation of 4E-BP1, and (3) mRNAs with long, complex 5′UTRs 
due to the recruitment of eIF4A 
201, 204-207
. In this way, mTOR may control up to 15% 
of the bulk translation of the cell 
198
. Translation regulation, especially through eIF4E, 
is directly linked to cell growth, via key growth promoting proteins such as c-Myc and 
cyclin D1 
208
. 
In addition to S6K and 4EBP1, mTOR also induces the activation of other proteins 
involved in translation and ribosome biogenesis. It was shown that TIF-1A, a 
transcription factor for RNA polymerase I, which is essential for the transcription of 
ribosomal RNAs, is activated in a mTOR-dependent manner 
209
. Eukaryotic 
elongation factor 2 (eEF2), a protein that mediates the translocation step of translation 
elongation in which the ribosome moves relative to the mRNA by one codon, is also 
regulated by mTOR. eEF2 is negatively regulated by eEF2 kinase. mTOR indirectly 
(partly through S6K) phosphorylates eEF2 kinase at several residues, thereby 
inactivating its kinase activity for eEF2 
210-212
. Recently it was shown that eEF2 
kinase may also be involved in the activation of autophagy (see below) 
213, 214
.  
 
Translation and ribosome biogenesis are among the most energetically intensive 
processes that a cell can perform 
215
. Therefore, these activities must be closely 
regulated during times of low energy (ATP) or nutrient (amino acid) availability. One 
mechanism by which low energy levels couple to the regulation of translation is via 
inhibition of mTOR. High amounts of AMP in the cell, which reflect a low energy 
status, activate AMP-activated protein kinase (AMPK). AMPK subsequently 
phosphorylates several targets to enhance catabolism and suppress anabolism, for 
example TSC2. AMPK-dependent phosphorylation of TSC2 enhances its GAP 
activity for Rheb and thus inhibits mTOR activity 
216
. Full activation of AMPK also 
requires phosphorylation of its activation loop by the serine/threonine kinase LKB1, 
which is a tumor suppressor that is mutated in the human Peutz-Jeghers syndrome 
217, 
218
.  
The availability of amino acids also regulates mTOR activity. Particularly leucine 
appears to be effective in activating mTOR 
219
. Some recent reports have identified 
the class III PI3K hVps34 as a critical regulator of mTOR activity 
17, 18, 220
. hVps34 
was shown to be activated by the presence of amino acids and subsequently activates 
mTOR and S6K downstream of TSC and Rheb, although the mechanism involved is 
still unclear. hVps34 also functions in the regulation of autophagy, and this process is 
negatively regulated by mTOR 
221
. Autophagy is a catabolic process involving the 
degradation of cellular components through the lysosomal machinery. Since this 
process likely supplies intracellular amino acids to maintain mTOR signaling, there is 
some logic in connecting these processes 
222
. Finally, many other forms of cellular 
stress, including hypoxia, ROS and osmotic stress, have been shown to regulate the 
activity of mTOR 
198
.  
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4. ANGIOGENESIS 
 
4.1. Background and definitions 
 
Mammalian cells require oxygen and nutrients for their survival and are therefore 
located within 100 to 200µm (the diffusion limit of oxygen) of blood vessels. 
Multicellular organisms develop and recruit new blood vessels by two distinct 
mechanisms: vasculogenesis and angiogenesis, generally called neovascularization. 
During embryonic development the first blood vessels arise from endothelial 
precursor cells (EPCs), which share an origin with hematopoietic progenitor cells 
(hemangioblasts). These EPCs assemble into a primitive vascular labyrinth of small 
capillaries, a process called vasculogenesis. Angiogenesis is the process whereby new 
vessels grow from pre-existing vessels through sprouting and remodeling. In the 
growing embryo the primitive vascular plexus further expands through angiogenesis 
into a highly organized vascular network of larger vessels branching into smaller 
ones, and with functional arteries, arterioles, capillaries, venules and veins. Capillaries 
are the smallest blood vessels, measuring only 5 to 10 µm in diameter, and enable the 
exchange of oxygen, nutrients and waste products between blood and surrounding 
tissues. Capillaries, together with post-capillary venules, are the vessels on which 
cytokines act to regulate vascular permeability and recruitment of leukocytes to 
inflamed tissue. The wall of capillaries consists of a single layer of endothelial cells 
(ECs). Larger vessels, however, become covered with mural cells in a process called 
vessel maturation or arteriogenesis. These mural cells, in essence pericytes and 
smooth muscle cells (SMCs), provide strength to the vessels and allow regulation of 
vessel perfusion 
1
. 
 
After birth, angiogenesis still contributes to further growth, but in the adult most 
blood vessels remain quiescent and angiogenesis normally only occurs in wound 
healing, in the cycling ovary and in the placenta during pregnancy. However,  in 
certain diseases, especially cancer, angiogenesis may become prominent (see below). 
Angiogenesis is tightly regulated by a balance of many pro- and anti-angiogenic 
factors (see Table 4.1.). In normal, healthy tissue, pro-angiogenic factors are 
delicately balanced by anti-angiogenic factors, keeping the angiogenic program off. 
During tissue repair or tumor growth on the other hand, pro-angiogenic factors are 
produced and/or anti-angiogenic factors are downregulated, thereby tipping the 
balance towards angiogenesis. This system is known as the angiogenic switch 
(Fig.4.1.) . 
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Fig. 4.1. The balance hypothesis of the ‘angiogenic switch’. Angiogenesis is tightly controlled by the 
balance of two sets of counteracting factors: angiogenesis activators and inhibitors (or pro- and anti-
angiogenic factors, respectively). In many pathological conditions this balance is disturbed, leading to 
either excessive or impaired angiogenesis. 
 
Two main forms of angiogenesis are generally recognized: sprouting angiogenesis 
and intussusception. In sprouting angiogenesis, pro-angiogenic factors stimulate 
endothelial cells in pre-existing blood vessels to degrade the basement membrane and 
to start to proliferate into the surrounding matrix towards the angiogenic stimulus, in 
the form of a solid sprout that remains connected with the original vessel. By contrast, 
in intussusceptive angiogenesis, the endothelial cells extend into the lumen of the pre-
existing blood vessel to divide a single vessel into two parallel vessels. It has now 
become clear that EPCs (also called angioblasts) from the bone marrow or present in 
circulation may also contribute to neovascularization in the adult (Fig.4.2.) 
2
.  
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Fig. 4.2. Angiogenesis and vasculogenesis. (A) Genesis of the vascular system during embryonic 
development. Mesodermal cells differentiate into hemangioblasts leading to the formation of primitive 
blood islands. The peripheral hemangioblasts differentiate into angioblasts, the precursors of 
endothelial cells. Then, the angioblasts migrate allowing the fusion of blood islands and their 
remodeling into tubular structures, giving rise to a first primitive vascular plexus. This vascular plexus 
remodels into larger vessels, which then further branch through the process of angiogenesis. (B) 
Mechanisms of angiogenesis. In sprouting angiogenesis, a sprout of endothelial cells expands and 
migrates towards the angiogenic stimulus, guided by an endothelial tip cell. Intussusception involves 
the insertion of interstitial tissue columns into the lumen of pre-existing blood vessels. EPCs recruited 
from the bone marrow or from circulation may also contribute to the endothelial lining of new blood 
vessels. Adapted from Lamalice et al., 2007 and Auguste et al., 2005 
3, 4
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4.2. Regulation of angiogenesis 
 
Table 4.1. Some naturally occurring angiogenesis activators and inhibitors. 
Activators Inhibitors 
VEGF family members VEGF-R1, soluble VEGF-R1 
VEGF-Rs, NRP-1 soluble NRP-1 
Ang-1, Tie-2 Ang-2* 
PDGF-BB, PDGF-Rs TSP-1, TSP-2 
TGF-1*, endoglin, TGF-Rs Angiostatin, related plasminogen kringles 
FGF, HGF Endostatin (collagen XVIII fragment) 
MCP-1, IL-8, other chemokines* Vasostatin; Calreticulin 
Integrins 11, v15, v3, v5, 51 Platelet factor-4 
VE-cadherin, PECAM IFN-, IFN-, IFN- 
Ephrins Meth-1, Meth-2 
Plasminogen activators, MMPs TIMPs, MMP inhibitors, PEX 
PAI-1* IP-10 
NOS, COX-2 IL-4, IL-12, IL-18 
AC133 Prothrombin kringle-2 
Id1/Id3 Prolactin 16kDa fragment 
TNF* VEGI 
Proliferin Canstatin; Tumstatin 
Angiogenin Osteopontin fragment; Fibronectin fragment 
Pleiothrophin Fragment of SPARC; Antithrombin III fragment 
Leptin Maspin; Restin; Proliferin-related protein 
* opposite effects in some contexts. Adapted from Carmeliet et al., 2000 
2
. 
 
4.2.1. Positive regulators of angiogenesis 
 
In 1984, the first pro-angiogenic factor was isolated by Shing and co-workers from a 
rat chondrosarcoma, based on its affinity for heparin 
5
. After purification and 
sequencing it turned out to be basic fibroblast growth factor (bFGF) 
6
. The fibroblast 
growth factor (FGF) family comprises more than 20 members, of which two have 
been associated with angiogenesis: acidic FGF (aFGF) (or FGF-1), and bFGF (or 
FGF-2). All FGF family members have high affinity for heparin and can associate 
with cell-surface heparan sulfate proteoglycans. Four tyrosine kinase receptors for 
FGFs have been identified: FGF-R1, -R2, -R3, and -R4. Both aFGF and bFGF are 
potent inducers of angiogenesis in many angiogenesis models, such as the chick 
chorioallantoic membrane (CAM) assay and the rabbit corneal neovascularization 
assay, even more potent than VEGF 
6-8
. aFGF and bFGF induce proliferation and 
migration of endothelial cells, production of urokinase-type plaminogen activator 
(uPA) and matrix metalloproteinases (MMPs), as well as the formation of tubular 
structures in vitro 
9-11
. By contrast, genetic manipulations have revealed that aFGF 
and bFGF have no significant role in embryonic angiogenesis. Both aFGF and bFGF 
knockout mice have normal vascular development, and even double knockout mice 
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are viable, suggesting that aFGF and bFGF play only limited roles under 
physiological conditions 
12-14
. However, bFGF-deficient mice display mild defects in 
wound healing, and topical application of aFGF or bFGF has been shown to 
accelerate wound healing in a number of animal models, pointing to a role of these 
FGFs in wound healing and vascular repair 
15, 16
. aFGF and bFGF are potent mitogens 
for endothelial cells, fibroblasts, SMCs and keratinocytes, and hence these growth 
factors can induce the rapid formation of granulation tissue that fills up a wound space 
early in the wound healing process 
17-20
. Interestingly, aFGF and bFGF lack a signal 
peptide for secretion by the endoplasmic reticulum-Golgi pathway. It has been 
suggested that these growth factors are stored within the cell, and are only released in 
case of cell damage or death 
21, 22
. aFGF and bFGF may also be secreted through an 
alternative pathway 
23, 24
. The high affinity of aFGF and bFGF for heparin and 
heparan sulfate allows storage of these FGFs in the extracellular matrix (ECM) and on 
the surface of cells until they are released by the actions of proteinases and 
heparinases that are produced during the angiogenic process 
25
.  Elevated levels of 
bFGF are found in many tumors and in certain tumor types, particularly melanoma, 
the bFGF levels appear to correlate with intratumoral microvessel density and cancer 
progression/prognosis 
11
. 
 
VEGF is probably the most important activator of both physiological and pathological 
angiogenesis. The VEGF family consists of seven members, called VEGF (or VEGF-
A), VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and placental growth factor 
(PlGF). Alternative exon splicing of the VEGF RNA results in the generation of at 
least six VEGF isoforms, of which VEGF165, the isoform consisting of 165 amino 
acids after cleavage of a signal sequence, is the predominant isoform 
26
. These VEGF 
family members exert their effects via three tyrosine kinase receptors: VEGF-R1 (or 
Flt-1), VEGF-R2 (or Flk-1/KDR), and VEGF-R3 (Fig.4.3.). VEGF binds to both 
VEGF-R2 and VEGF-R1. In addition, VEGF165 also binds to neuropilin 1 (NRP1) and 
NRP2, which act as coreceptors for VEGF-R2, and cell-surface heparan sulfate 
proteoglycans 
27
. Genetic manipulations have revealed the fundamental importance of 
the VEGF signaling pathway for physiological blood vessel formation in mice. All 
VEGF, VEGF-R1, VEGF-R2 or NRP1 knockout mice die in utero, having incomplete 
or absent vascular structures 
28-30
. Even mice having only a single allele of VEGF are 
embryonic lethal 
31, 32
. 
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Fig. 4.3. VEGF family members, their receptors, and most important signaling pathways. The 
VEGF-Rs have seven extracellular immunoglobulin-like domains. The extracellular domain of VEGF-
R3 is once cleaved and joined with a disulfide (S-S) bond. VEGF-R2 is the main signaling receptor on 
ECs and is a major regulator of vasculogenesis, angiogenesis, vasodilation and vascular permeability. 
VEGF-R3 is the main signaling receptor on lymphatic ECs and is involved in lymphangiogenesis. 
VEGF-R3 has also been associated with tumor angiogenesis. The extracellular domain of VEGF-R1 is 
also expressed as a soluble form (sR1). This soluble form of VEGF-R1 is an important modulator for 
the placental vasculature. Besides on ECs, VEGF-R1 is also expressed on monocytes and its activation 
leads to chemotaxis and tissue factor production in monocytes. NRPs are coreceptors for VEGF-R2. 
NRP1 binds VEGF165, PlGF-2, VEGF-B and VEGF-E; NRP2 binds VEGF145, VEGF165, PlGF-2 and 
VEGF-C. Adapted from Roy et al., 2006 
27
. 
 
VEGF was originally described as a vascular permeability factor secreted by 
carcinoma cell lines that enhanced permeability of skin blood vessels 
33
. Indeed, 
VEGF can enhance vascular permeability by increasing the vesicular transport 
through the cytoplasm of the endothelial cells, by inducing endothelial fenestrations, 
and by weakening endothelial cell-cell junctions, at least in part through tyrosine 
phosphorylation of VE-cadherin  
34-37
. This increased permeability, together with the 
VEGF-induced vasodilation, may be considered as the first step in the angiogenic 
process 
38
. Vasodilation and increased permeability lead to leakage of fluid and 
plasma proteins such as fibrin into the surrounding tissue. Cross-linked fibrin deposits 
may function as a provisional ECM that supports endothelial cell migration and new 
blood vessel formation 
39
. VEGF induces the production of proteolytic enzymes by 
endothelial cells, including MMPs and the plasminogen activators uPA and tissue-
type plasminogen activator (tPA) 
40-42
. MMPs and plasminogen activators mediate the 
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breakdown of the basement membrane that surrounds the blood vessel and ECM 
components, which allows the migration of endothelial cells. Plasminogen activators 
are serine proteases that convert the pro-enzyme plasminogen to plasmin, which then 
degrades fibrin and other ECM components. Plasmin may also activate MMPs 
43
. uPA 
is secreted as an inactive pro-enzyme, binds to the uPA receptor (uPAR) on 
endothelial cells and is proteolytically activated by MMP-2. The expression of uPAR 
on endothelial cells is also increased by VEGF 
44
. Plasminogen activators are 
inhibited by plasminogen activator inhibitor-1 (PAI-1), which is also induced by 
VEGF 
40
. It has been reported that uPAR promotes endothelial cell adhesion on the 
ECM component vitronectin, and that PAI-1 blocks this adhesion and thus enhances 
endothelial cell migration on vitronectin 
45
. MMPs are a family of zinc-dependent 
endopeptidases that are capable of degrading various components of the ECM and 
play an important role in tissue remodeling events such as angiogenesis and tumor 
invasion. MMPs are secreted as inactive pro-enzymes, which become activated by 
proteinases such as plasmin or other MMPs. VEGF induces the expression of the 
collagenase MMP-1 and the activation of the gelatinase MMP-2, which is 
constitutively secreted by endothelial cells 
41, 42, 46
. MMP-2 was shown to be 
responsible for the VEGF-induced activation of uPA bound to its cell-surface receptor 
uPAR 
47
. Besides by inducing ECM breakdown, VEGF also stimulates the migration 
of endothelial cells by directly increasing the motility of these cells 
3, 48
. VEGF 
furthermore induces proliferation and survival of endothelial cells through both the 
PI3K/Akt and MAPK pathways 
49-52
. Finally, VEGF induces sprouting and the 
formation of tubular structures in various in vitro and in vivo models 
53-55
. It has been 
shown in a retinal angiogenesis model that angiogenic sprouts are guided by tip cells 
at the invading front of angiogenic sprouts. These tip cells appear to cluster VEGF-
R2s and follow a VEGF gradient 
56
. VEGF-R1 and VEGF-R2 are also expressed on 
EPCs and VEGF may induce mobilization and recruitment of these cells to the site of 
neovascularization 
57, 58
. In conclusion, VEGF mediates the whole angiogenic process 
up to the formation of immature, but functional neovessels. Interestingly, sustained 
expression of VEGF, as is the case in many tumors, actually inhibits the maturation of 
new blood vessels, resulting in vascular beds that are tortuous, unorganized, dilated 
and leaky 
59, 60
. 
The expression of VEGF is regulated by the oxygen concentration in the cell via the 
transcription factors hypoxia-inducible factor (HIF)-1 and HIF-2. HIF-1 is a 
heterodimer of HIF-1 and aryl hydrocarbon nuclear translocator (ARNT), also called 
HIF-1. Under normoxic conditions, HIF-1 is a target for HIF prolyl hydroxylase, 
which makes HIF-1 a target for E3 ubiquitin ligase activity, leading to quick 
degradation by the proteasome. Under hypoxic conditions, HIF prolyl hydroxylase is 
inhibited and HIF-1 is stabilized. HIF-1 can then bind to HIF-responsive elements 
(HREs) in the promoter regions of VEGF and other genes, thereby inducing 
expression 
61
. The von Hippel-Lindau tumor suppressor protein (pVHL) plays an 
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important role in regulating HIF-1. pVHL binds to the modified HIF-1 and forms the 
recognition component for the E3 ubiquitin ligase complex that ubiquitinates HIF-1 
62, 63
. Mutations of the VHL gene are associated with increased VEGF expression and 
angiogenesis 
64
. The expression of VEGF is also induced by growth factors, such as 
EGF, FGF, PDGF, TGF- and TGF-, cytokines such as IL-1 and IL-6, and certain 
hormones 
65
. 
PlGF is a member of the VEGF family that was first identified in placenta but is now 
known to be also present in other tissues such as heart and lungs 
66
. Four human 
isoforms of PlGF have been described: PlGF-1, -2, -3, and -4 
67
. In mice, only PlGF-2 
is expressed 
68
. All isoforms bind to VEGF-R1, and PlGF-2 also binds to NRP1 and 
NRP2. Like VEGF, PlGF stimulates endothelial cell growth, migration and survival, 
recruitment of EPCs, and angiogenesis under certain conditions 
69-71
. In addition, 
PlGF has also been shown to be a survival factor for monocytes and macrophages, 
and is capable of recruiting these cells to sites of inflammation and angiogenesis 
72-74
. 
In contrast to mice deficient for VEGF signaling, PlGF knockout mice develop 
normally and are healthy and fertile 
75
. These mice have normal physiological 
angiogenesis. However, PlGF knockout mice have impaired angiogenesis under 
pathological conditions such as ischemia, wound healing and cancer. Thus PlGF 
appears to be specific for pathological angiogenesis, making it an interesting target for 
anti-angiogenic therapy 
71, 75, 76
. Most of the angiogenic effects of PlGF appear to be 
dependent on VEGF. In the absence of PlGF, VEGF binds to VEGF-R1, with 
minimal signaling activity. However, when PlGF is expressed, it displaces VEGF 
from VEGF-R1, making it available for signaling via VEGF-R2. VEGF-R1/VEGF-
R2 heterodimers have also been found that are activated by PlGF-2/VEGF 
heterodimers. Furthermore, binding of PlGF to VEGF-R1 has been shown to enhance 
VEGF-R2 phosphotyrosine levels, suggesting that there is cross-talk between these 
two receptors 
77
. To add to complexity, PlGF-1/VEGF heterodimers have been 
identified that are functionally inactive. Thus, PlGF-1 may function as a natural 
antagonist of VEGF 
78
. 
 
Angiopoietins (Angs) are a family vascular-specific growth factors that play an 
important role in angiogenesis. The human Ang family consists of three members, 
called Ang-1, Ang-2 and Ang-4. Mice do not express Ang-4, but express a fourth Ang 
family member, called Ang-3, which is believed to be the mouse orthologue of human 
Ang-4 
79
. The Angs signal via the tyrosine kinase receptor Tie-2, which is mainly 
expressed on endothelial cells. There is also a closely related Tie-1, which is a so-
called orphan receptor 
80
. Ang-1 is generally considered as an activator of Tie-2, while 
Ang-2 is considered to be a negative regulator of Tie-2 signaling. Ang-1 is mainly 
produced by mural cells, in essence pericytes and SMCs, and stabilizes the interaction 
of endothelial cells with mural cells. Mice overexpressing Ang-1 produce enlarged 
and more numerous vessels with highly regulated junctional complexes, that are 
resistant to VEGF-induced permeabilization 
81, 82
. Ang-1 has also been shown to 
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induce sprouting angiogenesis in vitro and this activity was synergistic with VEGF, 
suggesting that Ang-1 does not counteract VEGF-induced angiogenesis 
83
. Ang-1 
confers survival signals to endothelial cells via the PI3K/Akt pathway and 
upregulation of anti-apoptotic proteins such as the IAP family member survivin 
84
. 
Ang-2 is mainly produced by endothelial cells at sites of vascular remodeling. Ang-2 
thus regulates Tie-2 activity in an autocrine manner. Binding of Ang-2 to Tie-2 may 
render the receptor less responsive to Ang-1, leading to destabilization of the vessel 
85
. 
Mice overexpressing Ang-2 or deficient for Ang-1 or Tie-2 are embryonic lethal and 
display vascular defects attributed to defective vascular remodeling and disrupted 
interaction between endothelial cells and mural cells 
86-88
. In the absence of VEGF, 
Ang-2 induces regression of angiogenic sprouts, whereas in the presence of VEGF it 
promotes vascular sprouts 
80, 89
. The expression of Ang-1 and Ang-2 is inversely 
regulated. Ang-2 is upregulated by VEGF, hypoxia and inflammatory cytokines such 
as TNF 
90, 91
. By contrast, the expression of Ang-1 is downregulated by these stimuli 
80, 92
. Recently, Shim and colleagues have suggested that spatiotemporal changes of 
the Ang-1/Ang-2 balance are crucial to regulate the angiogenic cycle (Fig.4.4.) 
80
.  
 
Certain integrins appear to have specific functions in angiogenesis. Integrins mediate 
the interactions of endothelial cells with the ECM. Several integrins were shown to be 
upregulated in endothelial cells during angiogenesis, including the integrins 11, 
21, v3, v5 and 51 
93-96
. 11 and 21 bind to collagen and laminin, v5 
binds to vitronectin, 51 binds to fibronectin, while v3 binds to many ECM 
components containing an RGD (arginine, glycine, aspartic acid) sequence, such as 
vitronectin, fibronectin and fibrinogen. All these integrins have been shown to play 
crucial roles in angiogenesis and inhibition of these integrins using specific 
antagonists can completely block angiogenesis in experimental models 
96-100
. The 
activation of integrins transmits important survival signals and allows the functional 
connection between focal adhesions and the actin cytoskeleton that is required to 
drive cell migration 
101
. These integrins may also function as receptors for pro-
angiogenic growth factors. The integrins 51 and  v5 have been shown to bind 
Ang-1 and Ang-2, and this interaction promoted the migration of endothelial cells 
102
. 
Similarly it was shown that endothelial cells can adhere to the VEGF isoforms 
VEGF165 and VEGF189 via the integrin v3 and this interaction also stimulated 
endothelial cell migration and survival 
103
. v3 can also directly promote the 
migration and invasion of endothelial cells by binding to MMP-2 
104
. Furthermore, it 
has been shown that v3 associates with VEGF-R2 and participates in the full 
activation of this receptor 
105
. Antagonists of v3 potently blocked angiogenesis 
induced by VEGF, but not by bFGF. By contrast, inhibition of v5 blocked bFGF- 
but not VEGF-induced angiogenesis 
98
. Together, these data suggest that there is a 
close relationship between v3 and VEGF-signaling. 
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Fig. 4.4. The angiogenic cycle. (1) The angiogenic switch is triggered by hypoxia, inflammation, or 
genetic mutations that disrupt the balance between pro- and anti-angiogenic factors. (2) The 
upregulation of Ang-2 in response to these stimuli destabilizes the endothelium by decreasing the 
phosphorylation status of Tie-2. This results in increased vessel plasticity and more responsive 
endothelial cells. (3) The activated matrix proteases promote mural cell detachment and facilitate 
endothelial chemotaxis and sprouting in response to VEGF, Ang-1, FGF, PDGF, and hepatocyte 
growth factor (HGF). (4) As the angiogenic stimuli and the expression of Ang-2 gradually decrease, an 
equilibrium is reached that enables reinvestment of basement membrane and ECM, and mural cell 
recruitment to the nascent vasculature. Adapted from Shim et al., 2007 
80
. 
 
Ephrins and Eph receptors are a large family of membrane-bound/transmembranous 
ligands and tyrosine kinase receptors that play essential roles in axon guidance in the 
developing nervous system, but also in angiogenesis. Mouse embryos deficient for 
ephrin-B2 or its EphB4 receptor suffer fatal defects in early angiogenic remodeling 
106, 107
. Ephrin-B2 and EphB4 display remarkably reciprocal expression patterns. 
Ephrin-B2 is specifically expressed on arterial endothelial cells and SMCs, while 
EphB4 is mainly expressed on venous endothelial cells. Ephrin-B2/EphB4 signaling 
is critical for the establishment of arterial and venous identities and participates in the 
formation of arteriovenous contact by arresting endothelial cell migration at the 
arterial-venous interface 
108
. Ephrin-B2 and EphB4 have also been linked to breast 
cancer. Breast cancer cells express EphB4, while the tumor vasculature expresses 
ephrin-B2, suggesting the ephrin-B2/EphB4 signaling can also support tumor 
angiogenesis 
109, 110
. Ephrin-A1 has also been implicated in angiogenesis. Both TNF 
and VEGF induce the expression of ephrin-A1 in HUVECs as an immediate early 
gene product 
111, 112
. 
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PDGF-BB and TGF-1 play essential roles in vessel maturation. Nascent vessels are 
stabilized by the recruitment of mural cells and the production of ECM. PDGF-BB is 
secreted by endothelial cells, presumably in response to VEGF, and induces the 
recruitment of PDGF-R-positive mesenchymal progenitor cells, which then 
differentiate to vascular mural cells 
113
. Mural cells in turn produce Ang-1, which then 
further stabilizes the vessel. PDGF-BB also induces endothelial cell proliferation and 
tube formation in vitro and has potent angiogenic activity in the CAM assay 
114, 115
. 
TGF-1 and its receptors (TGF-RI, TGF-RII and endoglin) promote vessel 
maturation by stimulating ECM production and by inducing differentiation of 
mesenchymal cells to mural cells 
116, 117
. TGF-1 is expressed by a number of cells, 
including endothelial cells and mural cells, and, depending on the context and 
concentration, can have pro- or anti-angiogenic effects. At low concentration, it 
contributes to angiogenesis by upregulating proteinases and Id1, a protein required for 
proliferation and migration. At high doses, TGF-1 inhibits endothelial cell growth 
and induces vessel maturation 
59, 118
. TGF-1 also induces the expression of PAI-1, 
which promotes vessel maturation by preventing degradation of the provisional matrix 
around the nascent vessel 
59
. 
 
As endothelial cells are among the most important target cells of TNF, it is not 
surprising that TNF can also modulate the angiogenic process. Like it is the case for 
TGF-1, the angiogenic effect of TNF appears to be context and concentration 
dependent. TNF is a potent inducer of vessel permeabilization, and strongly 
synergizes with VEGF for this effects 
119
. It has even been shown that TNF knockout 
mice fail to respond to VEGF with an increase in vascular permeability, suggesting 
that TNF acts as a permissive factor for VEGF-induced vessel permeabilization, 
which is a crucial step early in the angiogenic process 
120
. Like VEGF, TNF induces 
expression of angiogenic factors such as ephrin-A1 and Ang-2 in cultured endothelial 
cells 
90, 111
. Ang-2 can in turn sensitize endothelial cells toward TNF and modulate 
TNF-induced expression of endothelial cell adhesion molecules 
121
. Low doses of 
TNF can stimulate chemotaxis and the formation of capillary tube-like structures of 
cultured endothelial cells in vitro, and induce capillary blood vessel formation in the 
rabbit cornea and CAM models of angiogenesis 
122, 123
. By contrast, TNF inhibits 
endothelial cell proliferation in response to bFGF in vitro, and at higher dose it can 
even induce endothelial cell apoptosis 
123, 124
. In particular the combination of TNF 
and IFN- appears to be capable of inducing endothelial cell death 125.  
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4.2.2. Negative regulators of angiogenesis 
 
Thrombospondin-1 (TSP-1) was the first naturally occurring inhibitor of angiogenesis 
to be described 
126, 127
. A few years later, a closely related protein, TSP-2, was also 
found to inhibit angiogenesis 
128
. TSPs are a family of ECM proteins that can bind to 
cell surface receptors and other ECM components. TSP-1 and TSP-2 are produced by 
several cell types, including platelets, endothelial cells, and fibroblasts. TSP-1 binds 
to integrin v3 as well as to CD36, a member of the scavenger receptor family, on 
endothelial cells 
129
. TSP-1 inhibits endothelial cell migration and proliferation, 
induces apoptosis, and blocks tube formation 
130, 131
. Moreover, TSP-1 renders 
endothelial cells refractory to stimulation with VEGF or bFGF 
132
. 
 
Many angiogenesis inhibitors are actually fragments of ECM components, basement 
membrane components or other proteins, and are generated by the actions of MMPs, 
plasmin or other proteinases. These include, among many others, the plasmin 
fragment angiostatin, the collagen fragments restin, tumstatin, canstatin, endostatin 
and arresten, the calreticulin fragment vasostatin, and the MMP-2 fragment PEX 
133-
140
. Angiostatin is a circulating angiogenesis inhibitor that was first isolated in 1994 
by the group of Folkman from the serum and urine of Lewis lung carcinoma (LLC)-
bearing C57BL/6 mice, while they were studying the interesting phenomenon that a 
primary tumor can inhibit the growth of its distant metastasis, and that removal of a 
primary tumor can lead to rapid growth of metastasis 
133
. Angiostatin can be generated 
from plasmin by the actions of several MMPs 
141
. Angiostatin can induce apoptosis 
and  inhibit migration and tube formation of endothelial cells in vitro, and is a potent 
inhibitor of tumor growth in vivo 
142, 143
. Several mechanisms of action have been 
proposed for the anti-angiogenic activities of angiostatin. It has been shown to bind to 
the ATP synthase on the surface of HUVECs and thus might interfere with the cells’ 
energy supply 
144
. In addition, angiostatin can interact with integrin v3 and might 
interfere with hepatocyte growth factor (HGF) signaling 
145, 146
. 
Endostatin was also first described by the group of Folkman, as a factor produced by a 
tumor cell line that can inhibit endothelial proliferation in vitro, angiogenesis in the 
CAM assay, and tumor growth in vivo 
134
. It is a carboxyterminal fragment of the 
basement membrane protein collagen XVIII, generated after cleavage by MMPs or 
cathepsin L 
147, 148
. Endostatin inhibits proliferation and migration of endothelial cells, 
most likely through binding with integrin 51 
149
. Other fragments of collagen, such 
as tumstatin, canstatin and arresten, have also been shown to inhibit endothelial cell 
proliferation and migration by binding to integrins 
150-152
.  PEX, a fragment of MMP-
2, binds to v3 and blocks the binding of MMP-2 to this integrin 
140
. 
 
Tissue inhibitors of MMPs (TIMPs) are endogenous inhibitors of MMPs. There are 4 
TIMPs, TIMP-1 to -4, which bind tightly to and inhibit the activity of almost all 
MMPs. Expression of TIMPs has been shown to block endothelial migration and 
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angiogenesis in several models 
153-155
. However, for some TIMPs additional, non-
inhibitory functions have been identified. For example, TIMP-2 can bind to pro-
MMP-2 and facilitate its cell surface activation by membrane type 1-MMP (MT1-
MMP) 
156, 157
.  
 
The activity of important pro-angiogenic growth factors is tightly regulated by several 
mechanisms. Soluble forms of VEGF-R1, NRP1, Tie-1 and Tie-2 have been 
identified, which may negatively regulate the activity of VEGF and Angs 
158-161
. 
Platelet factor 4 (or CXCL4), a chemokine released by platelets, can bind to both 
VEGF and bFGF, thereby inhibiting the binding of these growth factors to their 
receptors 
162, 163
. 
 
Finally, some cytokines have anti-angiogenic activity, for example IL-12, IFNs, and 
the TNF family member vascular endothelial growth inhibitor (VEGI) 
164
. The anti-
angiogenic activity of IL-12 was shown to be largely due to induction of IFN- 165. 
IFN- induces the expression of the anti-angiogenic chemokine CXCL10 in 
endothelial cells 
166
. CXCL10 inhibits endothelial tube formation in response to 
VEGF or bFGF via activation of its receptor CXCR3 
167, 168
. IFN- in combination 
with TNF has also been shown to downregulate the expression of integrin v3 on 
HUVECs 
169
. Moreover, Rüegg and co-workers demonstrated that treatment of 
cultured endothelial cells leads to decreased v3-dependent cell adhesion, resulting 
in detachment of endothelial cells and apoptosis 
170
. 
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4.3. Tumor vascularization 
 
4.3.1. Tumor angiogenesis 
 
Tumor growth depends on angiogenesis. The concept of tumor angiogenesis was first 
introduced by Folkman and colleagues in the early 1970s. They demonstrated that, in 
the absence of new blood vessel formation, tumors cannot grow beyond a size of 1 to 
2 mm in diameter 
171
. A tumor starts with a single cell that loses control over its cell 
cycle and starts proliferating, thereby forming a small nodule. However, when the 
tumor reaches a certain critical size, the oxygen and nutrients supplied by pre-existing 
vessels can no longer sufficiently reach the centre of the nodule and the tumor will 
stop growing. Tumor cells are still proliferating, but this is balanced by high rates of 
tumor cell apoptosis. The tumor is in a so-called dormant state. This dormant state can 
persist for a long period of time, even years, until, eventually, tumor cells have 
accumulated the required mutations to turn on the angiogenic switch. From that point 
on, the tumor is capable of inducing the growth of its own blood vessels, which 
deliver the necessary oxygen and nutrients to support the rapid expansion of the tumor 
172
. 
The angiogenic switch in tumors is mostly established by oncogene-driven expression 
of pro-angiogenic growth factors, such as VEGF, bFGF, PlGF, TGF-1, and others 
173-175
. Tumor cells can also induce the expression of pro-angiogenic factors by 
stromal cells in or near the tumor 
176
. Tumor angiogenesis is furthermore promoted by 
the hypoxic conditions in the tumor which upregulate the expression of VEGF, Ang-2 
and other angiogenic factors 
61, 91
. Most tumors acquire their blood supply by inducing 
sprouting angiogenesis, in essence the ingrowth of new blood vessels into the tumor 
from pre-existing ones. However, in recent years, some other mechanisms have been 
recognized. These include EPC recruitment, vessel cooption, mosaic blood vessels, 
and vasculogenic mimicry. 
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Fig. 4.5. Tumor vascularization. (A) Most tumors acquire their blood supply by inducing sprouting 
angiogenesis. Tumor cells secrete pro-angiogenic growth factors such as VEGF, bFGF or PDGF, which 
then activate their receptors on the endothelial cells of nearby vessels, thereby inducing endothelial cell 
proliferation, migration and survival, resulting in the ingrowth of new vessels into the tumor. 
Angiogenic factors are not all secreted by tumor cells. Some angiogenic proteins (both pro- and anti-
angiogenic) are scavenged by platelets, stored in alpha granules, and appear to be released within the 
tumor vasculature. New endothelial cells do not all originate from pre-existing vessels. A few are 
derived from circulating EPCs, which are recruited to the tumor by VEGF or other angiogenic growth 
factors, differentiate to endothelial cells, and become incorporated into the growing vessels. (B) Some 
alternative mechanisms of tumor vascularization have been identified. These include vessel cooption, 
mosaic vessels and vasculogenic mimicry. See text for further details. Adapted from Folkman, 2007  
and Auguste et al., 2005 
4, 177
. 
 
4.3.2. EPC recruitment 
 
EPCs are derived from stem cells present in the bone marrow. These stem cells, 
termed multipotent adult progenitor cells (MAPCs), express a specific cell surface 
marker, CD133, that has been associated with primitive undifferentiated cells 
178
. In 
vitro, MAPCs can differentiate into many adult tissue types when placed in the proper 
cytokine milieu 
179
. For example, MAPCs cultured on fibronectin and stimulated with 
VEGF have been shown to differentiate into endothelial cells 
180
. In the bone marrow, 
MAPCs can differentiate into early EPCs, which express CD133, CD34 and VEGF-
R2 
181
. Early EPCs within the osteoblastic zone of the bone marrow also express cKit 
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182
. cKit is the receptor for the glycoprotein Kit ligand (KitL), also known as stem cell 
factor. KitL exists in two forms: a membrane bound form, mKitL, and a soluble form, 
sKitL. It has been suggested that VEGF-R1 may play an important role in initiating 
the mobilization of EPCs. Stimulation of VEGF-R1 with PlGF or VEGF induces the 
secretion of MMP-9 by CD34
+
 bone marrow cells. MMP-9 subsequently cleaves 
mKitL from the surface of stromal cells in the bone marrow, thereby generating 
sKitL, which then binds to its receptor cKit on early EPCs. This results in EPC 
mobilization and release into the peripheral circulation 
183-186
. Early circulating EPCs 
further differentiate to late circulating EPCs which no longer express CD133, but 
express typical endothelial cell markers such as PECAM, VE-cadherin and von 
Willebrand factor (vWF) 
181
. There is a basal level of circulating EPCs in the blood, 
but when neovascularization is necessary and angiogenic stimuli such as VEGF or 
Ang-1 are released, the circulating pool of EPCs is increased 
187, 188
. The importance 
of EPC mobilization in tumor vascularization has been demonstrated in a mouse 
mutant for Id proteins. Id1

 Id3
double mutant mice display vascular defects and 
several tumors fail to grow in these mice due to impaired VEGF-induced mobilization 
and proliferation of EPCs, resulting in poor neovascularization 
189, 190
. In wild-type 
mice, injection of a neutralizing antibody against VEGF-R2, but not against VEGF-
R1, could block the recruitment of EPCs to tumor vasculature. However, it has been 
shown that another type of bone-marrow-derived progenitor cell, termed 
hematopoietic progenitor cell (HPC), expressing CD34, VEGF-R1 and CD11b, is also 
recruited to sites of neovascularization and may contribute to tumor vascularization, 
growth and metastasis 
58, 190, 191
. The extent of EPC recruitment and incorporation into 
the tumor vasculature is dependent on the tumor type, varying from 5% or less in 
most tumors up to 90% in the B6RV2 lymphoma implanted subcutaneously in mice 
190, 192
. As EPCs appear to be consistently recruited to tumors, it has been suggested 
that EPCs might be powerful tools to deliver angiogenesis inhibitors to the tumor 
vasculature 
4, 192
. 
 
4.3.3. Vessel cooption 
 
Tumors arising in highly vascularized tissues, such as brain and lung, can use another 
mechanism to acquire their blood supply, named vessel cooption by Holash and 
colleagues in 1999 
89, 193, 194
. Instead of inducing the ingrowth of new blood vessels 
into the tumor, the tumor cells can grow in cuffs around pre-existing blood vessels. 
By coopting vessels, tumors can also invade in the surrounding tissue. Cooption 
appears to depend on the site of tumor development. Implantation of a rat C6 glioma 
into rat brain, injection of rat RBA mammary adenocarcinoma cells into rat brain, 
metastasis of a Mel57 melanoma cells to brain, or metastasis of LLC cells to lungs 
were all shown to result in tumors growing by vessel cooption, whereas these tumors 
can induce sprouting angiogenesis when injected at other sites 
89, 195
. Interestingly, 
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Holash and colleagues found that coopted vessels displayed striking upregulation of 
Ang-2, which, in the absence of VEGF, resulted in vessel destabilization, endothelial 
cell apoptosis, and a dramatic decrease in vessel density by two weeks after 
implantation in the rat C6 glioma model. By four weeks after implantation, the tumor 
core was highly necrotic and the remaining cells were organized in cuffs around the 
few surviving vessels. The tumor periphery on other hand displayed expression of 
VEGF and robust angiogenesis 
89
. Vessel cooption is also found in human 
glioblastoma 
89
.  
 
4.3.4. Mosaic vessels 
 
Chang and co-workers showed that tumors can have blood vessels in which both 
endothelial cells and tumor cells form the luminal surface, and termed these vessels 
mosaic blood vessels 
196
. Thus, in mosaic blood vessels, tumor cells are in direct 
contact with blood. Mosaic blood vessel can originate by intravasation of tumor cells 
into the lumen of tumor vessels, during which the tumor cells stay temporarily in the 
capillary vessel wall. Moreover, angiogenic growth factors, such as bFGF and VEGF 
induce MMP-2 activity, thereby increasing the degradation of vessel basement 
membranes, which increases intravasation of tumor cells and thus the number of 
mosaic blood vessels. Alternatively, mosaic blood vessels may also be a consequence 
of endothelial cell apoptosis 
4, 196, 197
. 
 
4.3.5. Vasculogenic mimicry 
 
The concept of vasculogenic mimicry was introduced by Maniotis et al. in 1999 
198
. 
They observed that in aggressive forms of melanoma angiogenic vessels were only 
present at the border of the tumors, while inside the tumors vessels delineated with 
endothelial cells could not be found, and, remarkably, these tumors were not necrotic. 
Histological analysis revealed that there was a network of channels present in these 
tumor that was connected to the blood vessels in the periphery. Like real blood 
vessels, these vessels expressed endothelial cell markers such as vWF, PECAM, 
CD34, and VEGF-R2, and were lined by a thin basal membrane. However, no 
endothelial cells could be found. Instead, these vessels were composed of a layer of 
ECM lined by aggressive, undifferentiated tumor cells, and a layer of red blood cells 
in the vessel lumen 
198, 199
. Maniotis and colleagues furthermore demonstrated that 
these highly aggressive melanoma cells are capable of forming blood vessel-like 
channels and networks in three-dimensional cultures of matrigel or collagen in vitro, 
in the absence of endothelial cells or fibroblasts, and without the addition of soluble 
growth factors such as VEGF, bFGF, TGF- or PDGF 198. Gene expression profiling 
showed that these aggressive melanoma cells express endothelial cell markers such as 
VEGF-R2, VE-cadherin, Tie-1 and EphA2, as well as ECM components such as 
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collagens and laminin-5 2 chain 198, 200, 201. It has been suggested that laminin-5 2 
chain, in cooperation with MMP-2 and MT1-MMP, is required for vasculogenic 
mimicry by aggressive melanoma cells 
202
. Recently, it has been reported that EphA2, 
the receptor for ephrin-A1, and VE-cadherin act together to regulate melanoma 
vasculogenic mimicry 
203
. Besides in melanoma, vasculogenic mimicry has also been 
found in other types of cancer, including breast, lung, prostate and ovarian cancer 
4, 
204-207
. 
 
4.3.6. Abnormalities in tumor blood vessels 
 
The disorganized production of angiogenic factors makes tumor vessels structurally 
and functionally abnormal (Fig.4.6.). In contrast to normal vessels, tumor vessels are 
tortuous an dilated, with uneven diameter and excessive branching and shunts. 
Consequently, tumor blood flow is chaotic and variable, leading to hypoxic and acidic 
regions in tumors 
2, 208
. In addition, tumor vessel basement membrane, endothelial 
cell-cell junctions, endothelial cell shape, and pericyte coverage are abnormal, which 
make tumor vessels highly permeable compared to normal vessels 
209, 210
. The high 
permeability of tumor vessels, together with the absence of functional lymphatics, 
results in high interstitial fluid pressure in tumors 
2
. 
 
 
 
Fig. 4.6. Tumor vasculature is structurally and functionally abnormal. (A) Normal vasculature, 
composed of mature vessels, is well-organized and maintained by a perfect balance of pro- and anti-
angiogenic factors. (B) The disorganized production of angiogenic factors makes tumor vasculature 
abnormal. Tumor vasculature, which is largely composed of immature vessels, is characterized by 
tortuous vessels, with excessive branching and shunts, and increased permeability. From Jain et al., 
2001 
211
. 
 
  
 
141 Introduction: Angiogenesis 
4.4. References 
 
1. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932-936 (2005). 
2. Carmeliet, P. & Jain, R.K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 
(2000). 
3. Lamalice, L., Le Boeuf, F. & Huot, J. Endothelial cell migration during angiogenesis. 
Circulation research 100, 782-794 (2007). 
4. Auguste, P., Lemiere, S., Larrieu-Lahargue, F. & Bikfalvi, A. Molecular mechanisms of tumor 
vascularization. Critical reviews in oncology/hematology 54, 53-61 (2005). 
5. Shing, Y. et al. Heparin affinity: purification of a tumor-derived capillary endothelial cell 
growth factor. Science (New York, N.Y 223, 1296-1299 (1984). 
6. Esch, F. et al. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and 
comparison with the amino-terminal sequence of bovine brain acidic FGF. Proceedings of the 
National Academy of Sciences of the United States of America 82, 6507-6511 (1985). 
7. Folkman, J. & Klagsbrun, M. Angiogenic factors. Science (New York, N.Y 235, 442-447 
(1987). 
8. Gaudric, A., N'Guyen, T., Moenner, M., Glacet-Bernard, A. & Barritault, D. Quantification of 
angiogenesis due to basic fibroblast growth factor in a modified rabbit corneal model. 
Ophthalmic research 24, 181-188 (1992). 
9. Montesano, R., Vassalli, J.D., Baird, A., Guillemin, R. & Orci, L. Basic fibroblast growth 
factor induces angiogenesis in vitro. Proceedings of the National Academy of Sciences of the 
United States of America 83, 7297-7301 (1986). 
10. Slavin, J. Fibroblast growth factors: at the heart of angiogenesis. Cell biology international 19, 
431-444 (1995). 
11. Presta, M. et al. Fibroblast growth factor/fibroblast growth factor receptor system in 
angiogenesis. Cytokine & growth factor reviews 16, 159-178 (2005). 
12. Miller, D.L., Ortega, S., Bashayan, O., Basch, R. & Basilico, C. Compensation by fibroblast 
growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 
null mice. Molecular and cellular biology 20, 2260-2268 (2000). 
13. Ortega, S., Ittmann, M., Tsang, S.H., Ehrlich, M. & Basilico, C. Neuronal defects and delayed 
wound healing in mice lacking fibroblast growth factor 2. Proceedings of the National 
Academy of Sciences of the United States of America 95, 5672-5677 (1998). 
14. Dono, R., Texido, G., Dussel, R., Ehmke, H. & Zeller, R. Impaired cerebral cortex 
development and blood pressure regulation in FGF-2-deficient mice. The EMBO journal 17, 
4213-4225 (1998). 
15. Mellin, T.N. et al. Acidic fibroblast growth factor accelerates dermal wound healing in 
diabetic mice. The Journal of investigative dermatology 104, 850-855 (1995). 
16. Okumura, M., Okuda, T., Nakamura, T. & Yajima, M. Acceleration of wound healing in 
diabetic mice by basic fibroblast growth factor. Biological & pharmaceutical bulletin 19, 530-
535 (1996). 
17. Bennett, N.T. & Schultz, G.S. Growth factors and wound healing: biochemical properties of 
growth factors and their receptors. American journal of surgery 165, 728-737 (1993). 
18. Bennett, N.T. & Schultz, G.S. Growth factors and wound healing: Part II. Role in normal and 
chronic wound healing. American journal of surgery 166, 74-81 (1993). 
19. Winkles, J.A., Friesel, R., Alberts, G.F., Janat, M.F. & Liau, G. Elevated expression of basic 
fibroblast growth factor in an immortalized rabbit smooth muscle cell line. The American 
journal of pathology 143, 518-527 (1993). 
20. Shipley, G.D., Keeble, W.W., Hendrickson, J.E., Coffey, R.J., Jr. & Pittelkow, M.R. Growth 
of normal human keratinocytes and fibroblasts in serum-free medium is stimulated by acidic 
and basic fibroblast growth factor. Journal of cellular physiology 138, 511-518 (1989). 
21. McNeil, P.L., Muthukrishnan, L., Warder, E. & D'Amore, P.A. Growth factors are released by 
mechanically wounded endothelial cells. The Journal of cell biology 109, 811-822 (1989). 
22. Jackson, A. et al. Heat shock induces the release of fibroblast growth factor 1 from NIH 3T3 
cells. Proceedings of the National Academy of Sciences of the United States of America 89, 
10691-10695 (1992). 
23. Mignatti, P., Morimoto, T. & Rifkin, D.B. Basic fibroblast growth factor, a protein devoid of 
secretory signal sequence, is released by cells via a pathway independent of the endoplasmic 
reticulum-Golgi complex. Journal of cellular physiology 151, 81-93 (1992). 
 
142 Chapter 4 
24. Cao, Y. & Pettersson, R.F. Release and subcellular localization of acidic fibroblast growth 
factor expressed to high levels in HeLa cells. Growth factors (Chur, Switzerland) 8, 277-290 
(1993). 
25. Rusnati, M. & Presta, M. Interaction of angiogenic basic fibroblast growth factor with 
endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. 
International journal of clinical & laboratory research 26, 15-23 (1996). 
26. Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor 
(VEGF) and its receptors. Faseb J 13, 9-22 (1999). 
27. Roy, H., Bhardwaj, S. & Yla-Herttuala, S. Biology of vascular endothelial growth factors. 
FEBS letters 580, 2879-2887 (2006). 
28. Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient 
mice. Nature 376, 62-66 (1995). 
29. Fong, G.H., Rossant, J., Gertsenstein, M. & Breitman, M.L. Role of the Flt-1 receptor tyrosine 
kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70 (1995). 
30. Kawasaki, T. et al. A requirement for neuropilin-1 in embryonic vessel formation. 
Development (Cambridge, England) 126, 4895-4902 (1999). 
31. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the 
VEGF gene. Nature 380, 439-442 (1996). 
32. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a 
single VEGF allele. Nature 380, 435-439 (1996). 
33. Senger, D.R. et al. Tumor cells secrete a vascular permeability factor that promotes 
accumulation of ascites fluid. Science (New York, N.Y 219, 983-985 (1983). 
34. Kohn, S., Nagy, J.A., Dvorak, H.F. & Dvorak, A.M. Pathways of macromolecular tracer 
transport across venules and small veins. Structural basis for the hyperpermeability of tumor 
blood vessels. Laboratory investigation; a journal of technical methods and pathology 67, 
596-607 (1992). 
35. Kevil, C.G., Payne, D.K., Mire, E. & Alexander, J.S. Vascular permeability factor/vascular 
endothelial cell growth factor-mediated permeability occurs through disorganization of 
endothelial junctional proteins. The Journal of biological chemistry 273, 15099-15103 (1998). 
36. Esser, S., Lampugnani, M.G., Corada, M., Dejana, E. & Risau, W. Vascular endothelial 
growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. Journal of 
cell science 111 ( Pt 13), 1853-1865 (1998). 
37. Esser, S. et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. 
The Journal of cell biology 140, 947-959 (1998). 
38. Kroll, J. & Waltenberger, J. A novel function of VEGF receptor-2 (KDR): rapid release of 
nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochemical and 
biophysical research communications 265, 636-639 (1999). 
39. Bootle-Wilbraham, C.A., Tazzyman, S., Thompson, W.D., Stirk, C.M. & Lewis, C.E. Fibrin 
fragment E stimulates the proliferation, migration and differentiation of human microvascular 
endothelial cells in vitro. Angiogenesis 4, 269-275 (2001). 
40. Pepper, M.S., Ferrara, N., Orci, L. & Montesano, R. Vascular endothelial growth factor 
(VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in 
microvascular endothelial cells. Biochemical and biophysical research communications 181, 
902-906 (1991). 
41. Unemori, E.N., Ferrara, N., Bauer, E.A. & Amento, E.P. Vascular endothelial growth factor 
induces interstitial collagenase expression in human endothelial cells. Journal of cellular 
physiology 153, 557-562 (1992). 
42. Burbridge, M.F. et al. The role of the matrix metalloproteinases during in vitro vessel 
formation. Angiogenesis 5, 215-226 (2002). 
43. van Hinsbergh, V.W., Koolwijk, P. & Hanemaaijer, R. Role of fibrin and plasminogen 
activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. Exs 
79, 391-411 (1997). 
44. Mandriota, S.J. et al. Vascular endothelial growth factor increases urokinase receptor 
expression in vascular endothelial cells. The Journal of biological chemistry 270, 9709-9716 
(1995). 
45. Waltz, D.A., Natkin, L.R., Fujita, R.M., Wei, Y. & Chapman, H.A. Plasmin and plasminogen 
activator inhibitor type 1 promote cellular motility by regulating the interaction between the 
urokinase receptor and vitronectin. The Journal of clinical investigation 100, 58-67 (1997). 
46. Nguyen, M., Arkell, J. & Jackson, C.J. Human endothelial gelatinases and angiogenesis. The 
international journal of biochemistry & cell biology 33, 960-970 (2001). 
 
143 Introduction: Angiogenesis 
47. Prager, G.W., Breuss, J.M., Steurer, S., Mihaly, J. & Binder, B.R. Vascular endothelial growth 
factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial 
cells. Blood 103, 955-962 (2004). 
48. Rousseau, S., Houle, F. & Huot, J. Integrating the VEGF signals leading to actin-based 
motility in vascular endothelial cells. Trends in cardiovascular medicine 10, 321-327 (2000). 
49. Fujio, Y. & Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial 
growth factor in an anchorage-dependent manner. The Journal of biological chemistry 274, 
16349-16354 (1999). 
50. Gupta, K. et al. VEGF prevents apoptosis of human microvascular endothelial cells via 
opposing effects on MAPK/ERK and SAPK/JNK signaling. Experimental cell research 247, 
495-504 (1999). 
51. Gerber, H.P. et al. Vascular endothelial growth factor regulates endothelial cell survival 
through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for 
Flk-1/KDR activation. The Journal of biological chemistry 273, 30336-30343 (1998). 
52. Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocrine 
reviews 18, 4-25 (1997). 
53. Pepper, M.S., Ferrara, N., Orci, L. & Montesano, R. Potent synergism between vascular 
endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in 
vitro. Biochemical and biophysical research communications 189, 824-831 (1992). 
54. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. & Ferrara, N. Vascular endothelial 
growth factor is a secreted angiogenic mitogen. Science (New York, N.Y 246, 1306-1309 
(1989). 
55. Phillips, G.D. et al. Vascular endothelial growth factor (rhVEGF165) stimulates direct 
angiogenesis in the rabbit cornea. In vivo (Athens, Greece) 8, 961-965 (1994). 
56. Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. 
The Journal of cell biology 161, 1163-1177 (2003). 
57. Rafii, S., Heissig, B. & Hattori, K. Efficient mobilization and recruitment of marrow-derived 
endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. 
Gene therapy 9, 631-641 (2002). 
58. Rabbany, S.Y., Heissig, B., Hattori, K. & Rafii, S. Molecular pathways regulating 
mobilization of marrow-derived stem cells for tissue revascularization. Trends in molecular 
medicine 9, 109-117 (2003). 
59. Jain, R.K. Molecular regulation of vessel maturation. Nature medicine 9, 685-693 (2003). 
60. Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 3, 4-10 
(2005). 
61. Forsythe, J.A. et al. Activation of vascular endothelial growth factor gene transcription by 
hypoxia-inducible factor 1. Molecular and cellular biology 16, 4604-4613 (1996). 
62. Mole, D.R., Maxwell, P.H., Pugh, C.W. & Ratcliffe, P.J. Regulation of HIF by the von 
Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB life 52, 
43-47 (2001). 
63. Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by 
O2-regulated prolyl hydroxylation. Science (New York, N.Y 292, 468-472 (2001). 
64. Na, X. et al. Overproduction of vascular endothelial growth factor related to von Hippel-
Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in 
renal cell carcinomas. The Journal of urology 170, 588-592 (2003). 
65. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine 
reviews 25, 581-611 (2004). 
66. Persico, M.G., Vincenti, V. & DiPalma, T. Structure, expression and receptor-binding 
properties of placenta growth factor (PlGF). Current topics in microbiology and immunology 
237, 31-40 (1999). 
67. Yang, W., Ahn, H., Hinrichs, M., Torry, R.J. & Torry, D.S. Evidence of a novel isoform of 
placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells. Journal 
of reproductive immunology 60, 53-60 (2003). 
68. DiPalma, T. et al. The placenta growth factor gene of the mouse. Mamm Genome 7, 6-12 
(1996). 
69. Luttun, A. et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of 
tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature medicine 8, 831-840 
(2002). 
 
144 Chapter 4 
70. Marcellini, M. et al. Increased melanoma growth and metastasis spreading in mice 
overexpressing placenta growth factor. The American journal of pathology 169, 643-654 
(2006). 
71. Fischer, C. et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without 
affecting healthy vessels. Cell 131, 463-475 (2007). 
72. Adini, A., Kornaga, T., Firoozbakht, F. & Benjamin, L.E. Placental growth factor is a survival 
factor for tumor endothelial cells and macrophages. Cancer research 62, 2749-2752 (2002). 
73. Pipp, F. et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a 
monocyte-mediated mechanism. Circulation research 92, 378-385 (2003). 
74. Roy, H. et al. Adenovirus-mediated gene transfer of placental growth factor to perivascular 
tissue induces angiogenesis via upregulation of the expression of endogenous vascular 
endothelial growth factor-A. Human gene therapy 16, 1422-1428 (2005). 
75. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental 
growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. 
Nature medicine 7, 575-583 (2001). 
76. Luttun, A. et al. Loss of placental growth factor protects mice against vascular permeability in 
pathological conditions. Biochemical and biophysical research communications 295, 428-434 
(2002). 
77. Autiero, M. et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF 
receptors Flt1 and Flk1. Nature medicine 9, 936-943 (2003). 
78. Eriksson, A. et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and 
tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer 
cell 1, 99-108 (2002). 
79. Valenzuela, D.M. et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and 
humans. Proceedings of the National Academy of Sciences of the United States of America 96, 
1904-1909 (1999). 
80. Shim, W.S., Ho, I.A. & Wong, P.E. Angiopoietin: a TIE(d) balance in tumor angiogenesis. 
Mol Cancer Res 5, 655-665 (2007). 
81. Suri, C. et al. Increased vascularization in mice overexpressing angiopoietin-1. Science (New 
York, N.Y 282, 468-471 (1998). 
82. Thurston, G. et al. Leakage-resistant blood vessels in mice transgenically overexpressing 
angiopoietin-1. Science (New York, N.Y 286, 2511-2514 (1999). 
83. Koblizek, T.I., Weiss, C., Yancopoulos, G.D., Deutsch, U. & Risau, W. Angiopoietin-1 
induces sprouting angiogenesis in vitro. Curr Biol 8, 529-532 (1998). 
84. Papapetropoulos, A. et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the 
Akt/survivin pathway. The Journal of biological chemistry 275, 9102-9105 (2000). 
85. Scharpfenecker, M., Fiedler, U., Reiss, Y. & Augustin, H.G. The Tie-2 ligand angiopoietin-2 
destabilizes quiescent endothelium through an internal autocrine loop mechanism. Journal of 
cell science 118, 771-780 (2005). 
86. Sato, T.N. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel 
formation. Nature 376, 70-74 (1995). 
87. Suri, C. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during 
embryonic angiogenesis. Cell 87, 1171-1180 (1996). 
88. Maisonpierre, P.C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo 
angiogenesis. Science (New York, N.Y 277, 55-60 (1997). 
89. Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins 
and VEGF. Science (New York, N.Y 284, 1994-1998 (1999). 
90. Kim, I., Kim, J.H., Ryu, Y.S., Liu, M. & Koh, G.Y. Tumor necrosis factor-alpha upregulates 
angiopoietin-2 in human umbilical vein endothelial cells. Biochemical and biophysical 
research communications 269, 361-365 (2000). 
91. Oh, H. et al. Hypoxia and vascular endothelial growth factor selectively up-regulate 
angiopoietin-2 in bovine microvascular endothelial cells. The Journal of biological chemistry 
274, 15732-15739 (1999). 
92. Enholm, B. et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by 
serum, growth factors, oncoproteins and hypoxia. Oncogene 14, 2475-2483 (1997). 
93. Senger, D.R. et al. Angiogenesis promoted by vascular endothelial growth factor: regulation 
through alpha1beta1 and alpha2beta1 integrins. Proceedings of the National Academy of 
Sciences of the United States of America 94, 13612-13617 (1997). 
94. Brooks, P.C., Clark, R.A. & Cheresh, D.A. Requirement of vascular integrin alpha v beta 3 for 
angiogenesis. Science (New York, N.Y 264, 569-571 (1994). 
 
145 Introduction: Angiogenesis 
95. Stromblad, S. & Cheresh, D.A. Cell adhesion and angiogenesis. Trends in cell biology 6, 462-
468 (1996). 
96. Kim, S., Bell, K., Mousa, S.A. & Varner, J.A. Regulation of angiogenesis in vivo by ligation 
of integrin alpha5beta1 with the central cell-binding domain of fibronectin. The American 
journal of pathology 156, 1345-1362 (2000). 
97. Senger, D.R. et al. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support 
for vascular endothelial growth factor signaling, endothelial cell migration, and tumor 
angiogenesis. The American journal of pathology 160, 195-204 (2002). 
98. Friedlander, M. et al. Definition of two angiogenic pathways by distinct alpha v integrins. 
Science (New York, N.Y 270, 1500-1502 (1995). 
99. Brooks, P.C. et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing 
apoptosis of angiogenic blood vessels. Cell 79, 1157-1164 (1994). 
100. Eliceiri, B.P. & Cheresh, D.A. The role of alphav integrins during angiogenesis. Molecular 
medicine (Cambridge, Mass 4, 741-750 (1998). 
101. Giancotti, F.G. Complexity and specificity of integrin signalling. Nature cell biology 2, E13-
14 (2000). 
102. Carlson, T.R., Feng, Y., Maisonpierre, P.C., Mrksich, M. & Morla, A.O. Direct cell adhesion 
to the angiopoietins mediated by integrins. The Journal of biological chemistry 276, 26516-
26525 (2001). 
103. Hutchings, H., Ortega, N. & Plouet, J. Extracellular matrix-bound vascular endothelial growth 
factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. 
Faseb J 17, 1520-1522 (2003). 
104. Brooks, P.C. et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive 
cells by interaction with integrin alpha v beta 3. Cell 85, 683-693 (1996). 
105. Soldi, R. et al. Role of alphavbeta3 integrin in the activation of vascular endothelial growth 
factor receptor-2. The EMBO journal 18, 882-892 (1999). 
106. Wang, H.U., Chen, Z.F. & Anderson, D.J. Molecular distinction and angiogenic interaction 
between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 
741-753 (1998). 
107. Gerety, S.S., Wang, H.U., Chen, Z.F. & Anderson, D.J. Symmetrical mutant phenotypes of 
the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular 
development. Molecular cell 4, 403-414 (1999). 
108. Zhang, X.Q. et al. Stromal cells expressing ephrin-B2 promote the growth and sprouting of 
ephrin-B2(+) endothelial cells. Blood 98, 1028-1037 (2001). 
109. Noren, N.K., Lu, M., Freeman, A.L., Koolpe, M. & Pasquale, E.B. Interplay between EphB4 
on tumor cells and vascular ephrin-B2 regulates tumor growth. Proceedings of the National 
Academy of Sciences of the United States of America 101, 5583-5588 (2004). 
110. Kumar, S.R. et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. The 
American journal of pathology 169, 279-293 (2006). 
111. Holzman, L.B., Marks, R.M. & Dixit, V.M. A novel immediate-early response gene of 
endothelium is induced by cytokines and encodes a secreted protein. Molecular and cellular 
biology 10, 5830-5838 (1990). 
112. Cheng, N. et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular 
endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1, 2-11 (2002). 
113. Hellstrom, M., Kalen, M., Lindahl, P., Abramsson, A. & Betsholtz, C. Role of PDGF-B and 
PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic 
blood vessel formation in the mouse. Development (Cambridge, England) 126, 3047-3055 
(1999). 
114. Oikawa, T., Onozawa, C., Sakaguchi, M., Morita, I. & Murota, S. Three isoforms of platelet-
derived growth factors all have the capability to induce angiogenesis in vivo. Biological & 
pharmaceutical bulletin 17, 1686-1688 (1994). 
115. Battegay, E.J., Rupp, J., Iruela-Arispe, L., Sage, E.H. & Pech, M. PDGF-BB modulates 
endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. The Journal of 
cell biology 125, 917-928 (1994). 
116. Pepper, M.S. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall 
integrity. Cytokine & growth factor reviews 8, 21-43 (1997). 
117. Chambers, R.C., Leoni, P., Kaminski, N., Laurent, G.J. & Heller, R.A. Global expression 
profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of 
inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic 
switching. The American journal of pathology 162, 533-546 (2003). 
 
146 Chapter 4 
118. Carmeliet, P. Angiogenesis in health and disease. Nature medicine 9, 653-660 (2003). 
119. Risau, W. Angiogenesis is coming of age. Circulation research 82, 926-928 (1998). 
120. Clauss, M. et al. A permissive role for tumor necrosis factor in vascular endothelial growth 
factor-induced vascular permeability. Blood 97, 1321-1329 (2001). 
121. Fiedler, U. et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial 
role in the induction of inflammation. Nature medicine 12, 235-239 (2006). 
122. Leibovich, S.J. et al. Macrophage-induced angiogenesis is mediated by tumour necrosis 
factor-alpha. Nature 329, 630-632 (1987). 
123. Frater-Schroder, M., Risau, W., Hallmann, R., Gautschi, P. & Bohlen, P. Tumor necrosis 
factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. 
Proceedings of the National Academy of Sciences of the United States of America 84, 5277-
5281 (1987). 
124. Robaye, B., Mosselmans, R., Fiers, W., Dumont, J.E. & Galand, P. Tumor necrosis factor 
induces apoptosis (programmed cell death) in normal endothelial cells in vitro. The American 
journal of pathology 138, 447-453 (1991). 
125. Li, J.H. & Pober, J.S. The cathepsin B death pathway contributes to TNF plus IFN-gamma-
mediated human endothelial injury. J Immunol 175, 1858-1866 (2005). 
126. Good, D.J. et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically 
and functionally indistinguishable from a fragment of thrombospondin. Proceedings of the 
National Academy of Sciences of the United States of America 87, 6624-6628 (1990). 
127. Iruela-Arispe, M.L., Bornstein, P. & Sage, H. Thrombospondin exerts an antiangiogenic effect 
on cord formation by endothelial cells in vitro. Proceedings of the National Academy of 
Sciences of the United States of America 88, 5026-5030 (1991). 
128. Volpert, O.V. et al. Inhibition of angiogenesis by thrombospondin-2. Biochemical and 
biophysical research communications 217, 326-332 (1995). 
129. Varner, J.A. The sticky truth about angiogenesis and thrombospondins. The Journal of clinical 
investigation 116, 3111-3113 (2006). 
130. Bagavandoss, P. & Wilks, J.W. Specific inhibition of endothelial cell proliferation by 
thrombospondin. Biochemical and biophysical research communications 170, 867-872 
(1990). 
131. Jimenez, B. et al. Signals leading to apoptosis-dependent inhibition of neovascularization by 
thrombospondin-1. Nature medicine 6, 41-48 (2000). 
132. Iruela-Arispe, M.L., Lombardo, M., Krutzsch, H.C., Lawler, J. & Roberts, D.D. Inhibition of 
angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 
repeats. Circulation 100, 1423-1431 (1999). 
133. O'Reilly, M.S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression 
of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994). 
134. O'Reilly, M.S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. 
Cell 88, 277-285 (1997). 
135. Maeshima, Y. et al. Distinct antitumor properties of a type IV collagen domain derived from 
basement membrane. The Journal of biological chemistry 275, 21340-21348 (2000). 
136. Kamphaus, G.D. et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor 
growth. The Journal of biological chemistry 275, 1209-1215 (2000). 
137. Ramchandran, R. et al. Antiangiogenic activity of restin, NC10 domain of human collagen 
XV: comparison to endostatin. Biochemical and biophysical research communications 255, 
735-739 (1999). 
138. Colorado, P.C. et al. Anti-angiogenic cues from vascular basement membrane collagen. 
Cancer research 60, 2520-2526 (2000). 
139. Pike, S.E. et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses 
tumor growth. The Journal of experimental medicine 188, 2349-2356 (1998). 
140. Brooks, P.C., Silletti, S., von Schalscha, T.L., Friedlander, M. & Cheresh, D.A. Disruption of 
angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding 
activity. Cell 92, 391-400 (1998). 
141. Cornelius, L.A. et al. Matrix metalloproteinases generate angiostatin: effects on 
neovascularization. J Immunol 161, 6845-6852 (1998). 
142. Claesson-Welsh, L. et al. Angiostatin induces endothelial cell apoptosis and activation of 
focal adhesion kinase independently of the integrin-binding motif RGD. Proceedings of the 
National Academy of Sciences of the United States of America 95, 5579-5583 (1998). 
143. O'Reilly, M.S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains 
dormancy of human primary tumors in mice. Nature medicine 2, 689-692 (1996). 
 
147 Introduction: Angiogenesis 
144. Moser, T.L. et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. 
Proceedings of the National Academy of Sciences of the United States of America 96, 2811-
2816 (1999). 
145. Tarui, T., Miles, L.A. & Takada, Y. Specific interaction of angiostatin with integrin 
alpha(v)beta(3) in endothelial cells. The Journal of biological chemistry 276, 39562-39568 
(2001). 
146. Wajih, N. & Sane, D.C. Angiostatin selectively inhibits signaling by hepatocyte growth factor 
in endothelial and smooth muscle cells. Blood 101, 1857-1863 (2003). 
147. Heljasvaara, R. et al. Generation of biologically active endostatin fragments from human 
collagen XVIII by distinct matrix metalloproteases. Experimental cell research 307, 292-304 
(2005). 
148. Felbor, U. et al. Secreted cathepsin L generates endostatin from collagen XVIII. The EMBO 
journal 19, 1187-1194 (2000). 
149. Digtyar, A.V., Pozdnyakova, N.V., Feldman, N.B., Lutsenko, S.V. & Severin, S.E. 
Endostatin: current concepts about its biological role and mechanisms of action. Biochemistry 
72, 235-246 (2007). 
150. Sudhakar, A. et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic 
activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proceedings of the National 
Academy of Sciences of the United States of America 100, 4766-4771 (2003). 
151. Magnon, C. et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage 
initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer research 65, 
4353-4361 (2005). 
152. Sudhakar, A. et al. Human alpha1 type IV collagen NC1 domain exhibits distinct 
antiangiogenic activity mediated by alpha1beta1 integrin. The Journal of clinical investigation 
115, 2801-2810 (2005). 
153. Johnson, M.D. et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. 
Journal of cellular physiology 160, 194-202 (1994). 
154. Fernandez, H.A. et al. Inhibition of endothelial cell migration by gene transfer of tissue 
inhibitor of metalloproteinases-1. The Journal of surgical research 82, 156-162 (1999). 
155. Murphy, A.N., Unsworth, E.J. & Stetler-Stevenson, W.G. Tissue inhibitor of 
metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell 
proliferation. Journal of cellular physiology 157, 351-358 (1993). 
156. Wang, Z., Juttermann, R. & Soloway, P.D. TIMP-2 is required for efficient activation of 
proMMP-2 in vivo. The Journal of biological chemistry 275, 26411-26415 (2000). 
157. Rundhaug, J.E. Matrix metalloproteinases and angiogenesis. Journal of cellular and 
molecular medicine 9, 267-285 (2005). 
158. Gagnon, M.L. et al. Identification of a natural soluble neuropilin-1 that binds vascular 
endothelial growth factor: In vivo expression and antitumor activity. Proceedings of the 
National Academy of Sciences of the United States of America 97, 2573-2578 (2000). 
159. McCarthy, M.J. et al. Potential roles of metalloprotease mediated ectodomain cleavage in 
signaling by the endothelial receptor tyrosine kinase Tie-1. Laboratory investigation; a 
journal of technical methods and pathology 79, 889-895 (1999). 
160. Reusch, P. et al. Identification of a soluble form of the angiopoietin receptor TIE-2 released 
from endothelial cells and present in human blood. Angiogenesis 4, 123-131 (2001). 
161. Kendall, R.L. & Thomas, K.A. Inhibition of vascular endothelial cell growth factor activity by 
an endogenously encoded soluble receptor. Proceedings of the National Academy of Sciences 
of the United States of America 90, 10705-10709 (1993). 
162. Gengrinovitch, S. et al. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and 
VEGF165 using several concurrent mechanisms. The Journal of biological chemistry 270, 
15059-15065 (1995). 
163. Sato, Y., Abe, M. & Takaki, R. Platelet factor 4 blocks the binding of basic fibroblast growth 
factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells. 
Biochemical and biophysical research communications 172, 595-600 (1990). 
164. Zhai, Y. et al. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis 
inhibitor that suppresses the growth of colon carcinomas in vivo. Faseb J 13, 181-189 (1999). 
165. Voest, E.E. et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87, 
581-586 (1995). 
166. Strieter, R.M., Kunkel, S.L., Arenberg, D.A., Burdick, M.D. & Polverini, P.J. Interferon 
gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an 
 
148 Chapter 4 
inhibitor of angiogenesis. Biochemical and biophysical research communications 210, 51-57 
(1995). 
167. Angiolillo, A.L. et al. Human interferon-inducible protein 10 is a potent inhibitor of 
angiogenesis in vivo. The Journal of experimental medicine 182, 155-162 (1995). 
168. Bodnar, R.J., Yates, C.C. & Wells, A. IP-10 blocks vascular endothelial growth factor-
induced endothelial cell motility and tube formation via inhibition of calpain. Circulation 
research 98, 617-625 (2006). 
169. Defilippi, P. et al. Tumor necrosis factor alpha and interferon gamma modulate the expression 
of the vitronectin receptor (integrin beta 3) in human endothelial cells. The Journal of 
biological chemistry 266, 7638-7645 (1991). 
170. Ruegg, C. et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the 
disruption of the tumor vasculature induced by TNF and IFN-gamma. Nature medicine 4, 408-
414 (1998). 
171. Folkman, J. Tumor angiogenesis: therapeutic implications. The New England journal of 
medicine 285, 1182-1186 (1971). 
172. Folkman, J. Angiogenesis and apoptosis. Seminars in cancer biology 13, 159-167 (2003). 
173. Relf, M. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, 
acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived 
endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary 
breast cancer and its relation to angiogenesis. Cancer research 57, 963-969 (1997). 
174. Rak, J., Yu, J.L., Klement, G. & Kerbel, R.S. Oncogenes and angiogenesis: signaling three-
dimensional tumor growth. The journal of investigative dermatology. Symposium proceedings 
/ the Society for Investigative Dermatology, Inc 5, 24-33 (2000). 
175. Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2, 
727-739 (2002). 
176. Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 
715-725 (1998). 
177. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 
6, 273-286 (2007). 
178. Yin, A.H. et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. 
Blood 90, 5002-5012 (1997). 
179. Jiang, Y. et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 
418, 41-49 (2002). 
180. Reyes, M. et al. Origin of endothelial progenitors in human postnatal bone marrow. The 
Journal of clinical investigation 109, 337-346 (2002). 
181. Hristov, M., Erl, W. & Weber, P.C. Endothelial progenitor cells: isolation and 
characterization. Trends in cardiovascular medicine 13, 201-206 (2003). 
182. Bauer, S.M., Bauer, R.J. & Velazquez, O.C. Angiogenesis, vasculogenesis, and induction of 
healing in chronic wounds. Vascular and endovascular surgery 39, 293-306 (2005). 
183. Janowska-Wieczorek, A. et al. Growth factors and cytokines upregulate gelatinase expression 
in bone marrow CD34(+) cells and their transmigration through reconstituted basement 
membrane. Blood 93, 3379-3390 (1999). 
184. Rafii, S. et al. Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from 
bone marrow microenvironment. Annals of the New York Academy of Sciences 996, 49-60 
(2003). 
185. Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting 
VEGFR1(+) stem cells from bone-marrow microenvironment. Nature medicine 8, 841-849 
(2002). 
186. Heissig, B., Werb, Z., Rafii, S. & Hattori, K. Role of c-kit/Kit ligand signaling in regulating 
vasculogenesis. Thrombosis and haemostasis 90, 570-576 (2003). 
187. Asahara, T. et al. VEGF contributes to postnatal neovascularization by mobilizing bone 
marrow-derived endothelial progenitor cells. The EMBO journal 18, 3964-3972 (1999). 
188. Hattori, K. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal 
hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. The Journal of 
experimental medicine 193, 1005-1014 (2001). 
189. Lyden, D. et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of 
tumour xenografts. Nature 401, 670-677 (1999). 
190. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic 
precursor cells blocks tumor angiogenesis and growth. Nature medicine 7, 1194-1201 (2001). 
 
149 Introduction: Angiogenesis 
191. Kaplan, R.N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the 
pre-metastatic niche. Nature 438, 820-827 (2005). 
192. Davidoff, A.M. et al. Bone marrow-derived cells contribute to tumor neovasculature and, 
when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin 
Cancer Res 7, 2870-2879 (2001). 
193. Nagano, N., Sasaki, H., Aoyagi, M. & Hirakawa, K. Invasion of experimental rat brain tumor: 
early morphological changes following microinjection of C6 glioma cells. Acta 
neuropathologica 86, 117-125 (1993). 
194. Pezzella, F. et al. Non-small-cell lung carcinoma tumor growth without morphological 
evidence of neo-angiogenesis. The American journal of pathology 151, 1417-1423 (1997). 
195. Kusters, B. et al. Vascular endothelial growth factor-A(165) induces progression of melanoma 
brain metastases without induction of sprouting angiogenesis. Cancer research 62, 341-345 
(2002). 
196. Chang, Y.S. et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with 
flowing blood. Proceedings of the National Academy of Sciences of the United States of 
America 97, 14608-14613 (2000). 
197. Folkman, J. Can mosaic tumor vessels facilitate molecular diagnosis of cancer? Proceedings 
of the National Academy of Sciences of the United States of America 98, 398-400 (2001). 
198. Maniotis, A.J. et al. Vascular channel formation by human melanoma cells in vivo and in 
vitro: vasculogenic mimicry. The American journal of pathology 155, 739-752 (1999). 
199. Folberg, R., Hendrix, M.J. & Maniotis, A.J. Vasculogenic mimicry and tumor angiogenesis. 
The American journal of pathology 156, 361-381 (2000). 
200. Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene 
expression profiling. Nature 406, 536-540 (2000). 
201. Hendrix, M.J. et al. Expression and functional significance of VE-cadherin in aggressive 
human melanoma cells: role in vasculogenic mimicry. Proceedings of the National Academy 
of Sciences of the United States of America 98, 8018-8023 (2001). 
202. Seftor, R.E. et al. Cooperative interactions of laminin 5 gamma2 chain, matrix 
metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry 
of embryonic vasculogenesis by aggressive melanoma. Cancer research 61, 6322-6327 
(2001). 
203. Hess, A.R. et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel 
signaling pathway: implications for vasculogenic mimicry. Cancer biology & therapy 5, 228-
233 (2006). 
204. Passalidou, E. et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell 
carcinomas. British journal of cancer 86, 244-249 (2002). 
205. Shirakawa, K. et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. 
International journal of cancer 99, 821-828 (2002). 
206. Su, M. et al. Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo. Int 
J Gynecol Cancer (2007). 
207. Zhang, S., Zhang, D. & Sun, B. Vasculogenic mimicry: current status and future prospects. 
Cancer letters 254, 157-164 (2007). 
208. Helmlinger, G., Yuan, F., Dellian, M. & Jain, R.K. Interstitial pH and pO2 gradients in solid 
tumors in vivo: high-resolution measurements reveal a lack of correlation. Nature medicine 3, 
177-182 (1997). 
209. Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel 
leakiness. The American journal of pathology 156, 1363-1380 (2000). 
210. Baluk, P., Morikawa, S., Haskell, A., Mancuso, M. & McDonald, D.M. Abnormalities of 
basement membrane on blood vessels and endothelial sprouts in tumors. The American 
journal of pathology 163, 1801-1815 (2003). 
211. Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for 
combination therapy. Nature medicine 7, 987-989 (2001). 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vascular-targeting anticancer therapy 
 
Chapter 5 
  
 
 
 
 
153 Introduction: Vascular-targeting anticancer therapy 
5. VASCULAR-TARGETING ANTICANCER THERAPY 
 
5.1. Introduction 
 
The development of a tumor vasculature is essential for the survival, growth and 
metastasis of solid tumors. Folkman and colleagues postulated already in the early 
1970s that it should be possible to block tumor growth by inhibiting tumor 
angiogenesis, and that, by targeting the endothelial cells of newly formed blood 
vessels, it should be possible to cause sustained regression of established tumors to a 
size of 1-2 mm in diameter where survival is possible without a blood vessel supply 
1
. 
Targeting the tumor vasculature has clear-cut advantages over classical 
chemotherapeutics that aim at directly killing the tumor cells: (1) One small tumor 
vessel, composed of only a limited number of endothelial cells, supports the growth of 
thousands of tumor cells, thus destroying one endothelial cell might lead to starvation 
and death of many tumor cells. (2) Destroying only a small part of a microvessel 
affects the functionality of the whole vessel and downstream vessels. Thus, even if the 
vascular-targeting therapy reaches only a small percentage of endothelial cells, it can 
still be 100% effective. (3) As endothelial cells are readily accessible via blood, the 
delivery of a vascular-targeting drug to its target cells is not expected to be a problem. 
(4) One of the major problems associated with conventional chemotherapeutics is the 
development of drug resistance. In contrast to tumor cells, endothelial cells are 
genetically stable, and therefore should not become resistant to therapy 
2
. However, 
the latter is only partially true. Several mechanisms for the development of resistance 
to anti-angiogenic therapy have been described 
3
. For example, an anti-angiogenic 
therapy based on the inhibition of one pro-angiogenic factor might favor the selection 
of tumor cells that produce another pro-angiogenic factor, making the therapy no 
longer effective. One major drawback of a vascular-targeting therapy is that it is 
expected not to lead to a complete eradication of all tumor cells. At the rim of a 
tumor, tumor cells may be present that do not depend on the tumor vasculature, but on 
pre-existing nearby vessels. Continuous treatment with anti-angiogenic drugs might 
prevent the regrowth of the tumor from these few remaining tumor cells. Such a 
therapeutic approach is called a dormancy-inducing therapy and is meant to control 
cancer in a chronic fashion. Another, particularly promising solution is to combine a 
vascular-targeting therapy with other treatments which appear to be most effective in 
the well-oxygenated rim of the tumor, such as conventional chemotherapy, 
radiotherapy, immunotherapy, or radioimmunotherapy (RIT) 
4, 5
. 
 
The vascular-targeting anticancer drugs can be divided into three classes: 
angiogenesis inhibitors (AIs), vascular-disrupting agents (VDAs), and ligand-directed 
vascular-targeting agents (VTAs). AIs aim at inhibiting the formation of new blood 
vessels, whereas VDAs aim at damaging or disrupting established tumor vessels. AIs 
and VDAs are considered to be respectively cytostatic and cytotoxic for endothelial 
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cells. However, the distinction between these two groups is not always so clear. Some 
AIs may also induce regression of established tumor vessels. Ligand-directed VTAs 
use antibodies or peptides to target agents such as toxins, cytokines, or radio-isotopes 
specifically to the tumor vasculature. As ligand-based VTAs are usually intended to 
damage tumor blood vessels, these agents may be considered as a subclass of VDAs 
6, 
7
. 
 
 
5.2. Angiogenesis inhibitors 
 
Angiogenesis is essential for the growth of almost all solid tumors, while it is largely 
dispensable for the healthy adult body, making the angiogenic process an ideal target 
for cancer therapy. As the angiogenic cascade is regulated by a great variety of 
cytokines, receptors, enzymes and adhesion molecules, there is a vast number of 
possible targets for therapeutic intervention. However, the majority of AIs that have 
been developed somehow interfere with VEGF signaling. The VEGF pathway has 
been targeted by a variety of strategies, including monoclonal antibodies, such as 
bevacizumab, CDP791 and IMC-1121B, soluble receptors such as aflibercept (VEGF 
Trap), VEGF receptor tyrosine kinase inhibitors such as cediranib (AZD2171), 
semaxanib (SU5416), vatalanib (PTK787/ZK222584) and vandetanib (ZD6474), 
VEGF antisense oligonucleotides, and anti-VEGF ribozymes. In 2004, the first drug 
developed solely as an AI, bevacizumab (trade name Avastin), which is a monoclonal 
anti-VEGF antibody, was approved by the United States Food and Drug 
Administration (FDA) for use in the treatment of colorectal cancer in combination 
with standard chemotherapy 
8
. In 2005 bevacizumab was also approved by the 
European Medicine Agency (EMEA) for use in colorectal cancer. In animal models, 
anti-VEGF therapies not only efficiently block angiogenesis and growth of 
experimental tumors, but have also been shown to induce regression of existing tumor 
vessels by increasing endothelial cell death 
9
. In addition, anti-VEGF therapies may 
increase the efficacy of classical chemotherapeutic drugs or radiotherapy by 
‘normalizing’ the tumor vasculature, mainly by reducing vascular permeability and 
IFP, and increasing the intratumoral oxygen levels 
10, 11
. Besides the VEGF pathway, 
other promising targets of AIs are other RTKs, MMPs, and integrins. Many of these 
AIs were shown to be effective in animal models of cancer and are currently 
evaluated in clinical trials. The most important AIs are summarized in Table 5.1. 
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Table 5.1. Angiogenesis inhibitors in clinical development or practice. 
Class / Inhibitor Mechanism of action Developmental phase, cancer type* 
Endogenous inhibitors   
Angiostatin integrin v3 antagonist, endothelial 
ATP synthase inhibitor
§
 
Phase II: NSCLC 
Endostatin integrin 51 antagonist
§ Phase III: NSCLC 
IL-12 upregulates IFN- and CXCL10 Phase II: melanoma, lymphoma, multiple 
myeloma, ovarian, cervical, breast, 
prostate cancer, other cancers 
Antibodies   
Abergrin (MEDI-522 or 
Vitaxin) 
anti-v3 antibody Phase II: melanoma, prostate cancer 
Bevacizumab anti-VEGF antibody FDA-approved for colorectal cancer, 
breast cancer, NSCLC 
CDP791 pegylated F(ab’)2 antibody fragment 
directed against VEGF-R2 
Phase II: NSCLC 
IMC-1121B anti-VEGF-R2 antibody Phase II: hepatocellular carcinoma, RCC, 
melanoma 
Other proteins and peptides   
A6 uPAR antagonist Phase II: ovarian cancer, peritoneal 
carcinoma 
ABT-510 TSP-1 mimetic, binds to CD36 Phase II: melanoma, lymphoma, head 
and neck cancer, soft-tissue sarcoma, 
RCC, NSCLC 
Aflibercept (VEGF Trap) VEGF decoy receptor comprised of 
extracellular segments of VEGF-R1 
and VEGF-R2 
Phase III: pancreatic, colorectal, ovarian, 
prostatic cancer, NSCLC 
ATN-161 integrin 51 antagonist Phase II: RCC 
Cilengitide (EMD121974) integrin v3 and v5 antagonist Phase II: leukemia, glioma, glioblastoma, 
prostate cancer, melanoma 
Small molecule inhibitors   
2-methoxyestradiol inhibits HIF-1 and tubulin 
polymerization 
Phase II: glioblastoma, multiple 
myeloma, RCC, prostatic, ovarian cancer, 
other carcinomas 
AMG706 multi-targeted RTK inhibitor Phase III: NSCLC 
Axitinib (AG-013736) multi-targeted RTK inhibitor Phase III: pancreatic ductal carcinoma 
BIBF1120 multi-targeted RTK inhibitor Phase II: ovarian, fallopian tube, 
peritoneal cavity cancer 
BMS-275291 MMP inhibitor Phase III: NSCLC 
Cediranib (AZD2171) VEGF-R RTK inhibitor Phase III: colorectal, lung, fallopian tube, 
ovarian, peritoneal cavity cancer 
E7820 reduces integrin 2 subunit 
expression  
Phase II: colorectal cancer 
Erlotinib (OSI-774) EGF-R RTK inhibitor FDA-approved for NSCLC and pancreatic 
cancer  
Neovastat (AE-941) MMP inhibitor Phase III: NSCLC, kidney, breast, 
colorectal cancer 
Prinomastat (AG3340) MMP inhibitor Phase III: prostate cancer, NSCLC 
Semaxanib (SU5416) VEGF-R2 RTK inhibitor Phase III: colorectal cancer 
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Table 5.1. (continued) 
Sorafenib (BAY 43-9006) multi-targeted RTK inhibitor, Raf 
inhibitor 
FDA-approved for RCC 
Suramin blocks binding of various growth 
factors to their receptors 
Phase III: prostate cancer 
Thalidomide inhibits TNF production, inhibits 
VEGF and bFGF secretion of and 
cellular responses 
12
 
FDA-approved for multiple myeloma 
TKI-258 inhibitor of FGF-R3 and other RTKs Phase I: melanoma, multiple myeloma, 
AML 
Vandetanib (ZD6474) VEGF-R2 and EGF-R RTK inhibitor Phase III: NSCLC 
Vatalanib  
(PTK787/ ZK222584) 
VEGF-R1, -R2 and PDGF-R RTK 
inhibitor  
Phase III: colorectal cancer 
XL184 multi-targeted RTK inhibitor Phase II: NSCLC 
XL880 inhibitor of c-Met and other RTKs Phase II: RCC, gastric cancer, squamous 
cell carcinoma 
XL999 multi-targeted RTK inhibitor, Src 
inhibitor 
Phase II: multiple myeloma, AML, NSCLC, 
RCC, ovarian cancer, colorectal cancer 
* only the highest phase of clinical development is mentioned. For lower phase clinical trials see 
www.clinicaltrials.gov. AML: acute myeloid leukemia, RCC: renal cell carcinoma, NSCLC: non-
small-cell lung cancer. Based on Folkman et al., 2007 
13
. 
 
 
5.3. Vascular-disrupting agents 
 
5.3.1. Tubulin-binding agents 
 
Already in the 1930s it was found that the classic tubulin-binding agent colchicine had 
damaging effects on tumor vasculature and caused haemorrhage and necrosis of both 
animal and human tumors 
14
. However, its toxicity prevented any further clinical 
evaluation. Also the Vinca alkaloids vincristine and vinblastine, two other potent 
tubulin-binding agents, were found to have damaging effects on tumor vasculature 
15-
17
. Vincristine and vinblastine are currently used and evaluated in the clinic for the 
treatment of many different tumor types. However, these drugs only produce 
significant anti-vascular effects at doses close to their maximum tolerated dose 
(MTD). Therefore other, safer tubulin-binding agents were sought. The 
combretastatins were first isolated from the South African bush willow tree 
Combretum caffrum 
18
. A large number of natural and synthetic combretastatin 
analogs were tested for tubulin binding activity and cytotoxicity against a panel of 
tumor cells and the most active compound was combretastatin A4 (CA4) 
19
. CA4 has 
a similar structure as colchicine and binds to tubulin near the colchicine binding site, 
causing the destabilization of the tubulin polymers of the cytoskeleton 
20-22
. To 
increase solubility CA4 is produced as a CA4 phosphate (CA4P) prodrug 
23
. After 
administration, CA4P is cleaved by endogenous phosphatases to the active CA4. One 
of the first in vivo studies with CA4P showed rapid and irreversible vascular damage 
and haemorrhagic necrosis of a murine NT adenocarcinoma after a single injection of 
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the drug. In the same study it was shown that ex vivo perfusions with CA4P caused a 
rapid increase in vascular resistance in an isolated rat P22 carcinosarcoma, but not in 
normal rat hind limb 
24
. In the years thereafter, the tumor-specific anti-vascular effects 
of CA4P have been demonstrated in many other animal models as well as in man 
25-27
. 
Importantly, the vascular-damaging effects of CA4P can be achieved with doses of 
one-tenth of the MTD, offering a wide therapeutic window 
24
. CA4P is currently 
evaluated in phase I and II clinical trials for the treatment of solid tumors, particularly 
anaplastic thyroid cancer. Also other potent tubulin-binding VDAs are now being 
developed, including combretastatin A1 phosphate (OXi4503), the CA4 derivate 
AVE8062, and the colchicine derivate ZD6126 
28-33
. 
The anti-vascular effects of CA4P have been extensively studied. In vitro studies on 
HUVECs have shown that CA4P is a potent inhibitor of endothelial cell proliferation 
by arresting cells at the G2/M phase of mitosis, leading to mitotic cell death 
34
. By 
contrast, non-proliferating endothelial cells appear to be relatively resistant to CA4P-
induced cytotoxicity. Also HUVECs cocultured with SMCs are protected against 
CA4P-induced cell death, possibly through stabilization of the endothelial cell-cell 
interactions 
35
. These results may at least in part explain the specificity of CA4P for 
the immature tumor vasculature. However, other tubulin-binding agents such as the 
Vinca alkaloids are also known for their anti-mitotic properties but only produce anti-
vascular effects at doses close to their MTD, suggesting that other mechanisms may 
be involved in the vascular-damaging effect of CA4P. Indeed, Vincent and co-
workers found that CA4P inhibits endothelial migration and capillary tube formation, 
and increases vascular permeability predominantly by interfering with the VE-
cadherin/-catenin/Akt signaling pathway 36. CA4P induces the disruption of VE-
cadherin-mediated endothelial cell-cell contact, resulting in increased vascular 
permeability, increased IFP, and eventually collapse of the weakened tumor vessels. 
In addition, the loss of endothelial cell-cell contact results in exposure of the already 
abnormal basement membrane, which in turn can result in activation of the 
coagulation cascade and subsequent thrombus formation 
36, 37
. Vincent and colleagues 
furthermore demonstrated that CA4P synergizes with a monoclonal anti-VE-cadherin 
antibody for inducing regression of nascent tumor vessels and necrosis of a murine 
B16 melanoma, with minimal toxicity and without affecting normal, stabilized vessels 
35
. 
 
5.3.2. TNF and TNF-inducing flavonoids 
 
It is well-established that the TNF-induced tumor necrosis is characterized by a 
selective destruction of the tumor vasculature (see chapter 1.7). The mechanism 
responsible for this remarkable effect is, however, not yet completely understood. 
Several possible mechanisms have been proposed, which may all add up to cause the 
in vivo vascular-disrupting effect of TNF: (1) One obvious candidate mechanism is 
the induction of endothelial cell death. Several reports have shown that TNF alone or 
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in combination with IFN- is capable of triggering apoptotic or cathepsin-mediated 
cell death of cultured endothelial cells 
38-41
. (2) TNF may activate the coagulation 
cascade. TNF has been shown to inhibit the endothelial expression of the anti-
coagulant protein thrombomodulin and induce the expression of tissue factor, the 
principal initiator of coagulation 
42-45
. Intravascular thrombus formation may lead to 
vessel occlusion, endothelial damage and haemorrhage 
46
. (3) It has also been 
suggested that the infiltration of leukocytes through the activated endothelium might 
cause endothelial damage 
46
. (4) Rüegg and collegues have reported that treatment of 
HUVECs with TNF and IFN- suppresses the activation of integrin v3, leading to 
decreased endothelial cell adhesion and survival. They furthermore observed 
detachment and apoptosis of v3-positive endothelial cells of the tumor vasculature 
in melanoma patients treated with TNF and IFN-(via ILP) 47. (5) Recent evidence 
has suggested that TNF may induce vessel disruption by a very similar mechanism as 
CA4P. It has been reported that TNF increases the permeability of endothelial cell 
monolayers by inducing microtubule destabilization and actin rearrangement in a p38-
dependent manner, leading to disruption of VE-cadherin-based cell-cell junctions and 
the formation of intercellular gaps 
48
. TNF has also been shown to induce Fyn-
dependent tyrosine phosphorylation of VE-cadherin, which is known to facilitate the 
formation of intercellular gaps 
49
. Menon and colleagues reported that TNF treatment 
of endothelial cells, cultured under hypoxia and with melanoma conditioned medium 
to mimic ILP conditions, caused disappearance of VE-cadherin from cell-cell 
junctions, resulting in the appearance of gaps between endothelial cells from 3 hours 
after treatment. They furthermore demonstrated in human melanoma xenografts raised 
in mice that TNF selectively increased tumor vascular permeability by 3 hours after 
treatment and decreased tumor blood flow by 6 hours after treatment. The formation 
of gaps between endothelial cells and the shutdown of tumor blood flow by 3 to 6 
hours post-treatment was also observed in human melanoma patients after ILP with 
TNF plus melphalan 
50
. 
 
In the late 1980s it was found that the flavonoid flavone acetic acid (FAA) had 
unexpectedly high antitumor activity in murine models. FAA induced haemorrhagic 
necrosis of various established murine tumors 
51-53
. Subsequent experiments showed 
that FAA caused a selective shutdown of the tumor blood flow 
54-56
. As FAA has 
some pharmacological drawbacks, FAA-derivates were developed with higher dose-
potency. Of these compounds, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) was 
found to be more than 10-fold more potent than FAA 
57, 58
. DMXAA is currently in 
phase I and II clinical trials for the treatment of various solid tumors. The exact 
mechanism of action of FAA and DMXAA is still poorly understood. Several reports 
have suggested that these flavonoids exert their rapid anti-vascular effects via the 
localized release of TNF from activated macrophages within the tumor tissue 
59
. 
DMXAA has been shown to strongly induce TNF mRNA upregulation in both human 
and murine cells of the macrophage/monocyte lineage 
60
. Furthermore, it has been 
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shown that the antitumor activities as well as the toxic side-effects of FAA and 
DMXAA can be inhibited with anti-TNF antibodies and are strongly attenuated in 
TNF-R1 knockout mice, respectively 
61, 62
. By contrast, Ching and co-workers 
reported that DMXAA is capable of inducing apoptosis of cultured endothelial cells in 
the absence of TNF mRNA upregulation, and they did not observe an induction of 
TNF in one patient treated with DMXAA, suggesting that DMXAA may also have 
TNF-independent anti-vascular effects 
63
. 
 
 
5.4. Ligand-directed vascular-targeting agents 
 
The strategy behind ligand-directed VTAs is to join ligands that bind selectively to 
components of tumor blood vessels and agents that are capable of damaging blood 
vessels, in order to increase effectiveness and minimize side-effects. Ligand-directed 
VTAs, therefore, are composed of targeting and effector moieties that are linked 
together via chemical cross-linkers or peptide bonds. The targeting moiety is usually 
an antibody or a peptide directed against a marker that is selectively upregulated on 
tumor versus normal vasculature. The first experimental evidence for the efficacy of 
ligand-directed VTAs was published by Burrows and Thorpe in 1993 
64
. To obtain a 
tumor-specific vascular marker they used a neuroblastoma cell line that expressed 
IFN- to grow subcutaneous tumors in BALB/c nude mice. Endothelial cells do 
normally not express MHC class II unless stimulated with IFN-. Thus, the IFN- 
secreted by the tumor cells activated endothelial cells within the tumor to express 
MHC class II, which could then be targeted with an immunotoxin composed of a 
high-affinity anti-MHC class II antibody linked to the protein toxin ricin A-chain. 
Intravenous injection of this immunotoxin induced rapid occlusion of the tumor blood 
vessels followed by extensive haemorrhagic necrosis of the tumor, with no detectable 
damage to other tissues. 
Tumor-specific vascular markers currently evaluated in pre-clinical studies include 
molecules associated with angiogenesis and vascular remodeling such as VEGF and 
its receptors, integrins v3 and v5, fibronectin extradomain B, tenascin-C 
extradomain C, aminopeptidase-N (CD13), and the TGF- co-receptor endoglin 
(CD105); cell adhesion molecules induced by inflammatory mediators that are 
secreted by tumor cells or host cells that infiltrate the tumor such as VCAM-1 and E-
selectin; and other markers such as phosphatidylserine (PS), prostate-specific 
membrane antigen (PMSA), annexin A1, and the CD44 isoform CD44v6 
7
. The 
effectors used include toxins such as ricin, gelonin and Diphtheria toxin; cytotoxic 
drugs such as doxorubicin and neocarzinostatin; cytokines such as TNF, IL-2 and IL-
12; coagulation-inducing proteins such as tissue factor; short-lived radio-isotopes such 
as Actinium-225, Bismuth-213 and Iodine-131; and liposome-encapsulated drugs 
5
. 
Some examples of pre-clinical studies with ligand-directed VTAs are summarized in 
Table 5.2 (see also Table 1.2.). 
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Table 5.2. Examples of pre-clinical studies with ligand-directed VTAs. 
VTA Description / Results Refs 
K4-2C10-dgRA - conjugate of the toxin ricin A-chain (dgRA) and an anti-endoglin antibody 
- cytotoxic for murine endothelial cells in vitro; induced long-lasting complete 
inhibition of growth of human breast cancer cells in SCID mice 
[65] 
anti-VCAM-1-tTF - fusion protein of an anti-VCAM-1 antibody and the extracellular domain of tissue 
factor 
- induced thrombosis of tumor vessels and tumor growth retardation in mice 
bearing solid Hodgkin’s tumors 
[66] 
dox-RGD-4C 
dox-CNGRC 
- conjugate of doxorubicin and an Arg-Gly-Asp (RGD) sequence or an Asn-Gly-Arg 
(NGR) sequence -containing peptide, which selectively targets integrins v3 and 
v5 or aminopeptidase-N, respectively 
- induced vascular damage in human breast carcinoma xenografts in nude mice 
without apparent toxicity in other organs, compared to often lethal toxicity with 
free doxorubicin; no tumor vascular damage induced by equivalent dose of free 
doxorubicin 
[67] 
ScFv(L19)-tTF - antibody fragment directed to the extradomain B of fibronectin fused to the 
extracellular domain of tissue factor 
- induced complete and selective infarction of 3 different types of solid tumors in 
mice; complete tumor eradication was observed in 30% of treated mice without 
apparent side-effects 
[68] 
VEGF121/rGel - fusion protein of VEGF121 and the toxin gelonin 
- cytotoxic for VEGF-R2 overexpressing endothelial cells in vitro; inhibited growth 
of human melanoma and prostate cancer xenografts in nude mice; induced 
selective damage to vascular endothelium in human prostate cancer xenografts 
in nude mice 
[69] 
(131)I-L19-SIP - Iodine-131-labeled small immunoprotein (SIP) directed to the extradomain B of 
fibronectin 
- selective tumor uptake; inhibited tumor growth and improved survival in a 
colorectal tumor model 
[70] 
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6. NKT CELLS 
 
6.1. Definition 
 
Natural killer T (NKT) cells are a heterogenous group of lymphocytes that share 
properties of both T cells and NK cells (Fig.6.1.). They are often defined as cells that 
express a CD1d-restricted -TCR as well as the NK cell receptor NK1.1 (also 
known as NKR-P1C, Ly55, or CD161c). However, this definition is somewhat 
problematic as NK1.1 is only expressed in a limited number of mouse strains, 
including C57BL/6, but not in most other commonly used laboratory mouse strains 
such as 129, BALB/c, C3H/He, and many others; and even in C57BL/6 mice NKT 
cells are present that do not express NK1.1 
1
. Moreover, NKT-like cells have been 
identified that are not CD1d-restricted. NKT cells are also diversified in some other 
aspects such as the expression of CD4 and CD8 co-receptors, and the reactivity 
towards the glycolipid -galactosylceramide (GalCer) (see further). Thus, it has 
become clear that NKT cells are a heterogenous group of cells that vary in the 
expression of cell surface markers and most likely also in function. Therefore, NKT 
cells are nowadays classified, according to CD1d-dependence, NK1.1 expression, and 
reactivity towards GalCer, in at least three different classes (Table 6.1.).  
 
 
Fig. 6.1. NKT cells share properties of both NK and T cells. This Venn diagram incorporates some 
of the key features of NKT, T and NK cells. Characteristics that are unique to each lineage are shown 
in the non-overlapping sections. Characteristics that are common to two of these lineages are indicated 
in the overlapping areas (purple or orange). The central area (white) indicates characteristics that can be 
exhibited by all three lineages. From Godfrey et al., 2000 
2
.  
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Table 6.1. Categories of mouse NKT cells. Based on Godfrey et al., 2004 
3
. 
 Type I Type II Type III 
Other names Classical NKT cells, 
invariant NKT cells 
Non-classical NKT cells NKT-like cells, CD1d-
independent NK1.1
+
 T 
cells 
TCR -chain  V14-J18 Diverse, but some 
V3.2-J9, V8 
Diverse 
TCR -chain V8.2/7/2 Diverse, but some V8.2 Diverse 
Co-receptor CD4
+
 or DN CD4
+
 or DN CD4
+
, CD8
+
 or DN 
CD1d-dependence Yes Yes No 
GalCer reactivity Yes No No 
NK1.1 expression Yes* Heterogenous Yes 
IL-4 production Yes Yes No 
IFN- production Yes Yes Yes 
Location Thymus, liver  
(intestine, lymph node) 
Spleen, bone marrow Spleen, bone marrow 
* NK1.1 is expressed by resting, mature cells, but is low or absent in immature cells or post-activation. 
DN: CD4
-
 CD8
-
 double negative. 
 
The most studied and best characterized type of NKT cell is the type I NKT cell, also 
called classical NKT cell or invariant NKT (iNKT) cell. iNKT cells comprise 
approximately 80% of all CD1d-dependent NKT cells 
4, 5
. CD1d is a member of the 
CD1 family of MHC class I-related antigen-presenting molecules. CD1d is expressed 
by professional APCs (dendritic cells, macrophages and B cells), thymocytes, some 
intestinal epithelial cells, hepatocytes, and some other cells 
6-9
. In contrast to other 
MHC molecules which are involved in the presentation of peptide antigens, CD1d is 
specialized in the presentation of glyco- and phospholipids, although highly 
hydrophobic peptides have also been shown to bind to CD1d 
10
. In 1997, Kawano and 
co-workers reported the identification of the first iNKT cell-specific ligand presented 
by CD1d: GalCer, a glycolipid extracted from the marine sponge Agelas 
mauritianus (Fig.6.2.). Co-culture of iNKT cells and dendritic cells pulsed with 
GalCer induced proliferation of the iNKT cells and rapid production of large 
amounts of IL-4 and IFN-. Moreover, GalCer-stimulated iNKT cells were found to 
be capable of killing YAC-1 and tumor cells by an NK-like mechanism 
11
. The 
identification of this first CD1d-dependent, iNKT cell-specific ligand led to the 
development of a new tool to identify iNKT cells: tetramers of CD1d loaded with 
GalCer, which allowed to further characterize these cells 12-15. 
iNKT cells represent in mice approximately 0.5% of the T cell population in blood 
and peripheral lymph nodes, 0.5% of thymocytes, 2.5% of T cells in the spleen, and 
up to 30% of T cells in the liver, where they reside in the sinusoids. Although the 
tissue distribution is less well studied in humans, iNKT cells appear to be 
approximately 10 times less frequent in all these locations (Table 6.2.) 
16
. In mice 
iNKT cells express an invariant TCR composed of a V14-J18 rearranged TCR -
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chain combined with a V8.2, V7 or V2 TCR -chain (human iNKT cells express a 
homologues V24-J18/V11 TCR). The expression of the NK receptor NK1.1 
(CD161) appears to depend on the maturity and activation state of the iNKT cells. 
Immature iNKT cells do not express NK1.1 and expression of this marker is 
downregulated for at least several days after the activation of mature iNKT cells 
3, 17
. 
Mature NKT cells also express cytotoxic effector molecules such as perforin, 
granzyme B and FasL 
18
. Other NK markers such as the integrin subunit 2 (CD49b or 
DX5) and members of the Ly49 family of killer inhibitory receptors (KIRs) are not 
consistently expressed by iNKT cells. A high proportion of iNKT cells in the thymus 
expresses Ly49, whereas most liver iNKT cells lack this surface marker 
19
. On the 
other hand, most type III CD8
+
 NKT-like cells in the liver do express Ly49 
20
. 
Similarly, CD49b is expressed by only a minority of CD1d-dependent NKT cells, 
while most CD1d-independent NKT-like cells express this marker 
21
. 
 
Table 6.2. A comparison of mouse and human iNKT cells. From Godfrey et al., 2007 
22
. 
 Mouse Human 
TCR -chain  V14-J18 V24-J18 
TCR -chain V8.2, V7, V2 V11 
CD1d-dependent Yes Yes 
Thymus dependent Yes Probably 
GalCer reactive Yes Yes 
iGb3 reactive Yes Yes 
Immature phenotype NK1.1
low
; CD4
+
 (or DN ?) CD161
low
; CD4
+
 
Mature phenotype NK1.1
+
; CD4
+
 or DN CD161
+
; CD4
+
, DN, or CD8
+
 
Frequency in thymus ~0,2-0,5% ~0,001-0,01% 
Frequency in blood ~0,2-0,5% ~0,001-1% 
Frequency in spleen ~1% ND 
Frequency in liver ~20-40% ~1% 
DN: CD4
-
 CD8
-
  double negative. ND: not determined. 
 
 
6.2. Development 
 
The origin of iNKT cells has long been controversial, particularly because of some 
early reports showing the presence of (mainly CD8
+
) NK1.1
+
 T cells in athymic or 
neonatally thymectomized mice 
23-25
. Nevertheless, it is now well-established that 
iNKT cells are thymus-dependent and share a common origin with other -TCR+ T 
cells. iNKT cells segregate from conventional T cells at the CD4
+
 CD8
+
 double 
positive (DP) stage. DP thymocytes expressing the invariant V14 TCR are positively 
selected by other, CD1d-expressing DP thymocytes in the cortex 
22
. It is still unknown 
which endogenous ligands are presented by CD1d for positive selection. Several 
reports have suggested that the lysosomal glycosphingolipid 
isoglobotrihexosylceramide (iGb3) is the endogenous ligand used for NKT cell 
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selection (Fig.6.2.). Mice deficient in -hexosaminidase B, a lysosomal enzyme 
involved in the production of iGb3, display a 95% decrease in thymic NKT cell 
production, and iGb3 showed stimulatory activity towards both human and murine 
iNKT cells in vitro, albeit much weaker than GalCer 26. However, it was recently 
shown that mice deficient in iGb3 synthase, the enzyme directly responsible for the 
synthesis of iGb3, have normal development and function of iNKT cells, suggesting 
that iGb3 is not or at least not the only endogenous ligand involved in the thymic 
selection of iNKT cells 
27
. After positive selection, immature NKT cells downregulate 
CD8 and undergo several maturation steps to a NK1.1
-
 CD44
+
 DX5
+
 stage, where 
most cells leave the thymus to further maturate in the periphery to NK1.1
+
 CD4
+
 or 
double negative (DN) mature iNKT cells 
22
. 
 
 
6.3. Function 
 
iNKT are highly versatile cells at the interface between innate and adaptive immunity. 
They have been implicated in a broad array of immunological processes, from the 
control of infection and tumor immunity, to the development of autoimmune diseases 
and transplantation tolerance. The most striking effector function of iNKT cells is 
their ability to rapidly produce large amounts of both Th1 and Th2 cytokines upon 
activation, suggesting that these cells mainly have an immunoregulatory functions. 
Triggering of the TCR of iNKT cells, using anti-CD3 antibodies or GalCer-pulsed 
dendritic cells, results in rapid (within 1-2 hours) production of IFN-, TNF, IL-4 and 
IL-13 
11, 21, 28
. It has been reported that iNKT cells are able to release IL-4 and IFN- 
so rapidly upon activation because they posses some pre-formed mRNA for these 
cytokines in the resting state 
29, 30
. Stimulating iNKT cells by NK1.1 cross-linking has 
been shown to result in the production of IFN-, but not of IL-4 31. The cytokine 
production by iNKT cells is also influenced by the presence of other cytokines: IL-7 
enhances IL-4 production, whereas IL-12 enhances IFN- production 32, 33. These 
results suggest that the pattern of cytokines produced by iNKT cells will differ 
depending on the microenvironment. The immunoregulatory cytokines produced by 
iNKT cells can, in turn, activate or recruit other cell types, including NK cells, T cells 
(thereby directing Th1/Th2 differentiation), B cells, macrophages, and dendritic cells 
34-37
. 
 
iNKT cells have been shown to participate in host defense against some bacterial and 
parasitic infections. Some bacteria such as Sphingomonas and Ehrlichia muris, which 
are Gram-negative, LPS-negative members of the -Proteobacteria, contain cell wall 
components capable of specifically activating iNKT cells. In the case of 
Sphingomonas it was shown that the cell wall contains the glycosphingolipids -
glucuronosylceramide and -galacturonosylceramide which are structurally related to 
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GalCer (Fig.6.2.). During infection, Sphingomonas is phagocytosed by macrophages 
and dendritic cells and elicits an activation cascade similar to exogenous GalCer 38-
40
. The responses of iNKT cells to other bacteria, such as the Gram-negative, LPS-
positive Salmonella, or even to parasitic infections by the helminth Schistosoma 
mansoni, were shown to depend on -hexosaminidase B activity, suggesting that in 
the absence of a suitable microbial NKT ligand, iNKT cells can still become activated 
by presentation of the endogenous ligand iGb3 
40, 41
. In the case of Salmonella it has 
been demonstrated that iNKT cell activation was absolutely dependent on TLR 
signaling and IL-12 production by the APC. The proposed mechanism is that TLR 
signaling leads to IL-12 secretion by the APC which then enhances the ability of 
dendritic cells to stimulate iNKT cells through presentation of endogenous ligand 
16, 
42
. 
 
 
 
Fig. 6.2. iNKT cell ligands. (A) Marine sponge GalCer (KRN7000). (B) Sphingomonas -
glucuronosylceramide (GSL-1). (C) Mammalian iGb3. From Bendelac et al., 2007 
16
. 
 
iNKT cells have been implicated in a number of autoimmune and inflammatory 
diseases, including type I diabetes, lupus erythematosus, asthma and atherosclerosis. 
However, for each of these diseases contradictory studies have been reported, and at 
this point there is no decisive evidence for a specific role of iNKT cells in any of these 
diseases (recently reviewed by Bendelac et al. 
16
). For example, it was reported that 
CD1d- and J18-deficient mice, which both completely lack iNKT cells, exhibit 
decreased allergen-induced airway hyperreactivity in the alum-ovalbumin model of 
asthma 
43, 44
. However, similar studies by another group failed to observe differences 
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between CD1d-deficient and wild-type mice 
16
. Using GalCer-CD1d tetramers one 
group reported that more than 60% of CD4
+
 T cells in bronchoalveolar-lavage fluid of 
a panel of human patients with chronic asthma were iNKT cells, which predominantly 
produced Th2 cytokines 
45
. Again, another group found that less than 2% of T cells in 
samples of chronic asthma patients were iNKT cells, which was not significantly 
different from healthy control subjects 
46
. Thus, it remains controversial whether 
iNKT cells play a pathologic role in asthma. 
 
 
6.4. NKT cells in tumor immunity and cancer therapy 
 
Several reports have suggested a natural role of iNKT cells in tumor surveillance. The 
first evidence came from tumor rejection experiments of the MHC-negative F9 
embryonic carcinoma in mice. Depletion of either NK1.1
+
 cells,  T cells, or 
injection of anti-IL-4 antibodies rendered B6 mice significantly more susceptible to 
tumor formation. It was furthermore shown that IL-4-producing, NK1.1
+
 DN T cells 
accumulated in these F9 tumors, suggesting that these cells are involved in the tumor 
rejection in this model 
47
. More convincing data were published by Smyth and 
colleagues. They demonstrated that J18-deficient mice were two- to threefold more 
sensitive to tumor induction by the carcinogen methA. Moreover, they showed that 
tumors induced in J18-deficient mice grew after transplantation far more effectively 
in J18-deficient mice than in wild-type control mice. Smyth and co-workers 
furthermore demonstrated that host immune protection from methA-induced sarcoma 
is, besides iNKT cells, also dependent on NK cells, IL-12, IFN-, and perforin 48, 49. 
The most likely mechanism is then that IL-12, produced by CD1d-expressing APCs, 
stimulates iNKT cells to rapidly secrete IFN-, which then promotes secondary 
activation of NK cell proliferation and cytotoxicity (Fig.6.3.). A role of iNKT cells in 
tumor immunity is further supported by the observation that iNKT cells were reduced 
in number or functionally hyporeactive in human patients with advanced prostate 
cancer or progressive multiple myeloma 
50, 51
. A murine T cell lymphoma cell line has 
even been identified that sheds a glycolipid, gangliotriaosylceramide, that inhibited 
activation of iNKT cells in vitro 
52
. Together these data suggest that certain tumors 
may effectively evade the host’s antitumor immune response by inhibiting iNKT cell 
activation. 
 
iNKT cells are promising targets for cancer immunotherapy. Already before it was 
known that GalCer is a specific NKT cell ligand, it was reported that this compound 
had potent tumor growth inhibitory and antimetastatic activities in B16 tumor-bearing 
mice 
53, 54
. Antitumor and antimetastatic effects of GalCer have now been observed 
in many murine tumor models, including melanoma, lymphoma, colon, lung, and 
renal cell carcinoma; and similar or even stronger antitumor effects have been 
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obtained by treatment with dendritic cells pulsed with GalCer in vitro 55-60. First 
clinical trials in cancer patients with GalCer as a soluble drug as well as with 
GalCer-pulsed dendritic cells have already been completed, with limited success 61, 
62
. As GalCer induces secretion of both IFN- and IL-4 by iNKT cells, it has been 
suggested that the net antitumor effect of GalCer may be limited due to the 
counteracting effects of these cytokines. Therefore, more potent GalCer analogs are 
currently developed that favor the production of Th1 cytokines by human iNKT cells 
63
. 
The antitumor effect of GalCer in murine tumor models was shown to be critically 
dependent on IFN- and NK cells 64. It was furthermore shown that the production of 
IFN- by iNKT cells in response to GalCer requires IL-12 production by dendritic 
cells and direct contact between NKT cells and dendritic cells through CD40-CD40 
ligand interaction 
65
. It is now also clear that the potent antitumor effects of IL-12 
therapy are at least partly mediated by iNKT cells (Fig.6.3.) 
66-69
. Smyth and co-
workers demonstrated that the antitumor effect of GalCer requires subsequent IFN- 
production by iNKT cells and NK cells. The IFN- produced by iNKT cells is at least 
partly responsible for NK cell activation. The cytokines produced by iNKT and NK 
cells will most likely also induce bystander activation of other immune cells such as T 
cells, B cells, and macrophages (Fig.6.3.) 
70
. The activation of iNKT cells by GalCer 
appears to induce rapid downregulation of their TCR and rapid expansion, reaching 
maximum numbers around three days after GalCer administration, followed by a 
decline through apoptotic cell death, and long-lasting anergy of the remaining iNKT 
cells 
71
. It was recently shown that OX40 ligand (a member of the TNF superfamily) 
expressed on dendritic cells, through interaction with its receptor OX40 (CD134) on 
iNKT cells, strongly enhances iNKT cell activation, IFN- production, and antitumor 
immunity. Interestingly, the expression of OX40 ligand on dendritic cells can be 
upregulated by TNF 
72
. 
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Fig. 6.3. The role of NKT cells in tumor rejection. (A) In IL-12-mediated tumor rejection, 
exogenously administrated IL-12 may induce IFN- production by both NK and NKT cells. In IL-12-
induced, NKT cell-dependent tumor rejection, IFN- is known to be a key factor. Evidence exists for 
both IFN--dependent and perforin (Pfp)-dependent effector mechanisms. The relative roles of effector 
cells and associated molecules may vary in a tumor- and dose-dependent fashion. (B) In GalCer-
mediated tumor rejection, exogenously administered GalCer is presented to iNKT cells by CD1d on 
APCs. The process involves subsequent IFN- production by both iNKT cells and NK cells, and is IL-
12-dependent but perforin-independent (indep.). The importance of CD8
+
 T cells may be model-
dependent. (C) In natural tumor rejection, CD1d-restricted NKT cells may become activated by an 
endogenous, possibly tumor-derived, glycolipid antigen (endog. glycolipid Ag). Natural NKT cell-
mediated tumor rejection is dependent on IL-12, IFN-, and perforin. Besides NKT cells and NK cells, 
also CD8
+
 T cells appear to play an important role in natural tumor rejection. M macrophage. 
Adapted from Smyth et al., 2002 
73
. 
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7. RESEARCH OBJECTIVES 
 
Cancer is one of the leading causes of death in our modern world. Last year alone, 
approximately 7.6 million people died of cancer worldwide, which is approximately 
13% of all deaths. Cancer therapy, which classically comprises surgery, chemotherapy 
and radiotherapy, is nowadays curative in more than 60% of all cases (based on 5 year 
survival rates). However, for certain types of cancer, including lung, pancreatic, and 
liver cancer, current treatments are largely ineffective. Decades of research has made 
it possible that now new therapies are entering the field of cancer medicine, including 
anti-angiogenic therapy, vascular-disrupting therapy and immunotherapy. One 
particularly promising strategy may include the use of TNF. The anticancer potency 
of this inflammatory cytokine has been demonstrated in numerous animal models as 
well as in human patients, where it can induce rapid haemorrhagic necrosis of tumors. 
The therapeutic application of TNF is, however, severely hampered by potentially 
lethal side-effects, in essence severe hypotension, shock and organ failure, limiting 
the clinical application of TNF to administration via the ILP technique for the 
treatment of advanced melanomas and soft-tissue sarcomas of the limbs. 
Nevertheless, the high limb salvage rates obtained after ILP with TNF and melphalan 
clearly demonstrate the potential of TNF as an anticancer drug. The mechanism by 
which TNF exerts its tumor-destructive effect is not yet fully understood, but is 
known to involve an increased permeability of the tumor vasculature early after 
injection, which may be exploited to increase the tumor uptake of classically 
chemotherapeutics, followed by a selective destruction of this tumor vasculature. 
Moreover, TNF may induce the infiltration of immune cells in the tumor, although the 
importance of this effect is currently unknown. Previous work in our research group 
has demonstrated that the anticancer and shock-inducing effects of TNF are not 
inevitably linked. Mice can be protected against the TNF-induced shock with the sGC 
inhibitor methylene blue without impairing the antitumor effect. However, using 
potentially lethal doses of TNF together with an inhibitor of the toxic side-effects is 
not an attractive solution for human cancer therapy as failure of the inhibitor could 
lead to death of the patient. A safer strategy to lower the systemic toxicity of TNF 
would be to use lower doses of TNF or low-toxic TNF muteins in combination with 
sensitizers for the antitumor activity of TNF, such as IFN-. The work of An Goethals 
in our research group has confirmed that the direct target cells of TNF for its 
antitumor effect are the endothelial cells of the tumor vasculature. The abnormal 
structure (abnormal pericyte coverage, basement membrane, cell-cell junctions) and 
continuous remodeling of the tumor vasculature make this vasculature highly 
dependent on survival signaling, which is mainly conducted via the PI3K/Akt 
signaling pathway.  
 
 The first objective of the present study was to determine whether interfering with 
endothelial survival could potentiate the antitumor activity of TNF. PI3K, having 
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a bottleneck position in the survival pathway, was selected as a first target for a 
proof of principle. Other downstream targets, including Akt and mTOR, as well as 
the upstream target VEGF-R2 were also evaluated. We have furthermore 
examined the vascular-disrupting nature of the combination therapy of TNF and a 
PI3K inhibitor by using the dorsal skinfold window chamber model and several 
other histological approaches (see chapter 8). 
 
 The second objective of this study was to determine whether immune cells are 
required for the antitumor effect of TNF. Previous experiments conducted in our 
research group using IRF-1 knockout mice have suggested that certain immune 
cells may be essential for the full antitumor response to TNF. By using various 
knockout mouse strains that lack specified types of immune cells as well as by 
selective depletion of immune cells, we have identified one type of immune cell 
that may contribute to the antitumor effect of TNF. Elucidation of  the complete 
antitumor mechanism of TNF may reveal new targets for therapy. We have tested 
whether selective activation of this type of immune cell by exogenous drug 
administration could enhance the antitumor effect of TNF (see chapter 9). 
 
 The third objective of this study was to further elucidate the mechanism 
underlying the synergistic antitumor effect of TNF and IFN-. The work of Jeroen 
Hostens in our research group has demonstrated that, like it is the case for TNF, 
the direct target cell of IFN- is the endothelial cell of the tumor vasculature. We 
have now determined using various knockout mouse strains and by selective 
depletion of immune cells whether immune cells are required for the synergism of 
TNF and IFN-, and which types of immune cells may be involved (see chapter 
10). 
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inhibition of the PI3K/Akt survival pathway 
Chapter 8 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
185 Experimental work: Sensitization to TNF by inhibition of survival signaling 
8. SENSITIZATION OF THE TUMOR VASCULATURE TO THE VASCULAR-DISRUPTING 
EFFECT OF TNF BY INHIBITION OF THE PI3K/AKT SURVIVAL PATHWAY 
 
Abstract 
 
TNF is a cytokine with a remarkable antitumor activity. Both in animal models and in 
human patients, where it is used with high efficacy to treat regional tumors of the 
limbs via the ILP technique, it is capable of inducing haemorrhagic necrosis of 
tumors. Severe shock-inducing side-effects, however, preclude systemic treatments. 
Previous work in our research group has established that the endothelial cells of the 
tumor vasculature are the main target cells for the antitumor effect of TNF. The tumor 
vasculature is highly dependent on survival signals provided by a broad range of pro-
angiogenic factors (e.g. VEGF family members) and by adhesion receptor signaling 
(e.g. integrin v3, VE-cadherin), which are commonly mediated by the PI3K/Akt 
pathway. To determine whether inhibition of this pathway would sensitize to the 
antitumor effect of TNF, B16Bl6 melanoma bearing mice were treated with sub-
therapeutic TNF alone or in combination with one of the PI3K inhibitors wortmannin 
or LY294002. The response to either PI3K inhibitor plus TNF was striking, with 
tumor regression in all treated animals. We determined that by PI3K inhibition a 
tenfold reduction of the effective dose of TNF could be achieved. Comparable results 
were obtained using the Akt inhibitor perifosine or the mTOR inhibitor rapamycin. 
Importantly, PI3K/Akt pathway inhibition sensitized to the antitumor effect of TNF 
without concomitantly increasing the toxic side-effects of TNF. Using intravital 
microscopy and by histological examination of tumors we could demonstrate that the 
antitumor effect of wortmannin and TNF is characterized by a pronounced destruction 
of the tumor vasculature. In vivo Hoechst staining revealed a complete shutdown of 
the tumor blood as early as 6 hours after injection of wortmannin and TNF, with no 
recovery by 48 hours after injection, thus effectively starving the tumor to death. 
Finally, we demonstrated that TNF therapy synergizes with anti-angiogenic therapy, 
using a VEGF-R2 blocking antibody, for the induction of tumor necrosis in the 
B16Bl6 tumor model. Combining TNF with anti-angiogenic therapy is a novel 
concept in anticancer therapy. Taken together, we have shown that interfering with 
endothelial survival allows a significant reduction of the effective dose of TNF. 
 
 
 
 
 
This study was performed in collaboration with Dr. O. Feron and Dr. Pierre Sonveaux of the Unit of 
Pharmacology and Therapeutics (University of Louvain (UCL) Medical School, Brussels, Belgium) for 
the dorsal skinfold window chamber experiments, and with Dr. Bart Vanhaesebroeck (Queen Mary 
University of London, London, UK) who provided PI3K knock-in mice and intellectual input. 
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8.1. Introduction 
 
TNF is an inflammatory cytokine with a remarkable antitumor activity. Both in 
animal models and in human patients it can cause rapid haemorrhagic necrosis of 
tumors 
1, 2
. Its therapeutic application is, however, severely hampered by potentially 
lethal side-effects, i.e. severe hypotension which may lead to hypovolemic shock and 
organ failure 
3, 4
. Previous work in our research group has demonstrated that the 
antitumor and shock-inducing effects of TNF are not inevitably linked: mice can be 
protected against the TNF-induced shock with the sGC inhibitor methylene blue or by 
the induction of tolerance by repetitive administration of low doses of TNF, without 
impairing the antitumor effect 
5, 6
. The clinical application of TNF is currently limited 
to administration via the ILP technique for the treatment of irresectable melanomas 
and soft-tissue sarcomas of the limbs. The high limb salvage rate obtained after ILP 
with TNF and melphalan clearly demonstrates the potential of TNF as an anticancer 
drug 
2, 7
. Yet, despite these promising results, thus far no TNF-based therapy has 
proven to prolong patient survival. The reason for this discrepancy lies in the fact that 
patient survival is mainly determined by the presence of distant metastasis, which are 
not affected by the regional ILP treatment. Thus, to fully exploit the anticancer 
activities of TNF, systemic administration will be essential. Clinical studies with 
systemically administrated TNF have been performed, however, without success. 
Doses of 10 to 50 times lower than the estimated effective dose already caused severe 
toxic side-effects, and doses close to the maximum tolerated dose (~150-400µg/m
2
) 
produced only rare and minimal tumor responses 
8-10
. One strategy to allow systemic 
TNF application could be to use low, tolerable doses of TNF in combination with 
specific sensitizers for the antitumor effect of TNF. Another strategy may be to 
develop low-toxic TNF muteins. However, studies in mice with hTNF, which in the 
murine system can be considered as a low-toxic TNF mutein, have demonstrated that 
these TNF muteins will most likely also require sensitization to be effective 
1, 11
. 
 
The precise mechanism underlying the TNF-induced tumor necrosis remains poorly 
understood. It has become clear that the antitumor effect of TNF is completely host-
mediated and is independent of TNF-receptor expression on tumor cells. Stoelcker 
and colleagues demonstrated that the antitumor effect of TNF was maintained in 
TNF-R2
-/-
 mice, but absent in TNF-R1
-/-
 mice, suggesting that the antitumor effect of 
TNF is mediated by triggering the TNF-R1 on host cells 
12
. Previous work in our 
research group has extended these data by showing that TNF-R1 expression on 
neovasculature (controlled by a Flk-1 promoter) is sufficient for the antitumor effect 
of TNF, indicating that the endothelial cells of the tumor vasculature are the direct 
target cells of TNF 
13
. This is further supported by the observation, in experimental 
tumor models as well as in human ILP patients, that the TNF-induced tumor necrosis 
is characterized by a selective destruction of the tumor vasculature 
2, 14-16
. TNF may 
therefore be classified as a VDA. 
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The PI3K/Akt pathway is one of the main regulators of cell survival. Tumor 
vasculature, which is in contrast to normal vasculature not stabilized by normal 
pericyte coverage, basement membrane structure and endothelial cell-cell interactions, 
and is subject to constant remodelling due to imbalance of angiogenic factors 
produced in the tumor, may be greatly dependent on this survival pathway 
17-20
. The 
PI3K/Akt pathway is triggered by a broad range of pro-angiogenic factors, including 
growth factors, such as VEGF family members, and adhesion molecules, such as 
integrin v3 
21, 22
. Inhibition of PI3K has been shown to sensitize endothelial cells in 
vitro to the cytotoxic effects of TNF 
23-25
. Furthermore, Matschurat and colleagues 
reported a synergy of the PI3K inhibitor wortmannin and TNF for the induction of 
tumor necrosis in a murine MethA sarcoma model 
26
. 
 
In the present study we have investigated whether inhibition of the PI3K/Akt pathway 
would sensitize to the antitumor effect of TNF in the murine B16Bl6 melanoma 
model and other tumor models. We found that inhibition of PI3K or other components 
of the survival pathway, including Akt and mTOR, allowed a 10-fold reduction of the 
effective dose of TNF. We have shown that the combination therapy of PI3K 
inhibition and TNF resulted in a pronounced and selective destruction of the tumor 
vasculature. Furthermore, we found a synergy of TNF and anti-VEGF-R2 therapy. 
The combination of TNF and anti-angiogenic therapy is a novel concept in anticancer 
therapy.  
 
 
8.2. Materials and methods 
 
8.2.1. Mice 
 
Female C57BL/6J mice were purchased from Janvier, Le Genest-Saint-Isle, France. 
TNF-R1
-/-
 mice were generated and backcrossed 6 generations to the C57BL6/J 
background by Dr. Bluethmann, Roche Research, Basel, Switzerland 
27
. Kinase-death 
p110 knock-in (p110ki/ki) mice on C57BL/6 background were provided by Dr. Bart 
Vanhaesebroeck, Centre for Cell Signaling, Institute of Cancer, Queen Mary 
University of London, London, UK 
28
. B6.p110-/- mice were generated by Dr. Emilio 
Hirsch, University of Torino, Turin, Italy 
29
. The animals were housed in 14-10 hours 
light/dark cycles in a temperature-controlled, air-conditioned room, and received food 
and water ad libitum. The mice were used for experimentation at the age of 8-12 
weeks. All experiments were approved by and performed according to the guidelines 
of the local ethics committee of Ghent University, Belgium. 
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8.2.2. Cells 
 
B16Bl6 melanoma cells and EL4 lymphoma cells were cultured in RPMI-1640 
medium supplemented with 10% FCS, 2mM L-glutamine, 0,4mM Na-pyruvate, 50 
IU/ml penicillin G and 50µg/ml streptomycin sulphate 
30
. LLC-H61 carcinoma cells 
and PG19 melanoma cells were cultured in DMEM medium supplemented with 10% 
FCS, 2mM L-glutamine, 0,4mM Na-pyruvate, 50 IU/ml penicillin G and 50µg/ml 
streptomycin sulphate 
31
. B16Bl6 cells overexpressing a dominant-negative TNF-R1 
mutant (B16.dnTNF-R1) were generated in our laboratory by Dr. An Goethals. For 
tumor inoculation, cells were detached from the culture flask by a short EDTA 
treatment, washed three times in endotoxin-free, sterile DPBS (Sigma), and 
resuspended in DPBS. 
 
8.2.3. Reagents 
 
Wortmannin and rapamycin were purchased from Sigma. LY294002 was purchased 
from LC Laboratories. Perifosine was provided by Keryx Biopharmaceuticals. Rat 
anti-mouse VEGF-R2 antibodies and mouse anti-human tPA antibodies (mouse IgG 
control) were provided by ThromboGenix. Recombinant mTNF and hTNF were 
produced in our laboratory and had a specific activity of 1.28 x 10
8
 IU/mg and 6.8 x 
10
7
 IU/mg, and an endotoxin content (LAL assay) of 6.5 EU/mg and 36 EU/mg, 
respectively. 
 
8.2.4. Tumor experiments 
 
Mice were inoculated with 6 x 10
5
 (B16Bl6 and EL4) or 5 x 10
6
 (LLC and PG19) 
tumor cells s.c. in the back (day 0). Treatment was started when the tumor size index 
(TSI), the product of the largest perpendicular diameters in cm, was greater than 0.5 
(≥day 10). Unless otherwise indicated, PBS, hTNF (30µg), mTNF (0.7-7µg), 
wortmannin (5µg), Ly294002 (500µg), rapamycin (20µg), and perifosine (50-200µg) 
were administered daily for 10 consecutive days via paralesional injection (s.c. 
injection near the tumor site but outside the nodule), or i.p. injection (rapamycin). 
Wortmannin, perifosine and rapamycin were injected 1h before TNF. LY294002 was 
injected 15min before TNF. Anti-VEGF-R2 (800µg) and mouse IgG control (500µg) 
antibodies were injected i.p. on days 12, 14, 16, 18 and 20 after tumor inoculation. 
 
8.2.5. MTT cytotoxicity assay 
 
5000 B16Bl6 melanoma cells per well were seeded into a 96-well plate and incubated 
overnight in a culture oven (5% CO2). Serial dilutions of mTNF (0 to 10000 IU/ml in 
1/10 steps in rows) and wortmannin (0 to 20µM in 1/3 steps in columns) were added 
to each well. The plates were incubated for 48 hours, after which 3-(4,5-
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dimethyldiazol-2-yl)-2,5 diphenyl tetrazolium bromide (MTT) was added. 6 hours 
later SDS was added to dissolve the precipitate. OD was measured at 595 nm. The 
control well with the highest OD was set at 100% growth. 
 
8.2.6. CD31 staining 
 
B16Bl6 tumors and other tissues were frozen in cryo-embedding compound (Microm) 
on dry ice and stored at –70°C. Frozen sections were cut at 5µm. Sections were fixed 
in acetone for 10min at –20°C and washed in PBS. Nonspecific binding sites were 
blocked by incubation with 0.5% BSA in PBS for 30min. Rat anti-mouse CD31 
antibodies (BD Pharmingen) were diluted 1/50 in PBS/0.5% BSA, added to the slides 
and incubated overnight at 4°C. After washing in PBS, the slides were incubated for 
1h with AlexaFluor 568 anti-rat antibodies (BD Pharmingen), diluted 1/100 in 
PBS/0.5% BSA. Slides were washed twice in PBS and mounted with Vectashield 
with DAPI (Vector Labs). 
 
8.2.7. TUNEL staining 
 
Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling 
(TUNEL) staining was performed by using the DeadEnd Fluorometric TUNEL 
System, according to the manufacturer’s instructions (Promega). In short, 5µm frozen 
sections were fixed for 15min in 4% PFA, washed in PBS, and permeabilized by 
incubation for 10min with proteinases K (20µg/ml). After washing in PBS, the 
sections were fixed for 5min in 4% PFA, washed again in PBS, equilibrated, and 
incubated with the terminal deoxynucleotidyl transferase and Cy5-dUTP for 1h at 
37°C. The reaction was stopped by incubation in 2X SSC for 15min. The slides were 
washed three times in PBS and mounted with Vectashield with DAPI.  
 
8.2.8. In vivo Hoechst staining 
 
B16Bl6 tumor-bearing mice were injected i.v. with the DNA-binding dye Hoechst 
33342 (10mg/kg; Sigma). 1min later the mice were killed and tumors and other 
tissues were immediately frozen on dry ice in cryo-embedding compound and stored 
at –70°C. Sections were cut at 10µm and viewed on a Zeiss Axiophot 
photomicroscope under UV excitation. 
 
8.2.9. Dorsal skinfold window chamber model 
 
Dorsal skinfold window chambers were implanted in the back of adult male 
C57BL/6J mice by Dr. Pierre Sonveaux of the Unit of Pharmacology and 
Therapeutics, Department of Medicine, UCL Medical School, Brussels, Belgium. The 
window chambers were inoculated with 10 x 10
4
 LLC carcinoma cells. 20 days later 
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the mice were injected into the window chamber but outside the tumor nodule with 
PBS, mTNF (0.7µg) and/or wortmannin (5µg). For intravital microscopy, mice were 
anaesthetized with a mixture of xylazine and ketamine. 
 
8.2.10. Statistics 
 
For tumor experiments mice were stratified into treatment groups having non-
significantly different mean TSI (one-way ANOVA, P-value > 0.95) using Graphpad 
Prism 4.0. Results were evaluated for statistical significance by the two-tailed Mann 
Whitney U test. Calculations were performed using SPSS v11.0.  P-values below 0.05 
were considered statistical significant. 
 
 
8.3. Results 
 
8.3.1. Inhibition of PI3K sensitizes to the antitumor effect of TNF 
 
To determine whether inhibition of the PI3K/Akt pathway would sensitize to the 
antitumor effect of TNF, we used two different broad spectrum PI3K inhibitors: the 
potent, irreversible inhibitor wortmannin and the ATP-competitive, reversible 
inhibitor LY294002. One strategy to avoid lethal toxicity of TNF is to use low-toxic 
TNF muteins. In mice hTNF can be regarded as such a mutein: hTNF does not 
interact with the murine TNF-R2, is cleared much faster, and, consequently, causes 
only low systemic toxicity. In our B16Bl6 tumor model, treatment with hTNF results 
in a static effect, providing us a therapeutic window to test sensitizing agents. 
C57BL/6 mice bearing a subcutaneous B16Bl6 tumor were treated daily for ten 
consecutive days with wortmannin, LY294002, hTNF or a combination of hTNF and 
either PI3K inhibitor (Fig.8.1. and Table 8.1.). A range of LY294002 doses was tested 
(10µg – 500µg/mouse/day), and the dose that led to optimal tumor regression was 
determined to be 500µg per mouse per day. In control (PBS-treated) mice tumors 
grew exponentially. Treatment with LY294002 or wortmannin alone had respectively 
no or a marginal inhibiting effect on tumor growth. However, the response to either 
PI3K inhibitor plus hTNF was striking, with tumor regression in all treated animals. 
Moreover, complete regression (no palpable tumor at the 10
th
 day of treatment) of the 
B16Bl6 tumor was obtained in four of seven treated animals after treatment with 
wortmannin plus hTNF and in six of seven treated animals after treatment with 
LY294002 plus hTNF. A regrowth of the tumor from the rim of the lesion was 
observed in most animals after the treatment was stopped, which is characteristic of a 
vascular-targeting therapy.  
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Fig. 8.1. PI3K inhibition sensitizes to the antitumor effect of hTNF. (A) Tumor size and relative 
body weight after treatment with wortmannin and hTNF. (B) Idem after treatment with LY294002 and 
hTNF. The line under the graph represents the treatment period. Data are shown as mean ± SEM, n = 7. 
Statistical analyses (Mann Whitney U test, two-tailed) of hTNF vs. wortmannin + hTNF and hTNF vs. 
LY294002 + hTNF, * p < 0.05, # p < 0.01. Average body weight of the mice at day 10 was 
respectively 19.3g and 19.9g. 
 
Treatment with wortmannin or LY294002 alone did not cause apparent systemic 
toxicity. However, severe toxicity was observed when mice were treated with 
wortmannin plus hTNF. All animals appeared cachectic. Average weight loss reached 
a maximum of approximately 19% of total body weight at the fifth day of treatment, 
and three out of seven mice died before the end of treatment. When LY294002 was 
used in combination with hTNF, no significant increase in systemic toxicity was 
observed, suggesting that the observed toxicity is wortmannin-specific and is not 
linked to PI3K inhibition per se (Fig.8.1. and Table 8.1.). 
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Table 8.1. Responses to treatments with wortmannin, LY294002 and hTNF. 
 Tumor response §  
Treatment CR (%) PR (%) S (%) PD (%) D (%)  
PBS (n = 14) – – – 93 7 
Wortmannin (n = 7) – – – 100 – 
LY294002 (n = 7) – – – 100 – 
hTNF (n = 14) – 29 21 50 – 
Wortmannin + hTNF (n = 7) 57 – – – 43 
LY294002 + hTNF (n = 7) 86 – 14 – – 
§
 TSI at day 19 after tumor inoculation was compared to that on day 10. Tumor response was classified 
as follows: PD = progressive disease, increase of more than 25%; S = static, tumor size between –25% 
and 25%; PR = partial regression, decrease between –25% and –99%; CR = complete regression, no 
palpable tumor. D = animal died during treatment. – = none. 
 
We next evaluated whether inhibition of PI3K would allow a significant reduction of 
the effective dose of mTNF. When administered paralesional for ten consecutive days, 
a dose of 7µg of mTNF per day is required for inducing complete regression of a s.c. 
B16Bl6 tumor (Fig.8.2.). This treatment induces, however, marked systemic toxicity 
which becomes lethal for approx. 10% of treated mice. To determine the minimal 
effective dose of mTNF when combined with the PI3K inhibitor wortmannin, we 
performed a dose-response experiment in our B16Bl6 tumor model. mTNF doses 
ranging from 0.4µg to 7µg per day were tested. The response to low-dose mTNF plus 
wortmannin was synergistic
#
 and the minimal effective dose of mTNF was 
determined to be 0.7µg per day. mTNF alone at this dose induced only on average a 
static effect, with complete response in one out of six treated animals, while in 
combination with wortmannin, this dose caused complete tumor regression in five out 
of six treated animals (one mouse died early during treatment) (Fig.8.2.). 
Interestingly, this treatment caused only a moderate increase in systemic toxicity 
compared to low-dose mTNF alone. When the reversible PI3K inhibitor LY294002 
was given in combination with low-dose mTNF, a similar synergistic antitumor 
response was observed, inducing complete regression of the B16Bl6 tumor in four out 
of six treated animals, but here no corresponding increase in systemic toxicity was 
observed. These results suggest that a selective increase of the antitumor activity of 
TNF can be achieved by inhibition of PI3K signaling. 
 
 
 
 
 
# As used in this thesis, the term ‘synergistic’ refers to the phenomenon in which the common effect 
generated by treatment with two molecules is greater than the effect achieved with either molecule 
alone. It does not necessarily mean that the generated effect is greater than the sum of the individual 
effects of these molecules. 
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Fig. 8.2. PI3K inhibition allows 10-fold reduction of the effective dose of mTNF. (A) Dose-
response curve of B16Bl6 tumor growth in response to treatment with decreasing doses of mTNF. (B) 
Growth curve of B16Bl6 tumor after treatment with wortmannin, LY294002 and low-dose mTNF 
(0.7µg). All data are presented as mean + SEM, n = 6. The numbers between brackets indicate the 
number of mice with complete tumor regression on day 9 of treatment. 
§
 One mouse died during 
treatment with wortmannin + mTNF. 
 
The synergistic antitumor activity of wortmannin plus low-dose mTNF was also 
confirmed in other tumor models: the melanin-negative PG19 melanoma, the EL4 
lymphoma and the LLC carcinoma model (Fig.8.3.). 
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Fig. 8.3. Treatment with wortmannin and low-dose mTNF is similarly effective in other tumor 
models. Tumor response of B16Bl6 melanoma, EL4 lymphoma, LLC carcinoma and PG19 melanoma 
to treatment with wortmannin and low-dose mTNF (0.875µg). Data are shown as mean ± SEM, n = 6. 
 
8.3.2. The antitumor effect of TNF plus wortmannin is host-mediated 
 
Although previous research had shown that the antitumor effect of TNF is completely 
host-mediated, this did not certify that our combined treatment of TNF plus PI3K 
inhibitors acted by the same mechanism. To determine whether inhibition of PI3K 
could sensitize the TNF-resistant B16Bl6 cells to the cytotoxic effects of TNF in 
vitro, an MTT cytotoxicity assay was performed (Fig.8.4.). The combination of 
wortmannin and TNF had a modest synergistic effect, causing a growth inhibition of 
the B16Bl6 cells of  approx. 50% at the highest concentrations used. Interestingly, no 
cell death was observed. To investigate whether direct effects on the B16Bl6 tumor 
cells contribute to the in vivo synergistic antitumor effect of our combination therapy, 
wild-type C57BL/6 mice were inoculated with B16Bl6 cells rendered insensitive to 
TNF by overexpression of a dominant-negative TNF-R1 mutant (B16.dnTNF-R1), 
and TNF-R1
-/-
 mice were inoculated with B16Bl6 cells with normal TNF-R1 
expression (Fig.8.4.). In the wild-type mice bearing a TNF-insensitive B16Bl6 tumor 
treatment with wortmannin plus hTNF induced complete tumor regression in all 
treated mice, while, by contrast, treatment of TNF-R1
-/-
 mice had no significant effect 
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on tumor growth. Taken together, these results indicate that the synergistic antitumor 
effect of TNF plus wortmannin is host-mediated, and that direct cytotoxic or 
cytostatic effects on the melanoma cells are unimportant. 
 
 
Fig. 8.4. The antitumor effect of wortmannin plus TNF is host-mediated. (A) 48h MTT 
cytotoxicity assay. (B) Tumor growth curve of C57BL/6 mice inoculated with B16Bl6 cells rendered 
insensitive to TNF by overexpression of a dominant-negative TNF-R1 mutant (B16.dnTNF-R1). (C) 
Tumor growth curve of TNF-R1
-/-
 mice inoculated with B16Bl6 cells. The line under the graph 
represent the treatment period. Tumor growth graphs are shown as mean ± SEM, n = 6. 
 
8.3.3. Role of p110 isoforms in the sensitivity to the antitumor effect of TNF 
 
PI3K is ubiquitously expressed and is as such not an interesting therapeutic target. 
However, only the class I PI3K family members are involved in survival signaling 
downstream of receptor tyrosine kinases, GPCRs and non-receptor tyrosine kinases. 
Structurally, class I PI3Ks consist of a p110 catalytic subunit that is constitutively 
associated with a regulatory subunit. There are four p110 isoforms: p110, -, - and 
-. The isoforms p110 and – are ubiquitously expressed and homozygous knockout 
mice are embryonic lethal. The isoforms p110 and – on the other hand have a 
limited tissue distribution and their gene-deficient mice are viable and healthy 
32
. The 
latter two isoforms are predominantly expressed in leukocytes, although their 
presence has also been reported in other cells types, including endothelial cells 
33, 34
. 
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To determine whether one of these isoforms could confer survival signals to 
endothelial cells of the tumor vasculature which may protect these cells against the 
vascular-disrupting effect of TNF, p110-/- mice and p110ki/ki mice bearing a s.c. 
B16Bl6 tumor were treated with hTNF (Fig.8.5.). In both strains the response to 
hTNF treatment was static, on average, and not significantly different from the 
response to hTNF observed in wild-type mice, suggesting that neither p110 or p110 
play a critical role in determining the sensitivity to the antitumor effect of TNF. 
Interestingly however, p110ki/ki mice were markedly more sensitive to the toxic side-
effects of TNF: 5 out of 18 mice died due to treatment-induced toxicity, while 
lethality due to hTNF treatment was not observed in wild-type control mice. 
Moreover, treatment of p110ki/ki mice with either combination of hTNF and 
wortmannin or hTNF and IFN- resulted in 100% lethality. 
 
 
Fig. 8.5. p110-/- and p110-/- mice are not sensitized to the antitumor effect of TNF. (A) Tumor 
size of B16Bl6 tumor growing in p110-/- mice after treatment with hTNF. (B) Idem in p110ki/ki mice. 
The line under the graph represents the treatment period. Data are shown as mean ± SEM. The numbers 
between brackets below the curve indicate the number of mice that died due to treatment-induced 
toxicity. 
 
8.3.4. Inhibition of PI3K sensitizes to the vascular-disrupting effect of TNF 
 
First signs of necrosis in subcutaneous B16Bl6 tumors treated with wortmannin plus 
hTNF were macroscopically visible at 48 hours after the first injection as a black 
discoloration of the skin overlaying the tumor. By 72 hours, central necrosis of the 
tumor became apparent, followed by a progressive collapse of tumor from the centre 
towards the rim, which was in some cases associated with bleeding. Tumor necrosis 
was in most cases complete by 5 days after the start of treatment. Similar observations 
were made in haematoxylin & eosin-stained tumor sections: extensive haemorrhagic 
necrosis of the tumor became apparent from 48 hours after the first injection of hTNF 
plus wortmannin and necrosis was complete at 72 hours. Destruction of the tumor 
vasculature appeared to coincide with the overall necrosis of the tumor. However, 
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palpation of tumors treated with wortmannin plus hTNF revealed that there was a 
marked loss of rigidity by 24 hours after injection, which is indicative of a decrease in 
interstitial fluid pressure in the tumors, suggesting that early vascular events are 
taking place before necrosis becomes apparent.  
 
 
Fig. 8.6. Effects of wortmannin and hTNF on tumor vessel perfusion. Functional tumor (B16Bl6) 
vessels were visualized by in vivo Hoechst staining (blue) 6h and 48h after injection of hTNF. 
Wortmannin was injected 1h before hTNF. Adjacent pictures were taken and stitched to show the 
whole tumor section. Scale bar is approx. 2mm. 
 
We performed an in vivo Hoechst staining to assess the functionality of the tumor 
blood vessels after injection of wortmannin and hTNF (Fig.8.6.). 6 hours after 
injection of hTNF alone the tumor blood flow was significantly reduced compared to 
control tumors. Functional blood vessels were present in the rim of the tumor, 
particularly near the skin. A similar reduction was observed at 24 hours after 
injection. However, at 48 hours after injection of hTNF, tumor blood flow was almost 
completely recovered, except for the necrotic centre of the tumor. When wortmannin 
was injected prior to hTNF, perfusion of the tumor vasculature was completely 
blocked at 6 hours after treatment, but in contrast to treatment with hTNF alone, no 
recovery could be observed at 48 hours after injection. This persistent block of tumor 
blood flow could effectively starve the tumor cells to death. Together, these results 
suggest that tumor necrosis may be secondary to a complete block in tumor blood 
flow, and that endothelial PI3K signaling may be essential to survive the TNF-
induced vascular effects.  
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To visualize the gross effects of PI3K inhibition and TNF on tumor blood vessels, we 
used the dorsal skinfold window chamber model (Fig.8.7.). 20 days after tumor 
inoculation, when the LLC tumors were visible as a small protrusion of the skin 
opposing the window, the mice were injected with wortmannin and low-dose mTNF 
inside the window chamber but outside the tumor nodule. The LLC tumors had a 
dense microvascular network at that time. Injection of low-dose mTNF induced 
transient dilation of larger vessels in the window chamber visible at 6 hours after 
injection, with signs of vascular leakage (swelling of tissue in the window chamber) 
in 2 of 4 treated mice. No haemorrhage was observed. The tumor microvasculature 
appeared to be largely unaffected by the treatment and tumors grew as in control 
mice. Injection of wortmannin caused local haemorrhage at the site of injection in 3 of 
4 treated animals, which interfered with the visualization of the tumor vasculature. 
However, where the tumor microvasculature was visible, no effect could be observed 
and treatment did not affect tumor growth. Bleeding was never seen in PBS-treated 
animals, suggesting that the haemorrhage observed after injection of wortmannin is 
drug-related. The effect of the combined injection of wortmannin and low-dose 
mTNF was striking, with complete destruction of the vasculature in the tumor area. 
This was associated with swelling and haemorrhage which filled up the whole 
window chamber in all treated animals as early as 6 hours after injection. At 72 hours 
after injection, when haemorrhage was starting to get cleared, the tumor area was 
largely devoid of vasculature, while intact microvasculature was readily visible 
outside the tumor area, suggesting that the vascular-disrupting effect of our 
combination treatment is selective for the tumor neovasculature (Fig.8.8.). Tumors 
were undetectable at 72 hours after injections of wortmannin plus mTNF. 
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Fig. 8.7. Effects of wortmannin and mTNF on tumor vasculature in the dorsal skinfold window 
chamber model. Pictures of the tumor area were taken before and 6h, 12h, 24h and 48h after injection 
of wortmannin and low-dose mTNF (0.7µg). Representative pictures are shown. Original 
magnification: ×5 objective. 
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Fig. 8.8. Detail of a dorsal skinfold window chamber 72h after injection of wortmannin and low-dose 
mTNF showing intact microvasculature outside the tumor area (left of dashed line). Original 
magnification: ×5 objective. 
 
The vascular-disrupting effect of treatment with wortmannin and low-dose mTNF was 
further investigated by staining sections of s.c. B16Bl6 tumors for the endothelial 
marker CD31 (Fig.8.9.A.). B16Bl6 tumors were well vascularized. Tumor vessels 
were narrow, having small or undetectable lumina, indicative of high interstitial fluid 
pressure in the tumor. Treatment with wortmannin had no apparent effect on the 
tumor vasculature. Blood vessels of mTNF-treated tumors had markedly enlarged 
lumina, which was already visible at 4 hours after injection. Blood clots were present 
inside the enlarged vessels. However, blood coagulation may have occurred during 
dissection as no perfusion was performed to remove the blood from the tumor vessels 
before excision of the tumor. The endothelial lining of most vessels in mTNF-treated 
tumors remained intact. At 7 hours after injection, some tumor vessels could be 
observed that appeared to be filled with leukocytes. At 24 hours, the majority of 
tumor vessels was intact. Necrotic areas that contained some endothelial cell debris 
were present near the centre of the tumor, suggesting that treatment with low-dose 
mTNF may induce disruption of some tumor vessels. After treatment with the 
combination of wortmannin and low-dose mTNF, tumor vessels were enlarged as 
after treatment with mTNF alone, and intravascular blood clots were also visible. 
However, treatment with wortmannin plus mTNF induced pronounced disruption of 
the vessel wall. First gaps in the endothelial lining of the vessels were apparent from 6 
hours after treatment. Moreover, the space between the vascular endothelium and the 
surrounding tumor cells was markedly increased, suggesting that treatment may 
induce loss of both endothelial cell-cell and cell-matrix contact. The background 
staining surrounding the enlarged vessels is suggestive of vascular leakage. Disruption 
of the vessel wall was complete by 24 hours after treatment. Treatment affected the 
majority of tumor vessels. However, some intact vessels could be found in the 
periphery. 
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Fig. 8.9. (pp201-202) Treatment with wortmannin and mTNF induces selective disruption of the 
tumor vasculature. B16Bl6 tumor sections of 5h, 6h, 7h and 24h after injection of low-dose mTNF 
(Ld mTNF; 0.7µg) were stained for (A) endothelial cells by CD31 staining (bright red), and (B) cell 
death by TUNEL staining (bright green). Wortmannin (Wm) was injected 1h before mTNF. Sections 
were counterstained with DAPI (blue). Aspecific staining is visible in necrotic areas and clotted blood 
(dim red and green). Representative blood vessels are shown. Original magnification: ×20 objective. 
 
We performed a TUNEL staining to visualize cell death in these tumor sections 
(Fig.8.9.B.). In all tumors sections necrotic areas were present near the centre of the 
tumor. Healthy blood vessels adjacent to these necrotic areas were surrounded by a 
cuff of healthy tumor cells, revealing a typical island structure. In mTNF-treated 
tumors, some TUNEL-positive tumor vessels could be seen at 24 hours after 
treatment, and some necrotic areas were present close to apparently intact tumor 
vessels, suggesting that cell death may be caused by insufficient vessel perfusion. 
After treatment with wortmannin and mTNF, the first TUNEL-positive vessels could 
be observed already 7 hours after treatment, and by 24 hours the majority of tumor 
vessels stained TUNEL-positive. Apoptotic endothelial cells were difficult to 
distinguish as dying vessels were surrounded by TUNEL-positive tumor cells. Cell 
death was mostly necrotic. At the time points investigated, endothelial cell death 
appeared to coincide with tumor necrosis, suggesting that endothelial cell death is 
secondary to vessel occlusion. 
 
These spectacular vascular-disrupting effects prompted us to test whether a single 
injection of wortmannin and low-dose mTNF would be sufficient to induce complete 
regression of a B16Bl6 tumor. However, we found that this was not the case. One 
treatment with this combination therapy induced, on average, a static response. At 
least two consecutive treatments (24 hour interval) were required to induce complete 
tumor regression. 
 
8.3.5. Inhibition of Akt or mTOR sensitizes to the antitumor effect of TNF 
 
To evaluate whether this would be a generic solution in which PI3K inhibitors could 
be substituted by inhibitors of other components of the survival pathway, we first 
selected two targets downstream of PI3K: Akt and mTOR. Akt is directly downstream 
of class I PI3Ks and an obligatory component of the survival pathway. Perifosine is an 
alkylphospholipid that structurally resembles PI(3,4,5)P3, the principal product of 
class I PI3Ks. It was found to be a specific Akt inhibitor, most likely by interfering 
with the PH domain-mediated membrane recruitment and activation of Akt 
35
. 
Perifosine is currently being evaluated in clinical trials for the treatment of multiple 
tumor types. We treated B16Bl6 tumor-bearing mice with perifosine, sub-therapeutic 
TNF (hTNF or low-dose mTNF), or a combination of these drugs (Fig.8.10. and Table 
8.2.). Treatment with perifosine had no significant effect on tumor growth. Treatment 
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with a combination of perifosine and either hTNF or low-dose mTNF induced a 
pronounced synergistic antitumor effect, with tumor regression in five out of seven 
and six out of seven treated mice, respectively. Moreover, complete tumor regression 
was obtained in two out of seven mice for both combinations. Mildly increased 
systemic toxicity was observed after treatment with perifosine plus hTNF. Average 
weight loss reached a maximum of approximately 18% of total body weight at the 
fourth day of treatment. No lethality occurred. Increased toxicity was not observed 
after treatment with perifosine and low-dose mTNF. 
 
 
Fig. 8.10. Inhibition of Akt sensitizes to the antitumor effect of TNF. (A) Growth curve of B16Bl6 
tumor after treatment with perifosine (50µg) and hTNF. (B) Growth curve of B16Bl6 tumor after 
treatment with perifosine (200µg) and low-dose mTNF (0.7µg). The line under the graph represents the 
treatment period. All data are shown as mean ± SEM, n = 7. 
 
We next tested the mTOR inhibitor rapamycin. mTOR was selected as a target 
because (1) although mTOR is not a component of the survival pathway sensu stricto, 
it is a key regulator of proteins synthesis, which may be important to survive TNF 
stimulation; (2) the anticancer potency of rapamycin has previously been 
demonstrated in numerous tumor models, and mTOR inhibitors are currently being 
tested in clinical trials; (3) the PI3K inhibitor LY294002 is also a potent inhibitor of 
mTOR; and (4) treatment with rapamycin has been shown to inhibit Akt activity in 
HUVECs stimulated with TNF 
36-38
. We evaluated the antitumor effect of rapamycin, 
alone or in combination with TNF, in the B16Bl6 tumor model (Fig.8.11. and Table 
8.2.). In contrast to PI3K inhibitors, treatment with rapamycin alone caused a 
significant delay in tumor growth. This corresponded with the cytotoxic effect of 
rapamycin on B16Bl6 cells in vitro: a concentration of 20µM rapamycin caused a 
growth inhibition of approx. 60% in the 48 hour MTT cytotoxicity assay due to an 
almost complete inhibition of cell proliferation (no death cells or cell debris could be 
observed). However, in this in vitro assay no additional effects of TNF could be 
observed, while in vivo the response to rapamycin plus either hTNF or low-dose 
mTNF was striking, with regression of the B16Bl6 tumor in four out of six and all 
treated animals, respectively. Complete tumor regression was observed in respectively 
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two out of six treated animals and all treated animals. Notably, rapamycin did not 
increase the apparent toxic side-effects of TNF. The synergism of rapamycin and TNF 
was not existent in TNF-R1
-/-
 mice, suggesting that this is also a host-mediated effect. 
 
 
Fig. 8.11. Rapamycin sensitizes to the antitumor effect of TNF. (A) Growth curve of B16Bl6 tumor 
after treatment with rapamycin and hTNF, and (B) after treatment with rapamycin and low-dose mTNF 
(0.7µg). The line under the graph represents the treatment period. All data are shown as mean + SEM. 
For PBS and rapamycin alone n = 5, for other groups n = 6. 
 
Table 8.2. Responses to treatments with perifosine, rapamycin, and TNF. 
 Tumor response §  
Treatment CR (%) PR (%) S (%) PD (%) D (%) 
PBS (n = 24) – – – 92 8 
Perifosine 50µg (n = 7) – – – 100 – 
Perifosine 200µg (n = 7) – – – 86 14 
Rapamycin (n = 10) – – – 90 10 
hTNF (n = 13) – 15 23 62 – 
Perifosine + hTNF (n = 7) 29 43 14 14 – 
Rapamycin + hTNF (n = 6) 33 33 33 – – 
Low-dose mTNF (n = 13) 15 8 8 61 8 
Perifosine +mTNF (n = 7) 29 57 – 14 – 
Rapamycin +mTNF (n = 6) 100 – – – – 
§
 TSI before start of treatment was compared to that on the 10
th
 day of treatment. Tumor response was 
classified as follows: PD = progressive disease, increase of more than 25%; S = static, tumor size 
between –25% and 25%; PR = partial regression, decrease between –25% and –99%; CR = complete 
regression, no palpable tumor. D = animal died during treatment. – = none. 
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8.3.6. Synergy of TNF and anti-angiogenic therapy  
 
We showed that general inhibition of the PI3K/Akt pathway, using broad-spectrum 
inhibitors of PI3K, Akt or mTOR, significantly increased the antitumor activity of 
TNF, without concomitantly increasing overt toxic side-effects of TNF. However, 
PI3K, Akt and mTOR are ubiquitously expressed and have important functions in 
healthy tissue, and therefore these enzymes may not be ideal therapeutic targets, 
unless isoform-selective inhibitors could be used to increase specificity. Endothelial 
cells of the tumor vasculature, the principal target cells of TNF for its antitumor 
effect, are nowadays specifically targeted by an increasing number of anti-angiogenic 
drugs, many of which target growth factors receptors or adhesion molecules capable 
of signaling via the PI3K/Akt pathway. The contribution of each target molecule to 
total PI3K activation is, however, likely to differ depending on the tumor type. The 
growth of s.c. B16Bl6 tumors has recently been shown to be significantly suppressed 
by treatment with neutralizing anti-VEGF-R2 antibodies 
39
. We tested whether anti-
VEGF-R2 treatment would sensitize to the antitumor effects of TNF in the B16Bl6 
tumor model (Fig.8.12. and Table 8.3.). Treatment with mouse IgG control antibodies 
had no effect on tumor growth or response to TNF. Treatment with anti-VEGF-R2 
antibodies, however, induced a significant suppression of tumor growth, comparable 
to the effect reported by Fischer and colleagues 
39
. The antitumor effect of TNF was 
markedly increased by concomitant treatment with anti-VEGF-R2 antibodies. 
Combined treatment induced tumor regression in all treated animals, and complete 
tumor regression (no palpable tumor) was observed in three out of six animals after 
anti-VEGF-R2 plus hTNF treatment and two out of six animals after anti-VEGF-R2 
plus low-dose mTNF treatment. Complete tumor regressions did not occur in hTNF- 
or low-dose mTNF-treated mice. A mildly increased toxicity was observed in mice 
treated with anti-VEGF-R2 antibodies and hTNF, which was not observed when anti-
VEGF-R2 treatment was combined with low-dose mTNF. One animal died during 
treatment with anti-VEGF-R2 antibodies and low-dose mTNF, most likely due to 
extensive bleeding which is sometimes observed during haemorrhagic necrosis of the 
tumors. Our results suggest that VEGF is an important survival factor for endothelial 
cells of the tumor vasculature in B16Bl6 tumors, and that anti-angiogenic therapy may 
be used to increase the efficacy of sub-therapeutic TNF therapy. 
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Fig. 8.12. Anti-VEGF-R2 treatment synergizes with TNF. Growth curve of B16Bl6 tumor after 
treatment with (A) mouse IgG (mIgG) control antibody and hTNF, (B) mIgG control antibody and low-
dose mTNF (0.7µg), (C) anti-VEGF-R2 antibody and hTNF, and (D) anti-VEGF-R2 antibody and low-
dose mTNF. The line under the graph represents the treatment period. All data are shown as mean + 
SEM, n = 6. 
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Table 8.3. Responses to treatments with IgG control antibodies, anti-VEGF-R2 antibodies, and 
TNF. 
 Tumor response §  
Treatment CR (%) PR (%) S (%) PD (%) D (%) 
PBS (n = 6) – – – 100 – 
Mouse IgG control (n = 6) – – – 100 – 
Anti-VEGF-R2 (n = 6) – – – 100 – 
hTNF (n = 6) – 50 – 50 – 
Mouse IgG control + hTNF (n = 6) – – – 83 17 
Anti-VEGF-R2  + hTNF (n = 6) 50 50 – – – 
Low-dose mTNF (n = 6) – 33 17 33 17 
Mouse IgG control + mTNF (n = 6) – 50 – 33 17 
Anti-VEGF-R2  + mTNF (n = 6) 33 50 – – 17 
§
 TSI at day 12 after tumor inoculation was compared to that on day 21. Tumor response was classified 
as follows: PD = progressive disease, increase of more than 25%; S = static, tumor size between –25% 
and 25%; PR = partial regression, decrease between –25% and –99%; CR = complete regression, no 
palpable tumor. D = animal died during treatment. – = none. 
 
 
8.4. Discussion 
 
The primary findings of this study are: (1) inhibition of the PI3K/Akt pathway, using 
broad spectrum inhibitors of PI3K, Akt or mTOR, significantly increases the 
antitumor activity of TNF in the B16Bl6 melanoma and other tumor models, allowing 
at least a tenfold reduction of the effective dose of TNF; (2) PI3K/Akt pathway 
inhibition may increase the antitumor activity of TNF without concomitantly 
increasing its toxic side-effects; (3) the sensitizing effect of PI3K or mTOR inhibition 
to TNF is host-mediated; (4) inhibition of PI3K sensitizes the tumor vasculature to the 
vascular-disrupting effect of TNF; and (5) anti-angiogenic therapy using VEGF-R2 
blocking antibodies synergizes with TNF for the induction of tumor regression in the 
B16Bl6 tumor model. 
 
The dose-limiting toxicities of TNF are hypotension, liver toxicity, thrombocytopenia, 
leukopenia, and multi-organ failure, generally called ‘septic shock-like syndrome’ or 
SIRS 
2, 8, 9, 40-42
. Mice can be completely protected against the TNF-induced shock and 
lethality with the sGC inhibitor methylene blue, suggesting that both the lethal shock-
inducing and antitumor effects of TNF are vascular effects 
6, 43
. However, we have 
evidence that the antitumor and shock-inducing effects are mediated by different 
target cell populations. Transgenic Flk-1 TNF-R1 reactivation knockout mice, 
expressing the TNF-R1 solely on endothelial cells, were markedly less sensitive to the 
lethal shock-inducing effect of TNF, while the antitumor effect was preserved 
13
. We 
and others have also shown that the toxic side-effects and antitumor effects are not 
linked at the signaling level. Inhibition of the TNF-induced shock with methylene 
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blue did not affect the antitumor activity of TNF 
6
. Likewise, two acute phase 
proteins, 1-acid-glycoprotein and 1-antitrypsin, were shown to protect against the 
TNF-induced liver toxicity without affecting its antitumor activity 
43
. More recently, 
zinc-induced expression of HSP70 was shown to confer protection against TNF-
induced toxicity without interfering with the antitumor activity of TNF/IFN- therapy 
44
. In the present study we have demonstrated that PI3K/Akt/mTOR pathway 
inhibition may also allow to discriminate between the antitumor and toxic side-effects 
of TNF. Increased systemic toxicity was only observed when the PI3K inhibitor 
wortmannin was used, which may be due to the irreversible nature of this inhibitor. 
Toxicity was not observed when using the reversible broad-spectrum PI3K inhibitor 
LY294002, indicating that toxicity is not linked to PI3K inhibition per se. 
Interestingly, p110ki/ki mice were more sensitive to the TNF-induced toxic side-
effects, suggesting that a PI3K-dependent protective effect may exist. We have 
furthermore shown that the PI3K isoforms p110 and p110 are no determinants of 
the sensitivity to the antitumor effect of TNF. Together these data suggest that p110- 
or p110-selective inhibitors, which are currently being developed (e.g. PIK-75, PI-
103 and TGX-221 
45, 46
), have the best chance to mimic the sensitizing effect of broad-
spectrum PI3K inhibition with minimal risk of toxicity. 
 
It was previously shown that the antitumor effect of TNF is completely host-mediated, 
via triggering of the TNF-R1 on the tumor vasculature 
12, 13
. We have shown, by using 
TNF-R1
-/-
 mice, that the combination therapy of TNF and PI3K inhibition is also a 
host-mediated effect and that this treatment results in a pronounced destruction of the 
tumor vasculature, suggesting a similar antitumor effect as TNF monotherapy. This is 
further supported by the finding that the fast-cleared PI3K inhibitor LY294002 was 
largely ineffective when injected one hour before TNF, while its effectiveness was 
comparable to that of the irreversible inhibitor wortmannin when injected 15 minutes 
before TNF, suggesting that the sensitizing effect to TNF is only existent when PI3K 
inhibition and TNF stimulation occur at the same time, and thus most likely in the 
same cell. 
 
The mechanism underlying the vascular-disrupting effect of TNF is still largely 
unknown. We used intravital microscopy as well as several histological staining 
methods to visualize the gross effects of treatment with wortmannin and TNF on the 
tumor vasculature. Our data suggest that very rapidly after injection treatment leads to 
vascular leakage and haemorrhage, followed by complete shutdown of the blood flow 
in sensitive tumor vessels by 6 hours after injection. Destruction of the vessel wall 
was complete by 24 hours after injection. Matschurat and colleagues have shown that 
inhibition of PI3K led to enhanced TNF-induced expression of tissue factor, the prime 
initiator of blood coagulation, in HUVECs. They furthermore demonstrated that co-
injection of wortmannin promoted the TNF-induced necrosis of methA tumors, 
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thereby suggesting that the expression of tissue factor on endothelial cells of the 
tumor vasculature, leading to thrombus formation and occlusion of the tumor vessels, 
would be responsible for the antitumor effect of this combination therapy 
26
. Our 
findings, however, do not fully support this hypothesis. Intravascular thrombus 
formation is a protective mechanism to prevent haemorrhage in the case of vascular 
damage. The extensive vascular leakage and haemorrhage observed in the dorsal 
skinfold window chambers and sections of tumors treated with wortmannin and TNF 
suggest that vessel occlusion is secondary to disruption of the vessel wall. 
There is substantial in vitro data showing that PI3K inhibition can sensitize 
endothelial cells to TNF-induced cytotoxicity 
24, 25, 47
. Particularly interesting in this 
context is the finding that TNF itself is capable of activating PI3K and Akt 
23
. PI3K 
signaling was shown to be essential in certain cell types for the activation of NF-B, 
the main transcription factor responsible for TNF-induced anti-apoptotic signaling. 
However, this was not the case in HUVECs 
48
. Madge and co-workers demonstrated 
that TNF triggers a PI3K-mediated anti-apoptotic response in HUVECs that is 
independent of Akt and NF-B, and that inhibition of PI3K results in cathepsin B-
dependent, but caspase-independent cell death of these endothelial cells 
25
. These 
findings, however, do not fit with our in vivo data where the sensitizing effect of PI3K 
inhibition could be mimicked by Akt inhibition. Moreover, after treatment with 
wortmannin and TNF DNA fragmentation in tumor endothelial cells, a hallmark of 
apoptotic cell death, was only observed after disruption of the vessel wall and vessel 
occlusion had occurred. At that time endothelial cell death may also be a consequence 
of cell detachment (anoikis) or mere starvation.  
We hypothesize that the initial event in the vascular-disrupting effect of treatment 
with wortmannin and TNF is a loss of endothelial cell-cell contact and/or cell-matrix 
contact. Gaps in the endothelial lining of the tumor vessels were readily visible at 6 
hours after treatment. Similarly, Menon and colleagues reported the formation of gaps 
in the endothelial lining of the tumor vasculature between 3 and 6 hours after 
treatment with TNF in human melanoma xenografts in mice as well as in human 
melanoma patients after ILP, and they attributed this effect to a disappearance of VE-
cadherin from endothelial cell-cell junctions 
49
. The adherens junction component VE-
cadherin is known to play a critical role in endothelial cell-cell connections and tumor 
angiogenesis 
50
. It was recently shown that TNF can induce tyrosine phosphorylation 
of the intracellular domain of VE-cadherin, thereby weakening the VE-cadherin-based 
junctions and facilitating the formation of intercellular gaps 
51
. Disruption of VE-
cadherin junctions may lead to a shutdown of tumor blood flow by a mechanism of 
vascular collapse, in analogy with the vessel-disrupting mechanism reported for the 
tubulin binding drug CA4P. Disassembly of VE-cadherin junction would cause 
haemorrhage, an increase of interstitial fluid pressure, and eventually the collapse of 
the weakened tumor vessels 
52
. It is, however, currently unclear whether PI3K 
inhibition could exacerbate the TNF-induced disassembly of VE-cadherin junctions. 
The integrins v3 and v5 play an important role in endothelial cell-matrix adhesion 
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in neovasculature 
53
. Rüegg and colleagues showed that treatment of HUVECs with 
TNF and IFN- suppressed the activation of integrin v3, leading to a decrease in 
endothelial cell adhesion and survival, and they observed detachment and apoptosis of 
v3-positive endothelial cells in the tumor vasculature of melanoma patients after 
ILP with TNF plus IFN- 54. Furthermore, they demonstrated that Akt activity can 
strengthen integrin-dependent endothelial cell adhesion and can protect HUVECs 
against cell death induced by TNF and/or integrin v3/v5 inhibition 
55, 56
. Thus, 
TNF therapy is known to interfere with both endothelial cell-cell and cell-matrix 
adhesions. PI3K/Akt pathway inhibition may exacerbate this effect and/or 
compromise endothelial cell survival during periods of cell detachment.  
 
The observation that mTOR inhibition mimics the sensitizing effect of PI3K or Akt 
inhibition is not surprising as persistent mTOR inhibition was recently shown to 
inhibit Akt activation in HUVECs and other cell types 
37
. However, of all compounds 
tested, rapamycin was the most potent one, which may suggests that mTOR, as an 
important regulator of protein synthesis, could have an additional protective function 
not directly linked to Akt activation. It is long known that inhibition of protein 
synthesis can sensitize cultured endothelial cells to TNF-induced cytotoxicity 
57, 58
. 
 
Finally, we demonstrated that TNF therapy may synergize with anti-angiogenic 
therapy, which is a novel concept in anticancer therapy. We tested a VEGF-R2 
blocking antibody known to have anti-angiogenic activity in the B16Bl6 tumor model 
39
. This anti-VEGF-R2 antibody was able to mimic the sensitizing effect of broad-
spectrum PI3K/Akt pathway inhibition, suggesting that VEGF is an important 
survival factor for endothelial cells in B16Bl6 tumors. Interestingly, VEGF-R2 has 
been shown to interact with both VE-cadherin and integrin v3, and in both cases 
these interactions were linked to downstream PI3K activation, suggesting an 
important survival function of these complexes in VEGF-driven angiogenesis 
59, 60
. 
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9. INVARIANT NKT CELLS CONTRIBUTE TO TUMOR DESTRUCTION BY TNF 
 
Abstract 
 
TNF is a pro-inflammatory cytokine with a remarkable antitumor activity. Both in 
animal models and in human patients it is capable of inducing a rapid, haemorrhagic 
necrosis of tumors, characterized by a selective destruction of the tumor vasculature. 
Systemic treatment with TNF is, however, severely hampered by the pronounced 
shock-inducing properties of TNF. We and others have previously shown that the 
antitumor effect of TNF is completely host-mediated, and requires expression of the 
TNF-R1 only on the endothelial cells of the tumor vasculature. Experiments in our 
research group using IRF-1
-/-
 mice, which are deficient in mature NK cells, NKT cells 
and CD8
+
 T cells, have suggested that certain immune cells may also be important for 
the full antitumor response to TNF. In the present study we investigated, using 
immune-deficient mice and selective leukocyte depletion methods, which 
lymphocytes are required for the antitumor response to TNF. We found that no 
lymphocyte population was strictly essential for the antitumor activity of TNF. 
Athymic C57BL/6
nu/nu
 mice, lacking mature T lymphocytes and NKT cells, as well as 
NK cell-depleted mice showed similar responses to TNF as wild-type, immune-
competent mice. However, we found that four independent NKT-deficient mouse 
strains (IRF-1
-/-
, IL-15
-/-
, J18-/- and CD1-/-) displayed markedly reduced antitumor 
response to TNF. In IRF-1
-/-
 mice as well as in J18-/- mice this defect could be 
largely restored by transfer of leukocytes isolated from wild-type liver, which is 
particularly rich in NK1.1
+
 T cells. A role for NK1.1
+
 cells was also confirmed by 
selective depletion of these cells. Our results suggest that the recruitment and/or 
activation of invariant NKT cells is an important event in the cascade that leads to 
complete tumor destruction by TNF. Furthermore, we have extended this finding by 
showing that a single injection of the specific NKT cell ligand GalCer markedly 
increased the efficacy of a sub-therapeutic TNF treatment. Using IFN-R-deficient 
mice we showed that the latter effect is dependent on IFN- production. Taken 
together, we have shown that targeting invariant NKT cells may be a worthwhile 
approach to extend the therapeutic applicability of TNF. 
 
 
 
 
 
This work was performed in collaboration with the research group of Prof. Dr. Dirk Elewaut 
(Department of Rheumatology, Ghent University Hospital, Ghent, Belgium) who provided transgenic 
mice, reagents and intellectual input. It builds on observations made by Dr. Jeroen Hostens in our 
research group and reported in his PhD thesis.  
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9.1. Introduction 
 
TNF is a pro-inflammatory cytokine with a remarkable antitumor activity. Both in 
animal models and in human patients, where it is used in combination with melphalan 
to treat regional tumors of the limbs via the ILP technique, it is capable of inducing a 
rapid haemorrhagic necrosis of tumors, which is characterized by a selective 
destruction of the tumor vasculature. We and others have previously shown that this 
antitumor effect is completely host-mediated, and requires expression of the TNF-R1 
on the tumor endothelium 
1, 2
. These experiments have also indicated that TNF-R1 
expression on other cells than endothelial cells, most importantly tumor cells and 
immune cells, is unimportant for the full antitumor response to TNF. Certain immune 
cells may, however, be important for the antitumor effect of TNF. Eggermont and 
colleagues demonstrated that total body irradiation of tumor-bearing rats, thereby 
inducing general leukopenia, markedly decreased the tumor response and skin 
necrosis at the tumor site following ILP with TNF and melphalan 
3
. After TNF-based 
ILP, an inflammatory response is observed which results in a rapid recruitment of 
polymorphonuclear cells to the tumor, followed by the infiltration of macrophages 
and lymphocytes after several days to weeks 
4, 5
. Experiments performed in our lab 
using B16Bl6 tumor-bearing IRF-1
-/-
 mice, which fail to develop mature NK cells, 
NK1.1
+
 T cells and CD8
+
 T cells, revealed a markedly reduced antitumor response to 
TNF in these mice 
6-8
. Responsiveness could be partly restored by reconstitution with 
wild-type splenocytes, suggesting a role for lymphocytes in this model.  
 
In the present study we have investigated, by using immune-deficient mouse strains 
and selective lymphocyte depletion methods, which lymphocytes are involved in the 
antitumor mechanism induced by TNF. We found that no lymphocyte population was 
indispensible for the antitumor activity of TNF. However, we found that NKT-
deficient mice displayed a markedly reduced antitumor response to TNF. 
Furthermore, we have shown that pre-treatment with the specific NKT cell ligand 
GalCer markedly increased the efficacy of a sub-therapeutic TNF treatment. Taken 
together, our results suggest that targeting invariant NKT cells may be a worthwhile 
approach to extend the therapeutic applicability of TNF. 
 
 
9.2. Materials and methods 
 
9.2.1. Mice 
 
Female C57BL/6J mice and athymic C57BL/6
nu/nu
 mice were purchased from Janvier, 
Le Genest-Saint-Isle, France. IRF-1
-/-
 (B6.129S2-Irf1
tm1Mak
/J, stock nr. 002762), IFN-
R-/- (B6.129S7-Ifngr1tm1Agt/J, stock nr. 003288), and athymic C57BL/6nu/+ (B6.Cg-
Foxn1
nu
/J, stock nr. 000819) breeding couples were purchased from The Jackson 
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Laboratory, Bar Harbor, Maine, USA 
7, 9
. Athymic Swiss
nu/nu
 mice (ICO:Swiss-
Foxn1
nu
) were purchased from Charles River Laboratories, Saint-Germain-sur-
l’Arbresle, France. IL-15-/- mice on C57BL/6 background were generated by Dr. 
Peschon, Immunex Corporation, Seattle, Washington, USA 
10
. CD1
-/-
 mice were 
generated and backcrossed to C57BL/6 background by Dr. Van Kaer, Howard Hughes 
Medical Institute, Vanderbilt University School of Medicine, Nashville, Tennessee, 
USA 
11
. J18-/- mice were generated and backcrossed to C57BL/6 background by Dr. 
Taniguchi, Chiba University, Chiba, Japan 
12
. Transgenic mice expressing a 
dominant-negative IFN-R mutant controlled by a Flk-1 promoter (Flk-1 dnIFN-R) 
were generated and backcrossed to C57BL/6 background in our laboratory by Dr. 
Jeroen Hostens 
13
. All animals were housed in 14-10 hours light/dark cycles in a 
temperature-controlled, air-conditioned room, and received food and water ad libitum. 
The mice were used for experimentation at the age of 8-12 weeks. All experiments 
were approved by and performed according to the guidelines of the local ethics 
committee of Ghent University, Belgium. 
 
9.2.2. Cells 
 
B16Bl6 melanoma and EL4 lymphoma cells were cultured in RPMI-1640 medium 
supplemented with 10% FCS, 2mM L-glutamine, 0,4mM Na-pyruvate, 50 IU/ml 
penicillin G and 50µg/ml streptomycin sulphate 
14
. LLC-H61 carcinoma cells were 
cultured in DMEM medium supplemented with 10% FCS, 2mM L-glutamine, 0,4mM 
Na-pyruvate, 50 IU/ml penicillin G and 50µg/ml streptomycin sulphate 
15
. For tumor 
inoculation, cells were detached from the culture flask by a short EDTA treatment, 
washed three times in endotoxin-free, sterile DPBS (Sigma), and resuspended in 
DPBS. 
 
9.2.3. Reagents 
 
The NKT cell ligand GalCer was produced by Dr. Serge Van Calenbergh, 
Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent 
University, Ghent, Belgium. Rat anti-mouse IL-2R -chain antibodies, clone Tm1, 
were produced in our laboratory. The Tm1 hybridoma was generated and kindly 
provided by Dr. Tanaka, Tokyo Metropolitan Institute of Medical Science, Tokyo, 
Japan 
16
. Mouse anti-mouse NK1.1 antibodies, clone PK136, were purchased from 
BioXCell. The fluorochrome-labeled antibodies anti-NK1.1-FITC, anti-CD49b-FITC 
(clone DX5), and anti-TCR-PE were purchased from BD Pharmingen. FITC-labeled 
mouse CD1d tetramers loaded with GalCer were provided by Dr. Dirk Elewaut, 
Department of Rheumatology, Ghent University Hospital, Ghent, Belgium. 
Recombinant mTNF and hTNF were produced in our laboratory and had a specific 
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activity of 1.28 x 10
8
 IU/mg and 6.8 x 10
7
, and an endotoxin content (LAL assay) of 
6.5 EU/mg and 36 EU/mg, respectively. 
 
9.2.4. Tumor experiments 
 
Mice were inoculated with 6 x 10
5
 (B16Bl6 and EL4) or 5 x 10
6
 (LLC) tumor cells 
s.c. in the back (day 0). Treatment was started when the TSI, the product of the largest 
perpendicular diameters in cm, was greater than 0,5 (≥day 10). Unless otherwise 
indicated, mTNF (7µg) was administered daily for 10 consecutive days via 
paralesional injection (s.c. injection near the site of the tumor but outside the nodule). 
For GalCer experiments, GalCer (1µg) was injected i.p. on the first day of 
treatment, followed by daily treatment with low-dose mTNF (0.7µg) or hTNF (30µg) 
via paralesional injection for 9 consecutive days. 
 
9.2.5. Transfer of splenocytes and liver leukocytes 
 
Livers or spleens of wild-type C57BL/6 mice were passed through a 70µm cell 
strainer in complete DMEM medium. Red blood cells were lysed using Ack buffer 
(0.15M NH4Cl, 10mM KHCO3, 0.1mM Na2EDTA.2H2O, pH 7.2). Hepatocytes were 
removed by density gradient centrifugation using a 40%-70% Percoll gradient. Cells 
were washed twice in PBS and resuspended in PBS. For splenocyte transfer, IRF-1
-/-
 
mice were injected i.v. into the tail vein with 50 x 10
6
 splenocytes on day 5 after 
tumor inoculation. For transfer of liver leukocytes, IRF-1
-/-
 or J18-/- mice were 
injected i.v. into the tail vein with approx. 2 x 10
6
 cells (1:2 donor/acceptor ratio) on 
day 7 after tumor inoculation. Approx. 1% of splenocytes and 10-16% of liver 
leukocytes were NK1.1
+
TCR+ cells. 
 
9.2.6. In vivo depletion of NK and NK1.1+ cells 
 
Selective, long-term depletion of NK cells was obtained by a single i.p. injection of 
1mg of anti-IL-2R antibody (Tm1) on day 5 after tumor inoculation as described 17. 
Depletion was verified by a YAC-1 lysis assay and by flow cytometric analysis of 
leukocytes isolated from liver and spleen. For the YAC-1 lysis assay, splenocytes 
were isolated 6 days after injection of the anti-IL-2R antibody and cultured 
overnight in complete RPMI medium supplemented with 1000 IU/ml human IL-2. 
The cells were seeded into 96-well plates containing 20000 YAC-1 target cells per 
well with effector/target ratios of 100:1 to 0.2:1. The cells were co-incubated during 6 
hours, after which lysis of YAC-1 cells was determined by measuring lactate 
dehydrogenase in the medium with the Cytotox96 non-radioactive cytotoxicity assay 
kit (Promega). For flow cytometric analysis, leukocytes from liver and spleen were 
isolated 6 days after injection of the anti-IL-2R antibody and stained with pairs of 
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the following fluorochrome-labeled reagents to detect NK and NKT cells: anti-
NK1.1-FITC, anti-CD49b-FITC, GalCer CD1d tetramer-FITC, and anti-TCR-PE. 
Flow cytometry was performed on a FACSCalibur and results were analyzed with 
CellQuest software (BD Biosciences). Depletion of NK1.1
+
 cells, i.e. NK and NKT 
cells, was performed by i.p. injection of 200µg anti-NK1.1 antibody on days 8, 12, 16, 
and 20 after tumor inoculation. Depletion was verified by flow cytometric analysis of 
liver leukocytes isolated 3 days after injection of the anti-NK1.1 antibody. 
 
9.2.7. Statistics 
 
For tumor experiments mice were stratified into treatment groups having non-
significantly different mean TSI (one-way ANOVA, P-value > 0.95). Calculations 
and graphs were made using Graphpad Prism 4.0. 
 
 
9.3. Results 
 
9.3.1. Lymphocytes influence the response to TNF 
 
Previous work in our lab demonstrated that IRF-1
-/-
 mice, which fail to develop 
mature NK cells, NKT cells and CD8
+
 T cells, displayed a markedly reduced 
antitumor response to TNF. Responsiveness could be partly restored when these mice 
were injected with wild-type splenocytes 48 hours prior to inoculation with the 
B16Bl6 tumor cells 
8
. However, this effect was temporary, most likely due to washing 
out of the splenocytes before the end of the ten-day treatment period, and tumors 
which initially responded to treatment with mTNF already relapsed during the 
treatment period, resulting in no significantly different tumor response rate at the end 
of treatment. Moreover, this experiment could not exclude that the reduced response 
of IRF-1
-/-
 mice to treatment with mTNF would be due to absence of the IRF-1 
transcription factor.  IRF-1 is known to interfere with TNF/NF-B signaling 18, 19. To 
determine whether immunological defects are at the basis of the reduced antitumor 
activity of TNF in IRF-1
-/-
 mice, we compared the antitumor response to TNF in 
B16Bl6 tumor-bearing IRF-1
-/-
 mice and IL-15
-/-
 mice, which have comparable 
immune deficiencies (Fig.9.1.A-C and Table 9.1.). IL-15
-/-
 mice essentially lack 
mature NK cells and have markedly reduced numbers of NKT and memory phenotype 
CD8
+
 T cells 
10
. Treatment of wild-type C57BL/6 mice with mTNF resulted in 
complete regression of the B16Bl6 tumor (no palpable tumor at the 10
th
 day of 
treatment) in six out of seven treated mice. In both IRF-1
-/-
 and IL-15
-/-
 mice, 
however, the tumor response was markedly reduced, resulting in complete tumor 
regression in no and one out of seven treated mice, respectively. This suggests that the 
reduced antitumor response to TNF in these strains is due to the absence or reduced 
numbers of either NK, NKT or CD8
+
 T cells. 
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Fig. 9.1. Lymphocytes are important for the antitumor response to TNF. (A-D) Tumor growth 
curves of B16Bl6 melanoma in C57BL/6 wild-type (wt) mice, IRF-1
-/-
 mice, IL-15
-/-
 mice, and IRF-1
-/-
 
mice reconstituted with wild-type splenocytes. Data are shown as mean ± SEM. (E) Overlay of tumor 
growth curves after treatment with mTNF. Data are shown as mean + SEM. For C57BL/6 wt and IL-
15
-/-
 n = 7, for IRF-1
-/-
 n = 6. The line under the graph represents the treatment period.  
 
To further substantiate this we reconstituted IRF-1
-/-
 with wild-type splenocytes 
(Fig.9.1. and table 9.1.). Disappearance of the splenocytes before the end of the 
treatment period was avoided by transferring the splenocytes 5 days after tumor 
inoculation. We found that reconstitution of IRF-1
-/-
 mice with wild-type splenocytes 
markedly increased the sensitivity to TNF, resulting in complete tumor regression in 
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all surviving mice. However, three out of six treated mice died due to treatment-
related toxicity, suggesting that both the TNF-induced antitumor effect and toxic side-
effects are influenced by the presence of immune cells. Alternatively, the increased 
sensitivity to TNF may also be a consequence of the supranormal numbers of certain 
leukocytes after splenocyte transfer (see further), or the presence of contaminants (e.g. 
LPS) in the transferred cell preparation which could lead to inflammation.   
  
Table 9.1. Responses to treatment with mTNF in wild-type, IRF-1
-/-
 and IL-15
-/-
 mice. 
 Tumor response §  
Strain CR (%) PR (%) S (%) PD (%) D (%) 
C57BL/6 wt (n = 7) 86 14 – – – 
IRF-1-/- (n = 6) – 33 17 50 – 
IL-15-/- (n = 7) 14 43 – 43 – 
IRF-1-/- + wt splenocytes (n = 6) 50 – – – 50 
§
 TSI before start of treatment was compared to that on the 10
th
 day of treatment. Tumor response was 
classified as follows: PD = progressive disease, increase of more than 25%; S = static, tumor size 
between –25% and 25%; PR = partial regression, decrease between –25% and –99%; CR = complete 
regression, no palpable tumor. D = animal died during treatment. – = none. 
 
The similar results obtained in both IRF-1
-/-
 and IL-15
-/-
 strains suggest a role for 
either NK cells, NKT cells or CD8
+
 T cells in the antitumor mechanism induced by 
TNF. To determine whether T cells are involved in this effect, we treated tumor-
bearing athymic C57BL6
nu/nu
 mice and Swiss
nu/nu
 mice, which lack mature T 
lymphocytes including NKT cells (Fig.9.2.). A remarkable difference was observed 
between both strains, which appeared to be independent of the tumor type. Similar 
results were obtained for tumors induced by s.c. injection of human HT29 colon 
carcinoma cells or murine B16Bl6 melanoma cells. The antitumor response to TNF in 
Swiss
nu/nu
 mice was comparable to that in IRF-1
-/-
 or IL-15
-/-
 mice, which may reflect 
the importance of (NK)T cells for the antitumor activity of TNF. Complete tumor 
regression or lethality was not observed in Swiss
nu/nu
 mice. By sharp contrast, 
treatment of B16Bl6 tumor-bearing C57BL/6
nu/nu
 mice resulted in apparent tumor 
regression in all treated mice. However, five out of six treated animals succumbed due 
to toxic side-effects, suggesting that C57BL/6
nu/nu
 mice are more sensitive to TNF per 
se. 
 
224 Chapter 9 
 
Fig. 9.2. The antitumor activity of TNF in athymic nude mice. (A-B) Growth curve of B16Bl6 
melanoma in athymic C57BL/6
nu/nu
 and Swiss
nu/nu
 mice. Data are shown as mean ± SEM, n = 6. The 
line under the graph represents the treatment period.  
 
Analysis of spleen, liver, and blood leukocytes revealed that C57BL/6
nu/nu
 have two- 
to fourfold increased numbers of NK cells compared to wild-type C57BL/6 mice 
(Fig.9.3.). To investigate whether the increased number of NK cells could determine 
the increased sensitivity to TNF, we depleted NK cells in these mice by injecting an 
anti-IL-2R antibody which was previously shown to  induce selective, long-term 
elimination of NK cells 
17
. NK cell depletion of C57BL/6
nu/nu
 mice resulted in a 
markedly reduced sensitivity to TNF, with complete regression of the B16Bl6 tumor 
in only one out of six treated animals, and only one of six animals died during 
treatment. These results indicate that the presence of NK cells may indeed influence 
the response to TNF in this model. 
 
 
Fig. 9.3. NK cells determine the sensitivity to TNF in C57BL/6
nu/nu
 mice. (A) Growth curve of 
B16Bl6 tumor in NK cell-depleted C57BL/6
nu/nu
 mice. Data are shown as mean ± SEM, n = 6. The line 
under the graph represents the treatment period. (B) Flow cytometric analysis of splenocytes and liver 
leukocytes of C57BL/6 wild-type (wt), C57BL/6
nu/nu
 (nu/nu), and NK cell-depleted C57BL/6
nu/nu
 mice 
isolated 6 days after injection of the anti-IL-2R antibody. 
 
 
225 Experimental work: NKT cells contribute to tumor destruction by TNF 
To investigate the role of NK cells and NK1.1
+
 T cells in the antitumor activity of 
TNF in wild-type mice, we depleted these cells using either an anti-IL-2R antibody 
or an anti-NK1.1 antibody. Analysis of liver leukocytes showed that injection of the 
anti-IL-R2 antibody selectively depleted NK cells, not affecting hepatic invariant 
NKT cell numbers, while injection of the anti-NK1.1 antibody depleted both NK and 
NK1.1
+
 T cells, thus allowing us to make a distinction between both cell types 
(Fig.9.4.). Treatment of NK cell-depleted mice, after injection of the anti-IL-2R 
antibody, resulted in regression of the B16Bl6 tumor as in control mice, indicating 
that NK cells are not required for the antitumor activity of TNF. However, depletion 
of NK1.1
+
 cells resulted in a markedly reduced antitumor response to TNF, with 
complete tumor regression in only one out of six treated animals. Taken together, 
these results suggest a role for NK1.1
+
 T cells in the antitumor mechanism induced by 
TNF. 
 
 
Fig. 9.4. NK1.1
+
 T cells, but not NK cells, contribute to the antitumor activity of TNF. (A, C) 
Growth curve of B16Bl6 tumor in NK cell-depleted (anti-IL-2R; n = 7) mice and NK1.1+ cell-
depleted (anti-NK1.1; n = 6) mice. Data are shown as mean ± SEM. The line under the graph 
represents the treatment period. (B, D) Flow cytometric analysis of liver leukocytes isolated 
respectively 6 and 3 days after injection of anti-IL-2R or anti-NK1.1 antibodies. Tetramer: GalCer-
loaded mouse CD1d tetramer. 
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9.3.2. Invariant NKT cells contribute to the TNF-induced antitumor effect 
 
To further establish the involvement of NKT cells in the antitumor mechanism 
elicited by TNF, we used the NKT-deficient mouse strains J18-/- and CD1-/-. Both 
these strains lack classical invariant NKT cells (type I 
20
) and have no other overt 
defects than in NKT cells 
11, 12
. Treatment of these NKT-deficient strains resulted in 
both cases in a markedly reduced response to TNF compared to wild-type C57BL/6 
mice (Fig.9.5. and Table 9.2). For B16Bl6 melanoma, the complete response rate 
(complete regression) was 62% in wild-type C57BL/6 mice, while this was 19% and 
10% in J18-/- and CD1-/- mice, respectively. The objective response rates (complete 
+ partial regression) were respectively 73%, 29% and 34%. The difference was even 
further enlarged when we used lower doses of mTNF. Treatment of wild-type 
C57BL/6 mice with 3.5µg or 1µg of mTNF resulted in both cases in complete tumor 
regression in four of six treated animals, while no complete tumor regressions were 
observed in J18-/- mice treated with these doses. Furthermore, the reduced antitumor 
response in J18-/- appeared to be independent of the tumor type as similar results 
were obtained for EL4 lymphoma, although this tumor grew markedly slower in J18-
/-
 mice than in control mice. 
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Fig. 9.5. NKT cells contribute to the antitumor activity of TNF. (A-B) Growth curve of B16Bl6 
melanoma in C57B/6 wild-type (wt) and J18-/- mice, n = 6. (C) Growth curve of EL4 lymphoma in 
C57BL/6 wild-type and J18-/- mice, n = 7. (D) Growth curve of B16Bl6 melanoma in CD1-/- mice, n = 
7. All data are shown as mean ± SEM. The line under the graph represents the treatment period. 
 
To determine whether the responsiveness to TNF treatment in NKT-deficient mice 
could be restored by reconstitution with invariant NKT cells, we transferred 
leukocytes isolated from wild-type liver, which is particularly rich is invariant NK1.1
+
 
T cells, to J18-/- and IRF-1-/- mice (Fig.9.6. and table 9.2.). We determined that 
approx. 10 to 16% of all liver leukocytes were NK1.1
+
 T cells. Strikingly, transfer of 
wild-type liver leukocytes to J18-/- mice increased the objective response rate from 
29% to 100%. Transfer to IRF-1
-/-
 mice increased the objective response rate from 
17% to 50%. Interestingly, no increased toxicity was observed after transfer of wild-
type liver leukocytes. Taken together, these results indicate that invariant NKT cells 
are involved in the antitumor mechanism elicited by TNF. 
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Fig. 9.6. Reconstitution with wild-type liver leukocytes restores the antitumor activity of TNF in 
NKT-deficient mice. (A) Tumor response of B16Bl6 melanoma to treatment with mTNF in C57BL/6 
wild-type (wt) mice, J18-/- mice, and J18-/- mice reconstituted with wild-type liver leukocytes. (B) 
Idem for IRF-1
-/-
 mice. All data are shown as mean + SEM, n = 6. The line under the graph represents 
the treatment period. 
 
Table 9.2. Responses to treatment with mTNF in wild-type and NKT-deficient mice. 
 Tumor response §  
Strain CR (%) PR (%) S (%) PD (%) D (%) 
C57BL/6 wt (n =53) 62 11 4 15 8 
J18-/- (n = 31) 19 10 10 52 10 
CD1-/- (n = 21) 10 24 29 38 – 
IRF-1-/- (n = 12) – 17 25 50 8 
J18-/- + wt liver leukocytes (n = 6) 83 17 – – – 
IRF-1-/- + wt liver leukocytes (n = 6) 33 17 17 17 17 
§
 TSI before start of treatment was compared to that on the 10
th
 day of treatment. Tumor response was 
classified as follows: PD = progressive disease, increase of more than 25%; S = static, tumor size 
between –25% and 25%; PR = partial regression, decrease between –25% and –99%; CR = complete 
regression, no palpable tumor. D = animal died during treatment. – = none. 
 
9.3.3. GalCer sensitizes to the antitumor effect of TNF 
 
The finding that invariant NKT cells may contribute to tumor destruction upon TNF 
treatment prompted us to test whether selective activation of these cells with the 
marine sponge glycolipid GalCer could increase the efficacy of a low-toxic, sub-
therapeutic TNF treatment. B16Bl6 melanoma-bearing mice were injected with 
GalCer 24 hours before the start of a nine-day treatment with either hTNF or low-
dose mTNF (Fig.9.7. and Table 9.3.). Injection of GalCer alone had no effect on 
tumor growth. Treatment with either hTNF or low-dose mTNF induced respectively a 
static effect or a marginal growth inhibiting effect on the B16Bl6 tumor. Complete 
tumor regression was not observed. However, when mice were pre-treated with 
GalCer, treatment with hTNF or low-dose mTNF resulted in pronounced tumor 
destruction, with complete tumor regression in three of six and two of seven treated 
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animals, respectively. Similar results were obtained for LLC tumors, suggesting that 
this synergistic antitumor effect is not restricted to B16Bl6. Combination therapy was 
well tolerated, and mildly increased systemic toxicity (weight loss) was only observed 
after combination with hTNF. 
 
 
Fig. 9.7. Pre-treatment with GalCer increases the efficacy of a sub-therapeutic TNF treatment. 
(A) Growth curves of B16Bl6 tumor after treatment with GalCer and/or hTNF, n = 6. (B) Idem for 
low-dose mTNF (0.7µg), n = 7. (C) Growth curves of LLC tumor after treatment with GalCer and/or 
low-dose mTNF, n = 6. Data are shown as mean ± SEM. The arrow indicates the injection point of 
GalCer. The line under the graph represent the treatment period with TNF. 
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Table 9.3. B16Bl6 tumor response to treatments with GalCer and TNF. 
 Tumor response §  
Treatment CR (%) PR (%) S (%) PD (%) D (%) 
PBS (n = 13) – – – 92 8 
GalCer (n = 13) – – – 85 15 
hTNF (n = 6) – 17 33 50 – 
GalCer + hTNF (n = 6) 50 33 – – 17 
Low-dose mTNF (n = 7) – – – 86 14 
GalCer + mTNF (n = 7) 29 29 14 14 14 
§
 TSI before start of treatment was compared to that on the 10
th
 day of treatment. Tumor response was 
classified as follows: PD = progressive disease, increase of more than 25%; S = static, tumor size 
between –25% and 25%; PR = partial regression, decrease between –25% and –99%; CR = complete 
regression, no palpable tumor. D = animal died during treatment. – = none. 
 
GalCer-activated NKT cells are capable of rapidly producing large amounts of 
cytokines such as IFN- and IL-4 21. In particular IFN- may be important in our 
model because (1) this cytokine was previously shown to be critical for the antitumor 
activity of GalCer and (2) the synergy of TNF and IFN- in murine tumor models is 
well-established 
22, 23
. To investigate whether the synergistic antitumor activity of 
GalCer and TNF is dependent on endogenous IFN- production, we treated IFN-R-/- 
mice with GalCer and hTNF, and transgenic Flk-1 dnIFN-R mice, which express a 
dominant-negative IFN-R mutant controlled by a Flk-1 promoter, thereby rendering 
endothelial cells insensitive to IFN-, with GalCer and low-dose mTNF (Fig.9.8.). In 
both strains, pre-treatment with GalCer did not increase the response to TNF 
treatment, indicating that the synergy of GalCer and TNF is indeed IFN--
dependent. The absence of synergy in transgenic Flk-1 dnIFN-R mice suggests that 
the endogenous IFN- produced upon injection of GalCer acts by activating the 
endothelial cells of the tumor vasculature, as was shown previously for exogenously 
administered IFN- 13. 
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Fig. 9.8. The synergistic antitumor effect of GalCer and TNF is IFN--dependent. (A) Growth 
curve of B16Bl6 melanoma in IFN-R-/- mice after treatment with hTNF and GalCer, n = 5. (B) 
Growth curve of B16Bl6 melanoma in transgenic Flk-1 dnIFN-R mice after treatment with GalCer 
and low-dose mTNF (0.7µg), n = 6. Data are shown as mean ± SEM. The arrow indicates the injection 
point of GalCer. The line under the graph represent the treatment period with TNF. 
 
 
9.4. Discussion 
 
The primary findings of this study are: (1) tumor regression upon TNF treatment was 
observed in all immune-deficient and lymphocyte-depleted mice tested, suggesting 
that the antitumor activity of TNF is not strictly dependent on the presence of one 
particular lymphocyte population; however, (2) four independent NKT cell-deficient 
mouse strains (IRF-1
-/-
, IL-15
-/-
, J18-/- and CD1-/-) as well as NK1.1+ cell-depleted 
mice displayed similar, reduced antitumor response to TNF; (3) response to TNF in 
J18-/- and IRF-1-/- mice could be restored by reconstitution with wild-type liver 
leukocytes; and (4) pre-treatment with the specific NKT cell ligand GalCer 
markedly increased the efficacy of a sub-therapeutic TNF treatment. 
 
As TNF is a potent pro-inflammatory cytokine, it is not surprising that TNF-based 
therapies were shown to result in an infiltration of immune cells in tumors 
4, 5
. 
However, it remained to be elucidated whether these immune cells actively contribute 
to tumor destruction after TNF therapy. Eggermont and colleagues demonstrated that 
the tumor response to TNF-based ILP was markedly reduced in total body irradiated 
rats, suggesting that immune cells play an important role in the antitumor activity of 
TNF 
3
. Our experiments in IRF-1
-/-
 and IL-15
-/-
 mice, which both lack mature NK 
cells and have strongly reduced numbers of NKT and CD8
+
 T cells, support this 
hypothesis, and point to a role for cytotoxic lymphocytes. However, tumor response to 
treatment with mTNF was similar in athymic C57BL/6
nu/nu
 mice and NK cell-depleted 
mice as in immune-competent C57BL/6 wild-type mice, indicating that neither (NK)T 
nor NK cells are essential for the antitumor activity of TNF. One plausible 
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explanation for this discrepancy is that there might be sufficient functional 
redundancy between these different cytotoxic lymphocyte populations. NK cells, 
NKT cells and CD8
+
 T cells share many important effector functions, including IFN- 
production, FasL expression, and perforin/granzyme B-mediated cytotoxicity. The 
absence of one lymphocyte population may affect the functionality or proportion of 
another. For example, in athymic C57BL/6
nu/nu
 mice we observed a two- to four-fold 
increased number of NK cells in spleen and liver, and we found that this could be 
linked to an overall increased sensitivity to TNF. Interestingly, an increased 
sensitivity to TNF was also observed after transfer of wild-type splenocytes to IRF-1
-/-
 
mice. It would be interesting to investigate whether this effect was due to the 
supranormal number of NK cells in these mice after transfer. Taken together, our data 
indicate that the presence of certain cytotoxic lymphocyte populations may influence 
the sensitivity to both the antitumor effect and toxic side-effects of TNF. 
 
We demonstrated that the antitumor activity of TNF was markedly reduced in NKT-
deficient mouse strains as well as in NK1.1
+
 cell-depleted mice, suggesting that 
invariant NKT cells significantly contribute to the antitumor effect of TNF. However, 
even in NKT-deficient mice complete tumor regressions were observed after 
treatment with mTNF, albeit much less frequently than in wild-type mice, indicating 
that the antitumor activity is not strictly dependent on NKT cells but is facilitated by 
the presence of these cells. Invariant NKT cells have the unique ability to rapidly 
produce large amounts of immunoregulatory cytokines upon activation, most notably 
of IFN- 21, 24. The synergy of TNF and IFN- is well-known in our B16Bl6 tumor 
model 
23
. Previous experiments in our lab showed that the antitumor activity of TNF 
was unaffected in IFN-R-/- mice. However, treatment of IFN--/- mice with TNF 
resulted in the same initial tumor destruction as observed in wild-type mice, with 
complete regression of the B16Bl6 tumor, but this was followed by an early onset of 
relapse already during the ten-day treatment period. These results suggest that 
endogenous IFN- production, acting directly on the tumor cells, may contribute to 
the TNF-induced antitumor mechanism 
8
. We may now have identified invariant NKT 
cells as the source of this endogenous IFN-. However, endogenous IFN- production 
alone cannot explain the reduced response observed in NKT-deficient mice and 
therefore it is likely that other NKT cell-derived cytokines, potentially TNF, or 
cytotoxic effector functions are involved in this effect. As the antitumor activity of 
TNF requires only endothelial TNF-R1 expression, it is puzzling how NKT cells 
could be specifically recruited to and activated at the tumor site. 
2
. It was shown that 
murine NKT cells
 
exhibit robust response to
 
the inflammatory chemokines CXCL9 
and CXCL10, suggesting that these chemokines could act
 
to recruit NKT cells to sites 
of inflammation 
25
. However, we found that the antitumor activity of TNF was 
unaffected in CXCR3-deficient mice (data not shown). Thus, we can exclude a role 
for those chemokines in the antitumor effect of TNF.  
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The elucidation of the complete antitumor mechanism elicited by TNF is important as 
this may reveal new targets for therapeutic intervention. The finding that NKT cells 
may actively contribute to tumor destruction after high-dose TNF treatment prompted 
us to test whether specific activation of these cells could increase the efficacy of a 
low-toxic, sub-therapeutic TNF treatment. We demonstrated that pre-treatment with 
GalCer markedly increased tumor destruction induced by treatment with hTNF or 
low-dose mTNF. Using IFN-R-/- and transgenic Flk-1 dnIFN-R mice we could show 
that this effect was completely IFN--dependent and required functional IFN-R 
expression on endothelial cells, suggesting that GalCer acts by a similar mechanism 
as exogenously administered IFN- 8. An important question is of course whether 
using GalCer would be superior to treatment with IFN-. We started treatment with 
TNF 24 hours after i.p. injection of GalCer, when elevated serum levels of IFN- 
were already largely declined 
26
. Increased response to TNF was observed for at least 
several days after injection of GalCer, suggesting that GalCer may trigger a longer-
lasting sensitizing effect. It has been demonstrated that the antimetastatic effect of 
GalCer was dependent on the activation of NK cells and IFN- production by these 
cells, which is then most likely followed by bystander activation of other immune 
cells 
22, 27
. Although no overt toxicities were observed in our model, caution is 
required when combining TNF with GalCer as both these drugs are known to cause 
liver toxicity, which is one of the major dose-limiting toxicities of TNF 
28, 29
. More 
potent GalCer analogs are currently being developed with a Th1-biased cytokine 
profile 
30
. It will be most interesting to test whether these compounds would even 
further increase the antitumor activity of TNF. In conclusion, we have identified 
invariant NKT cells as a new, promising target to extend the therapeutic applicability 
of TNF.  
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10. THE SYNERGISTIC ANTITUMOR EFFECT OF TNF AND IFN- IS DEPENDENT ON 
NEUTROPHILS 
 
Abstract 
 
TNF, especially in combination with IFN-, is widely appreciated as being a 
promising anticancer therapy. The synergism of TNF and IFN- for inducing 
haemorrhagic necrosis of tumors in experimental models has led to the successful 
addition of IFN- to ILP with TNF and melphalan for the treatment of regionally 
advanced melanoma or sarcoma of the limbs. The mechanism underlying the in vivo 
synergistic antitumor effects of TNF and IFN-, however, remains poorly understood. 
In the current study we investigated whether immune cells, which appear to infiltrate 
tumors after TNF/IFN--based ILP, are involved in the synergistic antitumor effect of 
TNF and IFN-. We have previously shown that invariant NKT cells may contribute 
to tumor destruction upon treatment with TNF. Our present data indicate that the 
synergism of TNF and IFN- is independent of NKT cells or other lymphocytes. By 
contrast we found that the synergistic antitumor effect of TNF and IFN- was 
markedly reduced in PI3K-deficient mice, which display defective chemokine-
induced responses of neutrophils and monocytes/macrophages. Specific depletion of 
macrophages did not affect the synergistic antitumor effect of TNF and IFN- in our 
murine B16Bl6 melanoma model, while depletion of neutrophils completely 
abolished this synergism. Our data imply that the synergistic antitumor effect of TNF 
and IFN- is critically dependent on neutrophils and may have important implications 
for the addition of IFN- to TNF-based anticancer treatments. 
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10.1. Introduction 
 
TNF, a potent pro-inflammatory cytokine, is currently used in the clinic in 
combination with melphalan and mild hyperthermia to treat regionally advanced 
melanomas and soft tissue sarcomas of the limbs via the ILP technique. The high limb 
salvage rates obtained after TNF-based ILPs clearly demonstrate its potency as an 
anticancer drug. Co-treatment with IFN- has been shown to synergistically enhance 
the antitumor properties of TNF in numerous experimental tumor models 
1-3
. Also, 
although less striking than in animal models, clinical studies using ILP with the triple 
combination of TNF, IFN- and melphalan appear to result in consistently higher 
response rates than those using ILP with TNF and melphalan alone, suggesting that 
the synergistic effect of TNF and IFN- is also present in this system 4. In vitro, IFN- 
has been shown to sensitize for cytokine-induced cytotoxicity in an IRF-1-dependent 
manner 
5, 6
. However, we found that the synergistic antitumor effect of TNF and IFN-
 was apparent in IRF-1-deficient mice, suggesting that this effect is independent of 
IRF-1 
7
. Histological analysis of tumors revealed a selective destruction of the tumor-
associated vasculature after treatment with TNF and IFN-, and previous work in our 
laboratory showed that the synergistic antitumor effect of TNF and IFN- is 
dependent on endothelial IFN-R expression, indicating that the endothelial cells of 
the tumor vasculature are the target cells of TNF/IFN- combination therapy 4, 8-10. 
Recently, Li and colleagues demonstrated that IFN- can trigger the release of 
cathepsin B from lysosomes in HUVECs, thereby sensitizing these cells to TNF-
induced cathepsin B-dependent cell death 
11
. The mechanism underlying the in vivo 
synergistic antitumor effects of TNF and IFN- still remains to be elucidated. Our 
hypothesis is that IFN- may increase endothelial injury and tumor destruction by 
exacerbating the TNF-triggered inflammatory response. TNF and IFN- have been 
shown to synergistically upregulate the endothelial expression of cell adhesion 
molecules, such as ICAM-1 and VCAM-1, and monocyte/lymphocyte chemokines, 
such as CCL2, CCL5 and CXCL10 
12-14
. We have evidence that invariant NKT cells 
are implicated in the antitumor mechanism induced by TNF. However, previous work 
in our laboratory indicated that the synergism of TNF and IFN- was preserved in 
either IRF-1-deficient mice, which are largely devoid of mature NK cells, NKT cells 
and CD8
+
 T cells, athymic nude mice, and NK cell-depleted mice, suggesting that 
neither NK cells nor (NK)T cells are important for the synergistic antitumor effect of 
TNF and IFN-. 
 
Herein we report that the synergistic antitumor effect of TNF and IFN- is markedly 
reduced in PI3K-deficient mice, which display defective chemotaxis of neutrophils 
and monocytes. Specific depletion of monocytes/macrophages did not affect the 
synergistic antitumor effect of TNF and IFN- in our murine B16Bl6 melanoma 
model, while depletion of neutrophils completely abolished this synergism. Our data 
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imply that the synergistic antitumor effect of TNF and IFN- is critically dependent 
on neutrophils. This finding may have important implications for the addition of IFN-
 to TNF-based anticancer treatments. 
 
 
10.2. Materials and methods 
 
10.2.1. Mice 
 
Female C57BL/6J mice were purchased from Janvier, Le Genest-Saint-Isle, France. 
CD1
-/-
 mice were generated and backcrossed to C57BL/6 background by Dr. Luc Van 
Kaer, Vanderbilt University School of Medicine, Nashville, Tennessee, USA 
15
. 
B6.p110-/- (PI3K-/-) mice were generated by Dr. Emilio Hirsch, University of 
Torino, Turin, Italy 
16
. The animals were housed in 14-10 hours light/dark cycles in a 
temperature-controlled, air-conditioned room, and received food and water ad libitum. 
The mice were used for experimentation at the age of 8-12 weeks. All experiments 
were approved by and performed according to the guidelines of the local ethics 
committee of Ghent University, Belgium. 
 
10.2.2. Cells 
 
B16Bl6 melanoma cells were cultured in RPMI-1640 medium supplemented with 
10% FCS, 2mM L-glutamine, 0,4mM Na-pyruvate, 50 IU/ml penicillin G and 
50µg/ml streptomycin sulphate 
17
. For tumor inoculation, cells were detached from 
the culture flask by a short EDTA treatment, washed three times in endotoxin-free, 
sterile DPBS (Sigma), and resuspended in DPBS. 
 
10.2.3. Reagents 
 
Mouse anti-mouse NK1.1 antibodies (clone PK136) and rat anti-mouse Gr1 
antibodies (clone RB6-8C5) were purchased from BioXCell. Cyclophosphamide was 
purchased from Sigma. Liposome-encapsulated clodronate was a kind gift of Dr. Nico 
Van Rooijen, Free University Medical Center, Amsterdam, The Netherlands 
18
. 
Recombinant mTNF, hTNF and mIFN- were produced in our laboratory and had a 
specific activity of 1.28 x 10
8
 IU/mg, 6.8 x 10
7
 IU/mg and 1.16 x 10
8
 IU/mg, 
respectively. mTNF and hTNF had an endotoxin content (LAL assay) of 6.5 EU/mg 
and 36 EU/mg, respectively. 
 
10.2.4. Tumor experiments 
 
Mice were inoculated with 6 x 10
5
 B16Bl6 cells s.c. in the back (day 0). Treatment 
was started when the tumor size index (TSI), the product of the largest perpendicular 
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diameters in cm, was greater than 0.5 (≥day 10). PBS, hTNF (30µg), mTNF (7µg) and 
mIFN- (5000 IU) were administered daily for 10 consecutive days via s.c. injection 
near the tumor site but outside the nodule. 
 
10.2.5. In vivo depletion of neutrophils, macrophages or NK1.1+ cells 
 
Mice were depleted of neutrophils by i.p. injection of cyclophosphamide or anti-Gr1 
antibody as previously described 
19, 20
. Mice were injected with 3mg 
cyclophosphamide on day 9, and 2mg cyclophosphamide on days 12, 15 and 18 after 
tumor inoculation. For depletion using the anti-Gr1 antibody, mice received 0.5mg 
antibody on days 7, 9, 11, 13, 15 and 19 after tumor inoculation. Depletion of 
neutrophils was verified by differential leukocyte counting of May-Grünwald Giemsa-
stained blood smears taken of control (PBS-treated) mice on days 10, 13 and 19 after 
tumor inoculation. Monocytes/macrophages were depleted by injection of liposome-
encapsulated clodronate as previously described 
21
. Mice were injected i.p. with 200µl 
of the clodronate liposome solution on day 8, and 100µl on days 13 and 18 after 
tumor inoculation. Macrophage depletion was confirmed by flow cytometric analysis 
of splenocytes stained for CD11b and F4/80, prepared 3 days after injection of 
clodronate liposomes. Depletion of NK1.1
+
 cells, i.e. NK and NKT cells, was 
achieved by i.p. injection of 200µg anti-NK1.1 antibody on days 8, 12, 16, and 20 
after tumor inoculation. Depletion was verified by flow cytometric analysis of liver 
leukocytes prepared 3 days after injection of the anti-NK1.1 antibody and stained for 
NK1.1, CD49b (DX5) and TCR,.  
 
10.2.6. Statistics 
 
For tumor experiments mice were stratified into treatment groups having non-
significantly different mean TSI (one-way ANOVA, P-value > 0.95). Calculations 
and graphs were made using Graphpad Prism 4.0. 
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10.3. Results 
 
10.3.1. Lymphocytes are not required for the synergistic antitumor effect of TNF and 
IFN- 
 
We previously found that the synergistic antitumor effect of TNF and IFN- was still 
apparent in IRF-1
-/-
, C57BL/6
nu/nu
, Swiss
nu/nu
, and NK cell-depleted mice, suggesting 
that NK cells and (NK)T cells are not required for the synergism of TNF and IFN- 7. 
The tumor response to treatment with hTNF and IFN- was, however, markedly 
reduced in IRF-1
-/-
 mice compared to wild-type C57BL/6 mice. We previously 
attributed the reduced response to mTNF treatment in IRF-1
-/-
 and other NKT-
deficient mice to the absence of invariant NK1.1
+
 T cells (see chapters 9.3.1. and 
9.3.2.). To further assess the involvement of NKT cells in the synergistic antitumor 
effect of TNF and IFN-, we treated NKT-deficient CD1-/- mice and NK1.1-depleted 
mice with a combination of IFN- and mTNF or hTNF, respectively (Fig.10.1.). The 
synergistic antitumor effect of TNF and IFN- was apparent in both cases, confirming 
that this synergistic effect is independent of NKT cells. However, the tumor response 
to treatment with hTNF and IFN- was apparently reduced in NK1.1-depleted mice 
compared to control mice, albeit statistically not significantly. Therefore, at this 
moment we cannot exclude that invariant NKT cells may contribute to tumor 
destruction upon co-treatment with TNF and IFN-. Interestingly, treatment of CD1-/- 
mice with mTNF and IFN- resulted in complete eradication of the tumor in all seven 
treated mice, without apparent signs of toxicity (judged by the general condition, body 
weight and viability of the mice), while six of seven wild-type control mice died due 
to treatment-related toxicity, suggesting that NKT cells may also contribute to the 
toxic side-effects of treatment with TNF and IFN-. Taken together, our present data 
suggest that neither NKT cells nor other lymphocytes are required for the synergistic 
antitumor effect of TNF and IFN-. 
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Fig. 10.1. The synergistic antitumor effect of TNF and IFN- is independent of NKT cells. Growth 
curve of s.c. B16Bl6 melanoma in (A) C57BL/6 wild-type (wt; for PBS and hTNF n = 6, for other 
groups n = 7), (B) NK1.1-depleted (n = 6) and (C) CD1
-/-
 mice (n = 7) treated with hTNF and mTNF 
alone or in combination with IFN-. All data are shown as mean ± SEM. The line under the graph 
represents the ten-day treatment period. 
 
10.3.2. Neutrophils are required for the synergistic antitumor effect of TNF and IFN- 
 
When we were investigating whether the absence of certain PI3K isoform would 
sensitize mice to the antitumor effect of TNF, we unexpectedly found that in PI3K-/- 
mice the synergism of hTNF and IFN- was largely impaired (Fig.10.2.). Progressive 
disease was observed in 60% of PI3K-/- mice treated with hTNF and IFN- compared 
to 82% of mice treated with hTNF alone. In wild-type control mice progressive 
disease rates were 10% and 70%, respectively. Complete regression of the B16Bl6 
tumor upon treatment with hTNF and IFN- occurred in more than 50% of wild-type 
control mice, while this was rarely observed in PI3K-/- mice. These data suggest that 
a PI3K-dependent signaling event is required for the synergistic antitumor effect of 
TNF and IFN-. 
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Fig. 10.2. The synergism of hTNF and IFN- is abrogated in PI3K-/- mice. (A) Growth curve of 
B16Bl6 melanoma in PI3K-/- mice treated with hTNF alone or combination with IFN-, or mTNF. 
Data are shown as mean ± SEM, n = 6. The line under the graph represents the treatment period. (B, C) 
Tumor response to treatment with hTNF alone or in combination with IFN- in C57BL/6 wild-type 
(wt) and PI3K-/- mice. TSI before start of treatment was compared to that on the 10th day of treatment. 
Tumor response was classified as follows: PD = progressive disease, increase of more than 25%; S = 
static, tumor size between –25% and 25%; PR = partial regression, decrease between –25% and –99%; 
CR = complete regression, no palpable tumor. D = animal died during treatment. 
 
PI3K-/- mice have a number immunological defects, most prominently impaired 
chemokine-induced recruitment of neutrophils and monocytes/macrophages, and 
oxidative burst of neutrophils 
16, 22
. To investigate whether these defects could be at 
the basis of the impaired synergistic effect of hTNF and IFN- observed in PI3K-/- 
mice, we depleted wild-type mice of neutrophils or macrophages before treatment 
with hTNF and IFN- (Fig.10.3.). Neutrophils were first depleted by i.p. injection of 
the cytotoxic drug cyclophosphamide. The mice were effectively neutropenic by the 
start of the ten-day treatment period (day 13 after tumor inoculation), however, 
general leukopenia was induced by repeated injections of cyclophosphamide. The 
synergistic antitumor effect of hTNF and IFN- was largely abrogated by treatment 
with cyclophosphamide, suggesting that leukocytes, most likely neutrophils, are 
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required for the synergism of hTNF and IFN-. To further assess the involvement of 
neutrophils, we specifically depleted these cells by treatment with an anti-Gr1 
antibody. The depletion was specific and significant (P < 0.01 in unpaired t-test) on 
day 10 after tumor inoculation (treatment with hTNF and IFN- was started on day 
11). However, the depletion was not statistically significant on day 19 after tumor 
inoculation due to large interindividual variability in tumor-bearing mice. 
Nevertheless, in Gr1-depeleted mice the synergistic antitumor effect of hTNF and 
IFN- was markedly reduced compared to control mice. Complete tumor regressions 
were not observed in neutrophil-depleted mice.  
 
 
Fig. 10.3. The synergistic antitumor effect of hTNF and IFN- is dependent on neutrophils. 
Growth curves of s.c. B16Bl6 melanoma in (A) C57BL/6 control mice, (B, C) neutrophil-depleted 
mice, and (D) monocyte/macrophage-depleted mice treated with hTNF alone or in combination with 
IFN-. All data are shown as mean ± SEM, n = 6. The line under the graph represents the treatment 
period. 
 
Daley and co-workers recently reported that treatment with the anti-Gr1 antibody, 
clone RB6-8C5, may not only deplete neutrophils, but also Gr1
+
 
monocytes/macrophages 
23
. To determine whether monocytes/macrophages are 
involved in the synergistic antitumor effect of hTNF and IFN-, we specifically 
depleted these cells by injection of liposome-encapsulated clodronate. Macrophage 
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depletion, however, did not affect the response to treatment with hTNF and IFN-, 
which resulted in complete tumor regression in four of six treated animals. Taken 
together, these data indicate that neutrophils, but not monocytes/macrophages, are 
critically involved in the synergistic antitumor effect of TNF and IFN-. 
 
 
10.4. Discussion 
 
TNF, especially in combination with IFN-, is widely appreciated as being a 
promising anticancer therapy. Clinically, ILP with TNF and melphalan, with or 
without IFN- has proven to be a very successful alternative for amputation in 
patients with advanced melanoma or sarcoma of the limbs 
4
. Pronounced toxic side-
effects, particularly severe hypotension and organ toxicity, however, preclude 
systemic use of TNF in cancer patients 
24-26
. One strategy to allow systemic TNF 
application may be to develop low-toxic TNF muteins. Studies in mice using hTNF, 
which can be considered as a fast-cleared, low-toxic TNF mutein in the murine 
system, indicated that these low-toxic TNF muteins will most likely require 
combination with other drugs, such as IFN-, to be effective 1, 27. The mechanism 
underlying the remarkable synergistic antitumor effect of TNF and IFN-, however, 
remains poorly understood. We have now demonstrated that this effect is critically 
dependent on neutrophils. 
 
Extensive in vitro data exist showing that co-incubation with IFN- sensitizes 
endothelial cells to TNF-induced cell death 
11
. Also, Rüegg and co-workers reported 
that treatment of HUVECs with TNF and IFN- suppressed the activation of integrin 
v3, leading to decreased endothelial cell adhesion and survival. They furthermore 
observed detachment and apoptosis of v3-positive endothelial cells of the tumor 
vasculature in melanoma patients treated with TNF and IFN- 10. The finding that in 
our B16Bl6 melanoma model the synergistic antitumor effect of TNF and IFN- 
required the presence of neutrophils implies that IFN- did not significantly sensitize 
the tumor endothelium to the direct vascular-disrupting effects of TNF in this in vivo 
model. We hypothesize that IFN- rather increases endothelial injury by exacerbating 
the TNF-triggered inflammatory response. Neutrophils are recruited to sites of 
inflammation by expression on the activated endothelium of the adhesion molecules 
E-selectin and ICAM-1, both of which are synergistically upregulated by TNF and 
IFN- 13, 28, 29. The adhesion of neutrophils to activated endothelium may be sufficient 
to trigger cytotoxic effector functions, including respiratory burst and degranulation of 
granules containing proteolytic enzymes and myeloperoxidase 
30
. We can, however, 
exclude NO production as an important effector function as we previously found that 
the synergistic antitumor effect of TNF and IFN- was preserved in iNOS-deficient 
mice 
31
. 
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The finding that the synergistic antitumor effect of TNF and IFN- was largely 
abrogated in PI3K-/- mice, suggests that a GPCR-mediated signaling event is 
important in this effect 
16
. Neutrophils can be activated by a large number of 
chemotactic factors that signal via GPCRs, including the Glu-Leu-Arg (ELR)-positive 
chemokines CXCL1-8 (except CXCL4), and the lipid mediators PAF and LTB4, and 
it will be challenging to determine which factor(s) is/are involved 
30
. Another 
interesting observation made in PI3K-/- mice was that the antitumor effect of mTNF 
was preserved in these mice, suggesting that the antitumor mechanism of mTNF 
monotherapy is essentially different from that induced by hTNF and IFN- 
combination therapy. Similarly, the antitumor activity of mTNF was unaffected in 
cyclophosphamide-treated mice, indicating that the antitumor activity of mTNF is 
independent of neutrophils (data not shown). Taken together, our data suggest that 
IFN- does not sensitize for the intrinsic antivascular or antitumor effect of TNF, but 
allows to trigger an additional, neutrophil-dependent mechanism. This finding offers a 
new rationale for the addition of IFN- to TNF-based anticancer therapies. 
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11. GENERAL SUMMARY & DISCUSSION 
 
11.1. Summary 
 
TNF is a potent, pro-inflammatory cytokine that was originally discovered thanks to 
its remarkable antitumor activity. Via its two cell surface receptors, TNF-R1 and 
TNF-R2, it is involved in a wide range of (patho)physiological processes. As most 
information regarding TNF signaling, including the activation of the NF-B, MAPK, 
and cell death pathways, is derived from TNF-R1, this receptor is regarded as the 
primary signaling receptor. However, since TNF-R2 only fully responds to the 
membrane-bound form of TNF, but not the soluble form, its role may be 
underestimated. The major biological function of TNF appears to be that of a central 
mediator of inflammation. Tissue macrophages stimulated with LPS or other bacterial 
products rapidly produce TNF to activate the local endothelium. This results in 
increased blood flow due to the production of the vasodilators NO and PGI2, 
increased vascular permeability and vascular leakage due to weakening of endothelial 
cell-cell junctions and cytoskeletal reorganizations, and the recruitment of neutrophils, 
monocytes and other leukocytes to the site of inflammation through upregulation of 
chemokines and adhesion molecules, such as E-selectin, ICAM-1 and VCAM-1. 
Moreover, as an additional protective mechanism, TNF may shut off local blood 
supply by stimulating blood coagulation, or by causing direct or indirect endothelial 
cell death. The same mechanisms by which TNF so efficiently contains local infection 
may, however, become harmful, as is the case in sepsis or chronic inflammatory 
disorders such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. 
 
The in vivo antitumor activity of recombinant TNF and its synergy with IFN- were 
first demonstrated in the murine B16Bl6 melanoma model by Brouckaert and 
colleagues in 1986 
1
. TNF induces a rapid, haemorrhagic necrosis of experimental 
tumors, which is characterized by a selective destruction of the tumor vasculature. 
Despite promising results in animal models the first clinical trials with systemically 
administered TNF were disappointing. Doses of 10 to 50 times lower than the 
estimated effective dose already caused severe toxic side-effects, most importantly 
hypotension and organ failure. To circumvent these side-effects, Lejeune and co-
workers set up a locoregional treatment, in which TNF in combination with melphalan 
and sometimes IFN- is administered via the ILP technique to treat patients with 
locally advanced melanomas and soft tissue sarcomas of the limbs 
2
. The high 
response rates and similarly successful limb salvage rates obtained with this method 
clearly demonstrate the potential of TNF as an anticancer drug. However, as 
locoregional therapy has no effect on distant metastases, TNF-based ILP had thus far 
little impact on the final survival of patients, stressing the need for an effective and 
safe systemic treatment.  
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Previous work in our and other laboratories has established that the anticancer and 
toxic side-effects of TNF are not inevitably linked. Mice can be protected against the 
TNF-induced lethal shock with the sGC inhibitor methylene blue without impairing 
the antitumor effect 
3
. Also, two acute phase proteins, 1-acid-glycoprotein and 1-
antitrypsin, were found to confer protection against TNF-induced liver toxicity 
4
. 
More recently, the addition of zinc to drinking water of mice was shown to protect 
against TNF-induced lethal shock and bowel toxicity without affecting the 
effectiveness of TNF/IFN- therapy 5. These results clearly demonstrate that it should 
be feasible to set up a safe systemic treatment with TNF. However, using potentially 
lethal doses of TNF together with an inhibitor of the toxic side-effects is not an 
attractive solution for human cancer therapy as failure of the inhibitor could lead to 
death of the patient. A safer strategy to lower the systemic toxicity of TNF would be 
to use lower doses of TNF or low-toxic TNF muteins in combination with sensitizers 
for the antitumor activity of TNF, such as IFN-. In light of the latter strategy, we 
addressed three major questions in this thesis: 
 
(1) Can we sensitize for the antitumor effect of TNF by inhibiting endothelial 
survival signaling ? 
(2) Which immune cells are involved in the antitumor mechanism induced by 
TNF ? 
(3) How does IFN- sensitize for the antitumor effect of TNF ? 
 
 
 Sensitization to the antitumor effect of TNF by inhibition of endothelial 
survival signaling 
 
The precise mechanism underlying the TNF-induced tumor necrosis remains poorly 
understood. It has become clear that the antitumor effect of TNF is completely host-
mediated and independent of TNF-receptor expression on tumor cells. Stoelcker and 
colleagues demonstrated that the TNF-induced antitumor effect is maintained in TNF-
R2
-/-
 mice, but absent in TNF-R1
-/-
 mice, suggesting that the antitumor effect of TNF 
is mediated by triggering the TNF-R1 on host cells 
6
. Previous work in our research 
group has extended these data by showing that TNF-R1 expression on neovasculature 
(controlled by a Flk-1 promoter) is sufficient for the antitumor effect of TNF, 
indicating that the endothelial cells of the tumor vasculature are the direct target cells 
of TNF 
7
. This is further supported by the observation, in experimental tumor models 
as well as in human ILP patients, that the TNF-induced tumor necrosis is 
characterized by a selective destruction of the tumor vasculature 
2, 8-10
. TNF may 
therefore be classified as a VDA. 
 
The PI3K/Akt pathway is one of the main regulators of cell survival. Tumor 
vasculature, which is in contrast to normal vasculature not stabilized by normal 
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pericyte coverage, basement membrane structure and endothelial cell-cell interactions, 
and is subject to constant remodelling due to imbalance of angiogenic factors 
produced in the tumor, may be greatly dependent on this survival pathway 
11-14
. The 
PI3K/Akt pathway is triggered by a broad range of pro-angiogenic factors, including 
growth factors, such as VEGF family members, and adhesion molecules, such as 
integrin v3 
15, 16
. Inhibition of PI3K has been shown to sensitize endothelial cells in 
vitro to the cytotoxic effects of TNF 
17-19
. Furthermore, Matschurat and colleagues 
reported a synergy of the PI3K inhibitor wortmannin and TNF for the induction of 
tumor necrosis in a murine MethA sarcoma model 
20
. 
 
To determine whether inhibition of the PI3K/Akt survival pathway would sensitize to 
the antitumor effect of TNF, we treated B16Bl6 or other tumor-bearing mice with 
sub-therapeutic TNF alone or in combination with one of the PI3K inhibitors 
wortmannin or LY294002. The response to either PI3K inhibitor plus TNF was 
striking, with tumor regression in all treated animals. We determined that by PI3K 
inhibition a tenfold reduction of the effective dose of TNF could be achieved. 
Comparable results were obtained using the Akt inhibitor perifosine or the mTOR 
inhibitor rapamycin. Importantly, PI3K/Akt pathway inhibition sensitized to the 
antitumor effect of TNF without concomitantly increasing the toxic side-effects of 
TNF. Using intravital microscopy and by histological examination of tumors we could 
demonstrate that the antitumor effect of wortmannin and TNF is characterized by a 
pronounced destruction of the tumor vasculature, with disruption of the endothelial 
lining of the tumor vessels and haemorrhage. In vivo Hoechst staining revealed a 
complete shutdown of the tumor blood flow as early as 6 hours after injection of 
wortmannin and TNF, with no recovery by 48 hours after injection, thus effectively 
starving the tumor to death. Finally, we demonstrated that TNF therapy synergizes 
with anti-angiogenic therapy using a VEGF-R2 blocking antibody for the induction of 
tumor regression in the B16Bl6 melanoma model. Taken together, we have shown 
that interfering with endothelial survival allows a significant reduction of the effective 
dose of TNF. 
 
 
 Immune cells involved in the antitumor mechanism induced by TNF 
 
We and others have previously shown that the antitumor effect of TNF is completely 
host-mediated, and requires expression of the TNF-R1 on the tumor endothelium 
6, 7
. 
These experiments have also indicated that TNF-R1 expression on other cells than 
endothelial cells, most importantly tumor cells and immune cells, is unimportant for 
the full antitumor response to TNF. Certain immune cells may, however, be important 
for the antitumor effect of TNF. Eggermont and colleagues demonstrated that total 
body irradiation of tumor-bearing rats, thereby inducing general leukopenia, markedly 
decreased the tumor response and skin necrosis at the tumor site following ILP with 
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TNF and melphalan 
21
. After TNF-based ILP, an inflammatory response is observed 
which results in a rapid recruitment of polymorphonuclear cells to the tumor, followed 
by the infiltration of macrophages and lymphocytes after several days to weeks 
22, 23
. 
Experiments performed in our lab with B16Bl6 tumor-bearing IRF-1
-/-
 mice, which 
fail to develop mature NK cells, NK1.1
+
 T cells and CD8
+
 T cells, revealed a 
markedly reduced antitumor response to TNF in these mice 
24-26
. Responsiveness 
could be partly restored by reconstitution with wild-type splenocytes, suggesting a 
role for lymphocytes in this model. 
 
We investigated, using immune-deficient mice and selective lymphocyte depletion 
methods, which lymphocytes are involved in the antitumor mechanism induced by 
TNF. We found that no lymphocyte population was strictly required for the antitumor 
activity of TNF. Athymic C57BL/6
nu/nu
 mice, lacking mature T lymphocytes and NKT 
cells, as well as NK cell-depleted mice showed similar responses to TNF as wild-type, 
immune-competent mice. However, we found that four independent NKT-deficient 
mouse strains (IRF-1
-/-
, IL-15
-/-
, J18-/- and CD1-/-) displayed markedly reduced 
antitumor response to TNF. In IRF-1
-/-
 mice as well as in J18-/- mice we could 
largely restore this defect by transfer of leukocytes isolated from wild-type liver, 
which is particularly rich in NK1.1
+
 T cells. A role for NK1.1
+
 cells was also 
confirmed by selective depletion of NK1.1
+
 cells. Our results suggest that the 
recruitment and/or activation of invariant NKT cells is an important event in the 
cascade that leads to complete tumor destruction by TNF. Furthermore, we have 
extended this finding by showing that a single injection of the specific NKT cell 
ligand GalCer markedly increased the efficacy of a sub-therapeutic TNF treatment. 
Using IFN-R-deficient mice we showed that the latter effect is dependent on 
endogenous IFN- production. Taken together, we have shown that targeting invariant 
NKT cells may be a worthwhile approach to extend the therapeutic applicability of 
TNF.  
 
 
 The mechanism underlying the synergistic antitumor effect of TNF and IFN- 
 
Co-treatment with IFN- has been shown to synergistically enhance the antitumor 
activity of TNF in numerous experimental tumor models 
1, 27, 28
. Also, although less 
striking than in animal models, clinical studies using ILP with the triple combination 
of TNF, IFN- and melphalan appear to result in consistently higher response rates 
than those without IFN-, suggesting that the synergistic effect of TNF and IFN- is 
also present in this system 
2
. In vitro, IFN- has been shown to sensitize for cytokine-
induced cytotoxicity in an IRF-1-dependent manner 
29, 30
. However, we found that the 
synergistic antitumor effect of TNF and IFN- was still apparent in IRF-1-deficient 
mice, suggesting that in vivo this effect is independent of IRF-1 
26
. Histological 
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analysis of tumors revealed a selective destruction of the tumor-associated vasculature 
after treatment with TNF and IFN-, and previous work in our laboratory showed that 
the synergistic antitumor effect of TNF and IFN- is dependent on endothelial IFN-R 
expression, indicating that the endothelial cells of the tumor vasculature are the target 
cells of TNF/IFN- combination therapy 2, 31-33. Recently, Li and colleagues 
demonstrated that IFN- can trigger the release of cathepsin B from lysosomes in 
HUVECs, thereby sensitizing these cells to TNF-induced cathepsin B-dependent cell 
death 
34
. The mechanism underlying the in vivo synergistic antitumor effects of TNF 
and IFN-, however, still remains to be elucidated.  
 
We investigated whether immune cells, which appear to infiltrate tumors after 
TNF/IFN--based ILP, are involved in the synergistic antitumor effect of TNF and 
IFN-. Our data indicate that the synergism of TNF and IFN- is independent of NKT 
cells or other lymphocytes, which were previously shown to contribute to tumor 
destruction upon treatment with high-dose TNF alone. By contrast we found that the 
synergistic antitumor effect of TNF and IFN- was markedly reduced in PI3K-
deficient mice, which display defective chemokine-induced responses of neutrophils 
and monocytes/macrophages. Specific depletion of macrophages did not affect the 
synergistic antitumor effect of TNF and IFN- in our murine B16Bl6 melanoma 
model, while depletion of neutrophils completely abolished this synergism. Our data 
imply that the synergistic antitumor effect of TNF and IFN- is critically dependent 
on neutrophils. Therefore, we hypothesize that IFN- increases endothelial injury and 
tumor destruction by exacerbating the TNF-triggered inflammatory response. 
 
 
11.2. Discussion 
 
 The vascular-disrupting mechanism of TNF 
 
TNF-based therapies are characterized by a selective destruction of the tumor 
vasculature. This is not only observed in experimental animal models, but also in 
human patients treated via ILP 
2, 9
. The mechanism underlying this remarkable 
vascular-disrupting effect, however, still remains to be elucidated. In the present study 
we have shown that broad-spectrum PI3K inhibition sensitizes for this vascular-
disrupting effect of TNF. We used intravital microscopy as well as several 
histological staining methods to visualize the gross effects of treatment with 
wortmannin and TNF on the tumor vasculature. Our data suggest that very rapidly 
after injection treatment leads to vascular leakage and haemorrhage, followed by 
complete shutdown of the blood flow in most tumor vessels by 6 hours after injection. 
Destruction of the vessel wall was complete by 24 hours after injection. Matschurat 
and colleagues have shown that inhibition of PI3K leads to enhanced TNF-induced 
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expression of tissue factor, the prime initiator of blood coagulation, in HUVECs. They 
furthermore demonstrated that co-injection of wortmannin promoted TNF-induced 
necrosis of methA tumors, thereby suggesting that the expression of tissue factor on 
endothelial cells of the tumor vasculature, leading to thrombus formation and 
occlusion of tumor vessels, would be responsible for the antitumor effect of this 
combination therapy 
20
. Our findings, however, do not fully support this hypothesis. 
Intravascular thrombus formation is a protective mechanism to prevent haemorrhage 
in the case of vascular damage. The extensive vascular leakage and haemorrhage 
observed in dorsal skinfold window chambers and sections of tumors treated with 
wortmannin and TNF suggest that vessel occlusion is secondary to disruption of the 
vessel wall. 
 
There is substantial in vitro data showing that PI3K inhibition can sensitize 
endothelial cells to TNF-induced cytotoxicity 
18, 19, 35
. Particularly interesting in this 
context is the finding that TNF itself is capable of activating the PI3K/Akt pathway 
17
. 
In certain cell types PI3K signaling was shown to be essential for the activation of 
NF-B, the main transcription factor responsible for TNF-induced anti-apoptotic 
signaling. However, this was not the case in HUVECs 
36
. Madge and co-workers 
demonstrated that TNF triggers a PI3K-mediated anti-apoptotic response in HUVECs 
that is independent of Akt and NF-B, and that inhibition of PI3K results in cathepsin 
B-dependent, but caspase-independent cell death of these cultured endothelial cells 
19
. 
These findings, however, do not fit with our in vivo data where the sensitizing effect 
of PI3K inhibition could be mimicked by Akt inhibition. Moreover, after treatment 
with wortmannin and TNF DNA fragmentation in tumor endothelial cells, a hallmark 
of apoptotic cell death, was only observed after disruption of the vessel wall and 
vessel occlusion had occurred. At that time endothelial cell death may also be a 
consequence of cell detachment (anoikis) or mere starvation.  
 
We hypothesize that the initial event in the vascular-disrupting effect of TNF is a loss 
of endothelial cell-cell contact and/or cell-matrix contact. Gaps in the endothelial 
lining of the tumor vessels were readily visible at 6 hours after treatment with 
wortmannin and TNF. Similarly, Menon and colleagues reported the formation of 
gaps in the endothelial lining of the tumor vasculature between 3 and 6 hours after 
treatment with TNF in human melanoma xenografts in mice and in human melanoma 
patients after ILP, and they attributed this effect to a disappearance of VE-cadherin 
from endothelial cell-cell junctions 
37
. The adherens junction component VE-cadherin 
is known to play a critical role in endothelial cell-cell connections and tumor 
angiogenesis 
38
. It was recently shown that TNF can induce tyrosine phosphorylation 
of the intracellular domain of VE-cadherin, thereby weakening the VE-cadherin-based 
junctions and facilitating the formation of intercellular gaps 
39
. Disruption of VE-
cadherin junctions may lead to a shutdown of tumor blood flow by a mechanism of 
vascular collapse, in analogy with the vessel-disrupting mechanism reported for the 
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tubulin binding drug CA4P. Disassembly of VE-cadherin junction would cause 
haemorrhage, an increase of interstitial fluid pressure, and eventually the collapse of 
the weakened tumor vessels 
40
. It is currently unclear whether PI3K inhibition could 
exacerbate the TNF-induced disassembly of VE-cadherin junctions. The integrins 
v3 and v5 play an important role in endothelial cell-matrix adhesion in 
neovasculature 
41
. Rüegg and colleagues showed that treatment of HUVECs with TNF 
and IFN- suppressed the activation of integrin v3, leading to a decrease in 
endothelial cell adhesion and survival, and they observed detachment and apoptosis of 
v3-positive endothelial cells in the tumor vasculature of melanoma patients after 
ILP with TNF plus IFN- 33. Furthermore, they demonstrated that Akt activity can 
strengthen integrin-dependent endothelial cell adhesion and can protect HUVECs 
against cell death induced by TNF and/or integrin v3/v5 inhibition 
42, 43
. Thus, 
TNF therapy is known to interfere with both endothelial cell-cell and cell-matrix 
adhesions. PI3K/Akt pathway inhibition may exacerbate this effect and/or 
compromise endothelial cell survival during periods of cell detachment. 
 
 
 Immune cells involved in the antitumor mechanisms of TNF monotherapy 
and TNF/IFN- combination therapy 
 
As TNF is a potent pro-inflammatory and immunoregulatory cytokine, it is not 
surprising that TNF-based therapies were shown to result in an infiltration of immune 
cells in tumors 
22, 23
. However, it remained to be elucidated whether these immune 
cells actively contribute to tumor destruction after TNF/IFN- therapy. In the present 
study we have demonstrated that the antitumor activity of TNF was markedly reduced 
in NKT-deficient mice as well as in NK1.1
+
 cell-depleted mice, suggesting that 
invariant NKT cells significantly contribute to the antitumor effect of TNF. However, 
even in NKT-deficient mice complete tumor regressions were observed after 
treatment with mTNF, albeit much less frequently than in wild-type mice, indicating 
that the antitumor activity of TNF is not strictly dependent on NKT cells but is 
facilitated by the presence of these cells. Moreover, tumor response to treatment with 
TNF was similar in athymic C57BL/6
nu/nu
 mice, which also lack invariant NKT cells, 
as in immune-competent C57BL/6 wild-type mice. One plausible explanation for this 
discrepancy is that there might be sufficient functional redundancy between different 
cytotoxic lymphocyte populations. NK cells, NKT cells and CD8
+
 T cells share many 
important effector functions, including IFN- production, FasL expression, and 
perforin/granzyme B-mediated cytotoxicity. The absence of one lymphocyte 
population may affect the functionality or proportion of another. For example, in 
athymic C57BL/6
nu/nu
 mice we observed a two- to four-fold increased number of NK 
cells in spleen and liver, and we found that this could be linked to an increased 
sensitivity to TNF. Interestingly, a markedly increased sensitivity to TNF was also 
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observed after transfer of wild-type splenocytes to IRF-1
-/-
 mice. It would be 
interesting to investigate whether this effect was due to the supranormal number of 
NK cells in these mice after transfer. Taken together, we have shown that the presence 
of certain cytotoxic lymphocytes, particularly invariant NKT cells, increases the 
sensitivity to the antitumor effect of TNF. 
 
Invariant NKT cells have the unique ability to rapidly produce large amounts of 
immunoregulatory cytokines upon activation, most notably of IFN- 44, 45. Previous 
experiments in our lab with IFN-R-/- mice and IFN--/- indicated that endogenous 
IFN- production, acting directly on the tumor cells, may contribute to the TNF-
induced antitumor mechanism 
26
. We may now have identified invariant NKT cells as 
the source of this endogenous IFN-. However, endogenous IFN- production alone 
cannot explain the reduced responses observed in NKT-deficient mice and therefore it 
is likely that other NKT cell-derived cytokines, potentially TNF, or other effector 
functions are involved in this effect. As the antitumor activity of TNF requires only 
endothelial TNF-R1 expression, it is puzzling how NKT cells could be specifically 
recruited to and/or activated at the tumor site 
7
. One possible explanation is that the 
actions of TNF would result in the exposure of an endogenous, possibly tumor-
derived glycolipid antigen capable of activating NKT cells. 
 
The antitumor effects of mTNF monotherapy and hTNF/IFN- combination therapy 
are macroscopically as well as microscopically very similar. Both treatments induce a 
haemorrhagic necrosis of tumors that is characterized by a selective destruction of the 
tumor vasculature. The mechanisms underlying their antitumor effects are, however, 
essentially different: (1) Previous work in our lab, using IFN--/- and IFN-R-/- mice, 
demonstrated that the difference in antitumor activity of mTNF and hTNF cannot be 
explained by endogenous IFN- induction 32. (2) We have evidence that NKT cells 
contribute to the TNF-induced antitumor effect by a mechanism that is largely 
independent of endogenous IFN- production. However, in NKT-deficient IRF-1-/-, 
CD1
-/-
 and athymic Swiss
nu/nu
 mice, which all display reduced response to mTNF, co-
treatment of mTNF and IFN- induced complete tumor regression, suggesting that 
IFN- triggers an additional mechanism that circumvents the need for NKT cells. (3) 
We found that the synergistic antitumor effect of hTNF and IFN- was largely 
abrogated in PI3K-/- mice, while the antitumor effect of mTNF was unaffected in 
these mice. (4) Similarly, depletion of neutrophils using cyclophosphamide 
completely abolished the synergy of hTNF and IFN-, while depletion did not affect 
the antitumor activity of mTNF. Taken together, these data imply that the antitumor 
effect of hTNF/IFN- combination therapy is critically dependent on neutrophils, 
while this is not the case for mTNF monotherapy.  
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Extensive in vitro data exist showing that co-incubation with IFN- sensitizes 
endothelial cells to TNF-induced cell death 
34
. Also, Rüegg and co-workers reported 
that treatment of HUVECs with TNF and IFN- suppressed the activation of integrin 
v3, leading to decreased endothelial cell adhesion and survival. They furthermore 
observed detachment and apoptosis of v3-positive endothelial cells of the tumor 
vasculature in melanoma patients treated with TNF and IFN- 33. The finding that in 
our B16Bl6 melanoma model the synergistic antitumor effect of TNF and IFN- 
required the presence of neutrophils implies that IFN- did not significantly sensitize 
the tumor endothelium to the direct vascular-disrupting effects of TNF in this in vivo 
model. We hypothesize that IFN- increases endothelial injury by exacerbating the 
TNF-triggered inflammatory response. Neutrophils are recruited to sites of 
inflammation by expression on the activated endothelium of the adhesion molecules 
E-selectin and ICAM-1, both of which are synergistically upregulated by TNF and 
IFN- 46-48. The adhesion of neutrophils to activated endothelium may be sufficient to 
trigger cytotoxic effector functions, including respiratory burst and degranulation of 
granules containing proteolytic enzymes and myeloperoxidase 
49
. We can, however, 
exclude NO production as an important effector function as we previously found that 
the synergistic antitumor effect of TNF and IFN- was preserved in iNOS-deficient 
mice 
50
. The finding that the synergistic antitumor effect of TNF and IFN- was 
largely abrogated in PI3K-/- mice, suggests that a GPCR-mediated signaling event is 
important 
51
. Neutrophils can be activated by a large number of chemotactic factors 
that signal via GPCRs, including the Glu-Leu-Arg (ELR)-positive chemokines 
CXCL1-8 (except CXCL4), and the lipid mediators PAF and LTB4, and it will be 
challenging to determine which factor(s) is/are involved 
49
. In conclusion, our data 
suggest that IFN- does not sensitize for the intrinsic antivascular or antitumor effect 
of TNF, but allows to trigger an additional, neutrophil-dependent mechanism. This 
finding offers a new rationale for the addition of IFN- to TNF-based anticancer 
therapies. 
 
 
 GalCer versus IFN- 
 
The elucidation of the complete antitumor mechanism elicited by TNF is important as 
this may reveal new targets for therapeutic intervention. The finding that NKT cells 
may actively contribute to tumor destruction after TNF therapy prompted us to test 
whether specific activation of these cells could increase the efficacy of a low-toxic, 
sub-therapeutic TNF treatment. We demonstrated that pre-treatment with GalCer 
markedly increased tumor destruction induced by treatment with hTNF or low-dose 
mTNF. Using IFN-R-/- and transgenic Flk-1 dnIFN-R mice we could show that this 
effect was completely IFN--dependent and required functional IFN-R expression on 
endothelial cells, suggesting that GalCer acts by a similar mechanism as 
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exogenously administered IFN- 26. An important question is of course whether using 
GalCer would be superior to treatment with IFN-. For example, GalCer may offer 
better pharmacokinetics or induce IFN- production at the tumor site. We started 
treatment with TNF 24 hours after i.p. injection of GalCer, when elevated serum 
levels of IFN- were already largely declined 52. Increased response to TNF was 
observed for at least several days after injection of GalCer, suggesting that GalCer 
may trigger a longer-lasting sensitizing effect. It has been demonstrated that the 
antimetastatic effect of GalCer is dependent on the activation of NK cells and IFN- 
production by these cells, which is then most likely followed by bystander activation 
of other immune cells 
53, 54
. Although no overt toxicities were observed in our model, 
caution is required when combining TNF with GalCer as both these drugs are 
known to cause liver toxicity, which is one of the major dose-limiting toxicities of 
TNF 
55, 56
. More potent GalCer analogs with a Th1-biased cytokine profile are 
currently being developed 
57
. It will be most interesting to test whether these 
compounds would even further increase the antitumor activity of TNF.  
 
 
11.3. Conclusion & future perspectives 
 
The ultimate goal of this research project was to identify new therapeutic targets to 
selectively increase the antitumor activity of TNF, so that a safe and effective 
systemic treatment would become possible with low, tolerable doses of TNF. In this 
thesis we presented two new approaches towards this goal: first we demonstrated that 
interfering with endothelial survival, through inhibition of the PI3K/Akt/mTOR 
pathway, sensitized for the selective vascular-disrupting effect of TNF, and second we 
showed that specific pharmacological activation of invariant NKT cells, which appear 
to contribute to tumor destruction upon treatment with TNF, markedly increased the 
antitumor efficacy of TNF. Both these approaches allowed approximately a tenfold 
reduction of the effective dose of TNF in our murine tumor model. It would be 
interesting to investigate whether combining these approaches would further reduce 
the required dose of TNF. We also provided a new rationale for the addition of IFN- 
to TNF-based anticancer therapies by showing that this may trigger an additional, 
neutrophil-dependent antitumor mechanism. One important remark is that all 
combination treatments described in this thesis were performed by paralesional 
injection of TNF and IFN-. Thus, to really assess to safety and efficacy of these 
combination treatments, a clinically more relevant, systemic treatment should be set 
up. In case of survival pathway inhibition, the risk of side-effects could be minimized 
by using more selective inhibitors, for example PI3K isoform-selective inhibitors 
which are currently being developed or inhibitors of upstream components of the 
survival pathway such as receptor tyrosine kinase inhibitors and other angiostatics 
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which are already in clinical trials. Finally, our results may offer new insights into the 
antitumor mechanisms of TNF and IFN- (summarized in Fig.11.1.). 
 
 
 
 
Fig. 11.1. Potential mechanism for the vascular-disrupting and antitumor effect of TNF, and its 
synergy with IFN-. TNF and IFN- both act by activating their receptors on endothelial cells of the 
tumor vasculature. We hypothesize that the initial event in the TNF-induced destruction of the tumor 
vasculature is the weakening of endothelial cell-cell and/or cell-matrix contact, which would cause 
leakage, haemorrhage and tissue exposure, and compromise endothelial survival. Blood flow would 
then rapidly be shut off by a mechanism of vascular collapse and/or thrombosis. How invariant NKT 
cells (red arrows) contribute to TNF-induced tumor destruction is still to be elucidated, but could 
involve the production of cytokines such as IFN- and TNF. Alternatively, NKT cells could induce 
endothelial or tumor cell death through Fas- or perforin/granzyme B-mediated cytotoxicity. NKT cells 
may become activated by presentation of endogenous, possibly tumor-derived, glycolipid antigens. Co-
treatment with IFN- (blue arrows) synergistically upregulates the endothelial expression of adhesion 
molecules and chemokines. We hypothesize that this results in a massive infiltration of neutrophils, 
which would then exacerbate the TNF-induced endothelial damage by ROS production or 
degranulation. 
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12. ALGEMENE SAMENVATTING & DISCUSSIE 
 
12.1. Samenvatting 
 
TNF is een krachtig pro-inflammatoir cytokine dat oorspronkelijk ontdekt werd 
dankzij zijn opmerkelijke antitumorale activiteit. Via zijn twee celoppervlakte 
receptoren, TNF-R1 en TNF-R2, is het betrokken bij een groot aantal 
(patho)fysiologische processen. De meeste informatie over TNF signalisatie, zoals de 
activatie van de NF-B, MAPK en celdood signalisatiewegen, werd afgeleid van 
TNF-R1 en deze receptor wordt dan ook beschouwd als de belangrijkste. Het is echter 
mogelijk dat de rol van TNF-R2 onderschat wordt aangezien deze receptor alleen 
volledig geactiveerd wordt door de membraangebonden vorm van TNF, en niet door 
vrij TNF. Eén van de belangrijkste biologische functies van TNF is het mediëren van 
ontstekingsreacties. Weefsel macrofagen die gestimuleerd worden met LPS of andere 
bacteriële bestanddelen produceren snel TNF om de lokale bloedvaten te activeren. 
Dit resulteert in verhoogde doorbloeding door de productie van de vasodilatoren NO 
en PGI2, verhoogde vasculaire permeabiliteit door verzwakking van endotheliale cel-
cel juncties en cytoskeletale reorganisatie, en de rekrutering van neutrofielen, 
monocyten en andere witte bloedcellen naar de plaats van ontsteking door de 
opregulatie van chemokines en adhesie moleculen zoals E-selectine, ICAM-1 en 
VCAM-1. Bovendien kan TNF, als een additioneel beschermingsmechanisme, de 
lokale bloedtoevoer afsluiten door bloedstolling te stimuleren of door (in)directe 
endotheelceldood te veroorzaken. Dezelfde mechanismen waarmee TNF zo efficiënt 
lokale infecties kan bedwingen kunnen echter ook schadelijk worden, zoals in sepsis 
en chronisch inflammatoire aandoeningen zoals reumatoïde artritis, inflammatoir 
darmlijden en psoriasis. 
 
De in vivo antitumorale activiteit van recombinant TNF en zijn synergie met IFN- 
werden voor het eerst aangetoond in het muis B16Bl6 melanoma model door 
Brouckaert en medewerkers in 1986 
1
. TNF induceert een snelle, bloederige necrose 
van experimentele tumoren die gekenmerkt wordt door een selectieve vernietiging 
van de tumorvasculatuur. Ondanks veelbelovende resultaten in proefdiermodellen 
waren de eerste klinische studies met systemisch toegediend TNF echter 
teleurstellend. Dosissen van 10 tot 50 keer lager dan de geschatte effectieve dosis 
veroorzaakten al ernstige nevenwerkingen, met als belangrijkste lage bloeddruk en 
orgaanfalen. Om deze nevenwerkingen te vermijden, kwamen twee Belgische 
chirurgen, Lejeune en Liénard, op het idee om TNF in de ILP setting te gebruiken 
2
. 
ILP met TNF, melphalan en eventueel IFN- kan tegenwoordig gebruikt worden voor 
de behandeling van patiënten met vergevorderde tumoren (in-transit melanoma 
metastasen en zachte weefsel sarcomas) van de ledematen als alternatief voor 
amputatie. Het succes van deze methode demonstreert duidelijk het potentieel van 
TNF als een antikanker geneesmiddel. Aangezien locoregionale therapie echter geen 
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effect heeft op verafgelegen metastasen, heeft TNF-gebaseerde ILP tot op heden 
vrijwel geen invloed gehad op de finale overleving van kankerpatiënten, wat de 
noodzaak voor een effectieve en veilige systemische TNF behandeling benadrukt. 
 
Voorafgaand werk in onze en andere onderzoeksgroepen heeft duidelijk aangetoond 
dat de antitumorale en toxische effecten van TNF niet onlosmakelijk met elkaar 
verbonden zijn. Muizen kunnen beschermd worden tegen de TNF-geïnduceerde letale 
shock met behulp van de sGC inhibitor methyleenblauw zonder het antitumoraal 
effect nadelig te beïnvloeden 
3
. Ook zijn er twee acute fase eiwitten geïdentificeerd, 
1-zuur glycoproteïne en 1-antitrypsine, die de TNF-geïnduceerde leverschade 
kunnen verhinderen 
4
. Bovendien werd recent aangetoond dat het toevoegen van zink 
aan het drinkwater van muizen kan beschermen tegen de TNF-geïnduceerde letale 
shock en darmtoxiciteit zonder de antitumorale werking van TNF en IFN- teniet te 
doen 
5
. Deze resultaten tonen duidelijk aan dat het mogelijk moet zijn om een veilige 
systemische behandeling met TNF te ontwikkelen. Het gebruik van een mogelijks 
letale dosis TNF in combinatie met een inhibitor van de toxische nevenwerkingen is 
echter geen aantrekkelijke oplossing voor humane kankertherapie aangezien falen van 
de inhibitor de dood van de patiënt tot gevolg zou kunnen hebben. Een veiligere 
strategie om de systemische toxiciteit van TNF te verlagen zou zijn om lage TNF 
dosissen of laag-toxische TNF muteïnes te gebruiken in combinatie met stoffen die 
selectief de antitumorale activiteit verhogen, zoals IFN-. In het kader van deze laatste 
strategie behandelden we in deze scriptie drie grote vragen: 
 
(1) Kunnen we gevoeliger maken voor het antitumoraal effect van TNF door te 
interfereren met endotheliale overlevingssignalisatie ? 
(2) Welke immuuncellen zijn betrokken bij het antitumoraal mechanisme van 
TNF ? 
(3) Hoe versterkt IFN- het antitumoraal effect van TNF ? 
 
 
 Sensitisatie voor het antitumoraal effect van TNF door inhibitie van 
endotheliale overlevingssignalisatie 
 
Het preciese mechanisme achter de TNF-geïnduceerde tumor necrose is nog 
grotendeels onbekend. Het is duidelijk geworden dat het antitumoraal effect van TNF 
volledig gastheer-gemedieerd is en geen expressie van TNF-receptoren op de 
tumorcellen vereist. Stoelcker en medewerkers hebben bovendien aangetoond dat het 
antitumoraal effect van TNF behouden blijft in TNF-R2
-/-
 muizen, maar volledig 
afwezig is in TNF-R1
-/-
 muizen, wat suggereert dat de antitumorale werking van TNF 
gebeurt via de TNF-R1 op gastheercellen 
6
. Vroeger werk in onze onderzoeksgroep 
heeft dit verder onderbouwd door aan te tonen dat expressie van TNF-R1 alleen op de 
neovasculatuur (onder controle van een Flk-1 promotor) volstaat voor het volledig 
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antitumoraal effect van TNF, wat aangeeft dat de endotheelcellen van de 
tumorvasculatuur de directe doelwitcellen zijn van TNF 
7
. Dit wordt bevestigd door 
observaties in proefdiermodellen en ILP patiënten van een selectieve vernietiging van 
de tumorvasculatuur na behandeling met TNF 
2, 8-10
. TNF kan dus als een VDA 
beschouwd worden. 
 
De PI3K/Akt signalisatieweg is één van de belangrijkste regulatoren van cel 
overleving. Aangezien de tumorvasculatuur in tegenstelling tot de normale 
vasculatuur niet gestabiliseerd is door normale interacties met pericyten, structuur van 
de basale membraan en cel-cel juncties, en bovendien onderhevig is aan constante 
herschikking door onevenwichtigheid van angiogene factoren geproduceerd in de 
tumor, is het aannemelijk dat deze vasculatuur sterk afhankelijk is van deze 
overlevings-signalisatieweg 
11-14
. De PI3K/Akt signalisatieweg wordt geactiveerd 
door een groot aantal pro-angiogene factoren, o.a. groeifactoren, zoals leden van de 
VEGF familie, en adhesie molecules, zoals integrine v3 
15, 16
. Het werd aangetoond 
dat inhibitie van PI3K endotheelcellen in vitro gevoeliger maakt voor de cytotoxische 
effecten van TNF 
17-19
. Bovendien rapporteerden Matschurat et al. dat inhibitie van 
PI3K het antitumoraal effect van TNF versterkt in een muis MethA sarcoma model 
20
. 
 
Om na te gaan of inhibitie van de PI3K/Akt signalisatieweg gevoeliger zou maken 
voor het antitumoraal effect van TNF behandelden we B16Bl6 melanoma- of andere 
tumor-dragende muizen met subtherapeutisch TNF, alleen of in combinatie met één 
van de PI3K inhibitoren wortmannin of LY294002. De combinatie van een PI3K 
inhibitor met TNF resulteerde in een uitgesproken antitumoraal effect, met 
tumorregressie in alle behandelde dieren. We bepaalden dat PI3K inhibitie een 
tienvoudige verlaging van de benodigde TNF dosis toeliet. Vergelijkbare resultaten 
werden bekomen met de Akt inhibitor perifosine of de mTOR inhibitor rapamycin. 
Belangrijk is dat inhibitie van de PI3K/Akt signalisatieweg het antitumoraal effect van 
TNF versterkte zonder een gelijktijdige verhoging van de toxische nevenwerkingen 
van TNF te veroorzaken. Met behulp van intravitaal-microscopie en histologische 
analyse van tumoren toonden we aan dat behandeling met wortmannin en TNF een 
selectieve vernietiging van de tumorvasculatuur induceerde, met verbreking van 
onderling contact tussen endotheelcellen en bloeding. In vivo Hoechst kleuring gaf 
aan dat reeds 6 uur na injectie van wortmannin en TNF de doorbloeding van de tumor 
bijna volledig afgesloten was. 48 uur na injectie was de doorbloeding nog steeds niet 
hersteld, zodat de tumor effectief zou kunnen afsterven door ontbering. Tenslotte 
demonstreerden we dat anti-angiogene therapie met een VEGF-R2 blokkerend 
antilichaam eveneens de antitumorale activiteit van TNF versterkt in het B16Bl6 
melanoma model. Gezamenlijk tonen deze resultaten aan dat interfereren met 
endotheliale overlevingssignalisatie een significante verlaging van de effectieve TNF 
dosis toelaat. 
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 Immuuncellen betrokken bij het antitumoraal mechanisme van TNF 
 
Zoals reeds vermeld blijkt uit vroegere experimenten dat het antitumoraal effect van 
TNF volledig gastheer-gemedieerd is en enkel TNF-R1 expressie op het 
tumorendotheel vereist 
6, 7
. Deze experimenten toonden ook aan dat TNF-R1 expressie 
op andere cellen dan endotheelcellen, zoals tumorcellen en immuuncellen, 
onbelangrijk is voor het volledig antitumoraal effect van TNF. Bepaalde 
immuuncellen zouden echter wel betrokken kunnen zijn bij het antitumoraal 
mechanisme van TNF. Eggermont en collega’s toonden aan dat volledige 
lichaamsbestraling van tumordragende ratten, waarbij algemene leukopenie 
geïnduceerd werd, de tumorvernietiging en huidnecrose op de plaats van de tumor na 
ILP met TNF en melphalan merkbaar verminderde 
21
. Bovendien werd er na TNF-
gebaseerde ILP een inflammatoire respons waargenomen die resulteerde in een snelle 
infiltratie van neutrofielen in de tumor, gevolgd door de infiltratie van macrofagen en 
lymfocyten na enkele dagen tot weken 
22, 23
. Experimenten uitgevoerd in onze 
onderzoeksgroep met B16Bl6 tumor-dragende IRF-1
-/-
 muizen, die geen mature NK 
cellen, NK1.1
+
 T cellen en CD8
+
 T cellen ontwikkelen, lieten een sterk verminderde 
respons op TNF behandeling zien in deze immuun-deficiënte muizen 
24-26
. De 
antitumorale activiteit van TNF in IRF-1
-/-
 muizen kon gedeeltelijk hersteld worden 
door reconstitutie met wild-type splenocyten, wat een rol voor lymfocyten suggereert 
in dit model. 
 
We onderzochten, met behulp van immuun-deficiënte muizen en methodes om 
lymfocyten selectief te depleteren, welke lymfocyten betrokken zijn bij het 
antitumoraal mechanisme van TNF. We vonden dat geen enkele lymfocyt populatie 
strikt noodzakelijk was voor de antitumorale werking van TNF. Zowel athymische 
C57BL/6
nu/nu
 muizen, die geen mature T lymfocyten en NKT cellen hebben, als NK 
cel-gedepleteerde muizen vertoonden een gelijkaardige respons op TNF behandeling 
als wild-type controle muizen. Daarentegen vonden we dat vier onafhankelijke NKT 
cel-deficiënte muis stammen (IRF-1
-/-
, IL-15
-/-
, J18-/- en CD1-/-) een merkbaar 
verminderde respons op TNF behandeling vertoonden. We konden de antitumorale 
activiteit van TNF in IRF-1
-/-
 muizen en J18-/- muizen grotendeels herstellen door 
deze muizen voor de behandeling te injecteren met leukocyten geïsoleerd uit wild-
type lever, een orgaan dat bijzonder rijk is aan NK1.1
+
 T cellen. Een rol voor NK1.1
+
 
cellen werd ook bevestigd door selectieve depletie van deze cellen met behulp van een 
anti-NK1.1 antilichaam. Onze resultaten suggereren dat de rekrutering en/of activatie 
van invariante NKT cellen een belangrijke rol speelt in het antitumoraal mechanisme 
dat door TNF in gang wordt gezet. We hebben deze hypothese verder onderbouwd 
door aan te tonen dat een enkele injectie van het specifieke NKT cel ligand GalCer 
de doeltreffendheid van een subtherapeutische TNF behandeling merkbaar verhoogde. 
Met behulp van IFN-R-deficiënte muizen demonstreerden we dat het effect van 
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GalCer volledig afhankelijk is van endogene IFN- productie. Gezamenlijk tonen 
deze resultaten aan dat invariante NKT cellen mogelijks een interessant doelwit zijn 
om de therapeutische toepasbaarheid van TNF uit te breiden. 
 
 
 Het mechanisme achter het synergetisch antitumoraal effect van TNF en 
IFN- 
 
In vele experimentele tumormodellen werd aangetoond dat medebehandeling met 
IFN- de antitumorale activiteit van TNF synergetisch kan versterking 1, 27, 28. 
Bovendien kon men in klinische studies eveneens een trend tot beter resultaat 
waarnemen wanneer IFN- deel uitmaakte van de ILP behandeling, wat aanwijst dat 
de synergie van TNF en IFN- ook bestaat in dit systeem 2. In vitro bestaan er 
aanwijzingen dat IFN- gevoeliger maakt voor cytokine-geïnduceerde cytotoxiciteit 
op een IRF-1-afhankelijke manier 
29, 30
. Wij vonden daarentegen dat het synergetisch 
antitumoraal effect van TNF en IFN- nog steeds aanwezig was in IRF-1-deficiënte 
muizen, wat aangeeft dat dit in vivo effect onafhankelijk is van IRF-1 
26
. Uit 
histologische analyses blijkt dat behandeling met TNF en IFN- een selectieve 
vernietiging van de tumor-geassocieerde vasculatuur veroorzaakt 
2, 31, 32
. Bovendien 
heeft onderzoek in ons laboratorium aangetoond dat het synergetisch antitumoraal 
effect van TNF en IFN- afhankelijk is van IFN-R expressie op endotheelcellen 33. 
Dit wijst erop dat de endotheelcellen van de tumorvasculatuur de doelwitcellen zijn 
van TNF/IFN- combinatietherapie. Li en medewerkers hebben recent aangetoond dat 
IFN- de vrijstelling van cathepsine B uit lysosomen kan induceren in HUVECs, en 
dat dit sensitiseert voor TNF-geïnduceerde, cathepsine B-afhankelijke celdood 
34
. Het 
mechanisme achter het in vivo synergetisch effect van TNF en IFN- is echter nog 
grotendeels onbekend. 
 
We gingen na of immuuncellen, die in tumoren blijken te infiltreren na TNF/IFN--
gebaseerde ILP, betrokken zijn bij het synergetisch antitumoraal effect van TNF en 
IFN-. Onze resultaten geven aan dat de synergie van TNF en IFN- onafhankelijk is 
van NKT cellen of andere lymfocyten waarvan we voorheen hadden aangetoond dat 
ze kunnen bijdragen tot het antitumoraal effect van TNF. Daarentegen vonden we dat 
het synergetisch antitumoraal effect van TNF en IFN- sterk verminderd was in 
PI3K-deficiënte muizen, die defecten vertonen in chemokine-geïnduceerde responses 
van neutrofielen en monocyten/macrofagen. Specifieke depletie van macrofagen had 
geen effect op de synergie van TNF en IFN- in ons muis B16Bl6 melanoma model, 
terwijl depletie van neutrofielen deze synergie teniet deed. Onze data impliceren dat 
het synergetisch antitumoraal effect van TNF en IFN- strikt afhankelijk is van 
neutrofielen. Onze huidige hypothese is daarom dat IFN- endotheelschade en 
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tumorvernietiging vermeerdert door de TNF-geïnduceerde ontstekingsreactie te 
versterken. 
 
 
12.2. Discussie 
 
 Het bloedvat-vernietigend mechanisme van TNF 
 
TNF-gebaseerde behandelingen worden gekenmerkt door een selectieve vernietiging 
van de tumorvasculatuur. Dit wordt niet alleen in experimentele proefdiermodellen 
waargenomen, maar ook in patiënten die behandeld werden via ILP 
2, 9
. Het 
mechanisme achter dit opmerkelijk bloedvat-vernietigend effect moet echter nog 
ontrafeld worden. In deze studie hebben wij aangetoond dat breed-spectrum PI3K 
inhibitie sensitiseert voor dit bloedvat-vernietigend effect van TNF. We gebruikten 
intravitaal-microscopie en verscheidene histologische kleuringsmethodes om de grove 
effecten van behandeling met wortmannin en TNF op de tumorvasculatuur te 
visualiseren. Onze data geven aan dat deze behandeling zeer snel na injectie leidt tot 
lekkage van bloedvaten en bloeding, gevolgd door het volledig afsluiten van de 
doorbloeding van de meeste tumorbloedvaten tegen 6 uur na injectie. De vernietiging 
van de vaatwand was compleet tegen 24 uur na injectie. Matschurat en medewerkers 
hebben aangetoond dat inhibitie van PI3K de TNF-geïnduceerde expressie van tissue 
factor, de initiator van de extrinsieke bloedstollingscascade, verhoogt. Bovendien 
demonstreerden zij dat medebehandeling met wortmannin het antitumoraal effect van 
TNF versterkt in een muis MethA sarcoma model. Samen suggereren deze resultaten 
dus dat expressie van tissue factor op endotheelcellen van de tumorvasculatuur, wat 
bloedstolling en occlusie van bloedvaten zou veroorzaken, verantwoordelijk zou zijn 
voor het antitumorale effect van deze combinatietherapie 
20
. Onze bevindingen sluiten 
echter niet volledig aan bij deze hypothese. Intravasculaire bloedstolling is een 
beschermend mechanisme om in het geval van endotheelschade bloeding te 
verhinderen. De uitgesproken vasculaire lekkage en bloeding die we waarnamen na 
behandeling met wortmannin en TNF suggereren dat occlusie van bloedvaten pas 
gebeurt na vernietiging van de vaatwand.   
 
Het werd meermaals aangetoond dat PI3K inhibitie endotheelcellen in vitro 
gevoeliger kan maken voor TNF-geïnduceerde cytotoxiciteit 
18, 19, 35
. Bijzonder 
interessant in deze context is dat TNF blijkbaar zelf in staat is om de PI3K/Akt 
signalisatieweg te activeren 
17
. Het is zelfs aangetoond dat PI3K signalisatie in 
bepaalde celtypes noodzakelijk is voor de activatie van NF-B, de belangrijkste 
transcriptiefactor verantwoordelijk voor TNF-geïnduceerde anti-apoptotische 
signalisatie. Dit bleek echter niet het geval in HUVECs 
36
. Madge en medewerkers 
rapporteerden dat TNF in HUVECs een PI3K-gemedieerde anti-apoptotische respons 
induceert die onafhankelijk is van Akt en NF-B, en dat PI3K inhibitie deze 
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endotheelcellen sensitiseert voor een cathepsine B-afhankelijke, maar caspase-
onafhankelijke celdood 
19
. Dit komt echter niet overeen met onze in vivo data waar het 
sensitiserend effect van PI3K inhibitie kon nagebootst worden door Akt inhibitie. 
Bovendien werd er na behandeling met wortmannin en TNF in endotheelcellen alleen 
DNA fragmentatie, een kenmerk van apoptose, waargenomen nadat disruptie van de 
vaatwand en occlusie van bloedvaten hadden plaatsgevonden. Endotheliale celdood 
kan dan ook het gevolg zijn van het verlies van cel-extracellulaire matrix contact 
(anoikis) of louter ontbering. 
 
Onze huidige hypothese is dat een verlies van endotheliaal cel-cel en/of cel-
extracellulaire matrix contact aan de basis ligt van het bloedvat-vernietigend effect 
van TNF. Openingen tussen de endotheelcellen van de tumorvasculatuur waren 6 uur 
na injectie van wortmannin en TNF al waarneembaar. Menon et al. rapporteerden 
eveneens het verschijnen van openingen in de vaatwand van tumorbloedvaten tussen 3 
en 6 uren na behandeling met TNF, zowel in humane melanoma xenograften in 
muizen als in melanoma patiënten die behandeld werden via ILP. Ze schreven deze 
openingen toe aan het verdwijnen van VE-cadherine uit endotheliale cel-cel juncties 
37
. VE-cadherine is een essentieel onderdeel van adherens juncties tussen 
endotheelcellen en speelt een belangrijke rol in tumor angiogenese 
38
. Recent werd 
aangetoond dat TNF tyrosine fosforylatie van het intracellulair domein van VE-
cadherine kan induceren, waarvan geweten is dat het de VE-cadherine juncties 
verzwakt en dus de vorming van intercellulaire openingen vergemakkelijkt 
39
. 
Disruptie van VE-cadherine juncties zou de doorbloeding van de tumor kunnen 
stilleggen via een mechanisme van vasculaire collaps, zoals beschreven werd voor het 
bloedvat-vernietigend mechanisme van het tubuline-bindend geneesmiddel CA4P. 
Disruptie van VE-cadherine juncties zou bloeding, een verhoging van interstitiële 
vloeistofdruk, en uiteindelijk het dichtslaan van de verzwakte bloedvaten veroorzaken 
40
. Het is op dit ogenblik echter onduidelijk of PI3K inhibitie het effect van TNF op 
VE-cadherine juncties zou kunnen versterken. De integrines v3 en v5 spelen een 
belangrijke rol in endotheelcel-extracellulaire matrix adhesie in neovasculatuur 
41
. 
Rüegg en medewerkers hebben aangetoond dat behandeling van HUVECs met TNF 
en IFN- de activatie van integrine v3 onderdrukte, wat leidde tot een verminderde 
endotheelcel adhesie en overleving. Ook observeerden ze het loskomen en afsterven 
van v3-positieve endotheelcellen in de tumorvasculatuur van melanoma patiënten 
na ILP met TNF en IFN- 32. Recent demonstreerden ze bovendien dat Akt activatie 
de integrine-afhankelijke endotheelcel adhesie kan versterken en HUVECs kan 
beschermen tegen celdood geïnduceerd door TNF en/of door inhibitie van de 
integrines v3en v5 
42, 43
. Het is dus bekend dat TNF kan interfereren met zowel 
endotheliale cel-cel als cel-extracellulaire matrix interacties. Inhibitie van de 
PI3K/Akt signalisatieweg zou dit effect kunnen versterken of zou de overleving van 
de losgekomen endotheelcel kunnen ondermijnen. 
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 Immuuncellen betrokken bij het antitumoraal mechanisme van TNF 
monotherapie en TNF/IFN- combinatietherapie 
 
Aangezien TNF een krachtig pro-inflammatoir en immuun-regulerend cytokine is, is 
het weinig verrassend dat na TNF-gebaseerde behandelingen een infiltratie van 
immuuncellen in tumoren waargenomen werd 
22, 23
. Het was echter nog niet geweten 
of deze cellen ook actief bijdragen tot de tumorvernietiging na behandeling met 
TNF/IFN-. In deze studie toonden wij aan dat de antitumorale activiteit van TNF 
merkbaar verminderd was in NKT-deficiënte muizen en NK1.1
+
 cel-gedepleteerde 
muizen, wat suggereert dat invariante NKT cellen effectief bijdragen tot het 
antitumoraal effect van TNF. Desondanks werden volledige tumorregressies ook 
waargenomen in NKT-deficiënte muizen, zij het veel minder frequent dan in wild-
type muizen. Dit wijst erop dat de antitumorale werking van TNF niet strikt 
afhankelijk is van NKT cellen maar wel vergemakkelijkt wordt door de aanwezigheid 
van deze cellen. C57BL/6
nu/nu
 muizen, die eveneens geen invariante NKT cellen 
hebben, vertoonden echter een gelijkaardige respons op TNF behandeling als wild-
type controle muizen. Een mogelijke verklaring voor deze paradox is dat er voldoende 
functionele redundantie kan zijn tussen verschillende types van cytotoxische 
lymfocyten. NK cellen, NKT cellen en cytotoxische CD8
+
 T cellen delen veel 
belangrijke effector functies, zoals IFN- productie, FasL expressie en 
perforine/granzyme B-gemedieerde cytotoxiciteit. Bovendien kan de afwezigheid van 
één lymfocyt populatie de functionaliteit of proportie van een andere beïnvloeden. Zo 
observeerden wij in C57BL/6
nu/nu
 muizen een twee- tot viervoudig toegenomen 
percentage NK cellen in milt en lever, en we toonden aan dat dit gekoppeld kon 
worden aan een toegenomen gevoeligheid voor TNF. Een verhoogde gevoeligheid 
voor TNF werd ook geobserveerd na reconstitutie van IRF-1
-/-
 muizen met wild-type 
splenocyten. Het zou interessant zijn om te na te gaan of dit effect te wijten was een 
supernormaal aantal NK cellen in deze muizen na transfer. Samen tonen deze 
resultaten aan dat de aanwezigheid van bepaalde cytotoxische lymfocyten, in het 
bijzonder NKT cellen, de gevoeligheid voor het antitumoraal effect van TNF 
verhoogt.  
 
Invariante NKT cellen hebben de unieke eigenschap om snel grote hoeveelheden 
immuun-regulerende cytokines te produceren na activatie, met als meest opmerkelijke 
kandidaat IFN- 44, 45. Vroegere experimenten in ons lab met IFN-R-/- en IFN--/- 
muizen wezen erop dat endogene productie van IFN-, dat direct inwerkt op de 
tumorcellen, kan bijdragen tot het antitumoraal effect van TNF 
26
. Mogelijks hebben 
we nu invariante NKT cellen geïdentificeerd als de bron van dit endogeen IFN-. De 
productie van endogeen IFN- alleen kan echter de verlaagde respons waargenomen 
in NKT-deficiënte muizen niet volledig verklaren, en vermoedelijk spelen dus andere 
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cytokines, mogelijks TNF, of andere effector functies van NKT cellen een rol in het 
antitumoraal mechanisme van TNF. Aangezien alleen TNF-R1 expressie op 
endotheelcellen vereist is voor de antitumorale activiteit van TNF, is het momenteel 
onduidelijk hoe NKT cellen specifiek gerekruteerd worden naar de tumor en/of 
geactiveerd worden na behandeling met TNF 
7
. Een mogelijke verklaring kan zijn dat 
de acties van TNF zouden resulteren in de blootstelling van een endogeen glycolipide 
antigen, mogelijks afkomstig van de tumorcellen, dat in staat is om NKT cellen te 
activeren. 
 
De antitumorale effecten van mTNF monotherapie en hTNF/IFN- 
combinatietherapie zijn zowel macroscopisch als microscopisch sterk gelijkaardig. 
Beide behandelingen veroorzaken een bloederige necrose van tumoren die 
gekenmerkt wordt door een selectieve vernietiging van de tumorvasculatuur. De 
onderliggende mechanismen van deze antitumorale effecten zijn echter duidelijk 
verschillend: (1) Vroeger werk in onze onderzoeksgroep met IFN--/- en IFN-R-/- 
muizen heeft aangetoond dat het verschil in antitumorale activiteit tussen mTNF en 
hTNF niet verklaard kan worden door een verschil in endogene IFN- inductie 33. (2) 
We hebben aanwijzingen dat NKT cellen bijdragen tot het antitumoraal effect van 
TNF via een mechanisme dat grotendeels onafhankelijk is van endogene IFN- 
productie. In NKT-deficiënte IRF-1
-/-
, CD1
-/-
 en athymische Swiss
nu/nu
 muizen, die 
allemaal een verlaagde respons vertonen ten opzichte van mTNF, veroorzaakt 
mTNF/IFN- combinatietherapie echter wel volledige tumorregressie, wat suggereert 
dat IFN- een additioneel mechanisme in gang zet dat onafhankelijk is van NKT 
cellen. (3) We vonden dat het synergetisch antitumoraal effect van hTNF en IFN- 
sterk verminderd was in PI3K-/- muizen, terwijl de antitumorale activiteit van mTNF 
onaangetast was in deze muizen. (4) Depletie van neutrofielen met behulp van 
cyclofosfamide deed het synergetisch effect van hTNF en IFN- teniet, terwijl dit 
geen effect had op de antitumorale activiteit van mTNF. Deze resultaten impliceren 
dat het synergetisch antitumoraal effect van hTNF/IFN- combinatietherapie strikt 
afhankelijk is van neutrofielen, terwijl dit niet het geval is voor mTNF monotherapie. 
 
Er bestaan overtuigende in vitro gegevens die aantonen dat co-incubatie met IFN- 
endotheelcellen gevoeliger maakt voor TNF-geïnduceerde celdood 
34
. Rüegg en 
medewerkers hebben ook aangetoond dat behandeling van HUVECs met TNF en 
IFN- de activatie van integrine v3 onderdrukte, wat leidde tot een verminderde 
endotheelcel adhesie en overleving. Ook observeerden ze het loskomen en afsterven 
van v3-positieve endotheelcellen in de tumorvasculatuur van melanoma patiënten 
na ILP met TNF en IFN- 32. De bevinding dat in ons B16Bl6 melanoma model het 
synergetisch antitumoraal effect van TNF en IFN- de aanwezigheid van neutrofielen 
vereist, impliceert dat IFN- in dit in vivo model het tumorendotheel niet significant 
gevoeliger maakte voor de intrinsieke bloedvat-vernietigende effecten van TNF. Onze 
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hypothese is dat IFN- endotheelschade en tumorvernietiging vermeerdert door de 
TNF-geïnduceerde ontstekingsreactie te versterken. Neutrofielen worden gerekruteerd 
naar inflammatoire sites door opregulatie van de adhesie moleculen E-selectine en 
ICAM-1 op het geactiveerde endotheel. Zowel E-selectine als ICAM-1 worden 
synergetisch opgereguleerd door TNF en IFN- 46-48. De adhesie van neutrofielen op 
het geactiveerd endotheel zou kunnen volstaan om cytotoxische effector functies te 
activeren, zoals ‘oxidatieve burst’ en degranulatie van granules die proteolytische 
enzymes en myeloperoxidase bevatten 
49
. We kunnen NO productie echter uitsluiten 
als een belangrijke effector functie aangezien vroeger werk in onze groep aangetoond 
heeft dat het synergetisch antitumoraal effect van TNF en IFN- behouden was in 
iNOS-deficiënte muizen 
50
. De bevinding dat het synergetisch antitumoraal effect van 
TNF en IFN- sterk verminderd was in PI3K-/- muizen suggereert dat GPCR’s 
betrokken zijn in dit effect 
51
. Neutrofielen kunnen geactiveerd worden door een groot 
aantal chemotactische factoren die signaliseren via GPCR’s, zoals de Glu-Leu-Arg 
(ELR)-positieve chemokines CXCL1-8 (met uitzondering van CXCL4), en de lipide 
mediatoren PAF en LTB4 
49
. Het zal een uitdaging zijn om te bepalen welke factoren 
betrokken zijn. We kunnen besluiten dat onze resultaten aangeven dat IFN- niet 
sensitiseert voor het intrinsiek antivasculair of antitumoraal effect van TNF, maar 
toelaat om een additioneel, neutrofiel-afhankelijk mechanisme aan te slaan. Deze 
bevinding biedt een nieuwe rationale voor de toevoeging van IFN- aan TNF-
gebaseerde antikanker behandelingen. 
 
 
 GalCer versus IFN- 
 
De ontrafeling van het volledige antitumorale mechanisme van TNF is belangrijk 
omdat het nieuwe doelwitten kan opleveren voor therapeutische interventie. De 
bevinding dat NKT cellen mogelijks actief bijdragen tot het antitumoraal effect van 
TNF zette ons ertoe aan om te testen of specifieke activatie van deze cellen de 
doeltreffendheid van een laag-toxische, subtherapeutische TNF behandeling zou 
kunnen verhogen. We demonstreerden dat voorbehandeling met GalCer het 
tumorvernietigend effect van een behandeling met hTNF of lage-dosis mTNF 
merkbaar versterkte. Aan de hand van IFN-R-/- muizen en transgene Flk-1 dnIFN-R 
muizen konden we aantonen dat dit effect volledig afhankelijk is van IFN- en de 
expressie van een functionele IFN-R vereist op endotheelcellen. Dit wijst erop dat 
GalCer volgens een gelijkaardig mechanisme werkt als exogeen toegediend IFN-  
26
. Een belangrijke vraag is uiteraard of het gebruik van GalCer superieur zou zijn 
aan behandeling met IFN-. GalCer zou, bijvoorbeeld, een betere farmacokinetiek 
kunnen bieden of zou IFN- productie kunnen induceren op de juiste plaats, met name 
ter hoogte van de tumor. We startten de behandeling met TNF 24 uur na i.p. injectie 
van GalCer, wanneer de verhoogde serum concentraties van IFN- al grotendeels 
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afgenomen waren 
52
. We observeerden een verhoogde respons op TNF behandeling 
gedurende op zijn minst enkele dagen na injectie van GalCer, wat suggereert dat 
GalCer een langduriger sensitiserend effect veroorzaakt. Het is aangetoond dat het 
antimetastatisch effect van GalCer afhankelijk is van de activering van NK cellen en 
IFN- productie door deze cellen, wat dan hoogstwaarschijnlijk gevolgd wordt door 
de activatie van andere immuuncellen 
53, 54
. We hebben geen duidelijke toxische 
nevenwerkingen waargenomen na behandeling met GalCer en TNF. Desondanks is 
er toch enige voorzichtigheid geboden wanneer men deze twee geneesmiddelen wil 
combineren aangezien bekend is dat zowel TNF als GalCer leverschade kunnen 
veroorzaken, wat toch al één van de dosis-limiterende nevenwerkingen van TNF is 
55, 
56
. Krachtigere GalCer analogen met een meer Th1-geörienteerd cytokine profiel 
worden momenteel ontwikkeld 
57
. Het zou bijzonder interessant zijn om te testen of 
deze analogen de antitumorale activiteit van TNF nog verder zouden kunnen 
versterken. 
 
 
12.3. Conclusie & perspectieven 
 
Het finale doel van dit onderzoeksproject was om nieuwe therapeutische doelwitten te 
identificeren die het mogelijk maken om selectief de antitumorale activiteit van TNF 
te versterken, zodat een veilige en doeltreffende systemische behandeling met lage, 
tolereerbare dosissen TNF mogelijk zou worden. In dit proefschrift beschreven we 
twee nieuwe benaderingen om dit doel te bereiken: ten eerste demonstreerden we dat 
interfereren met endotheelcel overleving, door inhibitie van de PI3K/Akt/mTOR 
signalisatieweg, gevoeliger maakte voor het selectief bloedvat-vernietigend effect van 
TNF, en ten tweede toonden we aan dat we de antitumorale activiteit van TNF 
merkbaar konden versterken door farmacologische activatie van invariante NKT 
cellen, waarvan we aanwijzingen hebben dat ze bijdragen tot de tumorvernietiging na 
behandeling met TNF. Beide benaderingen lieten een tienvoudige verlaging van de 
effectieve TNF dosis toe in ons muis tumor model. Het zou interessant zijn om te 
onderzoeken of een combinatie van deze benaderingen de benodigde TNF dosis nog 
verder zou verlagen. We leverden ook een nieuwe rationale voor de toevoeging van 
IFN- aan TNF-gebaseerde antikanker behandelingen door aan te tonen dat dit toelaat 
om een additioneel, neutrofiel-afhankelijk mechanisme te induceren. Een belangrijke 
opmerking bij al deze combinatietherapieën is dat alle behandeling beschreven in dit 
proefschrift gebeurden via paralesionale injectie van TNF en IFN-. Dus, om de 
doeltreffendheid en veiligheid van deze combinatietherapieën echt te kunnen 
beoordelen, zou een klinisch meer relevante, systemische behandeling opgezet moeten 
worden. In het geval van overlevingssignalisatie inhibitie zou het risico op 
nevenwerkingen sterk verlaagd kunnen worden door gebruik te maken van meer 
selectieve inhibitoren, zoals PI3K isovorm-selectieve inhibitoren die momenteel 
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ontwikkeld worden, of inhibitoren van stroomopwaartste componenten van de 
overlevings-signalisatieweg, zoals receptor tyrosine kinase inhibitoren of andere 
angiostatica die al getest worden in klinische studies. Tot slot kunnen onze resultaten 
ook nieuwe inzichten bieden in de antitumorale mechanismen van TNF en IFN- 
(samengevat in Fig.12.1.) 
 
 
 
Fig. 12.1. Potentieel mechanisme van het bloedvat-vernietigend en antitumoraal effect van TNF, 
en zijn synergie met IFN-. TNF en IFN- werken beide door activatie van hun receptoren op het 
tumorendotheel. Onze hypothese is dat het verlies van endotheliaal cel-cel en/of cel-extracellulaire 
matrix contact aan de basis ligt van het bloedvat-vernietigend effect van TNF. Dit zou lekkage, 
bloeding en blootstelling van het onderliggende weefsel veroorzaken, en zou de overleving van 
endotheelcellen ondermijnen. De bloedtoevoer zou dan snel afgesloten worden door een mechanisme 
van vasculaire collaps en/of trombose. Hoe invariante NKT cellen (rode pijlen) bijdragen tot de TNF-
geïnduceerde tumorvernietiging is onbekend, maar zou de productie van cytokines zoals TNF en IFN- 
kunnen omvatten. Anderzijds zouden NKT cellen ook endotheel- of tumorceldood kunnen induceren 
via Fas- of perforine/granzyme B-gemedieerde cytotoxiciteit. NKT cellen zouden geactiveerd kunnen 
worden door de presentatie van endogene glycolipide antigenen, die mogelijks afkomstig zijn van 
tumorcellen. Medebehandeling met IFN- (blauwe pijlen) veroorzaakt synergetische opregulatie van 
chemokines en adhesie molecules op endotheelcellen. Onze hypothese is dat dit resulteert in een 
massale infiltratie van neutrofielen, die dan de TNF-geïnduceerde endotheelschade zouden versterken 
door ROS productie of degranulatie.  
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13. ADDENDUM: The response to mTNF treatment is dependent on the tumor size 
 
The response to anticancer treatment may differ depending on the tumor size. To 
determine whether this is also the case for TNF, we pooled data of B16Bl6 tumor-
bearing wild-type C57BL/6J mice treated with mTNF of 18 individual experiments, 
each with 5 to 7 mice per group, making a total of 116 mice (Fig.13.1.). Treatment 
with mTNF (7µg/day) was started when the average TSI (the product of the largest 
perpendicular diameters in cm) of each group was equal to or larger than 0.5 (≥ day 
10 after tumor inoculation). Tumor sizes (TSI) at the beginning of treatment varied 
from 0.16 to 1.1, with an average of 0.56. Treatment resulted in complete tumor 
regression (no palpable tumor; TSI = 0) in 69 of 116 mice (59%). Partial regression, 
static response or progressive disease (‘other’) was observed in 39 mice (33%). 8 
mice died during the ten-day treatment period without complete regression and were 
not further taken into account. The average TSI at the start of treatment of mice that 
underwent complete tumor regression was 0.59, while the average TSI of mice that 
did not undergo complete regression was only 0.49. This difference was statistically 
highly significant (p = 0.0017 in two-tailed t-test), indicating that the response to 
mTNF treatment is indeed dependent on the tumor size. This was even more 
pronounced when mice were grouped according to their initial TSI and complete 
response rates (number of mice that underwent complete tumor regression/total 
number of mice) were compared. Only 36% of mice with a TSI lower than 0.4 
displayed complete response, while the complete response rate was 80% or higher for 
mice with a TSI higher than 0.7. 
 
 
Fig. 13.1. Response to mTNF treatment is tumor size-dependent. (A) Tumor size at the start of 
treatment of mice that underwent complete tumor regression (CR) and mice that did not undergo 
complete tumor regression (other) during the ten-day treatment period with mTNF. Statistical analysis 
(two-tailed t-test; Graphpad Prism 4.0), ** p = 0.0017. (B) Complete response rate versus tumor size at 
the start of treatment. 
 
These results clearly show that mice with larger tumors have a higher chance of 
undergoing complete tumor regression when treated with mTNF than mice with 
smaller tumors. Interestingly, no such correlation could be found in the NKT-deficient 
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mouse strains J18-/-, CD1-/- and IL-15-/-. This could reflect that a critical tumor size 
or infarct size is required to induce an adequate immune response. It is widely 
accepted that TNF selectively disrupt neovasculature, while leaving the normal 
vasculature unharmed. The insult of disrupting the tumor neovasculature will increase 
rapidly with tumor size. As tumors can grow up to a size of 1-2 mm in diameter 
without angiogenesis, and the proportion of tumor cells depending on neovasculature 
instead of on pre-existing vasculature is lower in smaller tumors than in larger tumors, 
it can be expected that small tumors will respond less well to mTNF treatment. In 
addition, the conditions within the tumor (e.g. oxygen pressure, acidity, interstitial 
fluid pressure) may differ depending on the tumor size and influence the sensitivity of 
the tumor vasculature to the disruptive effects of TNF. Whatever may be the cause, 
the finding that the response to mTNF treatment is tumor size-dependent has 
important implications for the interpretation and comparison of historic data, and for 
setting up new experiments. 
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